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β2AR β2-Adrenoreceptor 
5-HT2A-CR Serotonin 5-HT2A-C receptor 
A1R, A2AR Adenosine A1 receptor, adenosine A2A receptor 
ACN Acetonitrile 
app Apparent 
AIP4 Atrophin‐1‐interacting protein 4 
AM Allosteric modulator 
AT1aR Angiotensin II type 1 receptor 
B2pin2 4,4,4’,4’,5,5,5’,5’-Octamethyl-2,2’-bi-1,3,2-dioxaborolane 
BINAP 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl 
BRET Bioluminescence resonance energy transfer 
BSS Behavioral satiety sequence 
CaSR Calcium sensing receptor 
CHO Chinese hamster ovary 
Cpr Cyclopropyl 
CXCR Chemokine receptor 
D1-5R Dopamine D1-5 receptor 
DAG Diacylglycerol 
DIPEA N,N-Diisopropylethylamine 
DMR Dynamic mass redistribution 
DOR -Opioid receptor 
EC25, EC70 25% or 70% of the maximal effective concentration 
ECD Extracellular domain 
ECL Extracellular loop 
EDC N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide  
Emax Maximal effect 
HeLa Henrietta Lacks 
HLM Human liver microsomes 
HOBt 1-Hydroxybenzotriazole 
 HTRF Homogeneous time-resolved fluorescence energy transfer 
ICL Intracellular loop 
Imax Maximal inhibition 
IP Inositol monophosphate 
IP3 Inositol-1,4,5-triphosphate 
JNK c‐Jun N-terminal kinase 
logBB Logarithm of partition coefficient between brain and blood 
LSD Lysergic acid diethylamide 
MLM Mouse liver microsomes 
MOR -Opioid receptor 
MW Microwave 
MWC Monod-Wyman-Changeux 
NAL Neutral allosteric ligand 
Ns 4-Nitrobenzenesulfonyl (nosyl) 
PAR Protease-activated receptor 
PLA, PLC Phospholipase A, phospholipase C 
p-TSA p-Toluenesulfonic acid 
qt Quintet 
RhoGEF Guanine nucleotide exchange factor Rho 
S1P Sphingosine-1-phosphate 
S-Phos 2-Dicyclohexylphosphino-2’,6’-dimethoxybiphenyl 
SCTR Secretin receptor 
TM Transmembrane 
tPSA Topological polar surface area 
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NUEVAS ESTRATEGIAS DIRIGIDAS A RECEPTORES ACOPLADOS A PROTEÍNAS G 
Los receptores acoplados a proteínas G son proteínas de membrana presentes en las células 
eucariotas, cuya estimulación extracelular se traduce en respuestas funcionales dentro de la 
célula. En función de su secuencia primaria, se pueden clasificar en cuatro clases diferentes: clase 
A o familia de la rodopsina, clase B o familia de la secretina, clase C o familia del glutamato y clase 
F o familia Frizzled.1,2 La activación de estos receptores tras la unión de un ligando en la zona 
extracelular induce cambios conformacionales que permiten al receptor interaccionar con la 
proteína G adecuada, la cual desencadena una serie de vías de señalización a través de 
segundos mensajeros. En algunos casos, las -arrestinas pueden actuar como vía de señalización 
alternativa e independiente.3 
Los receptores acoplados a proteínas G suponen el grupo más grande de receptores de 
membrana codificados por el genoma humano (~2%)4 y están asociados a una gran diversidad de 
enfermedades, lo que les convierte en dianas terapéuticas de multitud de programas de 
descubrimiento de fármacos. Tradicionalmente, el desarrollo de fármacos que actúan sobre estos 
receptores se ha centrado en encontrar agonistas o antagonistas que desplazan al ligando 
endógeno activando o bloqueando el receptor.5 Durante las dos últimas décadas, han aparecido 
nuevas estrategias como por ejemplo el desarrollo de ligandos biased,6 bitópicos,7 moduladores 
alostéricos,8,9 pepducinas10 o ligandos dirigidos a heterómeros de receptores acoplados a 
proteínas G (Figura 1).11 Algunas de estas metodologías han dado lugar a moléculas que se 
encuentran actualmente en ensayos clínicos o incluso comercializadas. En particular, los 
moduladores alostéricos presentan un gran número de ventajas con respecto a los ligandos 
ortostéricos “clásicos”, ofreciendo fundamentalmente una mayor eficacia y selectividad. La 
explotación de este fenómeno representa una nueva aproximación al descubrimiento de fármacos 
más seguros que ofrezcan el máximo beneficio causando un menor número de efectos 
secundarios. En este contexto, el presente trabajo de investigación está dirigido al desarrollo de 
moduladores alostéricos de la clase A de receptores acoplados a proteínas G como candidatos 
prometedores para abordar necesidades médicas importantes en la actualidad: ligandos del 
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receptor de serotonina 5-HT2C para el tratamiento de la obesidad (Capítulo A) y ligandos del 
receptor de dopamina D1 para la enfermedad de Parkinson (Capítulo B). 
 
 
Figura 1. Nuevas estrategias dirigidas al estudio de receptores acoplados a proteínas G como 
dianas terapéuticas. 
 
CAPÍTULO A: MODULADORES ALOSTÉRICOS DEL RECEPTOR DE SEROTONINA 5-HT2C 
La obesidad es un problema de salud a nivel mundial que supone además un importante 
factor de riesgo para el desarrollo de enfermedades crónicas.12,13 Entre la variedad de estrategias 
que existen para controlar el peso,14 la estimulación del receptor serotoninérgico 5-HT2C es la 
aproximación mediada por serotonina más avanzada para el control de la ingesta alimenticia y la 
consiguiente pérdida de peso.15,16 Sin embargo, la falta de selectividad por el receptor 5-HT2C 
supone un importante problema debido a los efectos secundarios derivados de la activación de los 
receptores 5-HT2A y 5-HT2B, tales como las alucinaciones o las valvulopatías cardíacas, 
respectivamente.17 Por lo tanto, se necesitan compuestos más seguros y eficaces para validar la 
utilidad clínica de los ligandos del receptor 5-HT2C como agentes anti-obesidad. En este sentido 
proponemos el desarrollo de moduladores alostéricos positivos del receptor 5-HT2C, capaces de 
ofrecer una mayor selectividad y una respuesta más fisiológica, como una estrategia novedosa 
para el tratamiento de esta enfermedad. 
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Para la identificación de hit(s), se realizó el screening de una quimioteca de Vivia Biotech de 
aproximadamente 1600 compuestos en la plataforma ExviTech© inventada y patentada por dicha 
compañía. Se trata de un equipo de alta sensibilidad para evaluar la activación de receptores 
acoplados a proteínas G. La plataforma está basada en citometría de flujo y utiliza un ensayo de 
movilización de calcio como medida de la actividad funcional del receptor. Tres compuestos 
mostraron una potenciación de la eficacia de la serotonina en células que expresaban el receptor 
5-HT2C, mientras que no se observó ningún efecto en los receptores 5-HT2A y 5-HT2B. En un 
ensayo funcional de cuantificación de los niveles de inositol fosfato el compuesto VA240 (1) 
incrementó la eficacia máxima de la serotonina en un 20%, validando su actividad alostérica. Así, 
el compuesto VA240 (Figura 2) se seleccionó como hit inicial para la búsqueda de nuevos 
moduladores del receptor 5-HT2C mediante un programa de química médica. 
 
Figura 2. El screening de la quimioteca de Vivia Biotech utilizando la plataforma ExviTech y la validación 
posterior mediante un ensayo funcional de cuantificación de inositol fosfato permitió identificar el hit VA240 
como modulador alostérico del receptor 5-HT2C, el cual entró en un programa de química médica. 
 
En el proceso de optimización se sintetizaron dos series de derivados de VA240 (compuestos 
2-37) contemplando modificaciones estructurales tanto en el anillo de pirimidina como en el de 
fenilo unidos al esqueleto de indol (Figura 3).  
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Figura 3. Modificaciones estructurales propuestas a partir del hit VA240. 
 
En la evaluación de su efecto alostérico en el receptor 5-HT2C en un ensayo de inositol fosfato, 
el compuesto 7 (VA012) produjo la potenciación más elevada de la eficacia máxima de la 
serotonina (35%) (Figura 4). Asimismo, VA012 no se une al sitio ortostérico, no presenta actividad 
agonista y no muestra actividad funcional en un panel de receptores acoplados a proteínas G. 
Cabe destacar que VA012 no altera la liberación de inositol fosfato en presencia o ausencia de 
serotonina en células que expresan los receptores 5-HT2A y 5-HT2B. Respecto a su evaluación in 
vivo, el nuevo compuesto identificado como modulador alostérico positivo penetró en el cerebro a 
unos niveles razonables ([cerebro]/[plasma] = 3.8 después de 120 min) y mostró actividad en 
modelos de obesidad en rata. VA012 fue capaz de inhibir la ingesta de manera dosis-dependiente 
cuando se administró intraperitonealmente (70% de inhibición a 10 mg/kg tras 120 min) (Figura 4). 
Además, en un modelo semicrónico (7 días, 2 mg/kg) se observó tanto una disminución en la 
ingesta como una pérdida de peso. Adicionalmente, el compuesto no induce efectos secundarios 
tales como actividad ansiogénica o aversión al sabor. Estos resultados confirman el interés de un 
modulador alostérico positivo del receptor 5-HT2C como una estrategia terapéutica prometedora 
para el tratamiento de la obesidad. 
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Figura 4. El compuesto VA012 se ha identificado como un modulador alostérico 
positivo del receptor 5-HT2C con un buen perfil farmacológico y resultó ser activo en 
modelos animales de obesidad. 
 
CAPÍTULO B: MODULADORES ALOSTÉRICOS DEL RECEPTOR DE DOPAMINA D1 
La enfermedad de Parkinson es un trastorno neurodegenerativo, progresivo y crónico que se 
caracteriza por la pérdida de células dopaminérgicas en la sustancia negra pars compacta en el 
cerebro. El reemplazo de dopamina con L-3,4-dihidroxifenilalanina, su precursor directo, y/o con 
agonistas de los receptores de dopamina son las terapias más ampliamente utilizadas.18-20 A pesar 
de su gran utilidad, éstas están asociadas con efectos secundarios, como la discinesia, la 
disminución progresiva del beneficio sintomático o el síndrome de desregulación dopaminérgica. 
Los medicamentos actualmente en uso como terapia de reemplazo de dopamina activan la familia 
D2 de receptores dopaminérgicos. El hecho de que estos agentes farmacológicos estimulen 
también los receptores D1 ha promovido el desarrollo de moléculas selectivas de este receptor con 
propiedades antiparkinsonianas.21 Sin embargo, ninguna de ellas ha llegado a comercializarse 
debido principalmente a problemas toxicológicos y farmacocinéticos. Teniendo esto en cuenta, 
junto con las ventajas que supone la modulación alostérica, proponemos el desarrollo de un 
modulador alostérico positivo específico del receptor de dopamina D1 como una estrategia 
dopaminérgica novedosa para el tratamiento de la enfermedad de Parkinson. 
La búsqueda de moduladores alostéricos del receptor D1 se abordó racionalmente mediante 
una estrategia de diseño basado en la estructura. Primeramente, se construyó un modelo de 
homología del receptor D1 considerando la estructura cristalográfica del receptor D3.22 En este 
modelo se buscaron interacciones iónicas que pudieran mimetizar el par iónico que existe en el 
receptor 2-adrenérgico entre el Asp192 y la Lys305, y cuya debilitación tras la activación del 
receptor ha sido demostrada experimentalmente mediante experimentos de resonancia magnética 
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nuclear.23,24 Así, el par iónico formado por la Lys81 y el Asp314 resultó clave para generar un 
modelo de farmacóforo del sitio de unión alostérico propuesto en el receptor D1 (Figura 5). 
Después, el screening virtual de compuestos comerciales de la base de datos ZINC en el modelo 
de farmacóforo, seguido del análisis mediante docking de ~200 compuestos en el modelo del 
receptor D1, dio lugar a treinta y cinco moléculas diversas que se adquirieron y se ensayaron in 
vitro para evaluar su efecto alostérico en el receptor. Entre ellos, el derivado de bifenilo 10Z-0706 y 
la sacarina 191421196 mostraron la mayor potenciación de eficacia máxima de la dopamina, y 
fueron seleccionados como hits que entraron en sendos programas de química médica (Figura 5). 
 
Figura 5. El diseño basado en la estructura permitió la identificación de los hits 10Z-0706 y 191421196 
como moduladores alostéricos del receptor D1. 
 
En el caso del compuesto 10Z-0706, el proceso hit-to-lead incluyó la síntesis de los 
compuestos 3-12 (Figura 6A) en los que se exploró la influencia de los grupos funcionales del 
esqueleto de bifenilo, el reemplazo del átomo de oxígeno del grupo alcoxi por un átomo de azufre 
o la introducción de átomos de flúor. Asimismo, se estudió la necesidad de dos anillos aromáticos 
en los compuestos 13 y 14. El análogo 5 (UCM-01212) con un grupo formilo en la posición 4 del 
bifenilo y un grupo OCH2F en la posición 2’ presentó la mayor eficacia como modulador alostérico 
positivo (Figura 6B). El compuesto potenció la eficacia máxima de la dopamina de forma 
concentración-dependiente –en un 33% y un 82% a las concentraciones de 1 y 10 μM, 
respectivamente– en el receptor D1, no presentó actividad agonista per se y es selectivo frente a 
los receptores D2, D3 y D4. Además, UCM-01212 no se unió al sitio ortostérico del radioligando 
[3H]SCH-23390, y el estudio del sitio alostérico mediante experimentos de mutagénesis dirigida 
permitió validar el modelo de docking propuesto. La evaluación de UCM-01212 en un modelo 
animal de la enfermedad de Parkinson mostró un aumento de la coordinación motora en el test del 
rotarod (50 mg/kg, ip) y una disminución de la discinesia producida por L-3,4-dihidroxifenilalanina 
(200 mg/kg, ip) (Figura 6B). Por tanto, UCM-01212 nos ha permitido establecer una prueba de 
concepto de la utilidad terapéutica de un modulador alostérico positivo del receptor D1 como una 
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novedosa estrategia para el tratamiento de la enfermedad del Parkinson. Sin embargo, su 
moderado perfil farmacocinético impidió su progreso como candidato a fármaco, por lo que nos 
propusimos optimizarlo con el fin de obtener un compuesto con un perfil farmacocinético mejorado. 
 
Figura 6. A. Compuestos propuestos a partir del hit 10Z-0706; B. UCM-01212 se ha 
identificado como un modulador alostérico positivo del receptor D1 con un moderado perfil 
farmacocinético y con actividad en un modelo animal de la enfermedad de Parkinson. 
 
En el proceso de optimización de UCM-01212, se exploró la sustitución del grupo formilo por 
grupos bioisósteros en los compuestos 23-34, el reemplazo del anillo aromático que contiene el 
grupo alcoxi por una piridina en el compuesto 54 y la introducción de un átomo de halógeno en los 
compuestos 55 y 56 (Figura 7A). La sulfoximina 33 (UCM-01306) (Figura 7B) mejoró tanto la 
actividad alostérica (potenciación del 55% de la eficacia máxima de la dopamina a 10 μM y 
concentración efectiva 50 de 60 nM a una [dopamina] = concentractión efectiva 70) como el perfil 
farmacocinético con respecto al del compuesto UCM-01212. Se ha llevado a cabo la síntesis 
enantioselectiva de los dos enantiómeros de UCM-01306 y ambos isómeros presentan buenos 
perfiles farmacológico y farmacocinético. Actualmente se está llevando a cabo su evaluación en 
modelos animales para estudiar su utilidad terapéutica para el tratamiento de la enfermedad de 
Parkinson. 
 
 
A
B
ZYHCX CHO
3-12
N
13, 14
N CHO
OCHYZ
X = O, S
Y, Z = H, F
Días
Actividad Discinesia
PERFUSIÓN
Ratones afaquia
Actividad en un modelo animal de 
la enfermedad de Parkinson
O
H
UCM-01212
Pot. eficacia máx. (a 10 M) = 82%
OCH2F
Perfil farmacocinético
moderado
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Figura 7. A. Modificaciones estructurales propuestas a partir de UCM-01212; B. UCM-01306 se 
identificó como un modulador alostérico positivo del receptor D1 con buenos perfiles farmacológico y 
farmacocinético. 
 
En un proceso paralelo, la estructura de sacarina del hit identificado 191421196 se consideró 
como un backup de nuestro proyecto de investigación. Se llevaron a cabo diferentes 
modificaciones estructurales en la molécula y entre los compuestos sintetizados (72-91) (Figura 
8A), el análogo 77 (UCM-01296) (Figura 8B) fue el que mostró una mayor eficacia como 
modulador alostérico positivo (potenciación del 65% de la eficacia máxima de la dopamina a 10 
μM). Además, exhibe un incremento del 41% sobre la concentración efectiva 70 de la dopamina, 
con una concentración efectiva 50 de 13.2 μM. Los datos actuales hacen de UCM-01296 un buen 
candidato para completar su caracterización farmacológica, el estudio de sus propiedades 
farmacocinéticas, y su posible evaluación in vivo. 
 
 
Figura 8. A. Modificaciones estructurales propuestas a partir del hit 191421196; B. UCM-01296 se 
identificó como un modulador alostérico positivo del receptor D1. 
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NOVEL STRATEGIES TARGETING GPCRs 
G protein-coupled receptors (GPCRs) are eukaryotic cell membrane proteins that transduce a 
wide range of extracellular stimuli into intracellular changes in cell function. Based on their amino 
acid sequence, they can be classified in four different classes: class A or rhodopsin-like family, 
class B or secretin-like family, class C or glutamate-like family, and class F or Frizzled receptor-like 
family.1,2 Activation of GPCRs upon ligand binding in the extracellular side triggers conformational 
changes that allow the receptor to interact with the corresponding heterotrimeric G protein, which 
initiates a series of downstream signalling pathways via second messenger molecules. 
Alternatively, -arrestins can act as signalling scaffolds for many GPCR pathways.3 
GPCRs represent the largest group of cell surface receptors encoded by the human genome 
(~2%)4 and have been associated to a multitude of human disorders, which makes them the focus 
of attention of many drug discovery programs. Traditionally, the development of drugs that target 
GPCRs has been focused on finding agonists or antagonists that displace the natural or 
endogenous ligand to activate or inhibit the receptor. Emerging knowledge of structure and 
physiological functions of GPCRs has begun to alter the approaches to drug discovery.5 Thus, over 
the past two decades, novel strategies such as the development of biased6 and bitopic ligands,7 
allosteric modulators,8,9 pepducins10 or ligands targeting GPCR heteromers11 have appeared 
(Figure 1). Some of these new approaches have proved to be productive, yielding molecules 
currently in clinical trials or even marketed. Specifically, allosteric modulators present several 
advantages in their mechanism of action over “classical” orthosteric ligands, allowing a higher 
efficacy and selectivity. The exploitation of this phenomenon could lead to a new approach in the 
process of discovering safer drugs that offer the maximum benefit while causing a lower amount of 
adverse effects. In this context, in the present work we propose the development of class A GPCR 
allosteric modulators as promising candidates to address major unmet medical needs: 
serotoninergic 5-HT2C receptor ligands targeting obesity (Chapter A) and dopaminergic D1 receptor 
ligands in order to tackle Parkinson’s disease (Chapter B). 
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Figure 1. Emerging strategies to approach the study of GPCRs as drug targets. 
 
CHAPTER A: ALLOSTERIC MODULATORS OF SEROTONIN 5-HT2C RECEPTOR 
Obesity is a major global health issue that supposes a great risk factor for chronic 
diseases.12,13 Among the variety of pharmacological strategies that can be used to control body 
weight,14 stimulation of serotonin (5-HT) 2C receptors is the most advanced approach towards 5-HT 
mediated control of food intake and associated reduction of body weight.15,16 However, selectivity 
against 5-HT2C receptor (5-HT2CR) seems crucial, since activation of 5-HT2A y 5-HT2B subtypes is 
associated with critical side effects, such as hallucinations and cardiac valvulopathy, respectively.17 
Clearly, further efficacy and safety data are needed to prove the clinical utility of 5-HT2CR ligands 
as anti-obesity agents. In this context, we propose the development of 5-HT2CR positive allosteric 
modulators (PAMs), which could produce higher selectivity and a more physiological response, as 
a novel strategy for the treatment of obesity. 
To address the hit(s) identification, a Vivia Biotech chemical library of approximately 1600 
compounds was screened on the proprietary ExviTech© platform (Figure 2). This highly sensitive 
method to assess activation of GPCRs is based on flow cytometry, and a functional whole cell 
assay was used to access activity by measuring calcium mobilization in response to receptor 
activation. Three compounds exhibited a potentiation of 5-HT effect in cells expressing the 5-
HT2CR, whereas no enhancement of 5-HT effect was observed for 5-HT2A and 5-HT2B receptors. 
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These three putative modulators identified in ExviTech platform were assessed for their ability to 
modulate the 5-HT2CR in a functional assay by determining inositol monophosphate (IP) levels in 
cells, a well characterized signalling pathway of receptor activation. In this manual assay 
compound VA240 (1) potentiated the 5-HT maximal effect (Emax) in a 20%. Hence, VA240 (Figure 
2) was selected as a starting hit for the search of new synthetic modulators of the 5-HT2CR through 
a medicinal chemistry program. 
 
 
Figure 2. High-throughput screening methodology to identify AMs of the 5-HT2CR using ExviTech platform 
and Vivia Biotech chemical library. Validation via IP-based functional assay allowed to identify hit VA240, 
which entered a medicinal chemistry program. 
 
Two series of analogs of VA240 (2-37) were synthesized considering structural modifications of 
the pyrimidine or the phenyl ring attached to the indole scaffold (Figure 3) and were assayed to 
examine the effect on functional activity and allosteric pharmacology at 5-HT2CR. As a result, 
compound 7 (VA012) (Figure 4) displayed the highest potentiation of 5-HT Emax (35%) in the IP 
assay. 
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Figure 3. Structural modifications proposed starting from validated hit VA240. 
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Further pharmacological characterization of compound VA012 revealed no binding at the 
orthosteric site, no intrinsic agonist activity, and no significant off-targets in a cellular functional 
GPCR profile. Importantly, VA012 did not alter 5-HT-induced IP release in the presence or absence 
of 5-HT in cells expressing 5-HT2A and 5-HT2B receptors. As for in vivo evaluation, the newly 
identified 5-HT2CR PAM entered the brain at reasonable levels ([brain]/[plasma] = 3.8 at 120 min) 
and exhibited activity in obesity models in rats. VA012 inhibited food intake in a dose-dependent 
manner when administered intraperitoneally (70% maximum inhibition at 10 mg/kg after 120 min) 
(Figure 4). Also, a positive effect in both food intake and body weight gain was observed in a semi-
chronic study (7 days, 2 mg/kg). Moreover, the compound induced neither anxiogenic effect nor 
conditioned taste aversion as side effects. These results support the interest of a 5-HT2CR PAM as 
a promising therapeutic approach for the treatment of obesity. 
 
 
Figure 4. Compound VA012 was identified as a 5-HT2CR PAM with a good pharmacological 
profile and anti-obesity properties in vivo. 
 
CHAPTER B: ALLOSTERIC MODULATORS OF DOPAMINE D1 RECEPTOR 
Parkinson’s disease (PD) is a chronic, progressive, and neurodegenerative disorder 
characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta in the 
brain. Dopamine (DA) replacement with its direct precursor L-3,4-dihydroxyphenylalanine (L-DOPA) 
and/or DA receptor agonists are among the most widely used therapies.18-20 Despite their 
usefulness, they are associated with adverse effects, such as dyskinesia, progressive decline in 
symptomatic benefit or DA dysregulation syndrome. In the DA replacement therapy, current 
pharmaceuticals activate dopamine D2-like receptors. The fact that these agents also stimulate 
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dopamine D1 receptors to some extent led to the development of some promising D1-selective 
agents with good antiparkinsonian properties,21 but they failed to reach the market mainly due to 
toxicological and pharmacokinetic problems. Taking all this into consideration, together with the 
advantages that allosteric modulation presents, we propose herein the development of a PAM that 
specifically targets the D1 receptor (D1R) as a potential novel strategy for the treatment of PD. 
Our search for D1R allosteric modulators was rationally approached using a structure-based 
drug design strategy. First, a homology model of the D1R was constructed based on the crystal 
structure of the D3 subtype.22 In this model, we searched for ionic interactions that could mimic the 
salt bridge formed by Asp192 and Lys305 in the 2-adrenergic receptor, which has been proved to 
weaken upon receptor activation through nuclear magnetic resonance experiments.23,24 Thus, the 
salt bridge between Lys81 and Asp314 was key to generate a pharmacophore model of a proposed 
allosteric binding site in the D1R (Figure 5). Then, a virtual screening of commercially available 
compounds from the ZINC database in the pharmacophore model and subsequent docking of ~200 
putative PAMs yielded thirty-five diverse molecules that were purchased and assessed in vitro for 
allosteric modulation of the receptor. Among them, biphenyl derivative 10Z-0706 and saccharin 
191421196 exhibited the highest potentiation of DA Emax and were selected as hits that entered into 
parallel medicinal chemistry programs (Figure 5). 
 
 
Figure 5. Structure-based drug discovery methodology allowed the identification of hits 10Z-0706 and 
191421196 as allosteric modulators for the D1R. 
 
Starting with compound 10Z-0706, the first step in the hit-to-lead process included the 
synthesis of compounds 3-14 (Figure 6A). Evaluation of the optimal position of both functional 
groups in the aromatic rings, the influence of the replacement of the oxygen for a sulfur or the 
introduction of fluorine atoms in the alkoxy moiety were studied in compounds 3-12. The 
importance of two aromatic features was evaluated in analogs 13 and 14. Among them, compound 
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5 (UCM-01212) bearing a formyl group in 4-position and OCH2F group in 2’-position was the most 
efficient PAM (Figure 6B). It increases the endogenous DA Emax in a dose-dependent manner –in 
33% and 82% at 1 and 10 μM, respectively–, is inactive in the absence of DA and exhibits subtype 
selectivity. In addition, UCM-01212 did not bind the orthosteric site, and the proposed allosteric 
binding site was studied through site-directed mutagenesis experiments, which validated the 
docking model. The evaluation of UCM-01212 in an animal model of PD revealed an increase of 
motor coordination in the rotarod test (50 mg/kg, ip) and a decrease of the dyskinesia produced by 
administration of L-DOPA (200 mg/kg, ip) (Figure 6B). Therefore, UCM-01212 allowed us to set the 
proof of concept of a D1R PAM as a potential novel therapy for the treatment of PD. However, its 
moderate pharmacokinetic (PK) profile hampered its progress as a drug candidate, and prompted 
us to search for a new compound with an improved PK profile. 
 
Figure 6. A. Proposed compounds related to hit 10Z-0706; B. Compound 
UCM-01212 was identified as a D1R PAM with a moderate PK profile and 
exhibited activity in an animal model of PD. 
 
In the optimization process of UCM-01212, replacement of the formyl group in compounds 23-
34, replacement of the phenyl ring for a pyridine in derivative 54, and introduction of a halogen 
atom in analogs 55 and 56 (Figure 7A) were explored. Novel sulfoximine derivative 33 (UCM-
01306) (Figure 7B) exhibited the best allosteric activity (55% potentiation of DA Emax at 10 μM and 
EC50 of 60 nM at a fixed [DA] = EC70). Importantly, it displayed an improved PK profile with respect 
to parent ligand UCM-01212. In compound UCM-01306 sulfoximine moiety provides chirality to the 
molecule; hence, we set up the synthetic route for the obtention of both enantiopure compounds. 
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Racemic and enantiomeric forms of UCM-01306 display good pharmacological and PK profiles, 
and are currently under evaluation in animal models in order to study their therapeutic utility for the 
treatment of PD. 
 
Figure 7. A. Proposed structural modifications related to compound UCM-01212; B. UCM-01306 
was identified as a D1R PAM with good pharmacological and PK profiles. 
 
In a parallel process the saccharin scaffold of identified hit 191421196 was considered a 
backup of our research project. Different structural modifications were carried out in the molecule 
and among the obtained compounds (72-91) (Figure 8A), analog 77 (UCM-01296) is the most 
efficient PAM synthesized so far among the saccharin derivatives (65% potentiation of DA Emax at 
10 μM) (Figure 8B). Moreover, it displays an Emax potentiation of 41% over DA EC70, with an EC50 of 
13.2 μM. Saccharin UCM-01296 is in an early development stage; current data makes it a 
promising candidate to continue with pharmacological characterization, study of PK properties, and 
hopefully in vivo evaluation. 
 
 
Figure 8. A. Proposed structural modifications related to hit 191421196; B. UCM-01296 was identified 
as a D1R PAM. Pharmacological and PK profiles are currently under progress prior to in vivo studies. 
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GENERAL INTRODUCTION. NOVEL STRATEGIES TARGETING GPCRs 
G protein-coupled receptors (GPCRs), also known as 7-transmembrane (7TM) receptors, are 
eukaryotic cell membrane proteins that transduce a wide range of extracellular stimuli (light, 
hormones, odours, peptides, and neurotransmitters among others) into intracellular changes in cell 
function. All of them share the same architecture, which consists of an extracellular N-terminal and 
an intracellular C-terminal ends, connected via 7TM -helices that are linked through three 
extracellular loops (ECLs) and three intracellular loops (ICLs). Based on their amino acid 
sequence, they can be classified in four different classes: class A or rhodopsin-like family, class B 
or secretin-like family, class C or glutamate-like family, and class F or Frizzled receptor-like family.1-3 
Activation of GPCRs upon ligand binding in the extracellular side triggers conformational 
changes that allow the receptor to interact with the corresponding heterotrimeric G protein, which 
exchanges a molecule of guanosine diphosphate (GDP) for guanosine triphosphate (GTP). As a 
result, the G protein dissociates affording -subunit (G and -subunit (G), which are free to 
interact with other intracellular proteins, such as adenylyl cyclase, RhoGEF or phospholipase C 
(PLC) (Figure 1).4 Consequently a series of downstream signalling pathways are initiated via 
second messenger molecules, such as cyclic adenosine monophosphate (cAMP), inositol-1,4,5-
trisphosphate (IP3), diacylglycerol (DAG), or calcium (Figure 1). Hydrolysis of GTP in the G 
monomer causes the reassociation with the G dimer, permitting the heterotrimer protein to await 
for a new activation of the receptor.5 On the other hand, -arrestins can act as alternative signalling 
scaffolds for many GPCR pathways, regulating the activity of effectors such as mitogen-activated 
protein kinases (MAPKs), including extracellular signal-regulated kinase –ERK– and c‐Jun N‐
terminal kinase –JNK–, tyrosine kinases (e.g., Src) and E3 ubiquitin ligases (e.g., atrophin‐1‐
interacting protein 4 –AIP4–) (Figure 1).6-8 
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Figure 1. In the classical view of GPCR signalling, an agonist binds to the receptor, leading to its 
interaction with heterotrimeric G proteins (right). Activated -subunits subsequently bind to 
intracellular proteins such as adenylyl cyclase, RhoGEF and PLC, and regulate their activity. These 
modulate downstream pathways directly or by generating second messengers (cAMP, DAG and IP3) 
that regulate further downstream effectors, such as protein kinase A and C (PKA and PKC). 
Following their liberation from the heterotrimeric G protein complex, the -subunits can also bind to 
and regulate certain downstream effectors, such as ion channels and PLC. Alternative signalling 
pathways may be triggered if arrestin binds to the intracellular side of the GPCR (left), instead of the 
G protein. These include interaction with effector proteins such as MAPKs, tyrosine kinases or E3 
ubiquitin ligases (Adapted from references 4 and 7). 
 
GPCRs represent the largest group of cell surface receptors encoded by the human genome 
(~2%), accounting for 797 GPCR-classified proteins according to the UniProt database.9 Taking 
also into account that these receptors have been associated to a multitude of human disorders, 
together with the fact that many diseases have been shown to be due to mutations and 
polymorphisms in GPCRs,10,11 it comes as no surprise that they have been the focus of attention of 
many drug discovery programs. An additional proof of the importance of these type of receptors is 
the Nobel Prize in Chemistry awarded in 2012 to Prof. Brian Kobilka and Prof. Robert Lefkowitz, in 
recognition for their efforts in the studies of GPCRs.12 It is estimated that drugs targeting these 
receptors account for a large amount of best-selling medicines and approximately half of the drugs 
on the market. 
Traditionally, the development of drugs that target GPCRs has been focused on finding 
agonists or antagonists that displace the natural or endogenous ligand to activate or inhibit the 
receptor. However, the remarkable structural similarity of the binding pockets due to evolutionary 
pressure13 has hampered the development of highly selective ligands across subtypes in a receptor 
family. Emerging knowledge of structure and physiological functions of GPCRs has begun to alter 
the approaches to drug discovery and is contributing to tackle this issue.14-16 Thus, over the past 
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two decades, novel strategies such as the development of biased and bitopic ligands, allosteric 
modulators, pepducins, as well as ligands targeting GPCR heteromers have appeared (Figure 2). 
Although these methodologies open new horizons for achieving safer and more efficient drugs, 
they also present challenges for their validation as effective therapeutics. 
 
 
Figure 2. Emerging strategies to approach the study, characterization and validation of GPCRs as drug 
targets. 
 
1. Biased ligands 
In the classical approach, researchers have seen receptors basically as two-state models and 
the development of ligands has led to compounds that either activate (agonists) or block 
(antagonists) the receptor by binding to the orthosteric site, that is, where the natural or 
endogenous ligand binds. The two-state model has also been able to explain the pharmacology of 
partial agonists showing lower efficacy compared to (full) agonists. The emerge over the past two 
decades of studies highlighting compounds that did not fit the “on-off” paradigm has forced modern 
pharmacological theory to envision the possibility that receptors may own a signalling repertoire 
which can be fully or partially activated. Consequently, receptors can exhibit a diversity of 
responses, which can be solely or simultaneously initiated. In this regard, a biased ligand for a 
GPCR can be defined as a molecule capable of selectively engaging one signalling pathway of a 
receptor over others of the same receptor, due to the stabilization of a certain conformation or a 
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concrete subset of conformations.17 Due to the fact that pathways dependent on G-protein and -
arrestin couplings are ubiquitous and generic, these have been the most studied by researchers 
worldwide aiming to obtain biased ligands (Figure 3). From a pharmacological point of view, biased 
ligands may allow to obtain therapeutic effects without affecting physiological functions mediated by 
the same receptor that are not related to the disease.18,19 
 
 
Figure 3. Biased ligands are capable of triggering one signalling pathway at the expense 
of others. G-protein (left) and β-arrestin (right) biased ligands have been obtained 
(Adapted from reference 17). 
 
The discovery of new biased ligands is not straightforward, since a high number of assays are 
needed for their characterization. Hence, a wide variety of pharmacological, biochemical and 
biophysical techniques are used to study this type of ligands, such as chemical labelling, nuclear 
magnetic resonance, X-ray crystallography, double electron-electron resonance and proximity-
based methodologies (bioluminescence and fluorescence resonance energy transfer, BRET and 
FRET), among others. Even though recent structural studies on GPCRs have provided 
considerable progress,20 there is not yet direct structural evidence for distinct receptor 
conformations linked to a specific signalling pathway. Consequently, the identification of biased 
ligands has largely relied upon serendipity or screening programs of compounds previously 
described as (partial) agonists or inverse agonists in a specific particular signalling,21,22 rather than 
rational design. 
The development of biased ligands is one of the most novel and recent strategies towards 
drug discovery in the GPCR field. To date, some examples have already appeared across a range 
of therapeutically important GPCRs, such as angiotensin II type 1 receptor (AT1aR), serotonin 5-
HT2A, 5-HT2C and 5-HT1A receptors, dopamine D1 and D2 receptors, μ-opioid receptor (MOR) and 
2-adrenergic receptor.23 Although no newly identified biased ligand has been marketed yet, a 
couple of them have reached clinical trials, which validates their importance as a promising 
therapeutic strategy targeting GPCRs. Compound TRV130 (oliceridine, Trevena Inc.) is a G-protein 
biased ligand of the MOR, currently in human clinical trials (phase III) for the treatment of acute 
General Introduction 
29 
severe pain (Table 1).24 On the other hand, the -arrestin biased ligand TRV027 targets the AT1aR, 
and is in clinical phase IIb for congestive heart failure (Table 1).25 
Table 1. Biased ligands currently in human clinical trials. 
Biased ligand Structure Receptor Indication Stage of development 
Oliceridine 
(TRV130) 
 
MOR Acute pain Phase III 
TRV027 
 
AT1aR Heart failure Phase IIb 
 
 
2. Allosteric modulators 
Allosteric modulators (AMs) can be defined as molecules that bind to a topographically distinct 
site, termed as allosteric site, from that of the endogenous ligand, known as the orthosteric binding 
site. Binding to the allosteric site produces conformational changes in the orthosteric site, that 
result in the modulation of the affinity, potency and/or efficacy of the endogenous ligand response. 
The term “allostery” was first coined by Monod and Jacob in 1961 to describe a newly 
identified phenomena observed in allosteric enzymes, composed of various subunits.26 These 
observations were first formalized in the Monod-Wyman-Changeux (MWC) model in 1965.27 Briefly, 
the binding of an effector to one subunit of the allosteric enzyme produces a conformational 
change, which is also generated in the rest of the subunits in a concerted manner. Soon after its 
publication, Koshland and collegues suggested an alternative model,28 in which the conformational 
change of the protein should occur as a sequential process upon binding of succesive molecules, 
instead of in a concerted fashion. Although in the beginning these models were used in 
enzymology, in the following years it became apparent that almost all protein superfamilies possess 
allosteric properties, including GPCRs.29 Based on this, these receptors display a spontaneous 
equilibrium between states and possess multiple binding sites; ligand binding (either allosteric or 
orthosteric) to any of these sites should stabilize a subset of conformational states at the expense 
of others. 
Advances in pharmacological and biochemical tools to characterize and validate receptor 
proteins as drug targets have uncovered different types of allosteric ligands: positive or negative 
allosteric modulators (PAMs or NAMs) that either potentiate or inhibit receptor response, 
respectively; neutral allosteric ligands (NAL) that bind to an allosteric site but they do not modulate 
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the activity of the receptor at any level (Figure 4); and allosteric agonists that are capable of directly 
activate the receptor from an allosteric site even in the absence of an orthosteric agonist.30,31 
 
 
Figure 4. Allosteric modulators bind to a topographically distinct site from the orthosteric 
binding site potentiating (PAMs), inhibiting (NAMs) or not modulating the receptor response 
(NAL) (Source: reference 32). 
 
GPCR AMs present unique advantages over orthosteric classical ligands, as well as 
challenges to achieve a successful detection and validation.32 The novel pharmacological 
characteristics of AMs are: 
- Saturability of the effect. AMs exert their action in the presence of the natural ligand, thus 
tuning cellular responses where the endogenous orthosteric ligand produces the 
physiological effect and maintaining its spatio-temporal “rhythms” (Figure 5).33 Besides, a 
complete occupancy of the orthosteric binding sites limits the action of the allosteric 
ligand, which produces a saturability of the effect (“ceiling effect”) and protects against a 
potential overdose of a drug. 
 
 
Figure 5. The effect of the endogenous agonist (a) is compared to the effect of the endogenous 
agonist in the presence of a PAM (b) and to that of an orthosteric agonist (c). The effect obtained 
in presence of a PAM is closer to the physiological response (Adapted from reference 33). 
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- Receptor selectivity. Allosteric ligands are capable of achieving greater selectivity among 
receptor subtypes due to the fact that they bind to a less conserved site, compared to the 
highly-conserved orthosteric binding site. 
- Differenciated modulation of the affinity and efficacy. The ability that an allosteric ligand 
has to modulate the affinity of an orthosteric ligand is not necessarily related to the effect 
it can have on its efficacy, and viceversa. There are examples in which one of the two 
properties is affected and the other is not (Figure 6).34 In this sense, it is important to set 
up the functional activity assays in the first phases of biological screening. 
 
 
Figure 6. Effects on the binding (left) or function (right) of an orthosteric agonist mediated 
by three different allosteric potentiators: the first (red) enhances orthosteric agonist affinity 
only; the second (blue) enhances orthosteric agonist efficacy only; the third (green) 
modestly enhances both affinity and efficacy, and also displays allosteric agonism 
(Source: reference 34). 
 
- Functional selectivity. When binding to a receptor, allosteric ligands have the ability to 
differentially activate certain subsets of intracellular signalling pathways to the relative 
exclusion of the others. Unique allosteric sites can be identified to target disorders more 
specifically by new drugs with fewer side effects. Nevertheless, this makes vital to 
evaluate the allosteric modulator in a wide variety of pharmacological tests, as the 
allosteric behavior can depend on the biological system under study.35 
- Probe dependence. The magnitude and direction of an allosteric effect can change 
depending on the nature of the interacting ligands. Many GPCRs have more than one 
endogenous orthosteric agonist, and totally different effects can be observed depending 
on which agonist is used to activate the receptor in the presence of a given allosteric 
modulator. 
The design, characterization and validation of AMs require the development of new 
experimental tools that meet their complex pharmacology, together with the application of already 
existing methodologies, such as protein crystallography, equilibrium ligand binding, ligand binding 
kinetics or functional assays.30,36,37 Moreover, operational models have been developed as a 
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powerful tool to quantify allosteric properties that go beyond simple measures of affinity, potency or 
efficacy.38 
GPCR AMs have spurred numerous ongoing research programs in both academia and 
industry over the last decade and a half. As a result, some compounds endowed with allosteric 
properties are currently in clinical trials,39 and two of them have already achieved Food and Drug 
Administration (FDA) approval (Table 2). These marketed drugs are cinacalcet, a NAM that targets 
the calcium sensing receptor (CaSR), a class C GPCR, for the treatment of hyperthyroidism,40 and 
maraviroc, a PAM of the chemokine receptor CCR5, a class A GPCR, for the treatment of HIV 
(Figure 7).41 
Besides, a high number of molecules have been reported as AMs, both exogenous and 
endogenous, targeting all classes of GPCRs for a wide range of diseases, such as multiple 
neurological and psychiatric disorders, cancer or metabolic disorders, among others.31,42,43 
 
Table 2. Reported allosteric modulators currently in clinical development or marketed (Source: reference 39). 
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Figure 7. Structures of the two marketed GPCR AMs. 
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3. Bitopic ligands 
In the late 1970s the design of bivalent ligands attached simultaneously to two binding sites 
was encompassed in the message-address concept, first coined by Schwyzer.44 According to this, 
a ligand exhibits a message component, which contains the structural motif responsible for receptor 
recognition and subsequent activation, and an address component, which provides additional 
ligand-receptor interactions. The latter can be located near the message component or in a more 
distal region, such as a different binding site in the same receptor, or even in a different one. Since 
the pioneering work of Portoghese,45,46 bivalent ligands have been used over the past three 
decades to gain subtype selectivity and study receptor dimerization. The turn of the millennium has 
witnessed the exploitation of the bivalent ligand concept as the driving force to develop bitopic or 
dualsteric ligands, mostly providing higher selectivity for the subtype receptor or at the signalling 
pathway level.47-50 
Recent studies in chemical biology of GPCR allostery have enabled the discovery of bitopic 
ligands, defined as molecules that can concominantly engage both the orthosteric and allosteric 
sites on a single GPCR. Bitopic ligands present various modes of binding, in which they can 
simultaneously interact with the orthosteric and allosteric sites, distribute between orthosteric or 
allosteric interactions via “flip-flop” mechanism, or concominantly by binding cooperatively to each 
site on a single receptor (Figure 8). 
 
 
Figure 8. Modes of binding for bitopic ligands: bitopic (top), “flip-
flop” (middle), or cooperative (bottom) (Source: reference 49). 
 
For the design of bitopic ligands, structural requirements of the receptor sites should be taken 
into account, i.e. the allosteric site must be accessible from the orthosteric site. Thus, recent growth 
of GPCR structural biology has considerably helped in the rational design of bitopic ligands. For 
instance, the solution of the structure of the dopaminergic D3 receptor bound to the antagonist 
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eticlopride revealed a “second” binding pocket extending out from the classic orthosteric domain 
that may be amenable to be targeted by bitopic ligands.51 In order to obtain a potent bitopic ligand, 
both orthosteric and allosteric pharmacophores of the molecule should be optimized. Although this 
can be done separately, it should be noted that the linker must also be considered. In this sense, 
both length and nature of the linker, together with global thermodynamic costs, must be taken into 
consideration when developing a bitopic ligand. 
Initially, the discovery of bitopic ligands was based on the reevaluation of existing ligands.52 
Since then, rationally designed bitopic ligands have seen the light throughout the past ten years. 
Examples are THRX-160209 and Hybrid 2 for M2 acetylcholine receptor (M2AChR),53,54 or LUF6258 
for the adenosine A1 receptor (A1R) (Table 3).55 
Important challenges remain yet to be unraveled in the development of bitopic ligands. At 
present, even though they have proved to be a valuable tool to carry out structural studies on 
GPCRs, no bitopic ligand has been marketed. 
Table 3. Structure of recent rationally designed bitopic ligands: orthosteric (red) and allosteric 
(green) pharmacophores separated by a linker (black). 
Bitopic ligand Structure Target receptor 
TRX-160209 
 
M2AChR 
Hybrid 2 
 
M2AChR 
LUF6258 
 
A1R 
 
 
4. Pepducins 
A pepducin is a molecule formed by a peptide and a lipid moiety separated by a linker, that 
targets GPCRs intracellularly (Figure 9). The peptide component is derived from the amino acid 
sequence of one of the three ICLs or the C-terminal tail of the GPCR; the lipid fragment is a 
phospholipid acting as the hydrophobic component (palmitate is the most widely used, but 
myristate and lithocholic acids are also described); and the linker is usually a peptide bond. 
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Figure 9. Pepducins are lipopeptide molecules that target 
allosterically one of the ICLs or the C-terminal tail of a GPCR. The 
lipid moiety is in most cases palmitate and the peptide component 
is derived from the amino acid sequence of the interaction. 
 
Pepducins were discovered by Kuliopolus and Covic and first published in 2002.56 Since then, 
the identification and development of these lipopeptides has been conducted mainly by the 
foundation of pharmaceutical companies exclusively dedicated to them (e.g. Anchor Therapeutics 
in Massachussets, USA). Pepducins clearly represent a novel approach to modulate GPCR 
activity.57 In this regard, they are endowed with some advantages compared to other peptide 
ligands, such as improved drug-like properties. However, pepducins are not suitable for central 
nervious system (CNS) diseases since they do not readily penetrate the blood-brain barrier. In 
order to study their pharmacokinetics, pharmacodynamics, bioavailability and biodistribution, 
fluorescent and radioactively labeled pepducins can be used to carry out FRET/BRET and 
quantitative whole-body autoradiography experiments, respectively.58 
Their peptidic nature allows to create large libraries in short time due to the fact that they can 
be designed using bioinformatic technologies and synthesized through solid phase methodologies. 
The most studied GPCRs that have been targeted by pepducins are the protease-activated 
receptors (PARs), chemokine receptors (CXCRs) and the sphingosine-1-phosphate (S1P) receptor. 
These projects have afforded compounds that have proved to be of potential therapeutic interest:59 
PZ-128 targets PAR-1 for the treatment of thrombotic diseases and acute coronary syndromes;60 
ATI-2341 acts at the CXCR4, and holds promise as a new therapeutic approach for the recruitment 
of hematopoietic stem and progenitor cells before autologous bone marrow transplantation;61 and 
KRX-725 activates the S1P3 receptor, which is implicated in the pathological processes of a 
number of diseases, including sepsis and cancer (Table 4).62 Especial attention must be drawn to 
compound PZ-128, currently undergoing phase II of clinical trials. 
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Table 4. Representative pepducins of therapeutic interest. 
Pepducin Sequencea Target Indication 
PZ-128 N-pal-KKSRALF-NH2 PAR1 Acute coronary syndroms (phase II) 
ATI-2341 N-pal-MGYQKKLRSMTDKYRL-NH2 CXCR4 Recruitment of hematopoietic stem and progenitor cells 
KRX-725 N-myr-MRPYDANKR-NH2 S1P3 Corneal angiogenesis 
a: N-pal stands for palmitate and N-myr stands for myristate 
 
5. Targeting GPCR heteromers 
A GPCR heteromer can be defined as a macromolecular complex composed of at least two 
receptor units or protomers, with biochemical and pharmacological properties different from those 
of its individual components (Figure 10).63 Those clusters of more than two protomers, representing 
higher-order oligomers, are referred as receptor mosaics. 
 
 
Figure 10. Ligands targeting GPCR heterodimer complexes produce an effect 
different from that upon binding to each individual protomer on its own, displaying 
novel pharmacological properties. 
 
The term heterodimerization was first coined by Fuxe in 1993 to describe specific interactions 
between different types of GPCRs.64 Since then, the use of a wide variety of tools and techniques 
to investigate the complex pharmacology of heterodimerization has led sometimes to opposite 
results. Thus, a set of standards, grouped in three criteria, have been proposed to allow for a 
thorough and critical evaluation of heteromers:65 i) heteromer components should colocalize and 
physically interact; ii) heteromers should exhibit properties distinct from those of the protomers; iii) 
heteromer disruption should lead to a loss of heteromer-specific properties. 
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Once a concrete heteromer has been experimentally validated, one can take advantage of its 
numerous benefits related to expanded pharmacological possibilities, alteration of cell surface 
delivery and retention, modulation of G protein coupling, cross-activation or cross-inhibition of 
signalling, modification of desensitization profiles, and promotion or reduction of internalization of 
the receptor. 
A vast array of biochemical and biophysical techniques have been developed throughout the 
past years, that have allowed to validate experimentally moonlighting GPCRs heteromers, 
regardless their complicated pharmacology.66,67 Among them, the most widely spread are 
proximity-based biophysical techniques (BRET and FRET), co-immunoprecipitation, proximity 
ligation assays, radioligand binding assays and functional reconstitution. 
A large number of studies have been carried out in order to understand the pharmacology of 
heterodimeric systems both in vitro and in vivo, which may afford novel therapeutic strategies in 
drug discovery targeting GPCRs.66-69 In this regard, a high number of heteromers have been 
validated for all classes of GPCRs. Representative examples are: -opioid receptor (DOR)-MOR 
and A2AR-D2R in class A, which have been proved to be useful to study analgesia associated with 
chronic opioid use and to target Parkinson’s disease (PD) and schizophrenia, respectively;70,71 
SCTR-AT1aR in class B, important for the osmoregulatory functions in the brain;72 mGlu2R-5-HT2AR 
in class C, a promising therapeutic strategy for the treatment of psychosis;73 and Fz1-Fz2 in class 
F, linked to familial exudative vitreoretinopathy (Table 5).74 
Table 5. Representative GPCR heteromers proved to be of therapeutic interest. 
GPCR class Example(s) Indication 
A 
DOR-MOR 
A2AR-D2R 
Analgesia 
Parkinson’s disease and schizophrenia 
B SCTR-AT1aR Osmoregulation in the brain 
C mGlu2R-5-HT2AR Psychosis 
F Fz1-Fz2 Familial exudative vitreoretinopathy 
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Altogether, a wide range of novel strategies are being developed aimed at targeting GPCRs in 
order to obtain safer and more efficient medicines. Some of these new approaches have proved to 
be productive, yielding molecules currently in clinical trials or even marketed. In particular, the 
present work will focus on the development of allosteric modulators as an opportunity to develop 
ligands with higher efficacy and selectivity. The exploitation of the allosteric phenomenon could 
lead to a new approach in the process of discovering safer drugs, which could offer the maximum 
benefit while causing a lower amount of adverse effects. In this context, we propose herein the 
development of class A GPCR allosteric modulators as promising candidates that will address 
major unmet medical needs: serotoninergic 5-HT2C receptor ligands targeting obesity (Chapter A) 
and dopaminergic D1 receptor ligands in order to tackle PD (Chapter B). 
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1. INTRODUCTION AND OBJECTIVES
 
Obesity, defined as having a body mass index equal to or greater than 30 kg/m2, is a major 
global health issue affecting nearly one billion adults worldwide and this number continues to rise.1 
Obesity is a major risk factor for chronic diseases, such as diabetes, cardiovascular pathology, and 
certain cancers.2 Hence, it is widely believed that obesity will become one of the leading causes of 
morbidity and mortality for this and future generations. A wide number of strategies have been used 
to tackle obesity since 1920, when synthetic thyroid hormone was first used as treatment. However, 
most of the marketed medicines had soon to be withdrawn mainly due to safety issues. Hence, the 
pharmaceutical options available to obese patients are currently limited, and there is a major need 
for new agents that can provide a safe and effective mechanism for inducing weight loss. Obesity 
medications can be classified into four categories: antidepressants (bupropion/naltrexone, 
Contrave®), fat blockers (orlistat, Xenical®, Alli®), diabetes medication (liraglutide, Victoza®) and 
stimulants that decrease appetite by increasing metabolism (Figure 1). In particular, stimulants 
appeared on the market in the mid 1930s and have been the most used worldwide over the last 
eight decades. Today, some of them are still prescribed as anti-obesity agents (diethylpropion 
―Tenuate Dospan®–, phendimetrazine –Bontril®–, phentermine –Adipex-p®, Duromine®–, 
lorcaserin –Belviq®–, phentermine/topiramate –Qsymia®–) (Figure 1) whereas others are now 
considered as weight loss supplements (2,4-dinitrophenol or sibutramine).3 
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Figure 1. Current available medications for the treatment of obesity. 
 
Among the variety of pharmacological approaches that can be used to control body weight, 
the serotonin (5-hydroxytryptamine, 5-HT) system has long been known to be involved in the 
modulation of food intake. Serotonin-based strategies encompass 5-hydroxytryptophan as 5-HT 
precursor, selective serotonin reuptake inhibitors (SSRIs) or selective receptor agonists.4 The 
current classification of the 5-HT receptor family, which has essentially remained unchanged since 
1994,5-7 includes fourteen receptor subtypes classified into seven major classes (5-HT1-7). The 5-
HT2 class comprises three GPCR members (5-HT2A, 5-HT2B, 5-HT2C) characterized by close 
sequence homology and coupling primarily via the Gq family of G proteins to intracellular signalling 
pathways such as phospholipase C and A (PLC and PLA).8 In particular, serotonin 2C receptors 
are exclusively expressed in the CNS where they are widely distributed in different brain regions. 
There is substantial evidence supporting that their modulation may offer therapeutic benefit in 
various pathological conditions, including schizophrenia, substance addiction, and obesity.9,10 In 
this regard, the 5-HT2C receptor (5-HT2CR) is critical for the anorectic effect of serotoninergic 
activation.11 The most convincing evidence of this fact comes from mice lacking the receptor12 (5-
HT2CR knock out mice) and the reduced satiating effects observed with dexfenfluramine (5-HT 
transporter inhibitor and 5-HT release promoter) in these mutant mice.13 It is important to stand out 
that drugs targeting 5-HT2CR reduce food intake by acting on the natural satiety mechanisms, as 
measured by behavioural satiety sequence (BSS). The BSS is the name given to the behaviour in 
which, as satiety develops, initial feeding is replaced with activity, then grooming and terminates 
with a prolonged period of resting/inactivity. This sequence can be used to distinguish between 
drugs that reduce food intake via satiety and other that do so by disrupting normal feeding 
behaviour, such as hyperactivity, sedation, nausea or malaise.4 
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Stimulation of 5-HT2C receptors is the most advanced approach towards serotonin mediated 
control of food intake and associated reduction in body weight. Multiple research efforts have 
identified several promising 5-HT2CR agonists that reduce food intake and body-weight gain.14-16 In 
2012, the 5-HT2CR agonist lorcaserin (Lorqess, Belviq®) (Figure 1) was approved by the FDA as a 
first-in-class anti-obesity drug. However, selectivity in 5-HT2CR activation may be pharmacologically 
critical because of the detrimental effects of 5-HT2A and 5-HT2B receptors activation that are 
respectively associated with potential hallucinogenic effects17 and cardiac valvulopathy.8,18 Indeed, 
increased risk of cardiovascular and cardiopulmonary diseases has led to the withdrawal of non-
selective serotoninergic drugs sibutramine and dexfenfluramine from the EU and the USA markets, 
respectively,19,20 and certain restrictions apply to the use of lorcaserin as its moderate 5-HT2BR 
activity might induce major cardiac side effects.21 Clearly, further efficacy and safety data are 
needed to prove the clinical utility of 5-HT2CR ligands as anti-obesity agents. 
In this context, the development of 5-HT2CR agonists with better selectivity profiles for this 
worldwide disease would be of great value. This represents a significant challenge, as the 
molecular determinants involved in ligand recognition by 5-HT2R subtypes are highly conserved.7 
More opportunities may emerge from targeting an allosteric binding site as opposed to the 
orthosteric site of the 5-HT2CR protein (Figure 2). PAMs should elicit a more physiologically relevant 
enhancement of receptor function compared to an orthosteric agonist (see General Introduction). 
To date, only one molecule has been reported as a 5-HT2CR PAM, which was identified via 
screening of a chemical library of Pharmacia (now Pfizer).22,23 A derivative of this modulator has 
recently been reported to potentiate 5-HT2CR signalling in vivo in a drug discrimination assay,24 
though no anti-obesity properties have been described to our knowledge. Therefore, the query for 
selectively acting 5-HT2C receptor modulators as a novel strategy for the treatment of obesity is still 
active. In the present work, this objective will be approached encompassing the following aims: 
 
1. Hit(s) identification. 
2. Optimization process. 
3. In vitro characterization of optimized compound(s). 
4. Animal models of obesity. 
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Figure 2. Allosteric modulators targeting the 5-HT2CR as a novel strategy for 
the treatment of obesity. 
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2. RESULTS AND DISCUSSION
 
2.1. Hit identification: high-throughput screening 
Vivia Biotech has developed a highly sensitive method to assess activation of GPCRs. The 
proprietary ExviTech© platform is based on flow cytometry, and a functional whole cell assay is 
used to access activity by measuring calcium mobilization in response to receptor activation. Prior 
to analysis, cells are loaded with Fluo 4, a reagent that fluoresces in response to calcium 
mobilization (Figure 3). For screening, the tested compounds were added to human embryonic 
kidney (HEK)-293 cells stably expressing 5-HT2CR, and after 10 min a 25% of the maximal effective 
concentration (EC25) of serotonin, the endogenous agonist, was added. The resulting percentage of 
cells that respond was then determined. The response for each well (i.e., compound) was 
compared to control receiving only an EC25 concentration of 5-HT (Figure 3). Specificity was 
simultaneously analyzed by screening cell lines expressing close family members –5-HT2A and 5-
HT2B subtypes– using multi-parametric flow cytometry and cell tracking dyes. 
A Vivia Biotech chemical library of approximately 1600 compounds was screened on 
ExviTech platform at a concentration of 10 μM. Three compounds exhibited a potentiation (~20%) 
of the effect produced by 5-HT EC25 in cells expressing the 5-HT2CR, whereas no enhancement of 
5-HT effect was observed for 5-HT2A and 5-HT2B receptors. The three putative modulators identified 
in ExviTech platform were validated for their ability to modulate the 5-HT2CR in a functional assay 
by determining IP levels in cells, a well characterized signalling pathway of receptor activation. The 
IP assay was performed in collaboration with Prof. Mabel Loza and Dr. José Brea at Universidad 
de Santiago de Compostela. This biological analysis was conducted in Henrietta Lacks (HeLa)-K1 
cells stably expressing physiological levels of the human 5-HT2CR (5-HT2CR-HeLa). Cells were 
treated with a fixed concentration of the tested compounds (10 μM) and increasing concentrations 
of 5-HT for 20 min at 37 ºC. After that time, IP formation was quantified by homogeneous time-
resolved fluorescence energy transfer (HTRF). A 5-HT dose-response curve was obtained in the 
presence of each compound, and potentiation of the 5-HT maximal effect (Emax) was measured. In 
this manual assay compound VA240 (1) (Figure 3) potentiated the IP release induced by 5-HT, with 
a 20% of enhancement of 5-HT Emax, which supports the allosteric activity at the 5-HT2CR. Hence, 
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VA240 was selected as a starting hit for the search of new synthetic modulators of the 5-HT2CR 
through a medicinal chemistry program. 
 
 
Figure 3. High-throughput screening methodology to identify AMs of the 5-HT2CR using ExviTech platform 
and Vivia Biotech chemical library. Validation via IP-based functional assay allowed to identify hit VA240, 
which entered a medicinal chemistry program. 
 
2.2. Optimization process: from VA240 to VA012 
Starting from validated hit VA240, two series of analogs were proposed considering structural 
modifications of the pyrimidine or the phenyl ring attached to the indole scaffold (Figure 4), to 
examine their effect on functional activity and allosteric pharmacology at the 5-HT2CR. 
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Figure 4. Structural modifications proposed starting from validated hit VA240. 
 
In compounds 2-10, the phenyl ring was maintained and different nitrogen-containing 
heterocycles were introduced. In the heterocycle subunit both the number and the relative position 
Results and discussion 
57 
of the nitrogen atom(s) were modified. The synthesis of compounds 2-10 was approached through 
reductive amination starting from 1-benzyl-1H-indole-3-carbaldehyde. This reaction was performed 
following a one-pot procedure or in two steps, isolating the intermediate imine, and the best yields 
were obtained when the second protocol was used (Scheme 1). Thus, derivatives 2-5 and 9 were 
prepared via one-pot reaction of 1-benzyl-1H-indole-3-carbaldehyde with the corresponding 
pyrimidin-, pyrazin-, pyridazin-, or pyridinamine in 1,2-dichloroethane using sodium 
triacetoxyborohydride as reducing agent. In the case of compounds 6-8 and 10, condensation of 1-
benzyl-1H-indole-3-carbaldehyde with pyridazin-4-amine or the appropriate pyridinamine, catalyzed 
by para-toluenesulfonic acid in refluxing toluene, afforded the corresponding imine, which was 
isolated and subsequently reduced with sodium borohydride in methanol. 
 
Scheme 1. Reagents and conditions: (a) amino N-heterocycle, 
NaBH(OAc)3, 1,2-dichloroethane, , 8-15 h, 7-37% (2-5, 9); (b) i) 
amino N-heterocycle, p-TSA, toluene, , 5-18 h; ii) NaBH4, MeOH, 0 
ºC to rt, 1-2 h, 33-73% (6-8, 10). 
 
Synthesized compounds 2-10 were assayed for their effect on 5-HT-induced IP release in 5-
HT2CR-HeLa cells. From the data in Table 1, in general pyridyl derivatives showed better values of 
potentiation than compounds with a heterocycle bearing two nitrogen atoms. In particular, 3-pyridyl 
derivative 7 exhibited the highest potentiation (35% at 10 μM) of the endogenous agonist effect. 
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Table 1. Effect of compounds 1-10 in 5-HT-induced IP production in 5-HT2CR-HeLa cells. 
 
Compound N-heterocycle 
Potentiation 
(%)a,b 
Compound N-heterocycle 
Potentiation 
(%)a,b 
VA240 (1) 
N N
 
20 6 
N N
 
0 
2 N
N
 
0 7 
N
 
35 
3 N N
 
0 8 N
 
25 
4 N
N
 
0 9 
N
 
0 
5 N
N
 
9 10 
N
 
21 
a: Potentiation of 5-HT Emax at a fixed [compound] = 10 μM; b: Values are obtained in duplicate. 
 
We next approached the synthesis of the second series of proposed compounds 11-37, 
where 3-pyridyl moiety was maintained as N-heterocycle and the phenyl ring of compound 7 was 
replaced. In analogs 11-33 substituents of different size and electronic effects (F, Cl, Br, Me, OMe, 
CF3, CN) were introduced in the benzene ring (see Figure 4). These compounds were prepared by 
N-alkylation of the indole intermediate 38 with the appropriate benzyl bromide derivative using 
sodium hydride as base (Scheme 2). Intermediate 38 was synthesized by reductive amination of 
1H-indole-3-carbaldehyde with pyridin-3-amine, following the two-step procedure above described. 
In addition, replacement of the benzene ring with a pyridine was considered in compounds 
34-36. Also, the benzene was replaced by a cyclopropane ring in compound 37 to explore the 
requirement of aromaticity at the 1-position of the indole scaffold. In the case of pyridine-containing 
derivatives 34-36, alkylation reaction of 38 with the corresponding (bromomethyl)pyridines failed 
using sodium hydride or cesium carbonate as base, and an alternative N-alkylation-reductive 
amination sequence was followed (Scheme 2). Thus, 1H-indole-3-carbaldehyde was N-alkylated 
with the appropriate bromide derivative in the presence of cesium carbonate to yield intermediates 
39-41, which after reductive amination with pyridin-3-amine afforded final compounds 34-36. 
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Similarly, cyclopropyl derivative 37 was synthesized by reductive amination of intermediate 42, 
obtained by alkylation of 1H-indole-3-carbaldehyde with (bromomethyl)cyclopropane using sodium 
hydride as base. 
N
H
N
NH
N
R
H
O
N
H
NH
N
(a)
(b)
38 11-33
N
O
(c) or (d)
39-42
N
NH
H
34-37
R R
(a)
N
R =
R = ,
X
N
 
Scheme 2. Reagents and conditions: (a) i) pyridin-3-amine, p-TSA, toluene, , 1-6 h; ii) 
NaBH4, MeOH, 0 ºC to rt, 15-60 min, 26-91%; (b) benzyl bromide derivative, NaH, DMF, rt, 15 
min, 30-87%; (c) 2-, 3- or 4-(bromomethyl)pyridine hydrobromide, Cs2CO3, DMF, rt, 2 h, 86-
94%; (d) (bromomethyl)cyclopropane, NaH, DMF, rt, 1 h, 97%. 
 
The new set of compounds 11-37 was tested in the IP functional assay and results are shown 
in Table 2. Regarding phenyl derivatives, a substituent in meta position is in general favoured 
against ortho and para (e.g., 12, 15, 32: 22%, 26%, 22% vs 11, 14, 31: 9%, 13%, 7% and 13, 16, 
33: 6%, 7%, 7%). However, no substantial improvement of the allosteric potentiation was observed 
as all the compounds exhibited lower values than unsubstituted analog 7. The replacement of 
benzene with heterocyclic pyridine or non-aromatic cyclopropane in analogs 34-37 was also 
detrimental. Hence, compound 7 (VA012) was selected for further pharmacological characterization 
as a new PAM of the 5-HT2CR. 
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Table 2. Effect of new compounds 11-37 in 5-HT-induced IP production in 5-HT2CR-HeLa cells. 
 
Compound R Pot. (%)a,b Compound R Pot. (%)a,b 
7 (VA012) 
 
35 24 
 
7 
11 
F  
9 25 
O  
6 
12 
F
 
22 26 
O
 
0 
13 
F
 
6 27 
O
 
0 
14 
Cl  
13 28 
CF3  
8 
15 
Cl
 
26 29 
CF3
 
0 
16 
Cl
 
7 30 
CF3
 
9 
17 
Br  
6 31 
CN  
7 
18 
Br
 
7 32 
CN
 
22 
19 
Br
 
0 33 
CN
 
7 
20 
F
F
 
9 34 
N  
9 
21 
Cl
F
 
9 35 N
 
25 
22 
 
24 36 
N
 
0 
23 
 
27 37 
 
0 
a: Potentiation of 5-HT Emax at a fixed [compound] = 10 μM; b: Values are obtained in 
duplicate. 
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2.3. In vitro pharmacological characterization of VA012 
VA012 was evaluated in the 5-HT-induced IP assay at different concentrations in Chinese 
hamster ovary (CHO) cells stably expressing 5-HT2CR (5-HT2CR-CHO). Results revealed a dose-
dependent increase of 5-HT Emax, as shown in Figure 5A, reaching 35% of potentiation at 10 μM. It 
should be noted that a lower concentration of 1 μM enhanced a 28% the effect of 5-HT. The 
compound did not induce IP release in the 5-HT2CR-CHO cells in the absence of 5-HT, so it does 
not present agonist activity per se (Figure 5B). Importantly, this profile for compound VA012 was 
distinguished from that seen in 5-HT2AR-CHO (Figures 5C and 5D) and 5-HT2BR-CHO (Figures 5E 
and 5F) cells in which neither the compound in the presence of 5-HT nor alone altered IP release. 
 
Figure 5. In vitro characterization of VA012. A. 5-HT curves in the presence of increasing 
concentrations of the compound; B. Effect of the compound in the absence of 5-HT; C. Allosteric 
effect of the compound in 5-HT2AR; D. Agonist effect of the compound in 5-HT2AR; E. Allosteric effect 
of the compound in 5-HT2BR; F. Agonist effect of the compound in 5-HT2BR. 
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In addition to the selectivity exhibited over 5-HT2 subtypes, no significant off-target activities 
were observed in a CEREP cellular functional GPCR profile of VA012 (Emax<20%, Imax<80%). 
In radioligand displacement assays derivative VA012 did not compete with the endogenous 
agonist (5-HT) or other orthosteric ligands (mesulergine, LSD and clozapine), supporting its binding 
to a different site of the receptor (Table 3). Importantly, the recently published crystal structure of 5-
HT2BR in complex with LSD (PDB ID: 5TVN) revealed that this orthosteric ligand extends to 
extracellular loop 2 (ECL2) and the extracellular space.25 The higher value of displacement 
obtained for [3H]LSD (67%) in the radioligand experiment suggests an overlap of the orthosteric 
binding site with a putative allosteric pocket in the extracellular domain (ECD) of the protein. 
Table 3. Binding displacement values of VA012 at human 5-HT2CR by using 
different orthosteric radioligands. 
 Binding displacement (%) at 10 μM 
 [3H]-5-HT [3H]Mesulergine [3H]LSD [3H]Clozapine 
VA012 37 26 67 36 
 
Overall, the in vitro characterization of compound VA012 proves its pharmacological profile as 
a selective allosteric modulator or the 5-HT2CR, which supports the exploration of its activity in vivo. 
 
2.4. Behaviour of VA012 in animal models of obesity 
The in vivo experiments for compound VA012 were performed in collaboration with Prof. 
Fernando Rodríguez de Fonseca at IBIMA (Málaga). Prior to the evaluation in animal models, in 
vivo brain permeability was studied (Figure 6). Results showed a ratio of concentrations of the 
compound in brain and plasma of 3.8 after 120 min when administered intraperitoneally (ip) at a 
dose of 10 mg/kg. Importantly, this ratio was maintained quite constant up to 6 h. These data 
prompted us to evaluate the compound in animal models of obesity. 
 
Figure 6. Study of brain permeability of VA012 in vivo. Concentration of compound 
in the brain (red) and in plasma (blue). 
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In vivo experiments were performed in male Wistar obese rats and tested compounds were 
administered ip. In a first experiment, food intake was monitored upon acute administration of 
studied compound VA012 (Figure 7A). Agonist WAY161503 was also assayed as a reference 
compound of 5-HT2CR activation (Figure 7B). Both compounds induced a reduction in feeding when 
they were acutely administered at 2 mg/kg. Food intake decrease produced by agonist 
WAY161503 was more intense at the earlier times (70% inhibition at 30 min) and almost vanished 
after 4 h. However, allosteric modulator VA012 reduced feeding with a higher efficacy and with a 
more prolonged action (70% inhibition at 120 min). Importantly, the effects were not eliminated after 
ketanserin pretreatment (data not shown), indicating no contribution of the 5-HT2AR. 
 
 
Figure 7. Acute model of obesity. A. Administration of VA012; B. Administration of the 5-HT2CR 
agonist WAY161503; * denotes statistical significance (P<0.01) when compared to control/saline; 
N = at least 8 animals per group. 
 
Next, both food intake and body weight were studied in a subchronic model of obesity. When 
administered in restricted food access conditions (4 h/day), VA012 reduced both food intake 
(Figure 8A) and body weight gain (Figure 8C). Similar results were observed after seven days of 
repeated administration of the compound in continuous food access conditions, where both, daily 
food intake (Figure 8B) and body weight gain (Figure 8D) decreased. 
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Figure 8. Subchronic model of obesity. A. Monitoring of food intake in restricted food conditions; B. 
Monitoring of food intake in continuous food conditions; D. Monitoring of body weight in restricted 
food conditions; D. Monitoring of body weight in continuous food conditions; * denotes statistical 
significance (P<0.01) when compared to control/saline; N = at least 8 animals per group. 
 
In order to establish whether VA012 induced side effects, we explored the possible 
appearance of anxiety or conditioned taste aversion. In the elevated plus maze test, VA012-treated 
(2 mg/kg) rats spent less time in enclosed arms, indicating no anxiogenic effect (Figure 9A). On the 
other hand, VA012 administration did not result in taste aversion (Figure 9B), indicating that the 
compound did not induce malaise, in contrast to LiCl used as positive control. 
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Figure 9. Study of possible side effects. A. Elevated plus maze test to explore anxiety; B. 
Conditioned taste aversion test; * denotes statistical significance (P<0.01) when compared to 
control/saline; N = at least 8 animals per group. 
 
Overall, in this project we have identified compound VA012 as a PAM of the 5-HT2CR with a 
good pharmacological profile (35% of 5-HT Emax potentiation), excellent anti-obesity properties in 
animal models (2 mg/kg, ip) and no significant side effects in vivo. These results support the 
interest of a 5-HT2CR PAM as a promising therapeutic approach for the treatment of obesity. 
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3. CONCLUSIONS 
 
In the screening of a chemical library from Vivia Biotech using the ExviTech© platform, 
compound VA240 (1) was identified as a hit for the search of allosteric modulators of the 5-HT2CR 
receptor through a medicinal chemistry program. Synthesis of new compounds 2-37 based on 
structural modifications around the indole scaffold of the identified hit was carried out. Among them, 
compound 7 (VA012, 35% 5-HT Emax potentiation) exhibited enhanced allosteric activity in a dose-
dependent manner, no significant off-target activities, no competition with the endogenous agonist 
5-HT or other orthosteric ligands, and a favourable brain/plasma ratio in rats ([brain]/[plasma] = 3.8 
at 10 mg/kg, ip). The compound was found to be very active in feeding models in rodents, reducing 
both food intake and body weight gain without inducing CNS-related malaise when administered 
either acutely or subchronically (2 mg/kg, ip). Thus, the new 5-HT2CR PAM identified in this work, 
VA012, represents a promising candidate for drug development as a putative anti-obesity agent. 
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Unless otherwise stated, the starting materials, reagents, and solvents were purchased as 
high-grade commercial products from Sigma-Aldrich, Acros, ABCR, Fluorochem, Scharlab, or 
Panreac. 
Analytical thin-layer chromatography (TLC) was run on Merck silica gel plates (Kieselgel 60 F-
254), with detection by UV light ( = 254 nm), 5% ninhydrin solution in ethanol or 10% 
phosphomolybdic acid solution in ethanol. Unless otherwise stated, products were purified by flash 
chromatography using a VARIAN 971-FP system with cartridges of silica gel (Varian, particle size 
50 μm). 
All compounds were obtained as oils, except for those whose melting points (m.p.) are 
indicated, which were solids. M.p. (uncorrected) were determined on a Stuart Scientific 
electrothermal apparatus. Infrared (IR) spectra were measured on a Bruker Tensor 27 instrument 
equipped with a Specac ATR accessory of 5200-650 cm-1 transmission range; frequencies () are 
expressed in cm-1. 1H-, 13C- and 19F-NMR spectra were recorded on a Bruker Avance 500 MHz (1H, 
500 MHz; 13C, 125 MHz) or Bruker DPX 300 MHz (1H, 300 MHz; 13C, 75 MHz; 19F, 300 MHz) 
instrument at room temperature (rt) at the Universidad Complutense de Madrid (UCM) NMR core 
facility. Bruker DPX 300 MHz equipment was used unless otherwise stated. Chemical shifts () are 
expressed in parts per million relative to the residual solvent peak for 1H and 13C nucleus (CDCl3: 
H = 7.26, C = 77.16; DMSO-d6: H = 2.50, C = 39.52) and to internal (trifluoromethyl)benzene for 
19F nucleus; coupling constants (J) are in hertz (Hz). The following abbreviations are used to 
describe peak patterns when appropriate: s (singlet), d (doublet), t (triplet), q (quartet), qt (quintet), 
m (multiplet), app (apparent), and br (broad). 2D NMR experiments –homonuclear correlation 
spectroscopy (H,H-COSY), heteronuclear multiple quantum correlation (HMQC) and heteronuclear 
multiple bond correlation (HMBC)– of representative compounds were acquired to assign protons 
and carbons of new structures. 
For all final compounds, purity was determined by high-performance liquid chromatography 
(HPLC) coupled to mass spectrometry (MS) using an Agilent 1200LC-MSD VL instrument, and 
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satisfactory chromatograms confirmed a purity of at least 95% for all tested compounds. LC 
separation was achieved with a SunFire C18 column (3.5 μm, 2.1 mm x 100 mm), together with a 
guard column (5 μm, 4.6 mm x 12.5 mm). The mobile phase consisted of A (1:1 ACN/methanol) 
and B (5 mM NH4OH pH 7), and the gradient is indicated in Table 4. MS analysis was performed 
with an ESI source. The capillary voltage was set to 3.0 kV and the fragmentor voltage was set at 
72 eV. The drying gas temperature was 350 ºC, the drying gas flow was 10 L/min, and the 
nebulizer pressure was 20 psi. Spectra were acquired in positive or negative ionization mode from 
80 to 800 m/z and in UV-mode at four different wavelengths (210, 230, 254, and 280 nm). 
IUPAC rules have been followed for naming all organic compounds. 
Table 4. HPLC gracient. 
t (min) %B 
0 90 
3 90 
20 5 
30 5 
 
4.1. General synthetic procedures 
General procedure A: one-pot reductive amination. To a suspension of 1-benzyl-1H-
indole-3-carbaldehyde (1.0 equiv) and NaBH(OAc)3 (3.0 equiv) in anhydrous 1,2-dichloroethane 
(10 mL/mmol), the corresponding amino N-heterocycle (2.5 equiv) was added under an argon 
atmosphere and the reaction was refluxed for 8-15 h. After this time, the mixture was allowed to 
reach rt, and it was diluted with DCM and washed with water. The organic layer was dried over 
Na2SO4, filtered and concentrated. The crude was purified by flash chromatography (some of them 
were slurred with hexane afterwards) to afford the final compounds 2-5, 9. 
General procedure B: reductive amination in two steps. p-Toluenesulfonic acid (0.1 equiv) 
was added to a solution of 1H-indole-3-carbaldehyde, 1-benzyl-1H-indole-3-carbaldehyde or 
intermediates 39-42 (1.0 equiv) and the corresponding amino N-heterocycle (1.2 equiv) in 
anhydrous toluene (8 mL/mmol) under an argon atmosphere. The reaction mixture was refluxed for 
1-18 h using a Dean-Stark equipment to remove water from the reaction medium. Solvent was 
concentrated off to afford the corresponding imine, which was used in the next step without further 
purification. 
NaBH4 (2.5 eq) was added portion-wise to a 0 ºC cooled solution of the previous imine in 
methanol (8 mL/mmol). The reaction was allowed to warm up to rt and stirred for 0.25-2 h. Then, 
the mixture was poured into brine, extracted with DCM (x2) and washed with water. The organic 
layer was dried over Na2SO4, filtered and concentrated. The crude was purified by flash 
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chromatography (some of them were slurred with hexane afterwards) to afford intermediate 38 or 
final compounds 6-8, 10, 34-37. 
General procedure C: N-alkylation reaction using sodium hydride. To a solution of 1H-
indole-3-carbaldehyde or 38 (1.0 equiv) in anhydrous DMF (15 mL/mmol) under an argon 
atmosphere, sodium hydride (60% suspension in mineral oil, 1.2 equiv) was added. The mixture 
was stirred at rt for 15 min and the corresponding bromoderivative (1.2 equiv) was added. The 
reaction was stirred at rt for 15-60 min, and then it was poured into brine and extracted with Et2O. 
The organic layer was washed with water, dried over Na2SO4, filtered and concentrated. The 
residue was used in the next step without further purification in the case of intermediate 42 and 
purified by flash chromatography (some of them were slurred with hexane afterwards) to afford final 
compounds 11-33. 
General procedure D: N-alkylation reaction using Cs2CO3. To a solution of 1H-indole-3-
carbaldehyde (1.0 equiv) and the corresponding (bromomethyl)pyridine hydrobromide (1.2 equiv) in 
anhydrous DMF (15 mL/mmol) under an argon atmosphere, Cs2CO3 (3.0 equiv) was added. The 
reaction was stirred at rt for 2 h. Then the mixture was poured into water, and extracted with DCM 
(x2). The combined organic layers were dried over Na2SO4, filtered and concentrated. DMF was 
removed under high vacuum, and the products 39-41 were used in the next step without further 
purification. 
 
4.2. Final compounds 2-10 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyrimidin-4-amine, 2. Following general procedure A, 
compound 2 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (300 mg, 1.28 mmol) and 
pyrimidin-4-amine (244 mg, 2.56 mmol) as an off-white solid (40 mg, 10%). Chromatography: 
hexane/EtOAc from 1:1 to 3:7 (then slurred with hexane). 
 
M.p.: 138-139 ºC. Rf: 0.34 (hexane/EtOAc 2:8). IR (ATR):  3249 (NH), 1600, 1506, 1462 
(Ar). 1H-NMR (CDCl3, 500 MHz):  4.69 (s, 2H, CH2NH), 5.16 (br s, 1H, NH), 5.30 (s, 2H, NCH2), 
6.36 (d, J = 5.4, 1H, H5), 7.10-7.17 (m, 4H, H2’, H5’, H2’’, H6’’), 7.22 (t, J = 8.1, 1H, H6’), 7.27-7.32 (m, 
4H, H7’, 3CHPh), 7.63 (d, J = 7.9, 1H, H4’), 8.17 (d, J = 5.7, 1H, H6), 8.61 (s, 1H, H2). 13C-NMR 
(CDCl3, 125 MHz):  37.3 (CH2NH), 50.2 (NCH2), 110.2 (C7’), 111.5 (C3’), 119.1 (C4’), 119.9 (C5’), 
122.6 (C6’), 127.0 (C2’’, C6’’), 127.1 (C2’), 127.2 (C3a), 127.9 (C4’’), 129.0 (C3’’, C5’’), 137.0 (C7a), 137.3 
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(C1’’), 155.5 (br s, C6), 158.9 (C2), 161.9 (C4), C5 not observed. HPLC (tR, min): 17.65. MS (ESI, 
m/z, %): 315.2 ([M + H]+, 100). 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyrimidin-2-amine, 3. Following general procedure A, 
compound 3 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (250 mg, 1.06 mmol) and 
pyrimidin-2-amine (202 mg, 2.12 mmol) as a pink solid (22 mg, 7%). Chromatography: 
hexane/EtOAc 7:3. 
 
M.p.: 111-112 ºC. Rf: 0.24 (hexane/EtOAc 7:3). IR (ATR):  3256 (NH), 1592, 1529, 1458 
(Ar). 1H-NMR (CDCl3, 500 MHz):  4.78 (d, J = 5.1, 2H, CH2NH), 5.29 (s, 2H, NCH2), 5.32 (s, 1H, 
NH), 6.54 (t, J = 4.8, 1H, H5), 7.12-7.14 (m, 4H, H2’, H5’, H2’’, H6’’), 7.19 (t, J = 7.3, 1H, H6’), 7.28-
7.32 (m, 4H, H7’, 3CHPh), 7.68 (d, J = 7.9, 1H, H4’), 8.31 (d, J = 3.9, 2H, H4, H6). 13C-NMR (CDCl3, 
125 MHz):  37.4 (CH2NH), 50.2 (NCH2), 110.0 (C5), 110.7 (C7’), 112.8 (C3’), 119.4 (C4’), 119.7 
(C5’), 122.3 (C6’), 126.9 (C2’), 127.0 (C2’’, C6’’), 127.5 (C3a), 127.8 (C4’’), 128.9 (C3’’, C5’’), 137.0 (C7a), 
137.5 (C1’’), 158.2 (C4, C6), 162.4 (C2). HPLC (tR, min): 18.65. MS (ESI, m/z, %): 315.2 ([M + H]+, 
100). 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyrazin-2-amine, 4. Following general procedure A, 
compound 4 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (250 mg, 1.06 mmol) and 
pyrazin-2-amine (202 mg, 2.12 mmol) as a brown solid (44 mg, 13%). Chromatography: 
hexane/EtOAc 1:1. 
 
M.p.: 108-109 ºC. Rf: 0.26 (hexane/EtOAc 6:4). IR (ATR):  3405 (NH), 1589, 1515, 1466 
(Ar). 1H-NMR (CDCl3):  4.70 (d, J = 4.9, 2H, CH2NH), 4.79 (br s, 1H, NH), 5.30 (s, 2H, NCH2), 
7.12-7.17 (m, 4H, H2’, H5’, H2’’, H5’’), 7.22 (td, J = 8.1, 1.0, 1H, H6’), 7.29-7.32 (m, 4H, H7’, 3CHPh), 
7.66 (d, J = 7.7, 1H, H4’), 7.82 (d, J = 2.8, 1H, H6), 7.89 (d, J = 1.3, 1H, H3), 8.04 (dd, J = 2.7, 1.5, 
1H, H5). 13C-NMR (CDCl3):  37.4 (CH2NH), 50.2 (NCH2), 110.1 (C7’), 112.2 (C3’), 119.2 (C4’), 119.8 
(C5’), 122.4 (C6’), 127.0 (C2’’, C6’’), 127.2 (C2’), 127.4 (C3a), 127.9 (C4’’), 129.0 (C3’’, C5’’), 132.5 (C5), 
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132.9 (C3), 137.0 (C7a), 137.3 (C1’’), 142.1 (C6), 154.6 (C2). HPLC (tR, min): 18.46. MS (ESI, m/z, 
%): 315.2 ([M + H]+, 100). 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyridazin-3-amine, 5. Following general procedure A, 
compound 5 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (390 mg, 1.66 mmol) and 
pyridazin-3-amine (316 mg, 3.32 mmol) as an off-white solid (40 mg, 8%). Chromatography: 
DCM/methanol 96:4. 
 
M.p.: 152-153 ºC. Rf: 0.27 (DCM/methanol 95:5). IR (ATR):  3248 (NH), 1598, 1509, 1467 
(Ar). 1H-NMR (CDCl3):  4.69 (d, J = 4.4, 2H, CH2NH), 5.19 (br s, 1H, NH), 5.30 (s, 2H, NCH2), 6.35 
(d, J = 5.8, 1H, H4), 7.09-7.16 (m, 4H, H2’, H5’, H2’’, H6’’), 7.19-7.25 (m, 1H, H6’), 7.29-7.35 (m, 4H, 
H7’, 3CHPh), 7.63 (d, J = 7.7, 1H, H4’), 8.16 (d, J = 4.9, 1H, H5), 8.60 (app s, 1H, H6). 13C-NMR 
(CDCl3):  37.2 (CH2NH), 50.2 (NCH2), 110.2 (C7’), 111.5 (C3’), 119.1 (C4’), 119.9 (C5’), 122.5 (C6’), 
127.0 (C2’’, C6’’), 127.1 (C2’), 127.2 (C3a), 127.9 (C4’’), 129.0 (C3’’, C5’’), 137.0 (C7a), 137.3 (C1’’), 155.3 
(C5), 158.8 (C6), 161.8 (C3), C4 not observed. HPLC (tR, min): 17.70. MS (ESI, m/z, %): 315.2 ([M + 
H]+, 100). 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyridazin-4-amine, 6. Following general procedure B, 
compound 6 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (380 mg, 1.62 mmol) and 
pyridazin-4-amine (185 mg, 1.94 mmol) as a brown solid (220 mg, 43%). Chromatography: 
DCM/methanol from 99:1 to 95:5 (then slurred with DCM/Et2O). 
 
M.p.: >208 ºC (decomp.). Rf: 0.26 (hexane/EtOAc 2:8). IR (ATR):  3420 (NH), 1592, 1462 
(Ar). 1H-NMR (DMSO-d6):  4.08 (s, 1H, NH), 4.45 (d, J = 5.2, 2H, CH2NH), 5.38 (s, 2H, NCH2), 
6.70 (dd, J = 6.1, 3.0, 1H, H5), 7.03 (app t, J = 7.3, 1H, H5’), 7.09-7.14 (m, 1H, H6’), 7.17-7.34 (m, 
5H, 5CHPh), 7.44 (d, J = 8.1, 1H, H7’), 7.55 (s, 1H, H2’), 7.62 (d, J = 7.7, 1H, H4’), 8.48 (d, J = 6.1, 
1H, H6), 8.62 (d, J = 2.6, 1H, H3). 13C-NMR (DMSO-d6):  37.0 (CH2NH), 49.0 (NCH2), 104.7 (br s, 
C5), 110.3 (C7’), 110.6 (C3’), 119.0 (C4’), 119.1 (C5’), 121.6 (C6’), 127.1 (C2’’, C6’’), 127.4 (C2’, C3a), 
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128.1 (C4’’), 128.5 (C3’’, C5’’), 136.3 (C7a), 138.3 (C1’’), 141.1 (C3), 145.4 (C4), 149.8 (C6). HPLC (tR, 
min): 17.10. MS (ESI, m/z, %): 315.2 ([M + H]+, 100). 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyridin-3-amine, 7 (VA012). Following general 
procedure B, compound 7 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (500 mg, 2.12 
mmol) and pyridin-3-amine (239 mg, 2.54 mmol) as a white solid (488 mg, 73%). Chromatography: 
hexane/EtOAc from 1:1 to 3:7. 
 
M.p.: 159-160 ºC. Rf: 0.31 (hexane/EtOAc 2:8). IR (ATR):  3398 (NH), 1585, 1471, 1332 
(Ar). 1H-NMR (CDCl3):  3.96 (br s, 1H, NH), 4.48 (d, J = 4.1, 2H, CH2NH), 5.30 (s, 2H, NCH2), 6.96 
(ddd, J = 8.2, 2.7, 1.2, 1H, H4), 7.08-7.33 (m, 10H, H5, 4CHindole, 5CHPh), 7.67 (d, J = 7.7, 1H, H4’), 
7.99 (d, J = 4.5, 1H, H6), 8.10 (d, J = 2.5, 1H, H2). 13C-NMR (CDCl3):  39.8 (CH2NH), 50.2 (NCH2), 
110.1 (C7’), 112.3 (C3’), 118.7 (C4), 119.2 (C4’), 119.8 (C5’), 122.4 (C6’), 123.8 (C5), 127.0 (C2’’,C6’’), 
127.1 (C2’), 127.4 (C3a), 127.9 (C4’’), 128.9 (C3’’, C5’’), 136.3 (C2), 137.0 (C7a), 137.4 (C1’’), 138.9 (C6), 
144.4 (C3). HPLC (tR, min): 19.67. MS (ESI, m/z, %) 314.4 ([M + H]+, 100). 
N-[(1-Benzyl-1H-indol-3-yl)methyl]pyridin-2-amine, 8. Following general procedure B, 
compound 8 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (510 mg, 2.17 mmol) and 
pyridin-2-amine (249 mg, 2.64 mmol) as a white solid (236 mg, 35%). Chromatography: 
hexane/EtOAc from 8:2 to 7:3 (then slurred with hexane). 
 
M.p.: 115-116 ºC. Rf: 0.31 (hexane/EtOAc 7:3). IR (ATR):  3417 (NH), 1599, 1495, 1466 
(Ar). 1H-NMR (CDCl3):  4.66 (d, J = 4.7, 2H, CH2NH), 4.70 (br s, 1H, NH), 5.29 (s, 2H, NCH2), 6.44 
(d, J = 8.4, 1H, H3), 6.60 (dd, J = 6.7, 5.5, 1H, H5), 7.11-7.16 (m, 4H, H2’, H5’, H2’’, H6’’), 7.18-7.23 
(m, 1H, H6’), 7.26-7.31 (m, 4H, H7’, 3CHPh), 7.39-7.45 (m, 1H, H4), 7.68 (d, J = 7.7, 1H, H4’), 8.14 
(dd, J = 5.0, 1.0, 1H, H6). 13C-NMR (CDCl3):  38.2 (CH2NH), 50.1 (NCH2), 107.2 (C3), 110.0 (C7’), 
112.9 (C3’), 113.0 (C5), 119.3 (C4’), 119.6 (C5’), 122.3 (C6’), 126.9 (C2’), 127.0 (C2’’, C6’’), 127.5 (C3a), 
127.8 (C4’’), 128.9 (C3’’, C5’’), 137.0 (C7a), 137.4 (C4), 137.5 (C1’’), 148.3 (C6), 158.9 (C2). HPLC (tR, 
min): 19.35. MS (ESI, m/z, %): 314.3 ([M + H]+, 100). 
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N-[(1-Benzyl-1H-indol-3-yl)methyl]-2-methylpyridin-3-amine, 9. Following general 
procedure A, compound 9 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (1.09 g, 4.63 
mmol) and 2-methylpyridin-3-amine (1.00 g, 9.25 mmol) as a yellow solid (318 mg, 21%). 
Chromatography: hexane/EtOAc from 1:1 to 3:7. 
 
M.p.: 107-108 ºC. Rf: 0.34 (hexane/EtOAc 2:8). IR (ATR):  3425 (NH), 1582, 1494, 1465 
(Ar). 1H-NMR (CDCl3):  2.36 (s, 3H, CH3), 3.77 (br s, 1H, NH), 4.49 (s, 2H, CH2NH), 5.31 (s, 2H, 
NCH2), 6.99 (dd, J = 8.1, 1.2, 1H, H4), 7.10 (dd, J = 8.1, 4.7, 1H, H5), 7.13-7.19 (m, 4H, H2’, H5’, H2’’, 
H6’’), 7.21-7.34 (m, 5H, H6’, H7’, 3CHPh), 7.69 (d, J = 7.6, 1H, H4’), 7.91 (dd, J = 4.7, 1.3, 1H, H6). 
13C-NMR (CDCl3):  20.6 (CH3), 39.9 (CH2NH), 50.2 (NCH2), 110.2 (C7’), 112.3 (C3’), 115.9 (C4), 
119.2 (C4’), 119.8 (C5’), 122.2 (C5), 122.4 (C6’), 127.0 (C2’’, C6’’), 127.1 (C2’), 127.5 (C3a), 127.9 (C4’’), 
128.9 (C3’’, C5’’), 137.0 (C7a), 137.2 (C6), 137.4 (C1’’), 142.4 (C2), 143.9 (C3). HPLC (tR, min): 19.41. 
MS (ESI, m/z, %): 328.3 ([M + H]+, 100). 
N-[(1-Benzyl-1H-indol-3-yl)methyl]-4-methylpyridin-3-amine, 10. Following general 
procedure B, compound 10 was obtained from 1-benzyl-1H-indole-3-carbaldehyde (500 mg, 2.12 
mmol) and 4-methylpyridin-3-amine (280 mg, 2.59 mmol) as a white solid (230 mg, 33%). 
Chromatography: hexane/EtOAc from 1:1 to 4:6 (then slurred with hexane/Et2O). 
 
M.p.: 112-113 ºC. Rf: 0.30 (hexane/EtOAc 2:8). IR (ATR):  3421 (NH), 1567, 1512, 1467 
(Ar). 1H-NMR (CDCl3):  2.09 (s, 3H, CH3), 3.66 (br s, 1H, NH), 4.56 (d, J = 3.7, 2H, CH2NH), 5.31 
(s, 2H, NCH2), 6.97 (d, J = 4.7, 1H, H5), 7.14-7.18 (m, 4H, H2’, H5’, H2’’, H6’’), 7.70 (td, J = 8.1, 1.1, 
1H, H6’), 7.27-7.35 (m, 4H, H7’, 3CHPh), 7.70 (d, J = 7.8, 1H, H4’), 7.96 (d, J = 4.7, 1H, H6), 8.16 (s, 
1H, H2). 13C-NMR (CDCl3):  17.1 (CH3), 40.1 (CH2NH), 50.2 (NCH2), 110.1 (C7’), 112.5 (C3’), 119.2 
(C4’), 119.8 (C5’), 122.4 (C6’), 124.9 (C5), 127.0 (C2’’, C6’’), 127.2 (C2’), 127.5 (C3a), 127.9 (C4’’), 129.0 
(C3’’, C5’’), 130.3 (C4), 132.2 (C2), 137.0 (C7a), 137.3 (C1’’), 139.3 (C6), 142.7 (C3). HPLC (tR, min): 
19.15. MS (ESI, m/z, %): 328.3 ([M + H]+, 100). 
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4.3. Final compounds 11-37 
N-(1H-Indol-3-ylmethyl)pyridin-3-amine, 38. Following general procedure B, compound 38 
was obtained from 1H-indole-3-carbaldehyde (4.00 g, 27.6 mmol) and pyridine-3-amine (3.20 g, 
34.0 mmol) as a pale yellow-colored foam (5.63 g, 91%). Chromatography: 6:4 hexane/EtOAc to 
EtOAc. 
 
1H-NMR (CDCl3):  3.97 (br s, 1H, NH), 4.50 (d, J = 3.0, 2H, CH2), 6.96 (m, 1H, H4), 7.07-7.28 
(m, 4H, H5, 3CHindole), 7.41 (m, 1H, H7’), 7.66 (d, J = 7.7, 1H, H4’), 7.98 (d, J = 4.6, 1H, H6), 8.10 (d, 
J = 3.6, 1H, H2), 8.25 (br s, 1H, NH). MS (ESI, m/z, %): 224.0 ([M + H]+, 100). 
N-{[1-(4-Fluorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 11. Following general 
procedure C, compound 11 was obtained from 38 (301 mg, 1.35 mmol) and 1-(bromomethyl)-4-
fluorobenzene (306 mg, 1.62 mmol) as a white solid (125 mg, 30%). Chromatography: 
hexane/EtOAc from 6:4 to 2:8. 
 
M.p.: 125-126 ºC. Rf: 0.23 (hexane/EtOAc 2:8). IR (ATR):  3405 (NH), 1589, 1509, 1467 
(Ar), 1222 (C-F). 1H-NMR (CDCl3, 500 MHz):  4.06 (br s, 1H, NH), 4.49 (s, 2H, CH2NH), 5.26 (s, 
2H, NCH2), 6.97-7.01 (m, 3H, H4, H3’’, H5’’), 7.08-7.12 (m, 4H, H5, H2’, H2’’, H6’’), 7.15 (ddd, J = 8.0, 
7.0, 1.1, 1H, H5’), 7.22 (app td, J = 7.7, 1.2, 1H, H6’), 7.28 (d, J = 8.2, 1H, H7’), 7.66 (d, J = 7.8, 1H, 
H4’), 7.99 (br s, 1H, H6), 8.13 (br s, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.8 (CH2NH), 49.5 
(NCH2), 110.0 (C7’), 112.5 (C3’), 115.9 (d, J = 21.5, C3’’, C5’’), 119.1 (C4), 119.3 (C4’), 119.9 (C5’), 
122.6 (C6’), 124.0 (C5), 126.8 (C2’), 127.4 (C3a), 128.6 (d, J = 7.5, C2’’, C6’’), 133.1 (d, J = 3.2, C1’’), 
135.7 (C2), 136.9 (C7a), 138.4 (C6), 144.5 (C3), 162.4 (d, J = 245.0, C4’’). 19F-NMR (CDCl3):  -114.8. 
HPLC (tR, min): 19.00. MS (ESI, m/z, %): 332.1 ([M + H]+, 100). 
N-{[1-(3-Fluorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 12. Following general 
procedure C, compound 12 was obtained from 38 (303 mg, 1.36 mmol) and 1-(bromomethyl)-3-
fluorobenzene (308 mg, 1.63 mmol) as an off-white solid (168 mg, 37%). Chromatography: 
hexane/EtOAc from 6:4 to 2:8. 
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M.p.: 137-138 ºC. Rf: 0.26 (hexane/EtOAc 2:8). IR (ATR):  3402 (NH), 1587, 1476 (Ar), 1249 
(C-F). 1H-NMR (CDCl3, 500 MHz):  3.97 (br s, 1H, NH), 4.50 (d, J = 3.7, 2H, CH2NH), 5.29 (s, 2H, 
NCH2), 6.78 (app d, J = 9.5, 1H, H2’’), 6.90 (dd, J = 7.6, 0.5, 1H, H6’’), 6.94-6.98 (m, 2H, H4, H4’’), 
7.10 (dd, J = 7.7, 4.6, 1H, H5), 7.12 (s, 1H, H2’), 7.16 (ddd, J = 8.0, 7.3, 1.1, 1H, H5’), 7.21-7.29 (m, 
3H, H6’, H7’, H5’’), 7.67 (d, J = 7.8, 1H, H4’), 7.99 (d, J = 4.7, 0.9, 1H, H6), 8.11 (d, J = 2.7, 1H, H2). 
13C-NMR (CDCl3, 125 MHz):  39.8 (CH2NH), 49.7 (d, J =1.9, NCH2), 110.0 (C7’), 112.8 (C3’), 113.9 
(d, J = 21.9, C2’’), 114.8 (d, J = 21.0, C4’’), 118.7 (C4), 119.3 (C4’), 120.0 (C5’), 122.4 (d, J = 2.9, C6’’), 
122.6 (C6’), 123.8 (C5), 126.8 (C2’), 127.4 (C3a), 130.5 (d, J = 8.4, C5’’), 136.3 (C2), 136.9 (C7a), 
139.0 (C6), 140.1 (d, J = 6.7, C1’’), 144.4 (C3), 163.2 (d, J = 245.4, C3’’). 19F-NMR (CDCl3):  -112.6. 
HPLC (tR, min): 18.89. MS (ESI, m/z, %): 332.1 ([M + H]+, 100). 
N-{[1-(2-Fluorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 13. Following general 
procedure C, compound 13 was obtained from 38 (260 mg, 1.16 mmol) and 1-(bromomethyl)-2-
fluorobenzene (263 mg, 1.39 mmol) as an off-white solid (157 mg, 41%). Chromatography: 
hexane/EtOAc from 6:4 to 2:8. 
 
M.p.: 154-155 ºC. Rf: 0.28 (hexane/EtOAc 2:8). IR (ATR):  3399 (NH), 1586, 1488, 1464 
(Ar), 1233 (C-F). 1H-NMR (CDCl3, 500 MHz):  3.95 (br s, 1H, NH), 4.48 (s, 2H, CH2NH), 5.34 (s, 
2H, NCH2), 6.91 (td, J = 7.7, 1.5, 1H, H6’’), 6.96 (ddd, J = 8.3, 3.0, 1.2, 1H, H4), 7.02 (td, J = 7.6, 
0.9, 1H, H5’’), 7.09 (t, J = 8.7, 1H, H3’’), 7.10 (dd, J = 8.2, 4.1, 1H, H5), 7.14-7.17 (m, 2H, H2’, H5’), 
7.22-7.27 (m, 2H, H6’, H4’’), 7.36 (d, J = 8.3, 1H, H7’), 7.66 (d, J = 7.9, 1H, H4’), 7.99 (d, J = 4.7, 1.1, 
1H, H6), 8.12 (d, J = 2.7, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.8 (CH2NH), 43.9 (d, J = 4.8, 
NCH2), 110.0 (C7’), 112.6 (C3’), 115.7 (d, J = 20.8, C3’’), 118.7 (C4), 119.2 (C4’), 119.9 (C5’), 122.5 
(C6’), 123.8 (C5), 124.5 (d, J = 14.6, C1’’), 124.6 (d, J = 3.5, C5’’), 127.0 (C2’), 127.4 (C3a), 129.2 (d, J 
= 3.8, C6’’), 129.7 (d, J = 8.1, C4’’), 136.3 (C2), 136.9 (C7a), 139.0 (C6), 144.4 (C3), 160.5 (d, J = 
245.1, C2’’). 19F-NMR (CDCl3):  -118.6. HPLC (tR, min): 19.08. MS (ESI, m/z, %): 332.1 ([M + H]+, 
100). 
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N-{[1-(4-Chlorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 14. Following general 
procedure C, compound 14 was obtained from 38 (300 mg, 1.34 mmol) and 1-(bromomethyl)-4-
chlorobenzene (340 mg, 1.66 mmol) as an off-white solid (326 mg, 70%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
 
M.p.: 152-153 ºC. Rf: 0.26 (hexane/EtOAc 2:8). IR (ATR):  3267 (NH), 1586, 1488, 1471 
(Ar). 1H-NMR (CDCl3):  3.99 (br s, 1H, NH), 4.50 (s, 2H, CH2NH), 5.27 (s, 2H, NCH2), 6.97 (ddd, J 
= 8.3, 2.9, 1.3, 1H, H4), 7.04 (d, J = 8.5, 2H, H2’’, H6’’), 7.09-7.30 (m, 7H, H5, 4CHindole, H3’’, H5’’), 7.71 
(app dt, J = 7.7, 1.0, 1H, H4’), 8.00 (dd, J = 4.6, 1.1, 1H, H6), 8.12 (d, J = 2.7, 1H, H2). 13C-NMR 
(CDCl3):  39.8 (CH2NH), 49.6 (NCH2), 110.0 (C7’), 112.7 (C3’), 118.8 (C4), 119.3 (C4’), 120.0 (C5’), 
122.6 (C6’), 123.9 (C5), 126.8 (C2’), 127.4 (C3a), 128.3 (C2’’, C6’’), 129.1 (C3’’, C5’’), 133.7 (C4’’), 135.9 
(C1’’), 136.2 (C2), 136.9 (C7a), 138.9 (C6), 144.4 (C3). HPLC (tR, min): 19.79. MS (ESI, m/z, %): 
348.2 ([M(35Cl) + H]+, 100), 350.2 ([M(37Cl) + H]+, 35). 
N-{[1-(3-Chlorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 15. Following general 
procedure C, compound 15 was obtained from 38 (260 mg, 1.16 mmol) and 1-(bromomethyl)-3-
chlorobenzene (288 mg, 1.40 mmol) as a white solid (247 mg, 61%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
 
M.p.: 136-137 ºC. Rf: 0.26 (hexane/EtOAc 2:8). IR (ATR):  3398 (NH), 1588, 1481, 1466 
(Ar). 1H-NMR (CDCl3):  3.99 (br s, 1H, NH), 4.50 (d, J = 2.7, 2H, CH2NH), 5.26 (s, 2H, NCH2), 
6.94-6.98 (m, 2H, H4, H6’’), 7.08-7.29 (m, 8H, H5, 4CHindole, 3CHPh), 7.67 (d, J = 7.7, 1H, H4’), 7.99 
(dd, J = 4.6, 0.8, 1H, H6), 8.11 (d, J = 2.8, 1H, H2). 13C-NMR (CDCl3):  39.8 (CH2NH), 49.6 (NCH2), 
110.0 (C7’), 112.8 (C3’), 118.7 (C4), 119.3 (C4’), 120.0 (C5’), 122.6 (C6’), 123.9 (C5), 125.0 (C6’’), 
126.9, 127.0 (C2’, C2’’), 127.4 (C3a), 128.1 (C5’’), 130.3 (C4’’), 134.9 (C3’’), 136.2 (C2), 136.9 (C7a), 
139.0 (C6), 139.5 (C1’’), 144.4 (C3). HPLC (tR, min): 19.77. MS (ESI, m/z, %): 348.2 ([M(35Cl) + H]+, 
100), 350.2 ([M(37Cl) + H]+, 37). 
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N-{[1-(2-Chlorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 16. Following general 
procedure C, compound 16 was obtained from 38 (300 mg, 1.34 mmol) and 1-(bromomethyl)-2-
chlorobenzene (386 mg, 1.88 mmol) as a white solid (295 mg, 63%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
 
M.p.: 143-144 ºC. Rf: 0.27 (hexane/EtOAc 2:8). IR (ATR):  3269 (NH), 1589, 1481, 1466 
(Ar). 1H-NMR (CDCl3):  3.98 (br s, 1H, NH), 4.50 (d, J = 4.0, 2H, CH2NH), 5.39 (s, 2H, NCH2), 6.64 
(dd, J = 7.7, 1.6, 1H, H6’’), 6.97 (ddd, J = 8.3, 2.9, 1.4, 1H, H4), 7.08-7.28 (m, 7H, H5, 4CHindole, H4’’, 
H5’’), 7.41 (dd, J = 8.0, 1.3, 1H, H3’’), 7.68 (app d, J = 7.4, 1H, H4’), 7.98 (dd, J = 4.7, 1.4, 1H, H6), 
8.11 (d, J = 2.8, 1H, H2). 13C-NMR (CDCl3):  39.8 (CH2NH), 47.8 (NCH2), 110.1 (C7’), 112.7 (C3’), 
118.7 (C4), 119.3 (C4’), 120.0 (C5’), 122.6 (C6’), 123.8 (C5), 127.1 (C2’), 127.3 (C3a), 127.4 (C5’’), 
128.2 (C6’’), 129.1 (C4’’), 129.7 (C3’’), 132.6 (C2’’), 135.0 (C1’’), 136.2 (C2), 137.0 (C7a), 139.0 (C6), 
144.4 (C3). HPLC (tR, min): 20.08. MS (ESI, m/z, %): 348.4 ([M(35Cl) + H]+, 100), 350.4 ([M(37Cl) + 
H]+, 32). 
N-{[1-(4-Bromobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 17. Following general 
procedure C, compound 17 was obtained from 38 (262 mg, 1.17 mmol) and 1-bromo-4-
(bromomethyl)benzene (350 mg, 1.40 mmol) as a white solid (322 mg, 70%). Chromatography: 
hexane/EtOAc from 8:2 to 2:8. 
 
M.p.: 156-157 ºC. Rf: 0.27 (hexane/EtOAc 2:8). IR (ATR):  3403 (NH), 1588, 1486, 1467 
(Ar). 1H-NMR (CDCl3):  3.97 (br s, 1H, NH), 4.49 (d, J = 3.1, 2H, CH2NH), 5.24 (s, 2H, NCH2), 
6.94-6.96 (m, 1H, H4), 6.97 (d, J = 8.4, 2H, H2’’, H6’’), 7.08-7.25 (m, 5H, H5, 4CHindole), 7.42 (d, J = 
8.4, 2H, H3’’, H5’’), 7.67 (app dt, J = 7.6, 1.2, 1H, H4’), 7.99 (br d, J = 4.2, 1H, H6), 8.10 (d, J = 2.8, 
1H, H2). 13C-NMR (CDCl3):  39.8 (CH2NH), 49.6 (NCH2), 110.0 (C7’), 112.7 (C3’), 118.8 (C4), 119.3 
(C4’), 120.0 (C5’), 121.8 (C4’’), 122.6 (C6’), 123.8 (C5), 126.9 (C2’), 127.4 (C3a), 128.6 (C2’’, C6’’), 132.1 
(C3’’, C5’’), 136.2 (C2), 136.4 (C1’’), 136.9 (C7a), 139.0 (C6), 144.4 (C3). HPLC (tR, min): 20.13. MS 
(ESI, m/z, %): 392.2 ([M(79Br) + H]+, 100), 394.2 ([M(81Br) + H]+, 99). 
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N-{[1-(3-Bromobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 18. Following general 
procedure C, compound 18 was obtained from 38 (300 mg, 1.34 mmol) and 1-bromo-3-
(bromomethyl)benzene (402 mg, 1.61 mmol) as a white solid (435 mg, 83%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
 
M.p.: 145-146 ºC. Rf: 0.27 (hexane/EtOAc 2:8). IR (ATR):  3406 (NH), 1588, 1480, 1467 
(Ar). 1H-NMR (CDCl3):  3.99 (br s, 1H, NH), 4.49 (d, J = 3.8, 2H, CH2NH), 5.26 (s, 2H, NCH2), 6.96 
(ddd, J = 8.4, 2.8, 1.4, 1H, H4), 7.00 (app d, J = 7.9, 1H, C6’’), 7.08-7.19 (m, 4H, H5, H2’, H5’, H5’’), 
7.23 (td, J = 8.2, 1.4, 1H, H6’), 7.25-7.30 (m, 2H, H7’, H2’’), 7.40 (br d, J = 8.4, 1H, H4’’), 7.67 (app dt, 
J = 7.8, 1.3, 1H, H4’), 7.99 (dd, J = 4.7, 1.4, 1H, H6), 8.11 (d, J = 2.9, 1H, H2). 13C-NMR (CDCl3):  
39.8 (CH2NH), 49.6 (NCH2), 110.0 (C7’), 112.8 (C3’), 118.7 (C4), 119.3 (C4’), 120.0 (C5’), 122.6 (C6’), 
123.1 (C3’’), 123.9 (C5), 125.5 (C6’’), 126.9 (C2’), 127.4 (C3a), 129.9 (C2’’), 130.5 (C5’’), 131.1 (C4’’), 
136.2 (C2), 136.9 (C7a), 139.0 (C6), 139.7 (C1’’), 144.4 (C3). HPLC (tR, min): 19.94. MS (ESI, m/z, 
%): 392.2 ([M(79Br) + H]+, 100), 394.2 ([M(81Br) + H]+, 88). 
N-{[1-(2-Bromobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 19. Following general 
procedure C, compound 19 was obtained from 38 (260 mg, 1.16 mmol) and 1-bromo-2-
(bromomethyl)benzene (350 mg, 1.40 mmol) as a white solid (367 mg, 81%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
 
M.p.: 127-128 ºC. Rf: 0.29 (hexane/EtOAc 2:8). IR (ATR):  3403 (NH), 1586, 1471 (Ar). 1H-
NMR (CDCl3, 500 MHz):  3.97 (br s, 1H, NH), 4.51 (d, J = 2.6, 2H, CH2NH), 5.36 (s, 2H, NCH2), 
6.57-6.60 (m, 1H, H6’’), 6.97 (ddd, J = 8.2, 3.0, 1.4, 1H, H4), 7.10 (dd, J = 8.2, 4.6, 1H, H5), 7.12-
7.15 (m, 3H, H2’, H4’’, H5’’), 7.17 (ddd, J = 8.0, 6.9, 1.4, 1H, H5’), 7.23 (td, J = 6.9, 1.3, 1H, H6’), 7.27 
(d, J = 7.0, 1H, H7’), 7.58-7.62 (m, 1H, H3’’), 7.69 (d, J = 7.9, 1H, H4’), 7.99 (dd, J = 4.6, 1.4, 1H, H6), 
8.12 (d, J = 2.9, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.9 (CH2NH), 50.3 (NCH2), 110.1 (C7’), 
112.8 (C3’), 118.8 (C4), 119.3 (C4’), 120.0 (C5’), 122.5 (C2’’), 122.7 (C6’), 123.8 (C5), 127.1 (C2’), 
127.3 (C3a), 128.0 (C5’’), 128.3 (C6’’), 129.3 (C4’’), 133.0 (C3’’), 136.3 (C2), 136.5 (C1’’), 137.0 (C7a), 
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139.0 (C6), 144.4 (C3). HPLC (tR, min): 20.33. MS (ESI, m/z, %): 392.2 ([M(79Br) + H]+, 94), 394.2 
([M(81Br) + H]+, 100). 
N-{[1-(2,4-Difluorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 20. Following general 
procedure C, compound 20 was obtained from 38 (260 mg, 1.16 mmol) and 1-(bromomethyl)-2,4-
difluorobenzene (288 mg, 1.39 mmol) as a white solid (331 mg, 82%). Chromatography: 
hexane/EtOAc from 8:2 to 2:8. 
 
 
M.p.: 138-139 ºC. Rf: 0.28 (hexane/EtOAc 2:8). IR (ATR):  3399 (NH), 1588, 1505, 1471 
(Ar), 1272 (C-F). 1H-NMR (CDCl3, 500 MHz):  3.97 (br s, 1H, NH), 4.48 (s, 2H, CH2NH), 5.29 (s, 
2H, NCH2), 6.75 (td, J = 8.1, 2.0, 1H, H3’’), 6.82-6.91 (m, 2H, H5’’, H6’’), 6.96 (ddd, J = 8.3, 2.7, 1.2, 
1H, H4), 7.10 (dd, J = 8.3, 4.7, 1H, H5), 7.14 (s, 1H, H2’), 7.16 (app td, J = 7.9, 0.9, 1H, H5’), 7.24 (td, 
J = 8.2, 0.9, 1H, H6’), 7.33 (d, J = 8.2, 1H, H7’), 7.66 (d, J = 7.9, 1H, H4’), 7.99 (d, J = 4.6, 1.1, 1H, 
H6), 8.10 (d, J = 2.8, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.8 (CH2NH), 43.4 (d, J = 4.2, NCH2), 
104.2 (t, J = 25.3, C3’’), 109.8 (C7’), 111.8 (dd, J = 21.2, 3.7, C5’’), 112.8 (C3’), 118.8 (C4), 119.3 (C4’), 
120.0 (C5’), 120.5 (dd, J = 14.9, 3.8, C1’’), 122.7 (C6’), 123.8 (C5), 126.8 (C2’), 127.4 (C3a), 130.0 (dd, 
J = 9.7, 5.6, C6’’), 136.2 (C2), 136.8 (C7a), 138.9 (C6), 144.4 (C3), 160.5 (dd, J = 247.8, 12.1, 
C2’’/C4’’), 162.7 (dd, J = 248.0, 11.9, C2’’/C4’’). 19F-NMR (CDCl3, 300 MHz):  -114.4 (d, J = 7.2, 1F), 
-110.6 (d, J = 7.2, 1F). HPLC (tR, min): 19.35. MS (ESI, m/z, %): 350.3 ([M + H]+, 100). 
N-{[1-(4-Chloro-2-fluorobenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 21. Following 
general procedure C, compound 21 was obtained from 38 (300 mg, 1.34 mmol) and 1-
(bromomethyl)-4-chloro-2-fluorobenzene (360 mg, 1.61 mmol) as an off-white solid (427 mg, 87%). 
Chromatography: hexane/EtOAc from 7:3 to 3:7. 
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M.p.: 136-137 ºC. Rf: 0.27 (hexane/EtOAc 2:8). IR (ATR):  3405 (NH), 1584, 1487, 1466 
(Ar). 1H-NMR (CDCl3, 500 MHz):  3.97 (br s, 1H, NH), 4.49 (s, 2H, CH2NH), 5.30 (s, 2H, NCH2), 
6.80 (t, J = 8.2, 1H, H6’’), 6.96 (ddd, J = 8.2, 2.8, 1.2, 1H, H4), 7.00 (dd, J = 8.3, 1.4, 1H, H5’’), 7.10 
(dd, J = 8.2, 4.7, 1H, H5), 7.11 -7.14 (m, 2H, H2’, H3’’), 7.15 -7.18 (m, 1H, H5’), 7.24 (td, J = 8.2, 0.9, 
1H, H6’), 7.31 (d, J = 8.2, 1H, H7’), 7.66 (d, J = 7.9, 1H, H4’), 7.99 (d, J = 4.6, 1.0, 1H, H6), 8.11 (d, J 
= 2.7, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.8 (CH2NH), 43.5 (d, J = 4.2, NCH2), 109.8 (C7’), 
112.9 (C3’), 116.6 (d, J = 24.6, C3’’), 118.8 (C4), 119.4 (C4’), 120.1 (C5’), 122.7 (C6’), 123.2 (d, J = 
14.8, C1’’), 123.8 (C5), 125.0 (d, J = 3.7, C5’’), 126.8 (C2’), 127.4 (C3a), 129.8 (d, J = 4.8, C6’’), 134.7 
(d, J = 10.0, C4’’), 136.2 (C2), 136.8 (C7a), 139.9 (C6), 144.4 (C3), 160.1 (d, J = 248.7, C2’’). 19F-NMR 
(CDCl3, 300 MHz):  -115.9. HPLC (tR, min): 20.12. MS (ESI, m/z, %): 366.3 ([M(35Cl) + H]+, 100), 
368.3 ([M(37Cl) + H]+, 63). 
N-{[1-(4-Methylbenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 22. Following general 
procedure C, compound 22 was obtained from 38 (360 mg, 1.61 mmol) and 1-(bromomethyl)-4-
methylbenzene (357 mg, 1.93 mmol) as a white solid (294 mg, 56%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
 
M.p.: 144-145 ºC. Rf: 0.37 (hexane/EtOAc 2:8). IR (ATR):  3399 (NH), 1588, 1482, 1467 
(Ar). 1H-NMR (CDCl3):  2.32 (s, 3H, CH3), 3.95 (br s, 1H, NH), 4.47 (d, J = 3.9, 2H, CH2NH), 5.25 
(s, 2H, NCH2), 6.96 (ddd, J = 8.3, 2.8, 1.3, 1H, H4), 7.03 (d, J = 8.1, 2H, H3’’, H5’’), 7.08-7.17 (m, 5H, 
H5, H2’, H5’, H2’’, H6’’), 7.22 (td, J = 6.9, 1.2, 1H, H6’), 7.32 (d, J = 8.1, 1H, H7’), 7.66 (d, J = 7.7, 1H, 
H4’), 7.98 (dd, J = 4.6, 1.2, 1H, H6), 8.10 (d, J = 2.8, 1H, H2). 13C-NMR (CDCl3):  21.2 (CH3), 39.8 
(CH2NH), 50.0 (NCH2), 110.1 (C7’), 112.2 (C3’), 118.7 (C4), 119.2 (C4’), 119.7 (C5’), 122.4 (C6’), 
123.8 (C5), 126.9 (C2’), 127.0 (C3’’, C5’’), 127.4 (C3a), 129.6 (C2’’, C6’’), 134.3 (C1’’), 136.2 (C2), 137.0 
(C7a), 137.6 (C4’’), 138.9 (C6), 144.4 (C3). HPLC (tR, min): 19.84. MS (ESI, m/z, %): 328.3 ([M + H]+, 
100). 
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N-{[1-(3-Methylbenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 23. Following general 
procedure C, compound 23 was obtained from 38 (265 mg, 1.19 mmol) and 1-(bromomethyl)-3-
methylbenzene (264 mg, 1.43 mmol) as a white solid (190 mg, 49%). Chromatography: 
hexane/EtOAc from 8:2 to 3:7. 
 
M.p.: 126-127 ºC. Rf: 0.40 (hexane/EtOAc 2:8). IR (ATR):  3393 (NH), 1588, 1482, 1467 
(Ar). 1H-NMR (CDCl3):  2.30 (s, 3H, CH3), 3.97 (br s, 1H, NH), 4.48 (s, 2H, CH2NH), 5.25 (s, 2H, 
NCH2), 6.91-6.98 (m, 3H, H4, H2’’, H4’’), 7.07-7.11 (m, 2H, H5, H6’’), 7.12 (s, 1H, H2’), 7.15-7.25 (m, 
3H, H5’, H6’, H5’’), 7.33 (d, J = 8.1, 1H, H7’), 7.67 (d, J = 7.7, 1H, H4’), 7.98 (dd, J = 4.6, 1.2, 1H, H6), 
8.10 (d, J = 2.8, 1H, H2). 13C-NMR (CDCl3):  21.6 (CH3), 39.8 (CH2NH), 50.2 (NCH2), 110.1 (C7’), 
112.2 (C3’), 118.7 (C4), 119.2 (C4’), 119.7 (C5’), 122.4 (C6’), 123.8 (C5), 124.1 (C2’’), 127.0 (C2’), 
127.3 (C3a), 127.8 (C4’’), 128.7 (C6’’), 128.8 (C5’’), 136.2 (C2), 137.0 (C7a), 137.3 (C1’’), 138.7 (C3’’), 
138.9 (C6), 144.4 (C3). HPLC (tR, min): 19.74. MS (ESI, m/z, %): 328.3 ([M + H]+, 100). 
N-{[1-(2-Methylbenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 24. Following general 
procedure C, compound 24 was obtained from 38 (265 mg, 1.19 mmol) and 1-(bromomethyl)-2-
methylbenzene (264 mg, 1.43 mmol) as a white solid (224 mg, 57%). Chromatography: 
hexane/EtOAc from 8:2 to 3:7. 
 
M.p.: 143-144 ºC. Rf: 0.40 (hexane/EtOAc 2:8). IR (ATR):  3401 (NH), 1588, 1482, 1466 
(Ar). 1H-NMR (CDCl3):  2.30 (s, 3H, CH3), 3.95 (br s, 1H, NH), 4.47 (d, J = 3.5, 2H, CH2NH), 5.26 
(s, 2H, NCH2), 6.78 (d, J = 7.5, 1H, H6’’), 6.95 (ddd, J = 8.3, 2.8, 1.2, 1H, H4), 7.00 (s, 1H, H2’), 7.08-
7.24 (m, 6H, H5, H5’, H6’, 3CHPh), 7.31 (d, J = 7.9, 1H, H7’), 7.68 (d, J = 7.6, 1H, H4’), 7.98 (br d, J = 
3.9, 1H, H6), 8.09 (br s, 1H, H2). 13C-NMR (CDCl3):  19.2 (CH3), 39.8 (CH2NH), 48.2 (NCH2), 110.0 
(C7’), 112.2 (C3’), 118.7 (C4), 119.2 (C4’), 119.8 (C5’), 122.4 (C6’), 123.8 (C5), 126.5 (C5’’), 126.8 (C2’), 
127.3 (C3a), 127.6 (C6’’), 128.0 (C4’’), 130.6 (C3’’), 135.0 (C1’’), 135.9 (C2’’), 136.2 (C2), 137.1 (C7a), 
138.9 (C6), 144.4 (C3). HPLC (tR, min): 19.77. MS (ESI, m/z, %): 328.3 ([M + H]+, 100). 
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N-{[1-(4-Methoxybenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 25. Following general 
procedure C, compound 25 was obtained from 38 (301 mg, 1.35 mmol) and 1-(bromomethyl)-4-
methoxybenzene (325 mg, 1.62 mmol) as a white solid (141 mg, 30%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
 
M.p.: 152-153 ºC. Rf: 0.26 (hexane/EtOAc 2:8). IR (ATR):  3400 (NH), 1587, 1482, 1466 
(Ar), 1246 (C-O-C). 1H-NMR (CDCl3):  3.78 (s, 3H, CH3), 3.94 (br s, 1H, NH), 4.47 (d, J = 2.8, 2H, 
CH2NH), 5.22 (s, 2H, NCH2), 6.83 (d, J = 8.7, 2H, H3’’, H5’’), 6.95 (ddd, J = 8.3, 2.8, 1.3, 1H, H4), 
7.06-7.10 (m, 4H, H5, H2’, H2’’, H6’’), 7.11-7.17 (m, 1H, H5’), 7.22 (td, J = 7.0, 1.1, 1H, H6’), 7.33 (d, J 
= 8.1, 1H, H7’), 7.65 (d, J = 7.8, 1H, H4’), 7.98 (dd, J = 4.6, 1.0, 1H, H6), 8.09 (d, J = 2.7, 1H, H2). 
13C-NMR (CDCl3):  39.8 (CH2NH), 49.7 (NCH2), 55.4 (CH3), 110.1 (C7’), 112.2 (C3’), 114.3 (C3’’, 
C5’’), 118.7 (C4), 119.2 (C4’), 119.7 (C5’), 122.3 (C6’), 123.8 (C5), 126.9 (C2’), 127.4 (C3a), 128.4 (C2’’, 
C6’’), 129.3 (C1’’), 136.2 (C2), 136.9 (C7a), 138.9 (C6), 144.4 (C3), 159.3 (C4’’). HPLC (tR, min): 18.92. 
MS (ESI, m/z, %): 344.3 ([M+H]+, 100). 
N-{[1-(3-Methoxybenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 26. Following general 
procedure C, compound 26 was obtained from 38 (300 mg, 1.34 mmol) and 1-(bromomethyl)-3-
methoxybenzene (324 mg, 1.61 mmol) as a brown solid (142 mg, 31%). Chromatography: 
hexane/EtOAc from 7:3 to 3:7. 
N
NH
N
3
3'
1''1' 3''
O
 
M.p.: 105-106 ºC. Rf: 0.26 (hexane/EtOAc 2:8). IR (ATR):  3396 (NH), 1587, 1489, 1466 
(Ar), 1263 (C-O-C). 1H-NMR (CDCl3):  3.74 (s, 3H, CH3), 3.97 (br s, 1H, NH), 4.48 (s, 2H, 
CH2NH), 5.26 (s, 2H, NCH2), 6.66-6.67 (m, 1H, H2’’), 6.71 (d, J = 7.6, 1H, H4’’), 6.80 (dd, J = 8.2, 
2.3, 1H, H6’’), 6.96 (ddd, J = 8.3, 2.8, 1.3, 1H, H4), 7.10 (dd, J = 7.9, 4.6, 1H, H5), 7.12 (s, 1H, H2’), 
7.12-7.17 (m, 1H, H5’), 7.22 (app t, J = 8.0, 2H, H6’, H5’’), 7.31 (d, J = 8.0, 1H, H7’), 7.66 (d, J = 7.7, 
1H, H4’), 7.98 (dd, J = 4.6, 0.9, 1H, H6), 8.10 (d, J = 2.6, 1H, H2). 13C-NMR (CDCl3):  39.8 
(CH2NH), 50.1 (NCH2), 55.3 (CH3), 110.1 (C7’), 112.3 (C3’), 112.8 (C2’’), 113.0 (C4’’), 118.7 (C4), 
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119.2 (C4’), 119.3 (C6’’), 119.8 (C5’), 122.4 (C6’), 123.8 (C5), 127.0 (C2’), 127.4 (C3a), 130.0 (C5’’), 
136.2 (C2), 137.0 (C7a), 138.9 (C6), 139.0 (C1’’), 144.4 (C3), 160.1 (C3’’). HPLC (tR, min): 18.92. MS 
(ESI, m/z, %): 344.3 ([M+H]+, 100). 
N-{[1-(2-Methoxybenzyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 27. Following general 
procedure C, compound 27 was obtained from 38 (360 mg, 1.61 mmol) and 1-(bromomethyl)-2-
methoxybenzene (388 mg, 1.93 mmol) as a white solid (360 mg, 65%). Chromatography: 
hexane/EtOAc from 1:1 to 2:8. 
 
M.p.: 103-104 ºC. Rf: 0.32 (hexane/EtOAc 2:8). IR (ATR):  3404 (NH), 1588, 1491, 1467 
(Ar), 1246 (C-O-C). 1H-NMR (CDCl3, 500 MHz):  3.87 (s, 3H, CH3), 3.94 (br s, 1H, NH), 4.48 (s, 
2H, CH2NH), 5.29 (s, 2H, NCH2), 6.77 (dd, J = 7.4, 1.2, 1H, H3’’), 6.82 (t, J = 7.3, 1H, H5’’), 6.90 (d, J 
= 8.2, 1H, H6’’), 6.96 (ddd, J = 8.3, 2.8, 1.3, 1H, H4), 7.09 (dd, J = 8.2, 4.6, 1H, H5), 7.12-7.15 (m, 
2H, H2’, H5’), 7.20-7.26 (m, 2H, H6’, H4’’), 7.36 (d, J = 8.3, 1H, H7’), 7.65 (d, J = 7.8, 1H, H4’), 7.98 
(dd, J = 4.6, 1.2, 1H, H6), 8.10 (d, J = 2.8, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.9 (CH2NH), 
45.2 (NCH2), 55.5 (CH3), 110.3 (C7’), 110.4 (C3’’), 111.9 (C3’), 118.7 (C4), 119.0 (C4’), 119.6 (C5’), 
120.8 (C5’’), 122.2 (C6’), 123.8 (C5), 125.7 (C1’’), 127.2 (C3a), 127.4 (C2’), 128.3 (C6’’), 129.0 (C4’’), 
136.3 (C2), 137.1 (C7a), 138.9 (C6), 144.5 (C3), 156.9 (C2’’). HPLC (tR, min): 19.43. MS (ESI, m/z, 
%): 344.3 ([M+H]+, 100). 
N-({1-[4-(Trifluoromethyl)benzyl]-1H-indol-3-yl}methyl)pyridin-3-amine, 28. Following 
general procedure C, compound 28 was obtained from 38 (260 mg, 1.16 mmol) and 1-
(bromomethyl)-4-(trifluoromethyl)benzene (332 mg, 1.40 mmol) as a white solid (256 mg, 58%). 
Chromatography: hexane/EtOAc from 7:3 to 2:8. 
 
M.p.: 141-142 ºC. Rf: 0.37 (hexane/EtOAc 2:8). IR (ATR):  3260 (NH), 1588, 1482, 1466 
(Ar), 1323 (C-F). 1H-NMR (CDCl3, 500 MHz):  4.01 (br s, 1H, NH), 4.51 (s, 2H, CH2NH), 5.35 (s, 
2H, NCH2), 6.97 (ddd, J = 8.3, 2.9, 1.3, 1H, H4), 7.10 (dd, J = 8.3, 4.8, 1H, H5), 7.12 (s, 1H, H2’), 
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7.15-7.24 (m, 5H, 3CHindole, H2’’, H6’’), 7.55 (d, J = 8.1, 2H, H3’’, H5’’), 7.68 (d, J = 7.8, 1H, H4’), 7.99 
(dd, J = 4.7, 1.1, 1H, H6), 8.12 (d, J = 2.7, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.8 (CH2NH), 
49.7 (NCH2), 109.9 (C7’), 113.0 (C3’), 118.9 (C4), 119.4 (C4’), 120.1 (C5’), 122.7 (C6’), 123.9 (C5), 
124.1 (q, J = 272.4, CF3), 126.0 (q, J = 3.7, C3’’, C5’’), 126.9 (C2’), 127.1 (C2’’, C6’’), 127.5 (C3a), 130.2 
(q, J = 32.5, C4’’), 136.1 (C2), 136.9 (C7a), 138.9 (C6), 141.5 (C1’’), 144.4 (C3). 19F-NMR (CDCl3):  
-62.9. HPLC (tR, min): 19.97. MS (ESI, m/z, %): 382.0 ([M+H]+, 100). 
N-({1-[3-(Trifluoromethyl)benzyl]-1H-indol-3-yl}methyl)pyridin-3-amine, 29. Following 
general procedure C, compound 29 was obtained from 38 (260 mg, 1.16 mmol) and 1-
(bromomethyl)-3-(trifluoromethyl)benzene (332 mg, 1.40 mmol) as a white solid (136 mg, 30%). 
Chromatography: hexane/EtOAc from 7:3 to 2:8. 
 
M.p.: 135-136 ºC. Rf: 0.38 (hexane/EtOAc 2:8). IR (ATR):  3264 (NH), 1586, 1471 (Ar), 1327 
(C-F). 1H-NMR (CDCl3, 500 MHz):  4.01 (br s, 1H, NH), 4.51 (s, 2H, CH2NH), 5.34 (s, 2H, NCH2), 
6.97 (ddd, J = 8.3, 2.8, 1.3, 1H, H4), 7.10 (dd, J = 8.2, 4.7, 1H, H5), 7.12 (s, 1H, H2’), 7.17 (ddd, J = 
7.9, 6.6, 1.5, 1H, H5’), 7.21 (br d, J = 7.8, 1H, H6’’), 7.22-7.27 (m, 2H, H6’, H7’), 7.41 (t, J = 7.8, 1H, 
H5’’), 7.45 (br s, 1H, H2’’), 7.54 (br d, J = 7.8, 1H, H4’’), 7.68 (d, J = 7.9, 1H, H4’), 7.99 (dd, J = 4.5, 
0.9, 1H, H6), 8.12 (d, J = 2.7, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  39.8 (CH2NH), 49.8 (NCH2), 
109.9 (C7’), 113.0 (C3’), 118.9 (C4), 119.4 (C4’), 120.1 (C5’), 122.8 (C6’), 123.7 (q, J = 3.8, C2’’), 123.9 
(C5), 124.0 (q, J = 272.4, CF3), 124.8 (q, J = 3.8, C4’’), 126.8 (C2’), 127.5 (C3a), 129.6 (C6’’), 130.2 
(C5’’), 131.3 (q, J = 32.5, C3’’), 136.1 (C2), 136.9 (C7a), 138.5 (C1’’), 138.9 (C6), 144.4 (C3). 19F-NMR 
(CDCl3):  -62.9. HPLC (tR, min): 19.81. MS (ESI, m/z, %): 382.0 ([M+H]+, 100). 
N-({1-[2-(Trifluoromethyl)benzyl]-1H-indol-3-yl}methyl)pyridin-3-amine, 30. Following 
general procedure C, compound 30 was obtained from 38 (300 mg, 1.34 mmol) and 1-
(bromomethyl)-2-(trifluoromethyl)benzene (395 mg, 1.65 mmol) as a white solid (404 mg, 79%). 
Chromatography: hexane/EtOAc from 7:3 to 3:7. 
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M.p.: 153-154 ºC. Rf: 0.40 (hexane/EtOAc 2:8). IR (ATR):  3264 (NH), 1588, 1483, 1467 
(Ar), 1313 (C-F). 1H-NMR (CDCl3, 500 MHz):  4.03 (br s, 1H, NH), 4.53 (s, 2H, CH2NH), 5.52 (s, 
2H, NCH2), 6.59 (d, J = 7.2, 1H, H6’’), 6.98 (ddd, J = 8.3, 2.8, 1.3, 1H, H4), 7.11 (dd, J = 8.2, 4.7, 1H, 
H5), 7.13 (s, 1H, H2’), 7.16-7.24 (m, 3H, 3CHindole), 7.31-7.37 (m, 2H, H4’’, H5’’), 7.71 (app t, J = 7.4, 
2H, H4’, H3’’), 7.99 (dd, J = 4.7, 1.1, 1H, H6), 8.12 (d, J = 2.7, 1H, H2). 13C-NMR (CDCl3, 125 MHz):  
39.8 (CH2NH), 46.5 (q, J = 3.4, NCH2), 110.0 (C7’), 113.0 (C3’), 118.9 (C4), 119.3 (C4’), 120.1 (C5’), 
122.8 (C6’), 123.9 (C5), 124.6 (q, J = 273.8, CF3), 126.2 (q, J = 5.8, C3’’), 127.1 (q, J = 30.9, C2’’), 
127.3 (C2’), 127.4 (C3a), 127.5 (C6’’), 127.7 (C4’’), 132.6 (C5’’), 136.2 (C2), 136.3 (C1’’), 137.0 (C7a), 
138.9 (C6), 144.4 (C3). 19F-NMR (CDCl3, 300 MHz):  -60.6. HPLC (tR, min): 20.37. MS (ESI, m/z, 
%): 382.0 ([M+H]+, 100). 
4-({3-[(Pyridin-3-ylamino)methyl]-1H-indol-1-yl}methyl)benzonitrile, 31. Following general 
procedure C, compound 31 was obtained from 38 (267 mg, 1.20 mmol) and 4-
(bromomethyl)benzonitrile (283 mg, 1.44 mmol) as a brown solid (214 mg, 53%). Chromatography: 
hexane/EtOAc from 7:3 to 2:8. 
 
M.p.: 117-118 ºC. Rf: 0.25 (hexane/EtOAc 2:8). IR (ATR):  3260 (NH), 2228 (CN), 1588, 
1482, 1466 (Ar). 1H-NMR (CDCl3):  4.01 (br s, 1H, NH), 4.51 (s, 2H, CH2NH), 5.36 (s, 2H, NCH2), 
6.96 (ddd, J = 8.2, 2.7, 1.2, 1H, H4), 7.08-7.23 (m, 7H, H5, 4CHindole, H3’’, H5’’), 7.58 (d, J = 8.3, 2H, 
H2’’, H6’’), 7.68 (dd, J = 7.0, 1.6, 1H, H4’), 7.99 (br d, J = 4.0, 1H, H6), 8.11 (d, J = 2.4, 1H, H2). 13C-
NMR (CDCl3):  39.8 (CH2NH), 49.8 (NCH2), 109.8 (C7’), 111.8 (C1’’), 113.2 (C3’), 118.6 (CN), 118.8 
(C4), 119.5 (C4’), 120.2 (C5’), 122.9 (C6’), 123.8 (C5), 126.8 (C2’), 127.3 (C3’’, C5’’), 127.4 (C3a), 132.8 
(C2’’, C6’’), 136.2 (C2), 136.8 (C7a), 139.0 (C6), 142.9 (C4’’), 144.3 (C3). HPLC (tR, min): 17.76. MS 
(ESI, m/z, %): 339.3 ([M+H]+, 100). 
3-({3-[(Pyridin-3-ylamino)methyl]-1H-indol-1-yl}methyl)benzonitrile, 32. Following general 
procedure C, compound 32 was obtained from 38 (267 mg, 1.20 mmol) and 3-
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(bromomethyl)benzonitrile (283 mg, 1.44 mmol) as a white solid (266 mg, 66%). Chromatography: 
hexane/EtOAc from 7:3 to 2:8. 
 
M.p.: 130-131 ºC. Rf: 0.21 (hexane/EtOAc 2:8). IR (ATR):  3268 (NH), 2230 (CN), 1587, 
1483, 1467 (Ar). 1H-NMR (CDCl3):  4.03 (br s, 1H, NH), 4.51 (s, 2H, CH2NH), 5.33 (s, 2H, NCH2), 
6.97 (ddd, J = 8.3, 2.8, 1.3, 1H, H4), 7.09-7.13 (m, 2H, H5, H2’), 7.14-7.25 (m, 3H, 3CHindole), 7.31 (br 
d, J = 7.9, 1H, H4’’), 7.35 (br s, 1H, H2’’), 7.41 (t, J = 7.7, 1H, H5’’), 7.56 (br d, J = 7.6, 1H, H6’’), 7.69 
(d, J = 7.5, 1H, H4’), 7.99 (dd, J = 4.6, 0.8, 1H, H6), 8.11 (d, J = 2.7, 1H, H2). 13C-NMR (CDCl3):  
39.8 (CH2NH), 49.4 (NCH2), 109.8 (C7’), 113.1 (C1’’), 113.2 (C3’), 118.6 (CN), 118.8 (C4), 119.5 (C4’), 
120.2 (C5’), 122.9 (C6’), 123.9 (C5), 126.7 (C2’), 127.5 (C3a), 129.8 (C4’’), 130.2 (C2’’), 131.1 (C6’’), 
131.6 (C5’’), 136.2 (C2), 136.7 (C7a), 139.0 (C6), 139.2 (C3’’), 144.3 (C3). HPLC (tR, min): 17.82. MS 
(ESI, m/z, %): 339.3 ([M+H]+, 100). 
2-({3-[(Pyridin-3-ylamino)methyl]-1H-indol-1-yl}methyl)benzonitrile, 33. Following general 
procedure C, compound 33 was obtained from 38 (267 mg, 1.20 mmol) and 2-
(bromomethyl)benzonitrile (292 mg, 1.49 mmol) as a white solid (289 mg, 72%). Chromatography: 
hexane/EtOAc from 7:3 to 2:8. 
 
M.p.: 126-127 ºC. Rf: 0.28 (hexane/EtOAc 2:8). IR (ATR):  3267 (NH), 2224 (CN), 1588, 
1482, 1466 (Ar). 1H-NMR (CDCl3):  4.01 (br s, 1H, NH), 4.51 (d, J = 3.2, 2H, CH2NH), 5.52 (s, 2H, 
NCH2), 6.84 (d, J = 7.6, 1H, H3’’), 6.97 (ddd, J = 8.2, 2.7, 1.1, 1H, H4), 7.11 (dd, J = 8.2, 4.6, 1H, 
H5), 7.15-7.27 (m, 4H, 4CHindole) 7.39 (td, J = 7.5, 1.1, 1H, H5’’), 7.44 (td, J = 7.6, 1.5, 1H, H4’’), 7.68-
7.73 (m, 2H, H4’, H6’’), 7.99 (br d, J = 3.6, 1H, H6), 8.11 (br s, 1H, H2). 13C-NMR (CDCl3):  39.8 
(CH2NH), 48.2 (NCH2), 109.9 (C7’), 110.9 (C1’’), 113.2 (C3’), 117.3 (CN), 118.8 (C4), 119.4 (C4’), 
120.2 (C5’), 122.9 (C6’), 123.8 (C5), 127.0 (C2’), 127.5 (C3a), 127.6 (C3’’), 128.4 (C5’’), 133.2 (C6’’), 
133.6 (C4’’), 136.3 (C2), 136.9 (C7a), 139.0 (C6), 141.1 (C2’’), 144.3 (C3). HPLC (tR, min): 17.99. MS 
(ESI, m/z, %): 339.3 ([M+H]+, 100). 
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N-{[1-(Pyridin-4-ylmethyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 34. Following general 
procedure D, 1-(pyridin-4-ylmethyl)-1H-indole-3-carbaldehyde (39) was obtained from 1H-indole-3-
carbaldehyde (500 mg, 3.44 mmol) and 4-(bromomethyl)pyridine hydrobromide (1.04 g, 4.11 mmol) 
as a yellow solid (696 mg, 86%), which was used in the next step without further purification. 
Next, following general procedure B, compound 34 was obtained from 39 (696 mg, 2.95 
mmol) and pyridin-3-amine (333 mg, 3.54 mmol) as a white solid (243 mg, 26%). Chromatography: 
DCM/methanol 97:3 (then slurred with EtOAc). 
 
M.p.: 141-142 ºC. Rf: 0.21 (DCM/methanol 95:5). IR (ATR):  3267 (NH), 1588, 1481, 1466 
(Ar). 1H-NMR (CDCl3):  4.02 (br s, 1H, NH), 4.51 (d, J = 3.4, 2H, CH2NH), 5.31 (s, 2H, NCH2), 6.94 
(d, J = 6.0, 2H, H3’’, H5’’), 6.98 (ddd, J = 8.1, 2.8, 1.3, 1H, H4), 7.09 (dd, J = 8.3, 4.6, 1H, H5), 7.12 (s, 
1H, H2’), 7.17-7.23 (m, 3H, 3CHindole), 7.67-7.70 (m, 1H, H4’), 7.99 (dd, J = 4.6, 1.2, 1H, H6), 8.11 (d, 
J = 2.8, 1H, H2), 8.52 (d, J = 6.0, 2H, H2’’, H6’’). 13C-NMR (CDCl3):  39.8 (CH2NH), 49.1 (NCH2), 
109.9 (C7’), 113.2 (C3’), 118.8 (C4), 119.4 (C4’), 120.2 (C5’), 121.5 (C3’’, C5’’), 122.8 (C6’), 123.9 (C5), 
126.9 (C2’), 127.4 (C3a), 136.2 (C2), 136.9 (C7a), 139.0 (C6), 144.3 (C3), 146.5 (C4’’), 150.4 (C2’’, C6’’). 
HPLC (tR, min): 15.79. MS (ESI, m/z, %): 315.4 ([M+H]+, 100). 
N-{[1-(Pyridin-3-ylmethyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 35. Following general 
procedure D, 1-(pyridin-3-ylmethyl)-1H-indole-3-carbaldehyde (40)26 was obtained from 1H-indole-
3-carbaldehyde (310 mg, 2.14 mmol) and 3-(bromomethyl)pyridine hydrobromide (650 mg, 2.57 
mmol) as a yellow oil (466 mg, 92%), which was used in the next step without further purification. 
Next, following general procedure B, compound 35 was obtained from 40 (460 mg, 1.95 
mmol) and pyridin-3-amine (220 mg, 2.34 mmol) as a white solid (262 mg, 43%). Chromatography: 
DCM/methanol from 97:3 to 95:5 (then slurred with hexane/Et2O). 
N
NH
N
N
3
3'
1' 3''
 
M.p.: 160-161 ºC. Rf: 0.21 (DCM/methanol 95:5). IR (ATR):  3274 (NH), 1613, 1480, 1466 
(Ar). 1H-NMR (CDCl3):  4.00 (br s, 1H, NH), 4.49 (s, 2H, CH2NH), 5.31 (s, 2H, NCH2), 6.96 (ddd, J 
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= 8.3, 2.8, 1.3, 1H, H4), 7.09 (dd, J = 8.2, 4.7, 1H, H5), 7.12 (s, 1H, H2’), 7.13-7.27 (m, 4H, 3CHindole, 
H4’’), 7.32 (t, J = 7.5, 1H, H5’’), 7.67 (d, J = 7.7, 1H, H4’), 7.98 (dd, J = 4.6, 1.2, 1H, H6), 8.13 (d, J = 
2.8, 1H, H2), 8.50-8.54 (m, 2H, H2’’, H6’’). 13C-NMR (CDCl3):  39.8 (CH2NH), 47.7 (NCH2), 109.9 
(C7’), 113.0 (C3’), 118.8 (C4), 119.4 (C4’), 120.1 (C5’), 122.7 (C6’), 123.9 (C5, C4’’), 126.7 (C2’), 127.5 
(C3a), 133.0 (C3’’), 134.6 (C5’’), 136.2 (C2), 136.8 (C7a), 138.9 (C6), 144.4 (C3), 148.5, 149.5 (C2’’, 
C6’’). HPLC (tR, min): 15.81. MS (ESI, m/z, %): 315.4 ([M+H]+, 100). 
N-{[1-(Pyridin-2-ylmethyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 36. Following general 
procedure D, 1-(pyridin-2-ylmethyl)-1H-indole-3-carbaldehyde (41) was obtained from 1H-indole-3-
carbaldehyde (500 mg, 3.44 mmol) and 2-(bromomethyl)pyridine hydrobromide (1.04 g, 4.11 mmol) 
as a brown solid (768 mg, 94%), which was used in the next step without further purification. 
Following general procedure B, compound 36 was obtained from 41 (765 mg, 3.24 mmol) and 
pyridin-3-amine (366 mg, 3.89 mmol) as an off-white solid (296 mg, 29%). Chromatography: 
DCM/methanol from 97:3 to 95:5 (then slurred with DCM/Et2O). 
N
NH
N
N
3
3'
1' 2''
 
M.p.: 133-134 ºC. Rf: 0.25 (DCM/methanol 95:5). IR (ATR):  3252 (NH), 1589, 1467 (Ar). 1H-
NMR (CDCl3):  4.00 (br s, 1H, NH), 4.50 (d, J = 4.4, 2H, CH2NH), 5.42 (s, 2H, NCH2), 6.74 (d, J = 
7.9, 1H, H3’’), 6.97 (ddd, J = 8.3, 2.8, 1.2, 1H, H4), 7.10 (dd, J = 8.3, 4.7, 1H, H5), 7.13-7.24 (m, 4H, 
3CHindole, H5’’), 7.29 (d, J = 7.7, 1H, H7’), 7.53 (td, J = 7.7, 1.8, 1H, H4’’), 7.67 (d, J = 7.4, 1H, H4’), 
7.98 (dd, J = 4.6, 1.2, 1H, H6), 8.11 (d, J = 2.8, 1H, H2), 8.59 (br d, J = 4.6, 1H, H6’’). 13C-NMR 
(CDCl3):  39.8 (CH2NH), 52.1 (NCH2), 110.1 (C7’), 112.7 (C3’), 118.7 (C4), 119.3 (C4’), 120.0 (C5’), 
120.9 (C3’’), 122.6 (C5’’), 122.7 (C6’), 123.8 (C5), 127.2 (C2’), 127.4 (C3a), 136.2 (C2), 136.9 (C7a), 
137.2 (C4’’), 138.9 (C6), 144.4 (C3), 149.6 (C6’’), 157.4 (C2’’). HPLC (tR, min): 16.34. MS (ESI, m/z, 
%): 315.2 ([M+H]+, 100). 
N-{[1-(Cyclopropylmethyl)-1H-indol-3-yl]methyl}pyridin-3-amine, 37. Following general 
procedure C, 1-(cyclopropylmethyl)-1H-indole-3-carbaldehyde (42)27 was obtained from 1H-indole-
3-carbaldehyde (1.00 g, 6.89 mmol) and (bromomethyl)cyclopropane (1.45 g, 10.74 mmol) as an 
off-white solid (1.33 g, 97%), which was used in the next step without further purification. 
Following general procedure B, compound 37 was obtained from 42 (504 mg, 2.53 mmol) and 
pyridin-3-amine (290 mg, 3.08 mmol) as a white solid (212 mg, 30%). Chromatography: from 
hexane/EtOAc 8:2 to EtOAc. 
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M.p.: 111-112 ºC. Rf: 0.37 (hexane/EtOAc 2:8). IR (ATR):  3393 (NH), 1587, 1481, 1468 
(Ar). 1H-NMR (CDCl3):  0.34-0.39 (m, 2H, CH2 cpr), 0.60-0.66 (m, 2H, CH2 cpr), 1.21-1.31 (m, 1H, 
CHcpr), 3.96 (d, J = 6.8, 2H, NCH2), 4.48 (s, 2H, CH2NH), 6.97 (dd, J = 8.2, 1.7, 1H, H4), 7.10-7.17 
(m, 2H, H5, H5’), 7.22 (s, 1H, H2’), 7.23-7.28 (m, 1H, H6’), 7.38 (d, J = 8.2, 1H, H7’), 7.66 (d, J = 7.9, 
1H, H4’), 7.99 (br s, 1H, H6), 8.11 (br s, 1H, H2). 13C-NMR (CDCl3):  4.3 (2CH2 cpr), 11.4 (CHcpr), 
39.9 (CH2NH), 50.8 (NCH2), 109.8 (C7’), 111.6 (C3’), 118.7 (C4), 119.1 (C4’), 119.5 (C5’), 122.1 (C6’), 
123.8 (C5), 126.4 (C2’), 127.2 (C3a), 136.2 (C7a), 136.8 (C2), 138.8 (C6), 148.1 (C3). HPLC (tR, min): 
18.38. MS (ESI, m/z, %): 278.1 ([M+H]+, 100). 
 

  
REFERENCES 
 

  
7. REFERENCES 
 
1. World Health Organization. http://www.who.int/gho/ncd/risk_factors/overweight_text/en/ 
(accessed March 2017). 
2. Colman, E. Food and Drug Administration's obesity drug guidance document: a short history. 
Circulation 2012, 125, 2156-2164. 
3. Rodríguez, J. E.; Campbell, K. M. Past, present, and future of pharmacologic therapy in obesity. 
Prim. Care Clin. Office Pract. 2016, 43, 61-67. 
4. Halford, J. C. G.; Harrold, J. A.; Lawton, C. L.; Blundell, J. E. Serotonin (5-HT) drugs: effects on 
appetite expression and use for the treatment of obesity. Curr. Drug Targets 2005, 6, 201-213. 
5. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; R., M. G.; Mylecharane, E. J.; Saxena, P. 
R.; Humphrey, P. P. A. VII. International union of pharmacology classification of receptors for 5-
hydroxytriptamine (serotonin). Pharmacol. Rev. 1994, 46, 157-203. 
6. Göthert, M. Serotonin discovery and stepwise disclosure of 5-HT receptor complexity over four 
decades. Part I. General background and discovery of serotonin as a basis for 5-HT receptor 
identification. Pharmacol. Rep. 2013, 65, 771-786. 
7. McCorvy, J. D.; Roth, B. L. Structure and function of serotonin G protein-coupled receptors. 
Pharmacol. Ther. 2015, 150, 129-142. 
8. Hoyer, D.; Hannon, J. P.; Martin, G. R. Molecular, pharmacological and functional diversity of 5-
HT receptors. Pharmacol. Biochem. Behav. 2002, 71, 533-554. 
9. Higgins, G. A.; Sellers, E. M.; Fletcher, P. J. From obesity to substance abuse: therapeutic 
opportunities for 5-HT2C receptor agonists. Trends Pharmacol. Sci. 2013, 34, 560-570. 
10. Di Giovanni, G.; De Deurwaerdere, P. New therapeutic opportunities for 5-HT2C receptor 
ligands in neuropsychiatric disorders. Pharmacol. Ther. 2016, 157, 125-162. 
11. Jensen, N. H.; Cremers, T. I.; Sotty, F. Therapeutic potential of 5-HT2C receptor ligands. 
TheScientificWorldJournal 2010, 10, 1870-1885. 
References 
100 
12. Tecott, L. H.; Sun, L. M.; Akana, S. F.; Strack, A. M.; H., L. D.; Dallman, M. F.; Julius, D. 
Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995, 374, 542-
546. 
13. Vickers, S. P.; Clifton, P. G.; Dourish, C. T.; Tecott, L. H. Reduced satiating effect of d-
fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology 1999, 143, 309-314. 
14. Lee, J.; Jung, M. E.; J., L. 5-HT2C receptor modulators: a patent survey. Expert Opin. Ther. 
Patents 2010, 20, 1429-1455. 
15. Monck, N. J. T.; Kennett, G. A. 5-HT2C Ligands: recent progress. Prog. Med. Chem. 2008, 46, 
281-390. 
16. Garfield, A. S.; Heisler, L. K. Pharmacological targeting of the serotonergic system for the 
treatment of obesity. J. Physiol. 2009, 587, 49-60. 
17. Kroeze, W. K.; Roth, B. L. The molecular biology of serotonin receptors: therapeutic 
implications for the interface of mood and psychosis. Biol. Psychiatry 1998, 44, 1128-1142. 
18. Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.; McBride, A.; Hufeisen, S. J.; 
Roth, B. L. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy 
associated with fenfluramine and other serotonergic medications. Circulation 2000, 102, 2836-
2841. 
19. Heisler, L. K.; Cowley, M. A.; Tecott, L. H.; Fan, W.; Low, M. J.; Smart, J. L.; Rubinstein, M.; 
Tatro, J. B.; Marcus, J. N.; Holstege, H.; Lee, C. E.; Cone, R. D.; Elmquist, J. K. Activation of 
central melanocortin pathways by fenfluramine. Science 2002, 297, 609-611. 
20. Astrup, A. Drug management of obesity - efficacy versus safety. N. Engl. J. Med. 2010, 363, 
288-290. 
21. DiNicolantonio, J. J.; Chatterjee, S.; O’Keefe, J. H.; Meier, P. Lorcaserin for the treatment of 
obesity? A closer look at its side effects. Open Heart 2014, 1, 1-3. 
22. Im, W. B.; Chio, C. L.; Alberts, G. L.; Dinh, D. M. Positive allosteric modulator of the human 5-
HT2C receptor. Mol. Pharmacol. 2003, 64, 78-84. 
23. Ding, C.; Bremer, N. M.; Smith, T. D.; Seitz, P. K.; Anastasio, N. C.; Cunningham, K. A.; 
Zhou, J. Exploration of synthetic approaches and pharmacological evaluation of PNU-69176E and 
its stereoisomer as 5-HT2C receptor allosteric modulators. ACS Chem. Neurosci. 2012, 3, 538-545. 
24. McAllister, C. E.; Hartley, R. M.; Zhang, G.; Fox, R. G.; Anastasio, N. C.; Wild, C.; Zhou, J.; 
Cunningham, K. A. In vivo evaluation of novel serotonin 5-HT2C receptor positive allosteric 
modulator CYD-1-79. Drug Alcohol Depend. 2015, 156, e102-e182. 
25. Wacker, D.; Wang, S.; McCorvy, J. D.; Betz, R. M.; Venkatakrishnan, A. J.; Levit, A.; Lansu, 
K.; Schools, Z. L.; Che, T.; Nichols, D. E.; Shoichet, B. K.; Dror, R. O.; Roth, B. L. Crystal structure 
of an LSD-bound human serotonin receptor. Cell 2017, 168, 377-389. 
References 
101 
26. Mashayekhi, V.; Haj Mohammad Ebrahim Tehrani, K.; Azerang, P.; Sardari, S.; Kobarfard, F. 
Synthesis, antimycobacterial and anticancer activity of novel indole-based thiosemicarbazones. 
Arch. Pharm. Res. 2013, doi:10.1007/s12272-013-0242-z. 
27. Li, X.; Gu, X.; Li, Y.; Li, P. Aerobic transition-metal-free visible-light photoredox indole C-3 
hormylation reaction. ACS Catalysis 2014, 4, 1897-1900. 
 
 
 
CHAPTER B 
ALLOSTERIC MODULATORS OF THE D1R 
 

 INTRODUCTION AND OBJECTIVES 
 
 
 
 
 
 
 
 
 
 

  
1. INTRODUCTION AND OBJECTIVES
 
Parkinson’s disease (PD) is a chronic, progressive, and neurodegenerative disorder 
characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta in the 
brain. To date, causative factors for PD remain yet unknown. The disease pattern includes motor 
(tremor, rigidity and bradykinesia) and non-motor symptoms (cognitive deficits, psychiatric and 
sleep disorders). Dopamine (DA) replacement with its direct precursor L-3,4-
dihydroxyphenylalanine (L-DOPA) is the most widely used therapy.1,2 To avoid peripheral 
transformation of L-DOPA into DA, which does not cross the blood brain barrier, it is 
coadministered with DOPA decarboxylase inhibitors (e.g., benserazide or carbidopa). Despite this 
treatment was proposed almost half a century ago, it is still the most powerful weapon against PD 
motor symptoms. 
In the long term, the therapeutic index of L-DOPA decreases and its antiparkinsonian action is 
very often associated with adverse effects, including progressive decline in symptomatic benefit 
(end-of-dose wearing-off and on-off phenomena) and dyskinesia. The short half life of L-DOPA 
produces a pulsatile stimulation of DA receptors that triggers the onset of motor complications. 
Hence, the current approach is based on the so-called continuous dopaminergic stimulation using 
agonists that activate the DA receptors. These can be classified based on the G protein they 
couple to: D1-like subtypes (D1 and D5) couple to Gs stimulating the production of the second 
messenger cAMP; and D2-like subtypes (D2, D3 and D4) couple to Gi inhibiting cAMP production. 
Agonists of DA receptors endowed with antiparkinsonian properties can be classified in 
ergoline (bromocriptine, lisuride, pergolide, cabergoline, dihydroergocryptine, piribedil) and non-
ergoline derivatives (pramipexole, rotigotine, ropinirole, apomorphine) (Figure 1).3 Ergoline 
derivatives mainly target D2-like receptors (D2Rs and D3Rs), and even though having a longer 
history, they are associated with critical side effects (cardiovascular and pulmonary fibrosis), 
leading to a drastic reduction of their clinical practice. Later, non-ergoline derivatives (second 
generation agonists) selectively targeting D3R started to appear due primarily to the promising role 
of this subtype in neuroprotection and the much less undesirable effects expected by its selective 
activation.4 
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Figure 1. Agonists of DA receptors endowed with antiparkinsonian properties. 
 
Despite their usefulness, the extensive prescription of DA receptor agonists over the past 
fifteen years have shown the appearance of some unexpected non-motor complications, such as 
DA dysregulation syndrome, that is related to important psychiatric disorders (depression, anxiety). 
At present, DA receptor agonists are useful at early stages as monotherapy, and at the more 
advanced phases in combination with L-DOPA to retard the development of motor complications. 
However, this therapy is essentially symptomatic and does not stop the progression of the disease. 
Besides, only motor symptoms can be contained with L-DOPA administration, whereas non-motor 
symptoms do not respond to the drug. Therefore, direct acting DA therapies are limited in 
effectiveness and there remains a significant unmet need for safe and effective treatment of PD. 
In the DA replacement therapy, activation of D2-like receptors has been clinically proved 
beneficial for the treatment of PD. The fact that these current pharmaceuticals also stimulate D1R to 
some extent, led to an extensive work toward the development of selective D1R agonists carried 
out in the 90s mainly by Richard Mailman and David Nichols.5 Even though some of these 
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promising agents were able to show excellent antiparkinsonian properties with reduced motor 
fluctuations, D1R agonists have failed to reach the market mainly due to toxicological and 
pharmacokinetic (PK) problems. Taking all this into consideration, together with the advantages 
that allosteric modulation presents (see General Introduction), we propose herein the development 
of a PAM that specifically targets the D1R as a potential novel DA strategy for the treatment of PD 
(Figure 2). In fact, the pharmaceutical company Eli Lilly & Co. has recently produced some 
promising D1R PAMs, but none of them has entered clinical trials yet.6,7 This overall objective 
encompasses the following aims for the present work: 
 
1. Hit(s) identification. 
2. Optimization process. 
3. In vitro characterization of optimized compound(s). 
4. Animal models of PD. 
 
 
Figure 2. PD is a neurodegenerative disorder produced by the loss of dopaminergic neurons in the brain and 
characterized by motor (tremor, rigidity, bradykinesia) and non-motor symptoms (cognitive deficits, 
psychiatric disorders). Even though DA replacement therapy with L-DOPA combined with DA receptor 
agonists is the most widely used, it is associated with critical side effects. We propose the development of 
AMs targeting the D1R as a potential novel therapy for PD. 
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2. RESULTS AND DISCUSSION
 
2.1. Hit identification: structure-based pharmacophore model 
The increasing number of published crystal structures of GPCRs has revealed the location of 
orthosteric and allosteric binding sites in the different families or classes of GPCRs (Figure 3).8,9 
The orthosteric binding site for ligands of class A GPCRs is mainly located within the 7TM domain10 
whereas allosteric binding sites are proposed to be located at the ECD.11 In contrast, class B 
GPCRs recognize large endogenous peptide ligands mainly through the ECD12 whereas allosteric 
binding sites for AMs are located in a small cavity within the 7TM domain near the intracellular 
site.13 In class C GPCRs, which exist as dimers, the orthosteric site that binds small endogenous 
ligands is located at the Venus flytrap domain of the ECD14 of one monomer and allosteric ligands 
are placed within the 7TM domain in a similar region as the orthosteric site in class A, in the same 
or in the other monomer.15 GPCRs of class F bind the endogenous ligand through the ECD, while 
no AMs are known for this family. Thus, the allosteric binding sites of classes B and C receptors 
are located within the 7TM domain, close to the known molecular switches that trigger receptor 
(in)activation.10 In contrast, the allosteric sites of class A GPCRs are located near the ECD, distant 
from these known switches and, as a consequence, the design of AMs for this class is more 
difficult. 
 
Figure 3. Orthosteric and allosteric binding sites in the different classes of GPCRs 
(Source: reference 9). 
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Our search for D1R AMs was rationally approached using a structure-based drug design 
strategy. First, a homology model of the receptor was constructed based on the crystal structure of 
the D3 subtype, published in 2010 in complex with the antagonist eticlopride (Figure 4A).16 To 
identify structural motifs at the ECD of the D1R that could modulate receptor function, we took 
advantage of the allosteric sites previously identified for other class A GPCRs. Importantly, nuclear 
magnetic resonance (NMR) spectroscopy studies in the 2-adrenergic receptor (2AR) have 
revealed a salt bridge between Asp192i+1 and Lys3057.32 (superscript refers to the Ballesteros-
Weinstein nomenclature system)17 that is weakened upon receptor activation (Figure 4B).18,19 In 
addition, an analysis of the crystal structures of certain class A receptors –muscarinic M1 and M2, 
and dopaminergic D2– in complex with AMs revealed the positions of the amino acids that are 
involved in the binding interactions. Thus, we explored the amino acid sequence of the D1R at 
positions 2.61, 2.64, and 2.65 in TM2; i-1, i+1, i+2 (where i corresponds to the conserved Cys 
engaged in a disulfide bond with Cys3.25 in TM3) in extracellular loop 2 (ECL2); and 7.32, 7.35, 
and 7.36 in TM7/ECL3, and searched for ionic interactions that could mimic the mentioned salt 
bridge (Figure 5). The amino acid sequence of the D1R indicates the presence of positively charged 
Lys812.61 and negatively charged Asp3147.36, and the constructed homology model supports a salt 
bridge formation between them. The side chains of these ionic residues and the amino acids 
identified at the key positions (see above) were the starting point to develop a structure-based 
pharmacophore of the putative allosteric binding site in the D3R-based homology model of the D1R. 
Accordingly, two hydrogen bond acceptor (HBA) features (green arrows and spheres) were 
positioned at 2.5 Å from the Nζ atom of Lys812.61 and the Oγ atom of Ser188i+2, two hydrogen bond 
donor (HBD) features (pink arrows and spheres) were positioned at 3.5 Å from the Oδ atom of 
Asp3147.36 and at 2.5 Å from the Oγ atom of Ser188i+2, and an aromatic feature (brown sphere) was 
positioned to interact with Phe3137.35 (Figure 6B). A pharmacophore model containing the five 
features was manually generated with the Discovery Studio software and a virtual screening of a 
small-molecule database should identify ligands binding to this allosteric site. 
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Figure 4. A. Crystal structure of the D3R in complex with eticlopride (PDB ID: 
3PBL) (space-filling representation); ECL2 is shown in green, ICL2 in purple, and 
disulfide bonds in brown; B. Comparison of the TM domains of D3R (brown) and 
β2AR (blue; PDB ID: 2RH1) (Source: reference 16). 
 
 
Figure 5. Amino acid sequences at positions 2.61, 2.64, 
and 2.65 in TM2; i-1, i+1, i+2 in ECL2; and 7.32, 7.35, and 
7.36 in TM7/ECL3 for muscarinic receptors (M1-5), 
adrenergic receptors (1-3) and DA receptors (D1-5). 
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Figure 6. A. Published crystal structures for class A GPCRs have revealed that the orthosteric binding 
site (blue) is mainly located within the 7TM domain whereas the allosteric binding sites (red) are located 
at the ECD; B. A D3R-based homology model of the D1R was used to develop a structure-based 
pharmacophore model consisting in five features: two HBAs (green), two HBDs (pink), and an aromatic 
system (brown). Pharmacophore elements are drawn as spheres or vectors indicating the directional 
nature of the hydrogen-bond chemical function. Compound 10Z-0706 (in wheat) was identified from the 
virtual screening of a library of compounds, by a fitting procedure to the pharmacophore model. The 
conserved Cys-Cys bridge between TM3 and ECL2 and the docking position of DA in the orthosteric 
binding site are shown as a reference. 
 
A ligand dataset from the ZINC database containing ~5.6 million commercially available 
compounds was filtered with Discovery Studio 3.5 and Open Babel according to molecular mass 
(200-300 daltons), logP (0–5), HBDs and HBAs (=2), and number of rotatable bonds (2-3), leading 
to ~10.000 compounds. Diverse conformations (between 10 and 50 per molecule, depending on its 
size) of these molecules were fitted to the pharmacophore model, resulting in a total of ~200 
putative PAMs. Finally, these compounds were docked in the D1R model and inspected for binding 
interactions with the receptor. This structure-based drug design methodology for hit identification 
yielded thirty-five diverse molecules that were purchased in eMolecules20 and assessed in vitro for 
allosteric modulation of the receptor (Figure 7). 
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Figure 7. Structure-based drug discovery methodology for the identification of AMs for the D1R. 
 
The primary screening assay was performed in collaboration with Prof. Mabel Loza and Dr. 
José Brea at Universidad de Santiago de Compostela. The functional activity of the selected 
compounds was determined in the human neuroblastoma SK-N-MC cell line, which has been 
reported to endogenously express D1R but not D5R.21 The effect of the compounds –at a fixed 
concentration of 10 μM– on DA concentration-response curves was measured using a cAMP 
production assay. A potentiation >20% in DA maximal effect (measured as Emax) was observed for 
eleven compounds (Figure 8A) that were considered potential PAMs of the receptor. Among them, 
biphenyl derivative 10Z-0706 and saccharin 191421196, exhibiting the highest increase in the DA 
Emax (58% and 40%, respectively, Figure 8B), were selected as initial hits. The structure and purity 
of these hits were confirmed by proton NMR (1H-NMR) and high-performance liquid 
chromatography (HPLC) coupled to mass spectrometry (MS). The results of a manual cAMP assay 
validated their potentiation of the DA Emax. Hence, the identified hits entered into medicinal 
chemistry programs including optimization process and in vivo validation of the drug candidate. 
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Figure 8. A. Compounds identified as PAMs of the D1R in the cAMP screening assay 
(potentiation of DA Emax >20% at a fixed concentration of compound of 10 μM); B. Hits 
selected for medicinal chemistry programs. 
 
2.2. Optimization process: from 10Z-0706 to UCM-01212 
To start with the hit-to-lead process, the compounds in Figure 9, related to hit 10Z-0706, were 
proposed. First, compounds 1 and 2 aimed to understand the key functional groups of the hit that 
are required for the positive modulation of DA maximum response in the D1R. Then, we evaluated 
the optimal position of both functional groups in the aromatic rings, the influence of the replacement 
of the oxygen for a sulfur or the introduction of fluorine atoms in the alkoxy moiety in compounds 3-
12. Besides, the importance of two aromatic features was evaluated in compounds 13 and 14. In 
order to produce novel and IP-free compounds, fluorine atoms were introduced in the alkoxy moiety 
of the proposed analogs. The incorporation of a fluorine atom in molecules has been a widespread 
strategy in hit/lead optimization to replace mostly hydrogen atoms, resulting in comparable 
pharmacological activity but with different physicochemical properties. In fact, almost 25% of the 
drugs contain at least one fluorine atom. Due to its small size and high electronegativity, 
applications in medicinal chemistry encompass the improvement of metabolic stability, 
bioavailability and protein-ligand interactions. Metabolic stability can be enhanced by blocking 
activated positions of the molecule, for instance in aromatic methoxy derivatives; modulation of 
lipophilicity can influence bioavailability, since aromatic fluorination increase lipophilicity and 
monofluorination or trifluoromethylation of saturated alkyl groups usually makes it drop; and 
modification of the pKa of the molecule can influence interaction with a target protein.22-24 
Biphenyl derivative
O
H
O
10Z-0706
Saccharin derivative
Compound % Increase in DA Emax
10Z-0706 58.0
191421196 40.0
K0808-1848 30.5
0191394551 29.2
OSSK789001 28.9
Z104483210 27.5
Z732813180 26.6
Z87614956 26.1
Z102925488 23.7
STK175441 21.6
0191415751 21.0
A B
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Figure 9. Proposed compounds related to hit 10Z-0706. 
 
2.2.1. Synthesis and screening of proposed compounds 1-14 
Compounds 1 and 2 are commercially available. The synthetic route of biphenyl derivatives 3-
12 was envisioned via a Suzuki-Miyaura cross coupling reaction, preceded or followed by a 
fluoroalkylation step. Thus, coupling between the proper phenylboronic acid derivative and the 
adequate bromobenzene derivative was carried out in the presence of Pd(PPh3)4 as catalyst and 
Na2CO3 as base under microwave (MW) irradiation or thermal conditions, affording intermediates 
15-17 (Scheme 1A). Next, treatment of 15-17 or commercial 4’-hydroxybiphenyl-4-carbaldehyde 
with chlorofluoromethane in N,N-dimethylformamide (DMF) allowed to obtain desired 
monofluoromethoxy derivatives 3-6 (Scheme 1A). This two-step synthetic methodology was also 
applied to prepare final compound 10, bearing an OCHF2 group. In this case, intermediate 17 was 
reacted with diethyl [bromo(difluoro)methyl]phosphonate as fluoroalkylating reagent (Scheme 1A). 
The rest of the difluoroalkoxy derivatives 7-9 were synthesized via direct coupling reaction 
between (4-formylphenyl)boronic acid and the corresponding commercially available 
bromodifluoroalkoxybenzene (Scheme 1B). It should be noted that compounds bearing the formyl 
and alkoxy groups in 2- and 2’-position were not proposed, since both 2’-hydroxybiphenyl-2-
carbaldehyde and 2’-alkoxybiphenyl-2-carbaldehyde are reported to undergo ring-closure to afford 
the corresponding hemiacetal or acetal, respectively.25 
In the case of alkylsulfanyl derivatives 11 and 12, direct coupling using 2-bromobenzenethiol 
as a starting material was not possible due to catalyst poisoning.26 Hence, fluoroalkylation of 2-
bromobenzenethiol with either chlorofluoromethane to obtain intermediate 18, or diethyl 
[bromo(difluoro)methyl]phosphonate to obtain compound 19 was carried out. Subsequent coupling 
reaction with (4-formylphenyl)boronic acid afforded final compounds 11 and 12 (Scheme 1C). 
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Scheme 1. Reagents and conditions: (a) Pd(PPh3)4, Na2CO3, THF/H2O, MW, 120 ºC, 
20 min or , on, 52-72%; (b) ClCH2F (2.0 M in DMF), Cs2CO3, DMF, -78 ºC to rt, on, 
59-84%; (c) BrF2CP(O)(OEt)2, KOH, ACN/H2O, -78 ºC to rt, on, 40-81%; (d) 
Pd(PPh3)4, Na2CO3, toluene/EtOH/H2O, MW, 120 ºC, 20 min or, on, 49-90%. 
 
Regarding arylpiperazine derivatives, compound 13 containing OCH2F group was synthesized 
starting from commercial 1-(2-hydroxyphenyl)piperazine via protection with di-tert-butyl 
dicarbonate, followed by fluoroalkylation of N-Boc piperazine 20 with chlorofluoromethane, to afford 
monofluorinated intermediate 21. Subsequently, deprotection with trifluoroacetic acid (TFA) and 
formylation with methyl formate yielded final arylpiperazine 13 (Scheme 2A). The OCHF2 analog 14 
was prepared by Buchwald-Hartwig coupling reaction of piperazine with commercial 2-
(difluoromethoxy)bromobenzene using Pd(OAc)2 and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl 
(BINAP) as catalytic system and Cs2CO3 as base to obtain intermediate 22. Then, formylation 
using methyl formate afforded compound 14 (Scheme 2B). 
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Scheme 2. Reagents and conditions: (a) Di-tert-butyl dicarbonate, triethylamine, DCM, rt, 
3 h, quantitative; (b) ClCH2F (2.0 M in DMF), Cs2CO3, -78 ºC to rt, on, 80%; (c) TFA, 
DCM, rt, 2 h, quantitative; (d) methyl formate, , 36-48 h, 58-60%; (e) Pd(OAc)2, BINAP, 
Cs2CO3, 1,4-dioxane, 100 ºC, on, 58%. 
 
All the synthesized compounds were assessed for functional activity in human neuroblastoma 
SK-N-MC cells expressing D1 receptors, using a cAMP production assay. Cells were treated with a 
fixed concentration of the tested compounds for 15 min at 25 ºC and increasing concentrations of 
DA were added and incubated for additional 15 min at 25 ºC. Treated cells were lysed and the 
cAMP concentration was quantified by an HTRF assay. A DA dose-response curve was obtained in 
the presence of each compound, and potentiation of the DA Emax was measured. The following 
workflow was established in order to indentify PAMs of the D1R. In the screening, the compounds 
that potentiate more than 25% the DA Emax at a fixed concentration of 10 μM were also assayed at 
1 μM. If the observed effect is dose-dependent, compounds were then tested in the cAMP assay, 
this time maintaining a fixed concentration of DA (=EC70) while increasing the concentration of the 
compound, and the potentiation of the DA effect was measured. Taking into consideration all these 
data, a compound would then be selected for further biological and pharmacological 
characterization. 
The results of the cAMP screening assays are expressed in Table 1. The removal of the 
formyl group in compound 1 or the alkoxy substituent in analog 2 led to less efficient PAMs (28% 
and 37% of DA Emax potentiation at 10 μM, respectively). Compounds 3-5 and 7-9 revealed that 2’-
position is the most favorable for the alkoxy group (5 and 9, with 82% and 45% of DA Emax 
potentiation at 10 μM, respectively). Hence, the position of the formyl group was explored in 2’-
fluoroalkoxy analogs 6 and 10, revealing a marked drop of activity when the carbonyl is situated in 
3-position (DA Emax potentiation of 23% and 12% at 10 μM, respectively). When compounds were 
tested at increasing concentrations in the presence of a fixed concentration of DA (=EC70), 
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compounds 5 and 9, bearing a formyl group in 4-position and a fluoroalkoxy moiety in 2’-position 
(OCH2F and OCHF2, respectively), potentiated DA effect the highest (91% and 62%, respectively, 
Table 1). In the best potentiators 5 and 9, replacement of oxygen for a sulfur atom in the alkoxy 
moiety did not improve the allosteric modulation in derivative 12 (44% potentiation at 10 μM, Table 
1) and a marked drop was observed in analog 11 (14% potentiation at 10 μM, Table 1). Besides, 
the presence of two aromatic features in the molecule appears to be essential, since a lack of 
potentiation was observed in arylpiperazine derivatives 13 and 14 (9% and 23% potentiation at 10 
μM, respectively, Table 1). 
Clearly, among the newly identified modulators of the D1R, compound 5 (UCM-01212) that 
contains a biphenyl scaffold bearing a formyl group in 4-position and OCH2F group in 2’-position is 
the most efficient PAM. It potentiates DA Emax in 33% and 82% at 1 and 10 μM, respectively, and it 
enhances DA effect in a 91% over DA EC70 (Table 1). 
Table 1. Effect of compounds 1-14 in DA-induced cAMP production in human neuroblastoma cell line. 
 
Compound CHO position X Y, Z 
XCHYZ 
position 
Potentiation (%)a,b [DA] = EC70 
@ 10 μM @ 1 μM Pot. (%)b,c EC50 (μM) 
10Z-0706 4 O H, H 4’ 57 6 61 1.18 
1 - O H, H 4’ 28 14 34 5.8 
2 4 - - - 37 11 41 22.8 
3 4 O H, F 4’ 29 0 N.D. N.D. 
4 4 O H, F 3’ 25 23 27 2.04 
5 (UCM-01212) 4 O H, F 2’ 82 33 91 12.7 
6 3 O H, F 2’ 23 22 N.D. N.D. 
7 4 O F, F 4’ 35 0 37 2.32 
8 4 O F, F 3’ 37 7 35 10.8 
9 4 O F, F 2’ 45 46 62 18.5 
10 3 O F, F 2’ 12 N.D. N.D. N.D. 
11 4 S H, F 2’ 14 N.D. N.D. N.D. 
12 4 S F, F 2’ 44 0 101 21.8 
13 - - H, F - 9 N.D. N.D. N.D. 
14 - - F, F - 23 N.D. N.D. N.D. 
a: Potentiation of DA Emax at a fixed concentration of compound; b: Values are obtained in duplicate; c: 
Potentiation of DA effect at a fixed [DA] = EC70; N.D. = Not Determined. 
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2.2.2. In vitro pharmacological characterization of UCM-01212 
Compound UCM-01212 was selected for further pharmacological characterizacion as a new 
PAM of the D1R. UCM-01212 was evaluated in the DA-induced cAMP assay at different 
concentrations in human SK-N-MC and mouse CAD neuroblastoma cell lines, resulting in dose-
dependent potentiation of DA effect in both cell lines (Figures 10A and 10B). The compound was 
also studied at high concentration of DA (=EC70) in the cAMP assay, and displayed a 91% of 
potentiation of DA effect, with an EC50 of 12.7 μM (Figure 10C). Next, UCM-01212 was assayed in 
the absence of DA and no response was observed. Importantly, the new PAM did not display 
agonist activity per se (Figure 10D). 
 
Figure 10. A. Dose-response curves for cAMP production in human SK-N-MC neuroblastoma 
cell line induced by DA (black line) and in the presence of UCM-01212 at the indicated 
concentrations (colored lines); B. Dose-response curves for cAMP production in mouse CAD 
neuroblastoma cell line induced by DA (black line) and in the presence of UCM-01212 at the 
indicated concentrations (colored lines); C. Dose-response curve for cAMP production of UCM-
01212 over DA EC70; D. Dose-response curves for cAMP production of DA (black line) and UCM-
01212 (red line). 
 
One of the most challenging aspects in the development of dopaminergic agents is the 
subtype selectivity. Hence, UCM-01212 was tested in the cAMP assay at a fixed concentration of 
10 μM, using transfected cells expressing the different receptor subtypes. Results showed that 
compound UCM-01212 did not potentiate DA Emax in any of the receptors examined, thus exhibiting 
subtype selectivity against D2, D3 and D4 receptors (Figure 11). 
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Figure 11. Selectivity profile of UCM-01212 towards D2, D3 and D4 receptors. 
 
2.2.3. Study of the allosteric binding site 
We have studied the allosteric binding site of compound UCM-01212 at the D1R. Initially, in 
order to confirm that UCM-01212 was not binding to the orthosteric site, competitive radioligand 
binding assays were performed employing [3H]SCH-23390 as radioligand, a selective ligand of the 
D1R. Results revealed that compound UCM-01212 was not able to displace [3H]SCH-23390 (12% 
of displacement at 10 μM), whereas haloperidol used as reference compound fully displaced the 
radioligand (Figure 12A). Thus, selected compound does not bind to the orthosteric site but it is 
located in an allosteric one, in agreement with a docking model carried out with UCM-01212 and 
ligand SCH-23390 (Figure 12B). In this model, the allosteric pocket is suggested to be placed 
within the side chains of Lys812.61, Phe3137.35, Asp3147.36 and Ser188i+2. 
The proposed allosteric binding site was studied through site-directed mutagenesis 
experiments in collaboration with Dr. Peter McCormick and Dr. Carme Lluis at Universidad de 
Barcelona. To test whether the allosteric binding site is formed by the side chains employed in the 
definition of the structure-based pharmacophore model, Lys812.61, Phe3137.35, Asp3147.36 and 
Ser188i+2 were mutated to Ala and the effect of UCM-01212 on DA-induced cAMP production was 
determined. As shown in Figure 12C, Lys812.61A and Ser188i+2A abrogate the effect of UCM-01212 
in enhancing the DA-induced maximum response and Asp3147.36A partly attenuates the increase of 
Emax. In contrast, Phe3137.35A does not affect DA effect. These data suggest that the 
Lys812.61··Asp3147.36 salt bridge, in conjunction with Ser188i+2 in ECL2, can modulate D1R function, 
in a similar manner as the Asp192i+1··Lys3057.32 salt bridge described for β2-AR,18 and can be used 
as a structural motif of the D1R for PAMs development. 
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The effect of UCM-01212 in enhancing the DA maximum response was also tested by 
resolution of the real-time signalling signature using a dynamic mass redistribution (DMR) assay, 
that is a label-free method based on optical detection of dynamic changes in cellular density 
following receptor activation (Figure 12D).27 Clearly, in the wild type (wt) D1R the magnitude of the 
signalling by DA increased in the presence of UCM-01212, confirming its role as a PAM. This 
phenomenon was not observed in the Lys812.61A, Asp3147.36A and Ser188i+2A mutant receptors 
and it is preserved in the Phe3137.35A mutant, which further supports that the new PAM UCM-
01212 enhances the DA effect via the Lys812.61··Asp3147.36 salt bridge and Ser188i+2 in ECL2. 
 
 
Figure 12. A. Radioligand competition assays measuring the displacement of [3H]SCH-23390 by UCM-01212 
(red) and haloperidol (black); B. Docking experiments for the binding of SCH-23390 (light blue) and PAM 
UCM-01212 (wheat) into the orthosteric and allosteric sites, respectively. The surface of both molecules 
predicts no superposition of sites; C. Effect of Ala mutation of Lys812.61, Phe3137.35, Asp3147.36 and Ser188i+2 
in DA maximum cAMP production at different concentrations of UCM-01212 (light blue, 0.1 μM; dark blue 10 
μM); D. Effect of the same mutations in the DMR assays in the absence (black) and in the presence of UCM-
01212 (blue, 10 μM). 
 
2.2.4. Pharmacokinetic properties of compound UCM-01212 
The next step was the evaluation of the PK properties in vitro of UCM-01212. In order to 
measure solubility, increasing concentrations of the compound were tested in a nephelometry 
experiment, which is a technique based on the measurement of the light scattered by turbidity. The 
results showed a maximum solubility value of 15 μM (Figure 13). 
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Figure 13. Representation obtained from nephelometry experiment for compound UCM-01212. 
 
Chemical stability was studied in dimethyl sulfoxide (DMSO), water and phosphate buffered 
solution (PBS) by incubating the compound at room temperature for two days and quantifying the 
remaining compound using HPLC-MS. Results (Table 2) showed that UCM-01212 was more stable 
in water (89% of remaining compound) than in DMSO (67% of remaining compound) and PBS 
(49% of remaining compound). In mouse serum, compound UCM-01212 showed a loss of 50% at 0 
ºC. Metabolic stability using mouse and human liver microsomes (MLM and HLM, respectively) as 
a measure of first-pass metabolism could not be measured due to a low detection of the compound 
by MS at the concentration used for the assay. An in vitro fluorescence-based inhibition assay was 
conducted with a panel of cytochromes P450 (CYP450). The compound exhibited a moderate 
inhibition of CYP1A2, CYP2C19 and CYP3A4 (IC50 = 0.83-6.53 μM), being inactive on CYP2C9 
and CYP2D6, important enzymes involved in drug metabolism (Table 2). 
Compound UCM-01212 was also tested for interaction with human serum albumin (HSA) 
using a commercial kit. Quantified by HPLC-MS, a binding to HSA >99% was determined at a 
concentration of 5 μM with a Kd = 4.34·10-6 M (Table 2). Additionally, we evaluated the cell 
permeability of UCM-01212 with the well-validated parallel artificial membrane permeability assay 
(PAMPA) technique. The compound showed a permeability value (P) of 20×10−6 cm/s (Table 2), 
intermediate between that of propranolol (P = 25×10−6 cm/s) and metoprolol (P = 9×10−6 cm/s), 
both highly permeable drugs used as references. Finally, hERG inhibition was determined as an 
indication of possible lethal side effects related with cardiac toxicity. In a hERG binding assay, 
UCM-01212 showed a low blockade of the K+ channel current (11% of inhibition at 10 μM, Table 2). 
Although UCM-01212 displayed a moderate PK profile (low solubitlity, high HSA binding and 
moderate inhibition in a panel of CYP450), we decided to use it as a proof of concept of the 
therapeutic interest of a D1R allosteric modulator before starting with its optimization. 
Table 2. PK profile for UCM-01212. 
Compound Solubility (μM) 
Chemical stability (%)a Serum 
stability (%)b 
CYP450 
profile 
HSA 
binding (%) 
P 
(cm/s) 
hERG 
inhition (%) Water DMSO PBS 
UCM-01212 15 89 67 49 50 
inactive in 
CYP2C9 and 
CYP2D6 
>99 20·10-6 11 
a: Percentage of remaining compound after two days at room temperature; b: Percentage of remaining compound at 0 ºC. 
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2.2.5. In vivo validation 
In vivo experiments were carried out in collaboration with Dr. Rosario Moratalla at Instituto 
Cajal of the Consejo Superior de Investigaciones Científicas. Pitx3-null mice were chosen as a 
model of PD with a high sensitivity to dopaminergic drugs. The design of the experiment to 
evaluate motor activity is depicted in Figure 14. In the procedure, which takes five days in total, the 
first two are adaptation period and in the third day L-DOPA and/or UCM-01212 (50 or 200 mg/kg, 
ip) are administered. Motor activity was evaluated each day after administration through the rotarod 
test and a model of dyskinesia. In the fifth day, mice are sacrified and brains are collected to 
measure FosB expression levels. 
 
Figure 14. In vivo experimental design to validate UCM-01212 in 
a model of PD. 
 
Results from the rotarod test showed that UCM-01212 (50 mg/kg, ip) increased motor 
coordination with respect to the vehicle at days 4 and 5 (Figure 15A). Besides, the compound (200 
mg/kg, ip) elicited a decrease of the dyskinesia produced by administration of L-DOPA at days 3 
and 4 (Figure 15B). 
As a marker of neuronal activity we used FosB induction which is expressed through D1R 
stimulation of the cAMP-dependent intracellular signalling pathway. Although FosB is constitutively 
expressed in the striatum,28-30 this expression was increased almost two fold after UCM-01212 
administration at low (50 mg/kg) and high (200 mg/kg) dosages in the totally denervated striatal 
region (Figure 16). This result indicates that UCM-01212 is able to increase FosB expression in the 
supersensitive, totally denervated, striatal neurons. 
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Figure 15. Evaluation in behaviour experiments of motor activity. A. Rotarod test; B. A model of dyskinesia. 
 
 
Figure 16. Levels of FosB expression in treated mice. A. Histograms represent the 
quantification of FosB immunoreactive nuclei in the partial and the total denervated striatal 
regions (### and ** denote statistical significance, P<0.05); B. Images show FosB 
expression in the striatum; C. Detail of dennervated striatal regions in non-treated mice. 
 
2.3. Optimization process: from UCM-01212 to UCM-01306 
At this point, UCM-01212 allowed us to set the proof of concept of a D1R PAM as a potential 
novel therapy for the treatment of PD. However, its moderate PK profile hampered its progress as a 
drug candidate, and prompted us to search for a new compound with an improved PK profile. 
Therefore, UCM-01212 entered an optimization program. In a first step, we explored the 
replacement of the formyl group due to its low prevalence in drugs caused by the chemical 
reactivity to engage in a reduction/oxidation pathway in vivo.31 Aldehyde bioisosters with HBA 
Vehicle
UCM-01212 50 mg/kg
UCM-01212 200 mg/kg
BA
Day
Vehicle
UCM-01212 50 mg/kg
UCM-01212 200 mg/kg
L-DOPA
L-DOPA + UCM-01212 50 mg/kg
L-DOPA + UCM-01212 200 mg/kg
Day
Rotarod Dyskinesia
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properties were considered in proposed compounds 23-34 (Figure 17). Classical bioisosters such 
as ketone, carboxylic acid, methyl ester and amide groups were suggested since they are also 
carbonyl-containing moieties. Non-classical bioisosters such as sulfone, sulfoxides, sulfonamides 
and sulfoximines, were also considered as they proved to have potential advantages in medicinal 
chemistry.32,33 
In general, the synthesis of the proposed compounds 23-34 was envisioned as a Suzuki-
Miyaura cross coupling reaction to construct the biphenyl scaffold and a fluoroalkylation reaction to 
obtain the OCH2F moiety (Figure 17). 
 
Figure 17. Proposed compounds 23-34 in the optimization process of UCM-01212 (5). 
 
Coupling reaction of the adequate bromobenzene derivative and the corresponding 
phenylboronic acid was performed using previously described conditions, to obtain desired 
biphenyl intermediates 35-39 (Scheme 3). Subsequently, fluoroalkylation reaction with a solution of 
chlorofluoromethane was carried out to afford final products 23-26 (Scheme 3), functionalized with 
a ketone, ester or sulfonamide group. Carboxylic acid 27 was then readily accessible through basic 
hydrolysis of methyl ester 24 in quantitative yield. 
 
Scheme 3. Reagents and conditions: (a) Pd(PPh3)4, Na2CO3, toluene/EtOH/H2O, 
MW, 120 ºC, 20 min or , on, 16-95%; (b) ClCH2F (2.0 M in DMF), Cs2CO3, DMF, 
-78 ºC to rt, on, 31-93%; (c) NaOH, THF/H2O, rt, 12 h, quantitative. 
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Regarding biphenyl compound bearing an amide group (28), coupling reaction between (4-
carbamoylphenyl)boronic acid and 2-bromophenol did not give the expected biphenyl derivative. 
Thus, compound 28 was synthesized via fluoroalkylation reaction of 2-bromophenol with 
chlorofluoromethane, prior to coupling of resultant fluorinated bromobenzene derivative 40 with (4-
carbamoylphenyl)boronic acid (Scheme 4). 
 
Scheme 4. Reagents and conditions: (a) ClCH2F (2.0 M in DMF), Cs2CO3, 
DMF, -78 ºC to rt, on, 97%; (b) Pd(PPh3)4, Na2CO3, toluene/EtOH/H2O, MW, 
170 ºC, 10 min, 32%. 
 
The synthesis of sulfone 29 was performed starting from intermediate 39, previously obtained 
through coupling between 2-hydroxyphenylboronic acid and 1-bromo-4-(methylsulfanyl)benzene 
(see Scheme 3). Oxidation of the sulfide group with hydrogen peroxide and ammonium molibdate 
tetrahydrate afforded intermediate 41 in a single operation, which was then fluoroalkylated to yield 
desired compound 29 (Scheme 5). 
 
Scheme 5. Reagents and conditions: (a) H2O2 (30%), 
(NH4)6Mo7O24·4H2O, methanol, 0 ºC to rt, 1 h, 75%; (b) 
ClCH2F (2.0 M in DMF), Cs2CO3, DMF, -78 ºC to rt, on, 97%. 
 
Sulfoxide analogs 30 and 31 were prepared from 1-bromo-4-(methylsulfanyl)benzene and 1-
bromo-4-(ethylsulfanyl)benzene (Scheme 6), respectively. Oxidation with m-chloroperbenzoic acid 
(mCPBA) and subsequent coupling of arylsulfoxides 42 and 43 with 2-hydroxyphenylboronic 
afforded biphenylsulfoxide intermediates 44 and 45. Final fluoroalkylation with chlorofluoromethane 
yielded desired compounds 30 and 31. 
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Scheme 6. Reagents and conditions: (a) mCPBA, DCM, 0 ºC to rt, 4 h, 83-92%; 
(b) Pd(PPh3)4, Na2CO3, toluene/EtOH/H2O, MW, 120 ºC, 20 min, 93-99%; (c) 
ClCH2F (2.0 M in DMF), Cs2CO3, DMF, -78 ºC to rt, on, 52-87%. 
 
As far as sulfoximines are concerned, several methods have been described for their 
preparation. The first synthetic method was reported by Johnson, through imination of the 
corresponding sulfoxide using externally added or in situ generated hidrazoic acid.34,35 This 
methodology was used for the synthesis of ethylsulfoximine derivative 32 (Scheme 7). Thus, 
imination of previously synthesized sulfoxide intermediate 43 (see Scheme 6) with hidrazoic acid, 
generated in situ with sodium azide and H2SO4, allowed to obtain the corresponding sulfoximine 
46. Next, coupling reaction with 2-hydroxyphenylboronic acid afforded the biphenyl scaffold 47 and 
final fluoroalkylation yielded desired compound 32. 
 
Scheme 7. (a) NaN3, H2SO4 (conc.), CHCl3, 45 ºC, on, 92%; (b) Pd(PPh3)4, Na2CO3, 
toluene/EtOH/H2O, MW, 120 ºC, 20 min, 90%; (c) ClCH2F (2.0 M in DMF), Cs2CO3, 
DMF, -78 ºC to rt, on, 84%. 
 
Even though the previous methodology has been extensively used, other synthetic routes 
have recently been developed due to safety issues related with hidrazoic acid. The most extensive 
work towards this aim has been carried out by Carsten Bolm and colleagues, providing a novel and 
straightforward methodology for the synthesis of NH sulfoximines, which consists of a sequence of 
imination, oxidation, and hydrolysis starting from the corresponding sulfide.36 Based on this 
methodology, commercial 1-bromo-4-(methylsulfanyl)benzene was reacted with cyanamide in the 
presence of recrystallized N-bromosuccinimide (NBS) and potassium tert-butoxide to yield the 
corresponding N-cyanosulfylimine 48, which can be used in the next step without further 
purification (Scheme 8). Intermediate 48 was oxidized with ruthenium tetroxide, generated in situ 
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from ruthenium (III) chloride and sodium periodate, to afford crude N-cyanosulfoximine derivative 
49, which was subsequently hydrolyzed by heating in 50% aqueous H2SO4 to obtain NH 
arylsulfoximine 50. Overall, this three-step synthetic route only needed purification at the last step 
and turned out to be a highly efficient methodology to obtain the sulfoximine moiety. Once the 
building block 50 was synthesized, coupling with 2-hydroxyphenylboronic acid gave intermediate 
51 that was fluoroalkylated with chlorofluoromethane to obtain final compound 33 (Scheme 8). 
Preparation of the N-methylsulfoximine 34 was first tried from compound 33 via the 
Eschweiler-Clarke reaction using formic acid and aqueous formaldehyde (Scheme 8). A complex 
mixture was obtained in which the desired product could not be detected. Intermediate 50 was 
used instead, affording the corresponding N-methylsulfoximine 52 in a quantitative yield, which was 
submitted to the coupling reaction and fluoroalkylation pathway to obtain desired compound 34 
(Scheme 8). Alternative methylation agents, such as trimethyloxonium tetrafluoroborate or methyl 
iodide, were not succesfull to obtain N-methylsulfoximines, probably due to the fact that they do not 
work well in low scale. 
 
Scheme 8. Reagents and conditions: (a) cyanamide, NBS, tBuOK, methanol, rt, 
1.5 h, quantitative; (b) RuCl3, NaIO4 (aq., 0.15 M), ACN/DCM, rt, 3 h, 83%; (c) 
H2SO4 (aq., 50%), , 2 h, 77%; (d) Pd(PPh3)4, Na2CO3, toluene/EtOH/H2O, MW, 
120 ºC, 20 min, 45-56%; (e) ClCH2F (2.0 M in DMF), Cs2CO3, DMF, -78 ºC to rt, 
on, 78-95%; (f) HCO2H, HCHO (aq., 37%), 100 ºC, 2 d, quantitative. 
 
Once all proposed compounds 23-34 were synthesized, their assessment as PAMs was 
carried out in the cAMP assay, following the established workflow (see section 2.2.1). Analysis of 
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the data in Table 3 showed that replacement of the aldehyde for other carbonyl-containing moieties 
(ketone, ester, carboxylic acid and amide in compounds 23, 24, 27, 28, respectively), sulfonamide 
(25, 26) or sulfonyl (29) resulted detrimental for the activity. On the other hand, a sulfinyl or 
sulfoximine group seems tolerable. In the case of sulfinyl derivatives a marked drop in activity was 
observed from methyl to ethyl analogs (30, 60% vs 31, 16% at 10 μM), while potentiation is 
maintained for sulfoximine analogs (32, 54% vs 33, 55% at 10 μM). Methylation of the nitrogen in 
the sulfoximine group produced a decrease in activity (34, 30% at 10 μM). Considering the most 
efficient PAMs in the series (30, 32 and 33), it is important to note that sulfoximine derivative 33 is 
two orders of magnitude more potent than parent compound UCM-01212 (EC50 = 60 nM, Table 3). 
Table 3. Effect of compounds 23-34 in DA-induced cAMP production in human 
neuroblastoma cell line. 
 
Compound R 
Potentiation (%)a,b [DA] = EC70 
@ 10 μM @ 1 μM Pot. (%)b,c EC50 (μM) 
UCM-01212 CHO 82 33 91 12.7 
23 COMe 11 N.D. N.D. N.D. 
24 COOMe 28 0 N.D. N.D. 
25 SO2NH2 29 0 42 4.93 
26 SO2NHMe 38 0 28 1.26 
27 COOH 7 N.D. N.D. N.D. 
28 CONH2 16 N.D. N.D. N.D. 
29 SO2Me 27 26 30 13.11 
30 SOMe 60 49 73 21.68 
31 SOEt 16 N.D. N.D. N.D. 
32 SO(NH)Et 54 12 50 30.2 
33 SO(NH)Me 55 25 25 0.06 
34 SO(NMe)Me 30 0 33 15.9 
a: Potentiation of DA Emax at a fixed concentration of compound; b: Values are 
obtained in duplicate; c: Potentiation of DA effect at a fixed [DA] = EC70; N.D. = Not 
Determined. 
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Compound 33 (UCM-01306) was then selected for further optimization due to the high 
potentiation of DA Emax (55% at 10 μM, see Table 3) and the high potency in the presence of DA 
(EC50 = 60 nM, see Table 3). 
We next considered new sulfoximine derivatives 54-56 (Figure 18). The replacement of the 
alkoxy-substituted aromatic ring in 33 for a pyridine in compound 54 aimed to increase solubility, 
and the introduction of a halogen atom as in compounds 55 and 56 in order to improve oral 
permeability and CNS penetration.37,38 
 
Figure 18. Proposed modifications in compound UCM-01306 (33) and synthetic 
approach for new compounds 54-56. 
 
The synthesis of the pyridine derivative 54 was approached starting from previously 
synthesized intermediate 50 and commercially available 2-bromopyridin-3-ol (Figure 18). None of 
the conditions tried to transform 2-bromopyridin-3-ol into the pinacol boronate derivative using 
bis(pinacolato)diboron (B2pin2) and different catalytic systems and bases allowed us to obtain the 
desired product (Scheme 9A). Intermediate 50 was successfully converted into the corresponding 
aryl boronate derivative by reaction with Pd(PPh3)4 and B2pin2, but it decomposed during 
purification in silica gel (Scheme 9B). Trying to avoid decomposition, a one-pot reaction was 
performed using Pd2(dba)3·CHCl3 adduct as catalyst. Although the coupled product was detected 
by HPLC-MS, the low conversion avoided isolation (Scheme 9C). 
Therefore, as an alternative route, 2-bromopyridin-3-ol was firstly fluoroalkylated and resulting 
intermediate 57 was coupled to the in situ generated boronate ester of compound 50 in a one-pot 
reaction to yield final compound 54 (Scheme 10). 
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Scheme 9. Unsuccessfull reations for the synthesis of final compound 54. 
 
 
Scheme 10. Reagents and conditions: (a) ClCH2F (2.0 M in DMF), Cs2CO3, DMF, -78 
ºC to rt, on, 73%; (b) i) 50, B2pin2, Pd2(dba)3·CHCl3, SPhos, KOAc, 1,4-dioxane, 110 ºC, 
on; (ii) Pd2(dba)3·CHCl3, K3PO4 (aq., 5 M), 110 ºC, on, 24%. 
 
According to the synthetic route proposed in Figure 18 for compounds 55 and 56, 
bromochloroarylsulfoximines 65 and 66 were prepared as previously set up via the imination, 
oxidation and hydrolysis sequence, starting from the corresponding bromochloroarylsulfides 58 and 
59 (Scheme 11). These sulfides were obtained by methylation of 4-bromo-2-chlorobenzenethiol 
and 4-bromo-3-chlorobenzenethiol (60), which was prepared through Leuckart reaction of 4-bromo-
3-chloroaniline. Then, coupling reaction of intermediates 65 and 66 with 2-hydroxyphenylboronic 
acid yielded biphenyl derivatives 67 and 68, and final fluoroalkylation afforded desired compounds 
55 and 56 (Scheme 11). 
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Scheme 11. Reagents and conditions: (a) i) NaNO2, HCl (conc.), potassium O-ethyl 
carbonodithioate, -5 to 75 ºC, 1.5 h; ii) KOH, EtOH, , on, 80% (2 steps); (b) MeI, K2CO3, acetone, 
rt, 5 h, 56%-quantitative; (c) cyanamide, NBS, KOtBu, methanol, rt, 1.5 h, quantitative; (d) RuCl3, 
NaIO4 (aq., 0.15 M), ACN/DCM, rt, 3 h, 84-89%; (e) H2SO4 (aq., 50%), , 2 h, 46-51%; (f) 
Pd(PPh3)4, Na2CO3, toluene/EtOH/H2O, MW, 120 ºC, 20 min, 77-89%; (g) ClCH2F (2.0 M in DMF), 
Cs2CO3, DMF, -78 ºC to rt, on, 80-96%. 
 
The new synthesized compounds 54-56 were screened as PAMs of the D1R in the cAMP 
assay. Data in Table 4 indicate that both the introduction of a chlorine atom in either 2’- or 3’-
position, and replacement of alkoxy-substituted aromatic ring for a pyridine produced an important 
depletion of allosteric activity of the compounds. 
Therefore, from the results obtained in the optimization process of UCM-01212, compound 
UCM-01306 (33) exhibited the best allosteric activity (see Table 3) and a drug-like profile (predicted 
values using ACD/Percepta® software for partition coefficient –logP– of 1.95, topological polar 
surface area –tPSA– of 58 Å2, blood-brain barrier uptake –logBB– of -0.17 and plasma protein 
binding –PPB– of 90%) and was selected for further pharmacological characterization and study of 
PK properties. 
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Table 4. Effect of compounds 54-56 in DA-induced cAMP 
production in human neuroblastoma cell line. 
 
Compound Cl position W Pot. (%)
a,b 
33 (UCM-01306) - CH 55 
54 - N 1 
55 3’ CH 12 
56 2’ CH 20 
a: Potentiation of DA Emax at a fixed [compound] = 
10 μM; b: Values are obtained in duplicate. 
 
2.3.1. In vitro pharmacological characterization and PK properties of UCM-01306 
Compound UCM-01306 was tested in DA-induced cAMP assay at different concentrations. 
Figure 19A shows a potentiation of the DA Emax in a dose-dependent manner, with a maximum 
value of 55% at 10 μM. Importantly, no potentiation was observed for UCM-01306 in the absence 
of DA, so it does not display intrinsic agonist activity (Figure 19B). In addition, the compound 
exhibited functional subtype selectivity against DA D2R (Figure 19C). 
When competitive radioligand binding assays were performed, results revealed that indeed 
compound UCM-01306 did not displace [3H]SCH-23390 (36% of displacement at 10 μM), in 
contrast to the full displacement by DA and haloperidol. Thus, derivative UCM-01306 is not binding 
the orthosteric binding site. 
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Figure 19. A. Dose-response curves for cAMP production induced by DA and in the 
presence of UCM-01306 at different concentrations; B. Dose-response curves for cAMP 
production of DA and UCM-01306; C. Selectivity of UCM-01306 over D2R. 
 
Regarding PK properties, they are detailed in Table 5. In nephelometry assay UCM-01306 
showed a solubility more than 3 times higher than UCM-01212 (50 μM vs 15 μM). Interaction with 
HSA protein revealed 79% binding with moderate dissociation constant for UCM-01306 (Kd = 
1.56·10-4 M), indicating a significant improvement compared to UCM-01212 (>99% binding). In 
addition, PAMPA showed a permeability value (P) of 24×10−6 cm/s for the compound, in the same 
range than reference propranolol (P = 25×10−6 cm/s) and higher than reference metoprolol (P = 
9×10−6 cm/s). Besides, hERG inhibition was determined and compound UCM-01306 showed a low 
blockade of the K+ channel current (21% of inhibition at 10 μM). Chemical stability in acid, basic 
and neutral media, together with PBS and DMSO was also studied. Quantification of remaining 
compound after seven days showed good to excellent stability: 100% in 0.1 M HCl, 50% in 0.1 M 
NaOH, 53% in water, 45% in PBS and 100% in DMSO. In mouse serum, 93% of the compound 
remained after 4 h, a much higher stability than that of enalapril used as reference (22% after 2 h). 
Compound UCM-01306 could not be tested in liver microsomes stability assays, probably due to 
complexation of the free NH of the sulfoxime group with MgCl2, used as cofactor in the experiment. 
Thus, stability in liver homogenates was carried out to assess first-pass metabolism. Liver 
homogenates were prepared and protein concentration was measured the day of the experiment. 
UCM-01306 was then incubated at a final concentration of 10 μM at 37 ºC for 24 h, showing values 
of remaining compound of 65% (for reference compound propranolol, 67% remained after 1 h). 
Hence, UCM-01306 displays a good stability profile overall. Additionally, UCM-01306 was 
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evaluated in a panel of CYP450. Low inhibition was observed for CYP2D6 and CYP34A 
(dibenzylfluorescein as substrate) (3% and 9% of inhibition, respectively), while moderate blockade 
was shown for CYP1A2, CYP2C9, CYP2C19 and CYP34A (7-benzyloxy-4-trifluoromethylcoumarin 
as substrate) (37-49% of inhibition). 
Altogether, UCM-01306 displays better pharmacological and PK profiles than parent 
compound UCM-01212 ( Table 5). 
 Table 5. Pharmacological and PK profiles for parent compound UCM-01212 and analog UCM-01306. 
 
  
Potentiation DA Emax (%)a 82 55 
EC50 (μM)b 12.7 0.06 
Agonism No intrinsic activity No intrinsic activity 
Selectivity Over D2, D3 and D4 receptors Over D2R 
Solubility (μM) 15 50 
HSA binding (%) >99 (Kd = 4.34·10-6 M) 79 (Kd = 1.56·10-4 M) 
P (cm/s) 20·10-6 24·10-6 
hERG inhibition (%)c 11 21 
Chemical stability (%)d 
Water: 89 
PBS: 49 
DMSO: 67 
HCl 0.1 M: 100 
NaOH 0.1 M: 50 
Water: 53 
PBS: 45 
DMSO: 100 
Mouse serum stability (%)e 50 93 
Liver homogenate stability (%)f - 65 
CYP450 inhibition Moderate Good 
a: Potentiation of DA Emax at a fixed [compound] = 10 μM; b: EC50 at a fixed [DA] = EC70; c: Percentage of 
inhibition at fixed [compound] = 10 μM; d: Remaining compound after 2 and 7 days for UCM-01212 and 
UCM-01306, respectively; e: Detected compound at 0 ºC for UCM-01212 and remaining compound after 
4 h at 37 ºC in the case of UCM-01306; f: Remaining compound after 24 h at 37 ºC. 
 
2.3.2. Enantiomers of UCM-01306 
In compound UCM-01306 the sulfoximine moiety provides chirality to the molecule; hence, we 
decided to synthesize each enantiomer separately in order to evaluate their activity as PAMs. To 
address that aim, the obtention of both enantiopure compounds was envisioned as a synthetic 
route in which chirality is introduced through asymmetric oxidation of an intermediate sulfide. Then, 
sulfoximine moiety could be obtained for each enantiomer in two additional steps (Figure 20). 
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Figure 20. Retrosynthetic analysis for the enantiomers of compound UCM-01306 (33). 
 
Fluoroalkylation reaction with chlorofluoromethane was carried out starting from previously 
synthesized intermediate 39 (see Scheme 3), to obtain monofluorinated sulfide derivative 70 
(Scheme 12A). Next, asymmetric oxidation of intermediate 70 using hydrogen peroxide as oxidant, 
vanadyl acetylacetonate as catalyst and the corresponding tert-leucinol derivative (R)- or (S)-71 as 
chiral ligand, yielded the enantiomerically pure sulfoxides (R)- and (S)-30. The synthesis of the 
chiral ligands was performed as reported in the literature via imine formation using 3,5-
diiodosalicylaldehyde and the corresponding commercially available enantiomer of tert-leucinol 
(Scheme 12B).39 Finally, sulfoximine group was obtained through a two-step pathway in which 
retention of the configuration of the chiral center was achieved, as described in the bibliography.40 
This encompassed an iron-catalyzed imination of the sulfoxide, affording the corresponding N-
nosylsulfoximine ((R)- and (S)-69), which was subsequently deprotected using benzenethiol in the 
presence of Cs2CO3, to yield final enantiopure sulfoximines (R)- and (S)-33 with an enantiomeric 
excess (ee) >99% (Scheme 12A). Enantiopurity of intermediates (R)- and (S)-30 and final 
compounds (R)- and (S)-33 was confirmed using chiral HPLC. 
Shortly after we synthesized both pure enantiomers (R)- and (S)-33, a novel approach for the 
synthesis of NH sulfoximines starting from the corresponding sulfoxide was published.41 Hence, 
ammonium carbamate was used as convenient ammonia source, together with 
diacetoxyiodobenzene in an open flask, to afford desired enantiopure sulfoximines in one step 
starting from (R)- or (S)-30 (Scheme 12C). This synthetic route represents indeed an improvement 
over the previous one as it is a metal-free and fast methodology that avoids the deprotection step. 
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Scheme 12. Reagents and conditions: (a) ClCH2F (2.0 M in DMF), Cs2CO3, DMF, -78 ºC to rt, on, 84%; (b) 
H2O2 (30%), (S)- or (R)-71, [VO(acac)2], CHCl3, 0 ºC (ice bath), 20 h, 59-64%, >99% ee; (c) NsNH2, 
PhI(OAc)2, [Fe(acac)3], ACN, rt, 20 h, 59-67%; (d) Cs2CO3, PhSH, ACN, rt, on, 69-91%, >99% ee; (e) EtOH, 
rt, on, 57-78% ; (f) Ammonium carbamate, PhI(OAc)2, MeOH, rt, 30-60 min (open flask), 61-67%. 
 
Once enantiomers (R)- and (S)-UCM-01306 were synthesized, they were assessed for 
allosteric activity at the D1R in the DA-induced cAMP assay. A dose-dependent potentiation of DA 
Emax was observed for both enantiomers with higher enhancements than the racemic compound 
(63% and 47% vs 35%, at 5 μM) (Figures 21A and 21B). They exhibited no intrinsic agonist activity 
(Figures 21C and 21D), selectivity against D2R (Figures 21E and 21F) and no binding to the 
orthosteric site (12% and 6% of radioligand displacement for (R)- and (S)-enantiomer, respectively, 
at 10 μM). In addition, evaluation of PK properties for both enantiomers (R)- and (S)-UCM-01306 
revealed a good profile, similar to that of the racemic compound (Table 6). 
Racemic and enantiomeric forms of identified D1R PAM UCM-01306 are currently under 
evaluation in animal models in order to study their therapeutic utility for the treatment of PD. 
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Figure 21. Pharmacological characterization of (R)- and (S)-UCM-01306. A. Dose-response curves of (R)-
UCM-01306 at different concentrations; B. Dose-response curves for (S)-UCM-01306 at different 
concentrations; C. Dose-response curves of DA and (R)-UCM-01306; D. Dose-response curves of DA and 
(S)-UCM-01306; E. Selectivity of (R)- UCM-01306 over D2R; F. Selectivity of (S)-UCM-01306 over D2R. 
 
Table 6. PK profile for UCM-01306 and its pure enantiomers. 
 UCM-01306 (R)-UCM-01306 (S)-UCM-01306 
Agonism No intrinsic activity No intrinsic activity No intrinsic activity 
Selectivity Over D2R Over D2R Over D2R 
HSA binding (%) 79 (Kd = 1.56·10-4 M) 82 (Kd = 1.28·10-4 M) 79 (Kd = 1.60·10-4 M) 
P (cm/s) 24·10-6 23·10-6 24·10-6 
hERG inhibition (%)a 21 27 24 
Mouse serum stability (%)b 93 90 95 
Liver homogenate stability (%)b 65 63 61 
CYP450 inhibition Good Good Good 
a: Percentage of inhibition at fixed [compound] = 10 μM; b: Remaining compound after incubation for 4h (mouse 
serum) or 24 h (liver homogenate) at 37 ºC. 
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2.4. Optimization process: from 191421196 to UCM-01296 
In a parallel process, identified hit 191421196 (40% of DA Emax potentiation, see Figure 8) 
also entered in a medicinal chemistry program, and the saccharin scaffold was considered a 
backup of our research project. 
To start with the hit-to-lead process, compounds 72-91 in Figure 22, related to hit 191421196, 
were proposed. In order to achieve novelty in the saccharin scaffold, we took advantage that 
introduction of substituents has not been that widely explored. Thus, we envisioned in a first step 
the introduction of a chlorine atom in the saccharin ring, considering its favourable influence in the 
predicted PK profile, using ACD/Percepta® software. In particular, PPB values showed a significant 
improvement and microsome stability (HLM) was predicted to be higher, since the chlorine could 
block first-pass metabolism through aromatic hydroxylation (Ar-OH). Moreover, predicted logP vary 
from negative values when saccharin is unsubstituted, to positive ones when a chlorine is 
introduced in the aromatic ring (Figure 22). In the proposed compounds, the influence of the chain 
length (n) and of different groups as amide substituents (R) was also considered. 
 
Figure 22. Structural modifications proposed in the optimization process of 
identified hit 191421196. Influence of a chloro substituent in predicted PK values 
from ACD/Percepta® software (a: Optimal, 1.50-2.50; b: Accepted, 45-90 Å2; c: 
Accepted: -0.50 to 1.50; d: Accepted, 40-90%). 
 
In a first series of representative chloro-substituted derivatives (72-79), one- and two-
methylene chains (n = 1, 2) were considered, together with unsubstituted and N-methylamides (R = 
H, Me). Their synthesis was planned as an alkylation reaction between 2-chloro-N-
methylacetamide or 3-chloropropanamide and the corresponding chlorosaccharins 92-95. These 
chlorosaccharin rings can be obtained through oxidative cyclization of the adequate o-
methylbenzenesulfonamides that are prepared starting from the corresponding benzenesulfonyl 
chlorides (Figure 23). 
Compound logPa tPSAb logBBc PPBd HLM 
 
-0.62 91.93 -0.28 45 Ar-OH 
 
0.21 91.93 -0.34 70 less Ar-OH 
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Figure 23. Retrosynthetic strategy for new proposed compounds 72-79. 
 
Starting benzenesulfonyl chlorides were commercially available, except for 4-chloro-2-
methylbenzenesulfonyl chloride 96,42 which was prepared from m-chlorotoluene in quantitative 
yield (Scheme 13A). Compound 96 was converted into benzenesulfonamide 97 by reaction with 
ammonia at room temperature. Transformation of sulfonamide 97 into the corresponding saccharin 
93 was performed via oxidative cyclization by treatment with an excess of H5IO6 in the presence of 
catalytic amounts of CrO3 in acetonitrile (ACN) at reflux.43 However, the laborious purification of 
compound 93 either by crystallization or column chromatography resulted in a considerable drop in 
the yield. An alternative cyclization reaction was then carried out using tert-butyl as protective 
group of the sulfonamide moiety (Scheme 13B). N-tert-Butylbenzenesulfonamides 98-100 were 
obtained starting from 3-, 5- or 6-chloro-2-methylbenzenesulfonyl chloride, respectively, by 
treatment with tert-butylamine.43 Subsequent H5IO6-CrO3 oxidation at room temperature and using 
acetic anhydride as drying agent allowed to obtain N-protected saccharins 101-103 that were 
treated with TFA to afford compounds 92, 94 and 95 (Scheme 13B). In this synthetic route 
protection of saccharins in the nitrogen atom permitted to obtain compounds 92, 94 and 95 without 
purification of the intermediates in a ~75% yield, markedly higher than the 21% for compound 93 in 
route A. 
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Scheme 13. Reagents and conditions: (a) ClSO3H, CHCl3, rt, 45 min, quantitative; (b) NH3 (0.5 M in 1,4-
dioxane), DCM, rt, 5 h, 67%; (c) H5IO6, CrO3, ACN, , on, 32%; (d) tBuNH2, TEA, DCM, 0 ºC to rt, 8 h, 90-
93%; (e) H5IO6, CrO3, Ac2O, ACN, rt, on, 82-84%; (f) TFA, , on, quantitative. 
 
Synthesis of final compounds 72-79 was performed through alkylation reaction of 
chlorosaccharins 92-95 with 2-chloro-N-methylacetamide or 3-chloropropanamide using sodium 
hydroxide as base (Scheme 14).44 
 
Scheme 14. Reagents and conditions: (a) NaOH, DMF, 150 ºC, 4-16 h, 15-35%. 
 
Final compounds 72-79 were assessed for activity as PAMs of the D1R in the cAMP assay, 
following the established workflow (see section 2.2.1). Analysis of the data in Table 7 shows that 
introduction of a chlorine atom in position 6 of the saccharin ring is clearly favourable for the activity 
(191421196: 40% at 10 μM vs 76 and 77: 45% and 65%, respectively, at 10 μM), whereas 
positions 4, 5 and 7 are detrimental (191421196: 40% at 10 μM vs 73, 75 and 79: 33%, 18% and 
19%, respectively, at 10 μM). 
Considering a chlorine atom at position 6 of the saccharin ring, we next studied the chain 
length (n = 1-4) to the amide group (R = H, Me) in compounds 80-85 (see Figure 22). Their 
synthesis was planned as depicted in Figure 24, via alkylation of saccharin intermediate 94 with 
the commercial haloalkanamides of one and two methylene units or with the corresponding 
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bromoalkanenitrile of three or four methylene units, followed by hydrolysis and final amide 
formation. 
 
Figure 24. Synthetic strategy for proposed compounds 80-85. 
 
Compounds 80 and 81 (n = 1 and 2, respectively) were successfully obtained by alkylation of 
the previously synthesized intermediate 94 with 2-bromoacetamide or 3-chloro-N-
methylpropanamide using sodium hydroxide as base (Scheme 15). 
 
Scheme 15. Reagents and conditions: (a) NaOH, DMF, 150 °C, on, 24-48%. 
 
Alkylation of compound 94 with 4-bromobutyronitrile or 5-bromovaleronitrile in the same 
conditions afforded intermediates 104 and 105 (Scheme 16). Treatment of derivatives 104 and 105 
with a 10% aqueous sodium hydroxide solution resulted in the hydrolysis of the cyano group 
together with the opening of the saccharin scaffold,45 leading to intermediates 106 and 107. Final 
reaction with the corresponding amine in the presence of N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide (EDC), 1-hydroxybenzotriazole (HOBt) and N,N-diisopropylethylamine (DIPEA) 
yielded desired compounds 82-85 via one-pot ring closure and amide formation (Scheme 16). 
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Scheme 16. (a) NaOH, DMF, 150 °C, on, 42-53%; (b) NaOH (aq., 10%), 130 °C, on, 58-96%; (c) 
NH3 (0.5 M in 1,4-dioxane) or CH3NH2 (2.0 M in THF), EDC, HOBt, DIPEA, DCM, rt, on, 27-99%. 
 
Compounds 80-85 were screened in the DA-induced cAMP assay and the obtained results 
are shown in Table 7. Analysis of the data shows that in one-methylene derivatives a methyl 
substituent in the amide group (R = Me) is required for activity (77: 65% at 10 μM vs 80: 8% at 10 
μM), whereas in two-methylene anologs both N-methyl (R = Me) and unsubstituted (R = H) amides 
are allowed (76, 81, 45% and 34% at 10 μM, respectively). Three-methylene derivatives 82 and 83 
moderately potentiate DA Emax (33% and 40% at 10 μM, respectively). However, potentiation 
drastically drops in analogs 84 and 85 with n = 4 in the chain (10% and 4% at 10 μM, respectively). 
Therefore, one- and two-methylene chains were selected for structural modifications in the amide 
group (see Figure 22). 
In the next step of the hit-to-lead process, different substituents (R) in the amide group were 
studied. Cyclopropyl (Cpr) (Van der Waals volume, Vw = 46.3 cm3/mol) and cyclohexyl (Cy) (Vw = 
84.2 cm3/mol) groups were tested as bulkier groups than methyl (Vw = 17.5 cm3/mol). Additionaly, 
phenyl was considered as an aliphatic/aromatic exchange. The synthesis of new compounds 86-91 
was proposed as depicted in Figure 25. Starting from saccharin 94, alkylation can be performed 
with the appropriate commercial chloroalkanamide. Alternatively, reaction of intermediate 94 with 
the adequate haloalkyl derivative bearing a terminal carboxylic acid and subsequent amide 
formation with cyclopropylamine, cyclohexylamine or aniline should yield final products. 
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Figure 25. Synthetic strategy for the preparation of saccharin derivatives 86-91. 
 
One-methylene analogs 86 and 90, bearing an N-cyclopropyl or an N-phenylamide 
substituent, were prepared by alkylation of saccharin 94 with 2-chloro-N-cyclopropylacetamide and 
2-chloro-N-phenylacetamide, respectively, using sodium hydroxide as base (Scheme 17). 
Compounds with a two-methylene chain bearing a Cpr or a phenyl substituent in the amide (87 and 
91, respectively), together with cyclohexyl derivatives (88, 89, n = 1 and 2, respectively) were 
synthesized through an alternative pathway. Alkylation of intermediate 94 with the corresponding 
bromoalkanoic acid afforded 108 and 109, that reacted with the adequate amine 
(cyclopropylamine, cyclohexylamine or aniline) in the presence of EDC, HOBt and DIPEA (Scheme 
17). 
 
Scheme 17. Reagents and conditions: (a) NaOH, DMF, 150 °C, on, 21-37%; (b) 
CprNH2, CyNH2 or PhNH2, EDC, HOBt, DIPEA, DCM, rt, 1 h, 10-39%. 
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Biological data of final compounds 86-91 in the cAMP assay (Table 7) indicated that N-
cyclopropylamide with one-methylene chain exhibited a moderate activity (86, 42% at 10 μM), 
whereas a marked drop of potentiation was observed for the two-methylene analog 87 (14% at 10 
μM). Clearly, cyclohexyl group was not tolerated as an amide substituent since neither 88 nor 89 
potentiated DA Emax in a significant manner (88, 89, 10% and 22%, respectively, at 10 μM). A 
phenyl substituent in compounds 90 and 91 produced a complete depletion of the allosteric activity, 
indicating that an aromatic moiety is not favourable as an amide substituent. 
Altogether, compound 77 is the most efficient AM synthesized so far among the saccharin 
derivatives (65% potentiation of DA Emax at 10 μM). Moreover, it displays a potentiation of 41% over 
DA EC70, with an EC50 of 13.2 μM. Therefore, 77 (UCM-01296) was selected for further in vitro 
evaluation of pharmacological and PK properties. 
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Table 7. Effect of compounds 72-91 in DA-induced cAMP production in human 
neuroblastoma cell line. 
 
Compound R n Cl position 
Potentiation (%)a,b 
@ 10 μM @ 1 μM 
191421196 Me 1 - 40 0 
72 H 2 4 18 N.D. 
73 Me 1 4 33 3 
74 H 2 5 12 9 
75 Me 1 5 18 8 
76 H 2 6 45 1 
77 (UCM-01296) Me 1 6 65 9 
78 H 2 7 14 N.D. 
79 Me 1 7 19 N.D. 
80 H 1 6 8 N.D. 
81 Me 2 6 34 0 
82 H 3 6 33 0 
83 Me 3 6 40 33 
84 H 4 6 10 N.D. 
85 Me 4 6 4 N.D. 
86 Cpr 1 6 42 0 
87 Cpr 2 6 14 N.D. 
88 Cy 1 6 10 N.D. 
89 Cy 2 6 22 0 
90 Ph 1 6 0 N.D. 
91 Ph 2 6 0 N.D. 
a: Potentiation of DA Emax at a fixed concentration of compound; b: 
Values are obtained in duplicate. 
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2.4.1. PK properties of UCM-01296 
The PK properties of UCM-01296 are shown in Table 8. Study of the interaction with HSA 
protein revealed 47% binding for UCM-01296 (Kd = 6.59·10-4 M). PAMPA showed permeability 
value (P) of 12×10−6 cm/s, intermediate between that of propranolol (P = 25×10−6 cm/s) and 
metoprolol (P = 9×10−6 cm/s). Chemical stability after seven days was good to excellent in DMSO 
and water (98% and 78% of remaining compound), moderate in PBS and in 0.1 M NaOH (42% of 
remaining compound), and low in 0.1 M HCl (18% of remaining compound). In mouse serum 
compound UCM-01296 exhibited a half-life time (t1/2) of 1 h, comparable to that obtained for 
enalapril (t1/2 = 1 h). As for metabolic stability, t1/2 of 20 and 33 min were obtained in HLM and MLM, 
respectively. 
Full pharmacological and PK profiles are currently being accomplished for compound UCM-
01296, prior to the evaluation in animal models, in order to assess the potential therapeutic utility of 
this newly identified D1R PAM. 
Table 8. PK profile for UCM-01296. 
Compound HSA binding (%) 
P 
(cm/s) 
Chemical stability (%)a Serum 
stabilityb 
HLM/
MLMb DMSO Water PBS 0.1 M NaOH 0.1 M HCl 
UCM-01296 47 12·10-6 98 78 42 42 18 60 20/33 
a: Remaining compound after 7 days at room temperature; b: t1/2 expressed in minutes. 
 
 
 
To sum up, in the present work we have identified two PAMs of the D1R. In the case of 
biphenyl derivative, racemic UCM-01306 and its pure enantiomers display good pharmacological 
and PK profiles, and are currently under evaluation in animal models in order to study their 
therapeutic utility for the treatment of PD. Saccharin analog UCM-01296 is in an earlier stage; 
current data makes it a promising candidate to continue with pharmacological characterization, 
study of PK properties, and hopefully in vivo evaluation. 
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3. CONCLUSIONS 
 
The present work is focused on the development of AMs of the D1R as a novel strategy to 
approach PD. A structure-based pharmacophore model allowed us to identify initial hits 10Z-0706 
and 191421196, that entered into parallel medicinal chemistry programs.  
Structural exploration around biphenyl derivative 10Z-0706 led to compound UCM-01212 that 
has been characterized as a new D1R PAM with a good pharmacological profile and moderate PK 
properties. Importantly, UCM-01212 has shown activity in an animal model of PD, which sets a 
proof of concept of the therapeutic interest of a D1R PAM as a novel strategy to tackle PD. In a next 
step, novel sulfoximine derivative UCM-01306 was characterized as an optimized compound. 
Racemic UCM-01306 and its pure enantiomers display good pharmacological and PK profiles, and 
are currently under evaluation in animal models in order to study their therapeutic utility for the 
treatment of PD 
Regarding saccharin derivative 191421196, the optimization process afforded compound 
UCM-01296, which is in an earlier stage. Current data makes it a promising candidate to continue 
with pharmacological characterization, study of PK properties, and hopefully in vivo evaluation. 
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4.1. Synthesis and characterization 
As far as general considerations are concerned, see Section 4.1 of Chapter A. Additionally, 
specific synthetic issues related to the present chapter are detailed below. 
Dry dichloromethane (DCM) and tetrahydrofuran (THF) were obtained by passing the 
previously degassed solvents through activated alumina columns using a Pure Solv™ Micro 100 
Liter solvent purification system. Acetone was dried under K2CO3. TEA was dried over KOH and 
distilled before use. Reactions under MW irradiation were performed in a Biotage Initiator 2.5 
reactor. 
Purification of compounds on glass column with silica gel type 60 (particle size 230-400 mesh 
from Merck) was performed in some indicated cases. 
NMR spectra were recorded on spectrometers indicated in page 71; alternatively, a Bruker 
Avance III 700 MHz (1H, 700 MHz; 13C, 175 MHz) in some indicated cases. As additional 
deuterated solvents were used,  are adequately expressed relative to their residual solvent peak 
for 1H and 13C nucleus (acetone-d6: H = 2.05, C = 29.84; methanol-d4: H = 3.31, C = 49.00). 
HPLC separation was achieved with a Zorbax SB-C3 column (5 μm, 2.1 mm x 50 mm) or a 
Eclipse XDB-C18 column (5 μm, 4.6 mm x 150 mm), together with a guard column (5 μm, 4.6 mm x 
12.5 mm). The gradient mobile phase consisted of A (95:5 water/methanol) and B (5:95 
water/methanol) with 0.1% ammonium hydroxide and 0.1% formic acid as solvent modifiers, and 
the gradients are indicated in Table 9. 
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Table 9. HPLC gradients. 
I II III IV V VI 
ta %B ta %B ta %B ta %B ta %B ta %B 
0 0 0 0 0 60 0 40 0 0 0 0 
2 0 2 0 10 100 11 100 2 0 5 0 
10 100 10 50 22 100 33 100 8 80 15 90 
25 100 20 100 28 60 36 40 12 100 22 100 
30 0 25 100 30 60 40 40 25 100 26 100 
  30 0     30 0 30 0 
a: time, t, is expressed in minutes. 
 
Optical rotation [] was measured on a Perkin Elmer 241 polarimeter or an Anton Paar MCP 
100 modular circular polarimeter using a sodium lamp ( = 589 nm) with a 1 dm path length; 
concentrations (c) are given as g/100 mL. 
For chiral compounds, enantiomeric purity was determined by chiral HPLC. Analysis was 
performed on an Agilent 1200LC-MSD VL instrument using a Daicel Chiralpak® IC column (5 μm, 
4.6 mm x 150 mm), together with a guard column (5 μm, 4.6 mm x 12.5 mm). The gradient mobile 
phase consisted of a 1:9 mixture of water/methanol, using a flow of 0.9 mL/min for the injection of 
the sample and 0.5 mL/min during the run. HPLC traces were compared to racemic samples of 
sulfoxide 30 and sulfoximine 33, which were obtained in the absence of any chiral catalysts as 
described in Sections 4.1.6 and 4.1.7, respectively. 
 
4.1.1. General synthetic procedures 
General procedure A for Suzuki-Miyaura cross coupling reaction. A solution of the 
corresponding bromoaryl derivative (1.00 equiv), arylboronic acid (1.05 equiv), and Na2CO3 (4.00 
equiv) in a 1:1 mixture of THF/water (16 mL/mmol) was degassed by bubbling argon for 10 min. 
Pd(PPh3)4 (0.06 equiv) was then added and the reaction was refluxed overnight or heated at 120 
ºC under MW irradiation for 20 min. After this time, the mixture was extracted with EtOAc and the 
organic phase was dried over Na2SO4, filtered and evaporated under reduced pressure. The 
residue was purified by column chromatography to afford the desired product. 
General procedure B for Suzuki-Miyaura cross coupling reaction. A solution of the 
corresponding bromoaryl derivative (1.00 equiv), arylboronic acid (1.05-1.20 equiv), and Na2CO3 
(2.00 equiv) in a 2:1.5:1 mixture of toluene/water/ethanol (6.5 mL/mmol) was degassed by bubbling 
argon for 10 min. Pd(PPh3)4 (0.06 equiv) was then added and the reaction was refluxed overnight 
or heated under MW irradiation. After this time, the mixture was extracted with EtOAc and the 
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organic phase was dried over Na2SO4, filtered and evaporated under reduced pressure. The 
residue was purified by recrystallization, column chromatography or preparative TLC to afford the 
desired coupled product. 
General procedure C: monofluoroalkylation reaction.46 To a mixture of the corresponding 
hydroxy- or sulfanylaryl derivative (1.00 equiv) and Cs2CO3 (1.60 equiv) in anhydrous DMF (7.0 
mL/mmol) at -78 ºC under an argon atmosphere, a solution of chlorofluoromethane (2.0 M in DMF, 
4.00 equiv) was added dropwise. The reaction was stirred and allowed to warm to rt overnight. 
Afterward, the mixture was diluted with water and the aqueous layer was extracted with Et2O (x3). 
The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure. The residue was purified by column chromatography or preparative TLC to afford the 
desired fluoromethylated compound. 
General procedure D: difluoroalkylation reaction.47 Diethyl 
[bromo(difluoro)methyl]phosphonate (2.00 equiv) was added in one portion to a -78 ºC cooled 
solution of the adequate hydroxy- or sulfanylaryl derivative (1.00 equiv) and KOH (20 equiv) in a 
1:1 mixture of ACN/water (10 mL/mmol) under an argon atmosphere, and the reaction was stirred 
and allowed to warm to rt overnight. Next, the mixture was diluted with water and the aqueous layer 
was extracted with Et2O (x3). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure. The residue was purified by column chromatography or 
preparative TLC to afford the corresponding difluoromethylated compound. 
General procedure E: three-step synthesis of NH arylsulfoximine derivatives. (a)48 N-
bromosuccinimide (1.5 equiv) was added to a solution of the corresponding (methylsulfanyl)arene 
(1.0 equiv), potassium tert-butoxide (1.2 equiv) and cyanamide (1.3 equiv) in anhydrous methanol 
(5 mL/mmol) under an argon atmosphere and the reaction mixture was stirred at rt for 1.5 h. Next, 
the solvent was evaporated under reduced pressure and the resulting residue was partitioned 
between DCM and water. The aqueous phase was extracted with DCM (x2) and the combined 
organic layers were dried over Na2SO4, filtered and the solvent was evaporated under reduced 
pressure. The crude N-cyanosulfylimine was used in the next step without further purification. 
(b)49 The crude N-cyanosulfylimine above synthesized was dissolved in a 1:1 mixture of 
anhydrous ACN/DCM (5 mL/mmol) under an argon atmosphere, RuCl3 (0.01 equiv) was added and 
the resulting brown mixture was stirred at rt for 5 min. Then 0.15 M solution of NaIO4 (1.50 equiv) in 
water was added and the reaction was stirred at rt until completion (TLC). Next, water was added 
and the mixture was extracted with DCM (x3). The combined organic layers were washed with sat. 
aqueous Na2S2O3 (x2) and brine, dried over Na2SO4, filtered and concentrated under reduced 
pressure. The crude N-cyanosulfoximine was used in the next step without further purification. 
(c)50 To the crude N-cyanosulfoximine, 50% aqueous H2SO4 (4.5 mL/mmol) was added and 
the mixture was heated at reflux for 2 h and then allowed to cool to rt. Next, neutralization at 0 ºC 
was performed with 50% aqueous NaOH and the reaction was extracted with DCM (x3). The 
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combined organic layers were dried over Na2SO4, filtered and the solvent was evaporated under 
reduced pressure. The crude residue was purified by column chromatography to afford the desired 
NH-sulfoximine. 
General procedure F: Eschweiler-Clarke reaction.51 A mixture of the corresponding NH-
sulfoximine (1.0 equiv), formaldehyde (37% in water, 4.4 mL/mmol) and formic acid (8.0 mL/mmol) 
was heated in an open flask at 100 ºC for 2 days. After evaporating the volatile substances under 
reduced pressure, the aqueous phase was neutralized using solid NaHCO3 and extracted with 
DCM (x3). The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude N-methylsulfoximine was either used in the next step without further 
purification or purified by column chromatography or preparative TLC. 
General procedure G: reaction of arenesulfonyl chloride derivatives with tert-
butylamine.43 To a solution of tert-butylamine (1.05 equiv) and TEA (1.05 equiv) in anhydrous 
DCM (4.0 mL/mmol) at 0 ºC under an argon atmosphere, a solution of the corresponding 
arenesulfonyl chloride (1.00 equiv) in anhydrous DCM (2 mL/mmol) was added dropwise. The 
reaction was stirred at 0 ºC for 2 h and afterward at rt for 6 h. After that time, the reaction mixture 
was washed with 0.1 N HCl, sat. NaHCO3 and brine. The organic layer was dried over Na2SO4, 
filtered and the solvent was evaporated under reduced pressure, obtaining the corresponding N-
tert-butylarenesulfonamide, which was used in the next step without further purification. 
General procedure H: oxidative cyclization of N-tert-butylarenesufonamides.43 A 
suspension of H5IO6 (8.00 equiv) in anhydrous ACN (1.6 mL/mmol sulfonamide) was stirred 
vigorously for 1 h at rt and under an argon atmosphere. Next, CrO3 (0.10 equiv) was added, 
followed by acetic anhydride (8.00 equiv). The resulting solution was cooled at 0 ºC and the 
corresponding N-tert-butylarenesulfonamide (1.00 equiv) was added. After stirring at 0 ºC for 15 
min, the reaction was warmed up to rt and stirred overnight. After that time, the solvent was 
removed under reduced pressure and the residue was extracted twice with EtOAc. The combined 
organic layers were successively washed with sat. aqueous NaHCO3 and NaHSO3 and brine, dried 
over Na2SO4 and filtered. The solvent was evaporated under reduced pressure, obtaining the 
corresponding N-tert-butylsaccharin derivative. 
General procedure I: deprotection of N-tert-butylsaccarins. A solution of the corresponding 
N-tert-butylsaccharin (1.00 equiv) in TFA (1 mL/mmol) was heated at reflux overnight. Next, 
volatiles were eliminated under reduced pressure and water was added to the residue. The 
aqueous layer was extracted with EtOAc (x3) and the combined organic layers were dried over 
Na2SO4, filtered and concentrated under reduced pressure, to yield the desired saccharin in 
quantitative yield. 
General procedure J: alkylation of saccharins with sodium hydroxide.44 A mixture of the 
adequate chloro-substituted saccharin (1.00 equiv), NaOH (1.10 equiv) and the corresponding 
haloalkyl derivative (1.20 equiv) in anhydrous DMF (2.7 mL/mmol) was heated at 150 °C overnight 
under an argon atmosphere. The solvent was evaporated under reduced pressure and the residue 
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was redissolved with EtOAc and washed with water (x3). The organic layer was dried over Na2SO4, 
filtered and the solvent was evaporated under reduced pressure. The crude was purified by 
recrystallization or column chromatography to afford the corresponding N-alkylated chloro-
saccharin derivative. 
General procedure K: synthesis of amides from benzoic acid or N-
carboxyalkylsaccharin derivatives. A solution of the corresponding benzoic acid or N-
carboxyalkylsaccharin derivative (1.00 equiv), EDC (2.50 equiv) and HOBt (2.50 equiv) in 
anhydrous DCM (2.1 mL/mmol) was stirred at rt for 1 h under an argon atmosphere. Then, a 
solution of the appropriate amine (2.00 equiv) and DIPEA (3.00 equiv) in anhydrous DCM (0.5 
mL/mmol) was added and the reaction was stirred overnight at rt. Next, the mixture was washed 
with 1 M HCl, sat. NaHCO3 solution (x2) and brine. The organic layer was dried over Na2SO4, 
filtered and the solvent was evaporated under reduced pressure. The crude was purified by column 
chromatography to afford the corresponding saccharin derivative. 
 
4.1.2. Final compounds 3-10 
 Hydroxybiphenylcarbadehydes 15-17 
3'-Hydroxybiphenyl-4-carbaldehyde, 15. Following general procedure A, compound 15 was 
obtained from 4-bromobenzaldehyde (99 mg, 0.535 mmol) and 3-hydroxyphenylboronic acid (77 
mg, 0.562 mmol) by heating under reflux overnight, as a white solid (60 mg, 57%). 
Chromatography: hexane to DCM. Spectroscopic data are in agreement with those reported.52 
 
M.p.: 177-178 ºC (lit.52 m.p. 173-175 °C). Rf: 0.25 (hexane/DCM 7:3). IR (ATR): 3234 (OH), 
1671 (CHO), 1597, 1564 (Ar). 1H-NMR (acetone-d6):  6.90-6.94 (m, 1H, H4’), 7.20-7.23 (m, 2H, 
H2’, H6’), 7.34 (t, J = 8.0, 1H, H5’), 7.86 (d, J = 8.3, 2H, H2, H6), 8.01 (d, J = 8.4, 2H, H3, H5), 8.61 (s, 
1H, OH), 10.09 (s, 1H, CHO). 13C-NMR (acetone-d6):  114.9 (C2’), 116.4 (C4’), 119.3 (C6’), 128.4 
(C2, C6), 130.9 (C3, C5), 131.0 (C5’), 136.6 (C4), 141.9 (C1’), 147.6 (C1), 158.9 (C3’), 192.6 (CHO). 
HPLC (Gradient-V, column C3, tR, min): 10.05. MS (ESI, m/z, %): 197.0 ([M - H]-, 100). 
2'-Hydroxybiphenyl-4-carbaldehyde, 16. Following general procedure A, compound 16 was 
obtained from 2-bromophenol (98 mg, 0.566 mmol) and (4-formylphenyl)boronic acid (89 mg, 0.594 
mmol) by heating at 120 ºC under MW irradiation for 20 min, as a white solid (81 mg, 72%). 
Chromatography: hexane to DCM. 
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M.p.: 118-120 ºC. Rf: 0.29 (DCM). IR (ATR):  3524 (OH), 1683 (CHO), 1216, 1172 (C-O). 1H-
NMR (acetone-d6):  6.98 (td, J = 7.4, 1.1, 1H, H5’), 7.04 (dd, J = 8.1, 1.0, 1H, H3’), 7.25 (ddd, J = 
8.0, 7.4, 1.7, 1H, H4’), 7.39 (dd, J = 7.6, 1.7, 1H, H6’), 7.84 (d, J = 8.3, 2H, H2, H6), 7.96 (d, J = 8.4, 
2H, H3, H5), 8.67 (br s, 1H, OH), 10.07 (s, 1H, CHO). 13C-NMR (acetone-d6):  116.7 (C3’), 120.6 
(C5’), 127.5 (C1’), 129.5 (C3, C5), 129.9 (C4’), 130.3 (C2, C6), 131.0 (C6’), 135.5 (C4), 145.5 (C1), 
154.8 (C2’), 192.1 (CHO). HPLC (Gradient-VI, column C3, tR, min): 10.39. MS (ESI, m/z, %): 197.0 
([M - H]-, 100). 
2'-Hydroxybiphenyl-3-carbaldehyde, 17. Following general procedure A, compound 17 was 
obtained from 2-bromophenol (118 mg, 0.680 mmol) and (3-formylphenyl)boronic acid (110 mg, 
0.714 mmol) by heating at 120 ºC under MW irradiation for 20 min, as a white solid (70 mg, 52%). 
Chromatography: hexane to hexane/EtOAc 95:5. 
 
M.p.: 93-94 ºC. Rf: 0.26 (hexane/EtOAc 9:1). IR (ATR):  3367 (OH), 1682 (CHO). 1H-NMR 
(CDCl3):  5.02 (br s, 1H, OH), 6.98 (dd, J = 8.5, 1.2, 1H, H3’), 7.05 (td, J = 7.5, 1.1, 1H, H5’), 7.26-
7.33 (m, 2H, H4’, H6’), 7.66 (t, J = 7.6, 1H, H5), 7.81 (dt, J = 7.7, 1.5, 1H, H6), 7.91 (dt, J = 7.6, 1.5, 
1H, H4), 8.05 (m, 1H, H2), 10.09 (s, 1H, CHO). 13C-NMR (CDCl3):  116.5 (C3’), 121.4 (C5’), 127.0 
(C1’), 128.8 (C4), 129.7 (C6’), 129.8 (C5), 130.6 (C2), 130.8 (C4’), 135.4 (C6), 136.9 (C3), 138.8 (C1), 
152.6 (C2’), 192.5 (CHO). HPLC (Gradient-I, column C18, tR, min): 15.53. MS (ESI, m/z, %): 196.9 
([M - H]-, 100). 
 [(Di)fluoromethoxy]biphenylcarbaldehydes 3-10 
4'-(Fluoromethoxy)biphenyl-4-carbaldehyde, 3. Following general procedure C, compound 
3 was obtained from 4’-hydroxybiphenyl-4-carbaldehyde (146 mg, 0.737 mmol) as a white solid 
(100 mg, 60%). Chromatography: hexane. 
 
M.p.: 86-87 ºC. Rf: 0.39 (hexane/DCM 7:3). IR (ATR):  1681 (CHO), 1241 (C-O-C), 1186, 
1091 (C-F). 1H-NMR (CDCl3):  5.77 (d, J = 54.3, 2H, CH2F), 7.19 (d, J = 8.6, 2H, H3’, H5’), 7.62 (d, 
J = 8.8, 2H, H2’, H6’), 7.72 (d, J = 8.2, 2H, H2, H6), 7.94 (d, J = 8.3, 2H, H3, H5), 10.05 (s, 1H, CHO). 
13C-NMR (CDCl3):  100.7 (d, J = 219.8, CH2F), 117.2 (d, J = 1.3, C3’, C5’), 127.5 (C2, C6), 128.9 
(C2’, C6’), 130.4 (C3, C5), 135.1, 135.2 (C4, C1’), 146.4 (C1), 157.3 (d, J = 3.1, C4’), 191.9 (CHO). 19F-
NMR (CDCl3):  -151.6. HPLC (Gradient-I, column C3, tR, min): 10.19. MS (ESI, m/z, %): 231.1 ([M 
+ H]+, 100). 
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3'-(Fluoromethoxy)biphenyl-4-carbaldehyde, 4. Following general procedure C, compound 
4 was obtained from 15 (51 mg, 0.257 mmol) as an oil (35 mg, 59%). Chromatography: hexane. 
 
Rf: 0.41 (hexane/DCM 7:3). IR (ATR):  1699 (CHO), 1205 (C-O-C), 1096 (C-F). 1H-NMR 
(acetone-d6):  5.94 (d, J = 54.4, 2H, CH2F), 7.18-7.22 (m, 1H, H4’), 7.47-7.53 (m, 3H, H2’, H5’, H6’), 
7.92 (d, J = 8.4, 2H, H2, H6), 8.03 (d, J = 8.5, 2H, H3, H5), 10.11 (s, 1H, CHO). 13C-NMR (acetone-
d6):  101.6 (d, J = 216.2, CH2F), 116.2 (d, J = 1.1, C2’), 117.2 (d, J = 1.0, C4’), 123.1 (C6’), 128.6 
(C2, C6), 130.9 (C3, C5), 131.4 (C5’), 136.8 (C4), 142.3 (C1’), 146.8 (C1), 158.2 (d, J = 2.8, C3’), 192.6 
(CHO). 19F-NMR (acetone-d6):  -151.2. HPLC (Gradient-I, column C3, tR, min): 11.67. MS (ESI, 
m/z, %): 230.9 ([M + H]+, 100). 
2'-(Fluoromethoxy)biphenyl-4-carbaldehyde, 5 (UCM-01212). Following general procedure 
C, compound 5 was obtained from 16 (1.01 g, 5.10 mmol) as an oil (0.94 g, 84%). 
Chromatography: hexane. 
 
Rf: 0.39 (hexane/DCM 7:3). IR (ATR):  1699 (CHO), 1215 (C-O-C), 1129, 1082 (C-F). 1H-
NMR (CDCl3):  5.68 (d, J = 54.3, 2H, CH2F), 7.19-7.28 (m, 2H, H3’, H5’), 7.37-7.44 (m, 2H, H4’, H6’), 
7.68 (d, J = 8.2, 2H, H2, H6), 7.94 (d, J = 8.4, 2H, H3, H5), 10.06 (s, 1H, CHO). 13C-NMR (CDCl3):  
100.9 (d, J = 218.6, CH2F), 116.0 (d, J = 1.4, C3’), 124.1 (C5’), 129.6 (C3, C5), 130.0 (C4’), 130.4 (C2, 
C6), 130.8 (C1’), 131.1 (C6’), 135.2 (C4), 144.3 (C1), 153.7 (d, J = 3.1, C2’), 192.1 (CHO). 19F-NMR 
(CDCl3):  -150.9. HPLC (Gradient-I, column C3, tR, min): 11.42. MS (ESI, m/z, %): 231.1 ([M + H]+, 
100). 
2'-(Fluoromethoxy)biphenyl-3-carbaldehyde, 6. Following general procedure C, compound 
6 was obtained from 17 (30 mg, 0.151 mmol) as an oil (22 mg, 64%). Chromatography: preparative 
TLC in toluene/methanol 98:2. 
 
Rf: 0.32 (toluene/methanol 98:2). IR (ATR):  1697 (CHO), 1264, 1218 (C-O-C), 1084 (C-F). 
1H-NMR (CDCl3):  5.68 (d, J = 54.4, 2H, CH2F), 7.20-7.30 (m, 2H, H3’, H5’), 7.39-7.42 (m, 2H, H4’, 
H6’), 7.60 (t, J = 7.7, 1H, H5), 7.80 (m, 1H, H6), 7.88 (m, 1H, H4), 8.02 (m, 1H, H2), 10.08 (s, 1H, 
CHO). 13C-NMR (CDCl3):  100.9 (d, J = 218.2, CH2F), 115.8 (d, J = 1.2, C3’), 124.1 (C5’), 128.5 
(C4), 128.9 (C6’), 129.7 (C5), 130.6 (d, J = 1.1, C1’), 131.1 (C2), 131.2 (C4’), 135.8 (C6), 136.5 (C3), 
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138.9 (C1), 153.7 (d, J = 3.3, C2’), 192.4 (CHO). 19F-NMR (CDCl3):  -148.9. HPLC (Gradient-I, 
column C3, tR, min): 10.48. MS (ESI, m/z, %): 252.8 ([M + Na]+, 100). 
4'-(Difluoromethoxy)biphenyl-4-carbaldehyde, 7. Following general procedure B, 
compound 7 was obtained from 1-bromo-4-(difluoromethoxy)benzene (97 mg, 0.649 mmol) and (4-
formylphenyl)boronic acid (117 mg, 0.779 mmol) by heating under reflux, as a white solid (92 mg, 
57%). Chromatography: hexane. 
 
M.p.: 140-141 ºC. Rf: 0.38 (hexane/DCM 7:3). IR (ATR):  1699 (CHO), 1240, 1191 (C-O-C), 
1126, 1050 (C-F). 1H-NMR (CDCl3):  6.59 (t, J = 73.6, 1H, CHF2), 7.24 (d, J = 8.7, 2H, H3’, H5’), 
7.64 (d, J = 8.7, 2H, H2’, H6’), 7.72 (d, J = 8.2, 2H, H2, H6), 7.96 (d, J = 8.3, 2H, H3, H5), 10.06 (s, 
1H, CHO). 13C-NMR (CDCl3):  115.9 (t, J = 260.6, CHF2), 120.1 (C3’, C5’), 127.7 (C2, C6), 128.9 
(C2’, C6’), 130.5 (C3, C5), 135.4 (C1’), 137.1 (C4), 146.1 (C1), 151.5 (t, J = 2.7, C4’), 192.0 (CHO). 19F-
NMR (CDCl3):  -83.3. HPLC (Gradient-I, column C3, tR, min): 10.37. MS (ESI, m/z, %): 249.0 ([M 
+ H]+, 100). 
3'-(Difluoromethoxy)biphenyl-4-carbaldehyde, 8. Following general procedure B, 
compound 8 was obtained from 1-bromo-3-(difluoromethoxy)benzene (154 mg, 0.692 mmol) and 
(4-formylphenyl)boronic acid (125 mg, 0.831 mmol) by heating under reflux, as a colorless oil (155 
mg, 90%). Chromatography: hexane. 
 
Rf: 0.41 (hexane/DCM 7:3). IR (ATR):  1695 (CHO), 1195 (C-O-C), 1114, 1031 (C-F). 1H-
NMR (CDCl3):  6.58 (t, J = 73.6, 1H, CHF2), 7.15-7.22 (m, 1H, H4’), 7.38-7.40 (m, 1H, H2’), 7.47-
7.49 (m, 2H, H5’, H6’), 7.74 (d, J = 8.3, 2H, H2, H6), 7.97 (d, J = 8.4, 2H, H3, H5), 10.07 (s, 1H, CHO). 
13C-NMR (CDCl3):  116.0 (t, J = 260.6, CHF2), 118.9 (C2’), 119.6 (C4’), 124.6 (C6’), 127.9 (C2, C6), 
130.5 (C3, C5), 130.6 (C5’), 135.8 (C4), 141.9 (C1’), 146.0 (C1), 151.8 (t, J = 2.7, C3’), 191.9 (CHO). 
19F-NMR (CDCl3):  -83.1. HPLC (Gradient-I, column C3, tR, min): 11.78. MS (ESI, m/z, %): 249.0 
([M + H]+, 100). 
2'-(Difluoromethoxy)biphenyl-4-carbaldehyde, 9. Following general procedure B, 
compound 9 was obtained from 1-bromo-2-(difluoromethoxy)benzene (154 mg, 0.692 mmol) and 
(4-formylphenyl)boronic acid (125 mg, 0.831 mmol) by heating under reflux, as an off-white solid 
(104 mg, 61%). Chromatography: hexane. 
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M.p.: 48-50 ºC. Rf: 0.40 (hexane/DCM 7:3). IR (ATR):  1696 (CHO), 1210 (C-O-C), 1114, 
1032 (C-F). 1H-NMR (CDCl3):  6.39 (t, J = 73.7, 1H, CHF2), 7.30-7.37 (m, 4H, H3’, H5’), 7.41-7.46 
(m, 4H, H4’, H6’), 7.68 (d, J = 8.3, 2H, H2, H6), 7.96 (d, J = 8.3, 2H, H3, H5), 10.08 (s, 1H, CHO). 13C-
NMR (CDCl3):  116.1 (t, J = 260.8, CHF2), 120.3 (C3’), 126.1 (C5’), 129.8 (C3, C5), 129.9 (C4’), 
130.3 (C2, C6), 131.4 (C6’), 133.0 (C1’), 135.5 (C4), 143.5 (C1), 148.2 (t, J = 2.5, C2’), 192.1 (CHO). 
19F-NMR (CDCl3):  -82.5. HPLC (Gradient-I, column C3, tR, min): 11.53. MS (ESI, m/z, %): 249.0 
([M + H]+, 100). 
2'-(Difluoromethoxy)biphenyl-3-carbaldehyde, 10. Following general procedure D, 
compound 10 was obtained from 17 (19 mg, 0.096 mmol) as an oil (10 mg, 40%). Chromatography: 
preparative TLC in toluene/methanol 98:2. 
 
Rf: 0.34 (toluene/methanol 98:2). IR (ATR):  1703 (CHO), 1217 (C-O-C), 1138, 1052 (C-F). 
1H-NMR (CDCl3):  6.39 (t, J = 73.7, 1H, CHF2), 7.29-7.35 (m, 1H, H5’), 7.35 (dd, J = 7.4, 1.4, 1H, 
H3’), 7.39-7.47 (m, 2H, H4’, H6’), 7.63 (t, J = 7.6, 1H, H5), 7.79 (dt, J = 7.8, 1.5, 1H, H6), 7.91 (dt, J = 
7.6, 1.4, 1H, H4), 8.00 (m, 1H, H2), 10.08 (s, 1H, CHO). 13C-NMR (CDCl3, 125 MHz):  116.1 (t, J = 
258.9, CHF2), 120.2 (C3’), 126.1 (C5’), 128.9 (C4), 129.1 (C6’), 129.6 (C5), 130.9 (C2), 131.5 (C4’), 
132.8 (C1’), 135.6 (C6), 136.7 (C3), 138.2 (C1), 148.2 (t, J = 2.5, C2’), 192.3 (CHO). 19F-NMR 
(CDCl3):  -80.9. HPLC (Gradient-I, column C3, tR, min): 11.53. MS (ESI, m/z, %): 271.1 ([M + Na]+, 
100). 
 
4.1.3. Final compounds 11, 12 
 Bromo[(di)fluoromethylsulfanyl]benzenes 18, 19 
1-Bromo-2-[(fluoromethyl)sulfanyl]benzene, 18. Following general procedure C, compound 
18 was obtained from 2-bromobenzenethiol (148 μL, 1.24 mmol) as an oil (211 mg, 77%). 
Chromatography: hexane. 
 
Rf: 0.56 (hexane/DCM 9:1). IR (ATR):  1485, 1450 (Ar), 963 (C-F). 1H-NMR (CDCl3):  5.79 
(d, J = 52.5, 2H, CH2F), 7.15 (td, J = 7.6, 1.6, 1H, H5), 7.34 (td, J = 7.7, 1.4, 1H, H4), 7.60 (d, J = 
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6.6, 2H, H3, H6). 13C-NMR (CDCl3):  86.8 (d, J = 216.3, CH2F), 124.2 (d, J = 2.9, C1), 128.4, 128.6 
(C4, C5), 130.2 (d, J = 2.3, C3), 133.3 (C6), 136.0 (d, J = 3.4, C2). 19F-NMR (CDCl3):  -185.3. 
1-Bromo-2-[(difluoromethyl)sulfanyl]benzene, 19. Following general procedure D, 
compound 19 was obtained from 2-bromobenzenethiol (278 mg, 1.42 mmol) as an oil (275 mg, 
81%). Chromatography: hexane. Spectroscopic data were in agreement with those reported.53 
 
Rf: 0.50 (hexane/DCM 95:5). IR (ATR):  1449, 1299 (Ar), 1074, 1045, 1023 (C-F). 1H-NMR 
(CDCl3):  6.92 (t, J = 56.9, 1H, CHF2), 7.27 (td, J = 7.6, 1.8, 1H, H5), 7.36 (td, J = 7.5, 1.6, 1H, H4), 
7.68 (dd, J = 6.4, 1.8, 1H, H3), 7.70 (dd, J = 6.2, 1.6, 1H, H6). 13C-NMR (CDCl3):  120.6 (t, J = 
274.6, CHF2), 128.4 (C5), 128.5 (t, J = 3.1, C2), 129.3 (t, J = 1.3, C1), 131.1 (C3), 133.9 (C4), 136.6 
(C6). 19F-NMR (CDCl3):  -92.5. 
 [(Di)fluoromethylsulfanyl]biphenylcarbaldehydes 11, 12 
2'-[(Fluoromethyl)sulfanyl]biphenyl-4-carbaldehyde, 11. Following general procedure B, 
compound 11 was obtained from 18 (98 mg, 0.436 mmol) and (4-formylphenyl)boronic acid (71 mg, 
0.458 mmol) by heating at 120 ºC under MW irradiation for 20 min, as an oil (52 mg, 49%). 
Chromatography: hexane to hexane/EtOAc 9:1. 
 
Rf: 0.38 (hexane/EtOAc 9:1). IR (ATR):  1701 (CHO), 958 (C-F). 1H-NMR (CDCl3):  5.63 (d, 
J = 52.6, 2H, CH2F), 7.32 (dd, J = 7.2, 2.0, 1H, H3’), 7.39 (td, J = 7.4, 1.6, 1H, H5’), 7.44 (td, J = 7.4, 
1.9, 1H, H4’), 7.56 (d, J = 8.1, 2H, H2, H6), 7.72 (dd, J = 7.3, 1.8, 1H, H6’), 7.97 (d, J = 8.2, 2H, H3, 
H5), 10.09 (s, 1H, CHO). 13C-NMR (CDCl3):  87.9 (d, J = 215.9, CH2F), 127.8 (C3’), 129.3 (C5’), 
129.6 (C3, C5), 130.2 (C4’), 130.4 (C6’), 130.4 (C2, C6), 133.2 (d, J = 3.0, C1’), 135.5 (C4), 141.8 (d, J 
= 2.5 Hz, C2’), 146.6 (C1), 192.0 (CHO). 19F-NMR (CDCl3):  -183.2. HPLC (Gradient-I, column C3, 
tR, min): 10.30. MS (ESI, m/z, %): 227.1 ([M - F]+, 100), 247.1 ([M + H]+, 36), 279.1 ([M + MeOH + 
H]+, 41). 
2'-[(Difluoromethyl)sulfanyl]biphenyl-4-carbaldehyde, 12. Following general procedure B, 
compound 12 was obtained from 19 (104 mg, 0.433 mmol) and (4-formylphenyl)boronic acid (70 
mg, 0.455 mmol) by heating at 130 ºC under MW irradiation for 20 min, as a solid (92 mg, 81%). 
Chromatography: hexane. 
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M.p.: 46-47 ºC. Rf: 0.46 (hexane/EtOAc 9:1). IR (ATR):  1702 (CHO), 1065, 1034 (C-F). 1H-
NMR (CDCl3):  6.66 (t, J = 56.6, 1H, CHF2), 7.39-7.48 (m, 3H, H3’, H4’, H5’), 7.52 (d, J = 8.1, 2H, 
H2, H6), 7.75 (dd, J = 7.5, 1.5, 1H, H6’), 7.95 (d, J = 8.2, 2H, H3, H5), 10.09 (s, 1H, CHO). 13C-NMR 
(CDCl3):  120.7 (t, J = 274.1, CHF2), 124.8 (t, J = 2.6, C1’), 129.1 (C3’), 129.5 (C3, C5), 130.0 (C5’), 
130.6 (C2, C6), 130.9 (C4’), 135.5 (C4), 136.4 (C6’), 145.7 (C2’), 146.6 (C1), 192.0 (CHO). 19F-NMR 
(CDCl3):  -91.6. HPLC (Gradient-I, column C3, tR, min): 12.27. MS (ESI, m/z, %): 265.0 ([M + H]+, 
100). 
 
4.1.4. Final compounds 13, 14 
 Piperazine intermediates 20-22 
tert-Butyl 4-(2-hydroxyphenyl)piperazine-1-carboxylate, 20. A solution of di-tert-butyl 
dicarbonate (536 mg, 2.46 mmol) in anhydrous DCM (5 mL) was added dropwise to a solution of 1-
(2-hydroxyphenyl)piperazine (406 mg, 2.23 mmol) and TEA (0.93 mL, 6.70 mmol) in anhydrous 
DCM (15 mL) under an argon atmosphere. The reaction was stirred at rt for 3 h. After this time, the 
mixture was washed with water and brine (x2). The organic layer was dried over Na2SO4, filtered 
and concentrated under reduced pressure to yield tert-butyl 4-(2-hydroxyphenyl)piperazine-1-
carboxylate 20 in quantitative yield, which was used in the next step without further purification. 
Spectroscopic data were in agreement with those reported.54 
 
1H-NMR (CDCl3):  1.49 (s, 9H, 3CH3), 2.80-2.84 (m, 4H, 2CH2NAr), 3.57-3.60 (m, 4H, 
2CH2NCO), 6.87 (td, J = 7.6, 1.5, 1H, H5’), 6.94-6.98 (m, 2H, H3’, OH), 7.07-7.14 (m, 2H, H4’, H6’). 
tert-Butyl 4-(2-fluoromethoxyphenyl)piperazine-1-carboxylate, 21. Following general 
procedure C, intermediate piperazine 21 was obtained from Boc-protected piperazine 20 (269 mg, 
0.966 mmol) as an oil (240 mg, 80%). Chromatography: hexane. 
 
Rf = 0.43 (hexane/EtOAc 7:3). IR (ATR):  1693 (CO), 1238 (C-O-C). 1H-NMR (CDCl3):  1.50 
(s, 9H, 3CH3), 3.01-3.04 (m, 4H, 2CH2NAr), 3.58-3.62 (m, 4H, 2CH2NCO), 5.77 (d, J = 54.6, 2H, 
CH2F), 6.97-7.18 (m, 4H, CHAr). 13C-NMR (CDCl3):  28.6 (3CH3), 44.0 (br s, 2CH2NAr), 51.0 
(2CH2NCO), 79.9 (C(CH3)3), 101.2 (d, J = 219.2, CH2F), 117.5 (C3’), 119.4 (C5’), 123.6 (C4’), 124.6 
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(C6’), 142.5 (C1’), 149.7 (d, J = 2.8, C2’), 154.9 (CO). HPLC (Gradient-I, column C18, tR, min): 12.40. 
MS (ESI, m/z, %): 291.1 ([M - F]-, 100). 
1-[(2-Difluoromethoxyphenyl)]piperazine, 22. A stirred solution of 2-
(difluoromethoxy)bromobenzene (336 mg, 1.480 mmol) in anhydrous 1,4-dioxane (12 mL) at rt was 
degassed by bubbling argon for 30 min. Then, Pd(OAc)2 (6.6 mg, 0.030 mmol), Cs2CO3 (962 mg, 
2.95 mmol) and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (92 mg, 0.148 mmol) were 
added and argon was bubbled for another 20 min. Finally, piperazine (509 mg, 5.91 mmol) was 
added and the reaction was stirred at 100 ºC overnight under an argon atmosphere. Next, the 
mixture was concentrated under reduced pressure and the residue was suspended in water and 
extracted with EtOAc (x3). The combined organic extracts were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by 
column chromatography using a gradient from DCM to 8:2 DCM/methanol, to afford intermediate 
piperazine 22 as an oil (197 mg, 58%). 
 
Rf = 0.37 (DCM/methanol 6:4). IR (ATR):  3396 (NH), 1112 (C-O-C), 1035 (C-F). 1H-NMR 
(acetone-d6):  2.97-3.04 (m, 8H, 4CH2), 6.77 (t, J = 75.5, 1H, CHF2), 7.00-7.11 (m, 3H, H3’, H4’, 
H5’), 7.19-7.24 (m, 1H, H6’). 13C-NMR (acetone-d6):  46.9 (2CH2NAr), 52.8 (2CH2NH), 117.8 (t, J = 
255.9, CHF2), 120.7 (C3’), 123.0 (C5’), 123.8 (C4’), 127.7 (C6’), 145.5 (t, J = 3.0, C2’), 146.0 (C1’). 
HPLC (Gradient-I, column C18, tR, min): 16.61. MS (ESI, m/z, %): 229.1 ([M + H]+, 100). 
 (Aryl)piperazinecarbaldehydes 13, 14 
4-(2-Fluoromethoxyphenyl)piperazine-1-carbaldehyde, 13. To a solution of 21 (220 mg, 
0.709 mmol) in anhydrous DCM (5.0 mL) under an argon atmosphere, TFA (2.7 mL, 35.4 mmol) 
was added and the reaction was stirred at rt until completion (TLC). Next, the mixture was washed 
with brine (x2) and the organic layer was dried over Na2SO4, filtered and evaporated under reduced 
pressure to afford 1-[2-(fluoromethoxyphenyl]piperazine as trifluoroacetate salt in quantitative yield, 
which was used in the next step without further purification. 
 
Rf = 0.30 (DCM/methanol 9:1). IR (ATR):  3008 (NH), 1203, 1153 (C-O-C). 1H-NMR 
(acetone-d6):  3.40-3.44 (m, 4H, 2CH2NAr), 3.55-3.58 (m, 4H, 2CH2NH), 5.86 (d, J = 54.7, 2H, 
CH2F), 7.04-7.19 (m, 4H, CHAr). 13C-NMR (acetone-d6):  44.9 (2CH2NAr), 48.5 (2CH2NH), 102.3 
(d, J = 216.7, CH2F), 118.5 (C3’), 120.4 (C5’), 124.7 (C4’), 125.3 (C6’), 142.5 (C1’), 150.6 (C2’). HPLC 
(Gradient-I, column C18, tR, min): 12.49. MS (ESI, m/z, %): 211.1 ([M + H]+, 100). 
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The trifluoroacetate salt of 1-[2-(fluoromethoxyphenyl]piperazine (149 mg, 0.709 mmol) above 
synthesized was treated with Na2CO3 (150 mg, 1.418 mmol) in a 1:1 mixture of water/Et2O to 
obtain the corresponding free amine, which was heated at reflux with methyl formate (67 mL, 1.05 
mol) for 36 h. Next, the mixture was concentrated under reduced pressure and the residue was 
purified by column chromatography using DCM as eluent, to afford the desired final compound 13 
as an oil (94 mg, 60%). 
 
Rf = 0.47 (hexane/DCM 1:9). IR (ATR):  1672 (CHO). 1H-NMR (CDCl3):  3.07-3.17 (m, 4H, 
2CH2NAr), 3.58-3.61 (m, 2H, CH2NCHO), 3.75-3.78 (m, 2H, CH2NCHO), 5.78 (d, J = 54.3, 2H, 
CH2F), 6.99-7.17 (m, 4H, 4CHAr), 8.13 (s, 1H, CHO). 13C-NMR (CDCl3):  40.6, 46.2 (2CH2NAr), 
50.6, 51.8 (2CH2NCHO), 101.0 (d, J = 219.6, CH2F), 117.2 (C3’), 119.8 (C5’), 124.6 (C4’, C6’), 141.2 
(C1’), 149.8 (d, J = 3.3, C2’), 161.5 (CHO). 19F-NMR (CDCl3):  -75.3. HPLC (Gradient-I, column 
C18, tR, min): 18.90. MS (ESI, m/z, %): 239.1 ([M + H]+, 100). 
4-(2-Difluoromethoxyphenyl)piperazine-1-carbaldehyde, 14. A mixture of methyl formate 
(19 mL, 0.305 mol) and 22 (47 mg, 0.206 mmol) was heated at reflux for 48 h (TLC). Next, the 
mixture was concentrated under reduced pressure and the residue was purified by column 
chromatography using a gradient from DCM to DCM/EtOAc 9:1, to afford the desired final 
compound 14 as a solid (30 mg, 58%). 
 
M.p.: 84-86 ºC. Rf = 0.47 (DCM/EtOAc 9:1). IR (ATR):  1666 (CHO), 1232 (C-O-C), 1105 (C-
F). 1H-NMR (acetone-d6):  2.99-3.03 (m, 2H, CH2NAr), 3.07-3.10 (m, 2H, CH2NAr), 3.58-3.66 (m, 
4H, 2CH2NCHO), 6.97 (t, J = 75.4, 1H, CHF2), 7.06-7.28 (m, 4H, 4CHAr), 8.09 (s, 1H, CHO). 13C-
NMR (acetone-d6):  40.4, 46.1 (2CH2NAr), 51.2, 52.4 (2CH2NCHO), 117.9 (t, J = 256.0, CHF2), 
121.1 (C3’), 122.8 (C5’), 124.6 (C4’), 127.7 (C6’), 145.0 (C1’), 145.6 (t, J = 3.1, C2’), 161.3 (CHO). 19F-
NMR (acetone-d6):  -82.1. HPLC (Gradient-I, column C18, tR, min): 17.73. MS (ESI, m/z, %): 
256.9 ([M + H]+, 100). 
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4.1.5. Final compounds 23-31 
 2-Hydroxybiphenyls 35-45 
1-[2'-Hydroxybiphenyl-4-yl]ethanone, 35. Following general procedure B, compound 35 
was obtained from 2-bromophenol (425 mg, 2.41 mmol) and (4-acetylphenyl)boronic acid (484 mg, 
2.89 mmol) by heating under reflux, as a white solid (220 mg, 43%). Chromatography: hexane to 
DCM. Spectroscopic data were in agreement with those reported.55 
 
M.p.: 145-147 ºC (lit.55 m.p. 145-148 °C). Rf: 0.35 (DCM). IR (ATR):  3311 (OH), 1664 (CO), 
1275 (C-O-C). 1H-NMR (CDCl3):  2.66 (s, 3H, CH3), 5.15 (br s, 1H, OH), 6.97-7.01 (m, 1H, H3’), 
7.04 (td, J = 7.5, 1.0, 1H, H5’), 7.28-7.34 (m, 2H, H4’, H6’), 7.64 (d, J = 8.5, 2H, H2, H6), 8.08 (d, J = 
8.5, 2H, H3, H5). HPLC (Gradient-III, column C18, tR, min): 17.51. MS (ESI, m/z, %): 210.9 ([M - H]-, 
100). 
Methyl 2'-hydroxybiphenyl-4-carboxylate, 36. Following general procedure B, compound 
36 was obtained from 2-bromophenol (201 mg, 1.16 mmol) and [(4-
methoxycarbonyl)phenyl]boronic acid (217 mg, 1.21 mmol) by heating at 100 ºC under MW 
irradiation for 20 min, as a white solid (41 mg, 16%). Chromatography: glass column from hexane 
to hexane/EtOAc 8:2. 
 
M.p.: 128-130 ºC. Rf: 0.39 (hexane/EtOAc 8:2). IR (ATR):  3398 (OH), 1696 (CO), 1286 (C-
O). 1H-NMR (acetone-d6):  3.90 (s, 3H, CH3), 6.96 (td, J = 7.5, 0.8, 1H, H5’), 7.02 (d, J = 8.1, 1H, 
H3’), 7.23 (td, J = 8.0, 1.6, 1H, H4’), 7.36 (dd, J = 7.6, 1.6, 1H, H6’), 7.75 (d, J = 8.4, 2H, H2, H6), 8.04 
(d, J = 8.4, 2H, H3, H5), 8.57 (s, 1H, OH). 13C-NMR (acetone-d6):  52.3 (CH3), 117.2 (C3’), 121.0 
(C5’), 128.1 (C1’), 129.2 (C4), 129.9 (C3, C5), 130.2 (C4’), 130.3 (C2, C6), 131.4 (C6’), 144.6 (C1), 
155.2 (C2’), 167.2 (CO). HPLC (Gradient-IV, column C18, tR, min): 23.58. MS (ESI, m/z, %): 227.1 
([M - H]-, 100). 
2’-Hydroxybiphenyl-4-sulfonamide, 37. Following general procedure B, compound 37 was 
obtained from 4-bromobenzenesulfonamide (100 mg, 0.424 mmol) and (2-hydroxyphenyl)boronic 
acid (64 mg, 0.466 mmol) by heating at 120 ºC under MW irradiation for 20 min, as a solid (96 mg, 
90%). Chromatography: hexane to hexane/EtOAc 6:4. 
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M.p.: 204-205 ºC. Rf: 0.15 (hexane/EtOAc 2:8). IR (ATR):  3523 (OH), 3338, 3246 (NH2), 
1331, 1162 (SO2), 1101 (C-O). 1H-NMR (acetone-d6):  6.58 (br s, 2H, NH2), 6.97 (t, J = 7.5, 1H, 
H5’), 7.02 (d, J = 8.0, 1H, H3’), 7.24 (td, J = 8.0, 1.4, 1H, H4’), 7.36 (dd, J = 7.7, 1.4, 1H, H6’), 7.77 (d, 
J = 8.4, 2H, H2, H6), 7.92 (d, J = 8.2, 2H, H3, H5), 8.65 (s, 1H, OH). 13C-NMR (acetone-d6):  
117.1(C3’), 121.0 (C5’), 126.6 (C3, C5), 127.8 (C1’), 130.3 (C4’), 130.5 (C2, C6), 131.4 (C6’), 143.1 
(C1), 143.5 (C4), 155.1 (C2’). HPLC (Gradient-I, column C18, tR, min): 14.12. MS (ESI, m/z, %): 
267.0 ([M + NH4]+, 100). 
2’-Hydroxybiphenyl-4-(N-methyl)sulfonamide, 38. Following general procedure B, 
compound 38 was obtained from 4-bromo-N-methylbenzenesulfonamide (100 mg, 0.400 mmol) 
and (2-hydroxyphenyl)boronic acid (61 mg, 0.440 mmol) by heating at 120 ºC under MW irradiation 
for 20 min, as a solid (100 mg, 95%). Chromatography: hexane to hexane/EtOAc 6:4. 
 
M.p.: 140-141 ºC. Rf: 0.18 (hexane/EtOAc 2:8). IR (ATR):  3313 (NH, OH), 1316, 1159 
(SO2), 1097 (C-O). 1H-NMR (acetone-d6):  2.62 (d, J = 5.2, 3H, CH3), 6.33 (br m, 1H, NH), 6.97 
(td, J = 7.5, 1.1, 1H, H5’), 7.03 (dd, J = 8.1, 1.0, 1H, H3’), 7.25 (ddd, J = 8.1, 7.4, 1.7, 1H, H4’), 7.37 
(dd, J = 7.6, 1.6, 1H, H6’), 7.82 (d, J = 8.7, 2H, H2, H6), 7.87 (d, J = 8.7 Hz, 2H, H3, H5), 8.64 (s, 1H, 
OH). 13C-NMR (acetone-d6):  29.5 (CH3), 117.2 (C3’), 121.1 (C5’), 126.6 (C3, C5), 127.6 (C1’), 130.4 
(C4’), 130.7 (C2, C6), 131.4 (C6’), 138.7 (C1), 143.9 (C4), 155.2 (C2’). HPLC (Gradient-I, column C18, 
tR, min): 15.07. MS (ESI, m/z, %): 262.0 ([M - H]-, 100). 
4'-(Methylsulfanyl)biphenyl-2-ol, 39. Following general procedure B, compound 39 was 
obtained from 1-bromo-(methylsulfanyl)benzene (150 mg, 0.716 mmol) and (2-
hydroxyphenyl)boronic acid (112 mg, 0.788 mmol) by heating at 120 ºC under MW irradiation for 20 
min, as an off-white solid (141 mg, 91%). Chromatography: hexane to hexane/EtOAc 9:1. 
 
M.p.: 78-79 ºC. Rf: 0.44 (hexane/EtOAc 6:4). IR (ATR):  3530, 3425 (OH), 1480, 1447 (Ar), 
1180 (C-O). 1H-NMR (CDCl3):  2.54 (s, 3H, CH3), 5.13 (br s, 1H, OH), 6.97-7.03 (m, 2H, H3, H5), 
7.22-7.30 (m, 2H, H4, H6), 7.36-7.43 (m, 4H, H2’, H3’, H5’, H6’). 13C-NMR (CDCl3):  15.8 (CH3), 
116.0 (C3), 121.1 (C5), 127.2 (C3’, C5’), 127.7 (C1), 129.2 (C4), 129.6 (C2’, C6’), 130.3 (C6), 133.8 
(C1’), 138.6 (C4’), 152.6 (C2). HPLC (Gradient-I, column C18, tR, min): 18.57. MS (ESI, m/z, %): 
214.8 ([M - H]-, 100). 
Experimental section 
174 
1-Bromo-2-(fluoromethoxy)benzene, 40. Following general procedure C, compound 40 was 
obtained from 2-bromophenol (471 mg, 2.72 mmol) as a colorless oil (541 mg, 97%). 
Chromatography: hexane. 
 
Rf: 0.46 (hexane/DCM 8:2). IR (ATR):  1478 (Ar), 1233 (C-O-C), 1091, 1033 (C-F). 1H-NMR 
(CDCl3):  5.76 (d, J = 54.2, 2H, CH2F), 7.01 (td, J = 8.1, 1.4, 1H, H5), 7.20 (d, J = 8.2, 1H, H3), 
7.32 (td, J = 8.3, 1.4, 1H, H4), 7.59 (dd, J = 8.0, 1.4, 1H, H6). 13C-NMR (CDCl3):  101.3 (d, J = 
221.0, CH2F), 113.4 (C1), 117.5 (J = 1.3, C3), 125.1 (C5), 128.9 (C4), 133.8 (C6), 153.7 (C2). 19F-
NMR (CDCl3):  -149.6. 
4'-(Methylsulfonyl)biphenyl-2-ol, 41. Intermediate 39 (100 mg, 0.462 mmol) and 
(NH4)6Mo7O28·4H2O (70.2 mg, 0.046 mmol) were dissolved in anhydrous methanol (1.2 mL) under 
an argon atmosphere. The mixture was then cooled at 0 ºC and hydrogen peroxide (30%, 189 μL, 
1.85 mmol) was added at a rate of 0.2 mL/min, mantaining the reaction temperature below 8 ºC. 
The reaction was stirred at 0 ºC for 30 min and then allowed to warm up to rt over 1 h. Next, the 
mixture was cooled to 0 ºC and sat. aqueous Na2SO3 (0.55 mL) was added dropwise so that the 
reaction temperature did not exceed 15 ºC. Water was added and the mixture was extracted with 
EtOAc (2x). The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude was purified by column chromatography from DCM to DCM/EtOAc 
9:1 to afford the desired product as a white solid (86 mg, 75%). 
 
M.p.: 148-149 ºC. Rf: 0.44 (DCM/EtOAc 9:1). IR (ATR):  3394 (OH), 1294, 1146 (SO2). 1H-
NMR (acetone-d6):  3.16 (s, 3H, CH3), 6.98 (td, J = 7.5, 1.1, 1H, H5), 7.04 (dd, J = 8.1, 0.9, 1H, 
H3), 7.26 (ddd, J = 8.1, 7.5, 1.7, 1H, H4), 7.38 (dd, J = 7.6, 1.7, 1H, H6), 7.87 (d, J = 8.7, 2H, H2’, 
H6’), 7.97 (d, J = 8.6, 2H, H3’, H5’), 8.69 (s, 1H, OH). 13C-NMR (acetone-d6):  44.4 (CH3), 117.2 
(C3), 121.1 (C5), 127.4 (C1), 127.8 (C3’, C5’), 130.6 (C4), 130.9 (C2’, C6’), 131.5 (C6), 140.3 (C4’), 
145.1 (C1’), 155.2 (C2). HPLC (Gradient-I, column C18, tR, min): 21.31. MS (ESI, m/z, %): 246.8 ([M 
- H]-, 100). 
Alkylarylsulfoxides 42, 43. General procedure. To a solution of the corresponding 
(methylsulfanyl)arene (1.00 equiv) in anhydrous DCM (14 mL/mmol) under an argon atmosphere, a 
solution of mCPBA (77%, 1.05 equiv) in anhydrous DCM (5 mL/mmol) was added at a rate of 8 
mL/min at 0 ºC, and the reaction was stirred for 30 min before warming up to rt. After 3 h, the 
mixture was filtered with a short pad of silica gel and washed with sat. aqueous NaHCO3. Next, the 
aqueous layer was extracted with DCM (x3), and the combined organic layers were washed with 
Experimental section 
 
175 
water, dried over Na2SO4, concentrated under reduced pressure. The residue was purified by 
column chromatography to afford the desired alkylarylsulfoxide derivative. 
1-Bromo-4-(methylsulfinyl)benzene, 42. Following the previous general procedure, 
compound 42 was obtained from 1-bromo-4-(methylsulfanyl)benzene (0.72 g, 3.55 mmol) as a 
solid (0.64 g, 83%). Chromatography: hexane to hexane/EtOAc 7:3. Spectroscopic data were in 
agreement with those reported.56 
 
M.p.: 84-85 ºC (lit.57 m.p.: 82-83 ºC). Rf: 0.34 (hexane/EtOAc 2:8). IR (ATR):  1569, 1470, 
1384 (Ar), 1045 (SO). 1H-NMR (acetone-d6):  2.72 (s, 3H, CH3), 7.64 (d, J = 9.0, 2H, H2, H6), 7.78 
(d, J = 9.0, 2H, H3, H5). 13C-NMR (acetone-d6):  44.2 (CH3), 125.1 (C1), 126.4 (C3, C5), 133.1 (C2, 
C6), 147.7 (C4). HPLC (Gradient-I, column C18, tR, min): 19.68. MS (ESI, m/z, %): 218.7 ([M(79Br) + 
H]+, 100), 220.7 ([M(81Br) + H]+, 100). 
1-Bromo-4-(ethylsulfinyl)benzene, 43. Following the previous general procedure, compound 
43 was obtained from 1-bromo-4-(ethylsulfanyl)benzene (1.08 g, 4.97 mmol) as an oil (1.06 g, 
92%). Chromatography: hexane to hexane/EtOAc 7:3. Spectroscopic data were in agreement with 
those reported.58 
 
Rf: 0.36 (hexane/EtOAc 2:8). IR (ATR):  1572 (Ar), 1313, 1145 (SO). 1H-NMR (CDCl3):  
1.97 (t, J = 7.4, 3H, CH3), 2.68-2.80 (m, 1H, 1/2CH2), 2.85-2.96 (m, 1H, 1/2CH2), 7.48 (d, J = 8.5, 
2H, H2, H6), 7.66 (d, J = 8.3, 2H, H3, H5). 13C-NMR (CDCl3):  7.6 (CH3), 50.8 (CH2), 129.2 (C1), 
129.4 (C3, C5), 132.7 (C2, C6), 137.8 (C4). HPLC (Gradient-I, column C18, tR, min): 14.40. MS (ESI, 
m/z, %): 233.0 ([M(79Br) + H]+, 100), 235.0 ([M(81Br) + H]+, 100). 
4'-(Methylsulfinyl)biphenyl-2-ol, 44. Following general procedure B, compound 44 was 
obtained from 42 (100 mg, 0.493 mmol) and (2-hydroxyphenyl)boronic acid (81 mg, 0.592 mmol) 
by heating at 120 ºC under MW irradiation for 20 min, as a solid (106 mg, 93%). Chromatography: 
DCM to DCM/EtOAc 8:2. 
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M.p.: 179-180 ºC. Rf: 0.31 (DCM/EtOAc 6:4). IR (ATR):  3261 (OH), 1451 (Ar), 1275 (C-O), 
1026 (SO). 1H-NMR (methanol-d4):  2.85 (s, 3H, CH3), 6.90-6.95 (m, 2H, H3, H5), 7.21 (td, J = 7.7, 
1.5, 1H, H4), 7.30 (d, J = 7.5, 1H, H6), 7.73 (d, J = 8.4, 2H, H2’, H6’), 7.81 (d, J = 8.4, 2H, H3’, H5’). 
13C-NMR (methanol-d4):  43.5 (CH3), 117.1 (C3), 121.0 (C5), 124.5 (C3’, C5’), 128.3 (C1), 130.4 
(C4), 131.6 (C6, C2’, C6’), 143.6 (C1’), 144.1 (C4’), 155.7 (C2). HPLC (Gradient-II, column C18, tR, 
min): 21.33. MS (ESI, m/z, %): 230.7 ([M - H]-, 100). 
4'-(Ethylsulfinyl)biphenyl-2-ol, 45. Following general procedure B, compound 45 was 
obtained from 43 (130 mg, 0.559 mmol) and (2-hydroxyphenyl)boronic acid (95 mg, 0.671 mmol) 
by heating at 120 ºC under MW irradiation for 20 min, as a solid (136 mg, 99%). Chromatography: 
hexane to hexane/EtOAc 6:4. 
 
M.p.: 210-211 ºC. Rf: 0.25 (hexane/EtOAc 2:8). IR (ATR):  3172 (OH), 1452 (Ar), 1005 (SO). 
1H-NMR (methanol-d4):  1.22 (t, J = 7.4, 3H, CH3), 2.86-2.97 (m, 1H, 1/2CH2), 3.00-3.12 (m, 1H, 
1/2CH2), 6.90-6.95 (m, 2H, H3, H5), 7.20 (td, J = 8.5, 2.7, 1H, H4), 7.30 (dd, J = 8.2, 1.8, 1H, H6), 
7.68 (d, J = 8.6, 2H, H2’, H6’), 7.80 (d, J = 8.7, 2H, H3’, H5’). 13C-NMR (methanol-d4):  6.37 (CH3), 
50.9 (CH2), 117.1 (C3), 121.1 (C5), 125.1 (C3’, C5’), 128.3 (C1), 130.4 (C4), 131.4 (C2’, C6’), 131.6 
(C6), 141.1 (C1’), 144.0 (C4’), 155.7 (C2). HPLC (Gradient-I, column C18, tR, min): 14.55. MS (ESI, 
m/z, %): 245.1 ([M - H]-, 100). 
 (Fluoromethoxy)biphenyls 23-31 
1-[2'-(Fluoromethoxy)biphenyl-4-yl]ethanone, 23. Following general procedure C, 
compound 23 was obtained from 35 (220 mg, 1.04 mmol) as a solid (195 mg, 77%). 
Chromatography: hexane. 
 
M.p.: 70-71 ºC. Rf: 0.36 (hexane/DCM 7:3). IR (ATR):  1679 (CO), 1267, 1216 (C-O-C), 1084 
(C-F). 1H-NMR (CDCl3):  2.65 (s, 3H, CH3), 5.67 (d, J = 54.4, 2H, CH2F), 7.19-7.28 (m, 2H, H3’, 
H5’), 7.38-7.44 (m, 2H, H4’, H6’), 7.62 (d, J = 8.4, 2H, H2, H6), 8.03 (d, J = 8.4, 2H, H3, H5). 13C-NMR 
(CDCl3):  26.8 (CH3), 101.0 (d, J = 219.7, CH2F), 116.1 (J = 1.1, C3’), 124.1 (C5’), 128.3 (C3, C5), 
129.8 (C4’), 129.9 (C2, C6), 131.0 (d, J = 1.3, C1’), 131.1 (C6’), 136.0 (C4), 142.9 (C1), 153.7 (d, J = 
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3.1, C2’), 197.9 (CO). 19F-NMR (CDCl3):  -148.9. HPLC (Gradient-I, column C18, tR, min): 17.59. 
MS (ESI, m/z, %): 245.1 ([M + H]+, 100). 
Methyl 2'-(fluoromethoxy)biphenyl-4-carboxylate, 24. Following general procedure C, 
compound 24 was obtained from 36 (40 mg, 0.175 mmol) as a solid (42 mg, 93%). 
Chromatography: hexane. 
 
M.p.: 61-62 ºC. Rf: 0.45 (hexane/EtOAc 9:1). IR (ATR):  1721(CO), 1280 (C-O-C), 1108 (C-
F). 1H-NMR (CDCl3):  3.96 (s, 3H, CH3), 5.66 (d, J = 54.4, 2H, CH2F), 7.22 (td, J = 7.7, 1.1, 1H, 
H5’), 7.27 (dd, J = 7.6, 1.0, 1H, H3’), 7.39 (d, J = 7.6, 1H, H6’), 7.37-7.43 (m, 1H, H4’), 7.60 (d, J = 
7.5, 2H, H2, H6), 8.10 (d, J = 8.6, 2H, H3, H5). 13C-NMR (CDCl3):  52.5 (CH3), 101.3 (d, J = 219.6, 
CH2F), 116.3 (d, J = 1.1, C3’), 124.3 (C5’), 129.3 (C1’), 129.8 (C3, C5), 130.0 (C2, C6, C4’), 131.3 (C4), 
131.4 (C6’), 142.9 (C1), 154.0 (d, J = 3.0, C2’), 167.4 (CO). 19F-NMR (acetone-d6):  -148.9. HPLC 
(Gradient-IV, column C3, tR, min): 18.46. MS (ESI, m/z, %): 261.1 ([M + H]+, 100). 
2’-(Fluoromethoxy)biphenyl-4-sulfonamide, 25. Following general procedure C, compound 
25 was obtained from 37 (15 mg, 0.060 mmol) as a solid (5 mg, 31%). Chromatography: 
preparative TLC in DCM/EtOAc 85:15. 
 
M.p.: 153-154 ºC. Rf: 0.29 (DCM/EtOAc 85:15). IR (ATR):  3336, 3273 (NH2), 1335, 1163 
(SO2), 1088 (C-F). 1H-NMR (acetone-d6, 500 MHz):  5.83 (d, J = 54.4, 2H, CH2F), 6.61 (br s, 2H, 
NH2), 7.25 (td, J = 7.4, 1.0, 1H, H5’), 7.34 (d, J = 8.2, 1H, H3’), 7.43-7.48 (m, 2H, H4’, H6’), 7.69 (d, J 
= 8.6, 2H, H2, H6), 7.95 (d, J = 8.6, 2H, H3, H5). 13C-NMR (acetone-d6, 125 MHz):  101.9 (d, J = 
215.6, CH2F), 116.5 (d, J = 1.0, C3’), 124.7 (C5’), 126.7 (C3, C5), 130.7 (C4’), 130.8 (C2, C6), 131.3 
(d, J = 0.8, C1’), 131.9 (C6’), 142.5 (d, J = 1.2, C1), 143.8 (d, J = 3.9, C4), 154.5 (d, J = 2.9, C2’). 19F-
NMR (acetone-d6):  -150.9. HPLC (Gradient-I, column C18, tR, min): 14.86. MS (ESI, m/z, %): 
299.0 ([M + NH4]+, 100). 
2’-(Fluoromethoxy)biphenyl-4-(N-methylsulfonamide), 26. Following general procedure C, 
compound 26 was obtained from 38 (24 mg, 0.089 mmol) as an oil (12 mg, 45%). Chromatography: 
preparative TLC in DCM/methanol 95:5. 
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Rf: 0.38 (DCM/methanol 95:5). IR (ATR):  3295 (NH2), 1324, 1163 (SO2), 1095, 1082 (C-O-
C). 1H-NMR (acetone-d6):  2.63 (d, J = 5.1, 3H, CH3), 5.84 (d, J = 54.3, 2H, CH2F), 6.39 (br q, J = 
4.9, 1H, NH), 7.26 (t, J = 7.4, 1H, H5’), 7.35 (d, J = 8.3, 1H, H3’), 7.45-7.50 (m, 2H, H4’, H6’), 7.74 (d, 
J = 8.5, 2H, H2, H6), 7.89 (d, J = 8.6, 2H, H3, H5). 13C-NMR (acetone-d6, 125 MHz):  29.6 (CH3), 
101.8 (d, J = 215.6, CH2F), 116.5 (C3’), 124.7 (C5’), 127.7 (C3, C5), 130.8 (C4’), 131.0 (C2, C6), 131.1 
(C1’), 131.9 (C6’), 139.4 (C1), 142.9 (C4), 154.5 (d, J = 3.0, C2’). 19F-NMR (acetone-d6):  -151.0. 
HPLC (Gradient-I, column C18, tR, min): 15.99. MS (ESI, m/z, %): 296.1 ([M + H]+, 100), 313.1 ([M 
+ NH4]+, 81). 
2'-(Fluoromethoxy)biphenyl-4-carboxylic acid, 27. Compound 24 (39 mg, 0.150 mmol) 
was dissolved in a solution of NaOH (62 mg, 1.50 mmol) in a 1:1 mixture of THF/water (0.45 mL) 
and the reaction was stirred at rt for 12 h. Next, pH was adjusted to 1 with sat. aqueous NaHSO4 
and the mixture was diluted with brine. The product was extracted with EtOAc (x3) and the 
combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure to afford the final product 27 as a white solid (37 mg, quantitative). 
 
M.p.: 197-198 ºC. Rf: 0.20 (hexane/EtOAc 6:4). IR (ATR):  1675 (CO), 1218 (C-O-C). 1H-
NMR (acetone-d6):  5.83 (d, J = 54.5, 2H, CH2F), 7.26 (td, J = 7.5, 1.1, 1H, H5’), 7.36 (d, J = 8.7, 
1H, H3’), 7.45 (d, J = 7.2, 1H, H6’), 7.44-7.49 (m, 1H, H4’), 7.66 (d, J = 8.4, 2H, H2, H6), 8.10 (d, J = 
8.4, 2H, H3, H5). 13C-NMR (acetone-d6):  101.4 (d, J = 216.7, CH2F), 116.1 (d, J = 1.1, C3’), 124.2 
(C5’), 129.6 (C1’), 129.7 (C3, C5), 130.0 (C2, C6), 130.1 (C4’), 131.2 (C4), 131.3 (C6’), 143.0 (C1), 
154.0 (d, J = 3.2, C2’), 167.0 (COOH). 19F-NMR (acetone-d6):  -150.8. HPLC (Gradient-IV, column 
C18, tR, min): 28.20. MS (ESI, m/z, %): 245.1 ([M - H]-, 100). 
2'-(Fluoromethoxy)biphenyl-4-carboxamide, 28. Following general procedure B, compound 
28 was obtained from 40 (121 mg, 0.590 mmol) and (4-carbamoylphenyl)boronic acid (110 mg, 
0.649 mmol) by heating at 170 ºC under MW irradiation for 10 min, as a solid (37 mg, 32%). 
Chromatography: preparative TLC in DCM/methanol 95:5. 
 
M.p.: 166-168 ºC (hexane/methanol). Rf: 0.28 (DCM/methanol 95:5). IR (ATR):  3389, 3181 
(NH2), 1639 (CO), 1217 (C-O-C). 1H-NMR (acetone-d6):  5.82 (d, J = 54.5, 2H, CH2F), 6.66 (br s, 
1H, NH), 7.24 (td, J = 7.7, 1.1, 1H, H5’), 7.33 (d, J = 8.6, 1H, H3’), 7.42-7.47 (m, 3H, H4’, H6’, NH), 
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7.61 (d, J = 8.5, 2H, H2, H6), 8.00 (d, J = 8.5 Hz, 2H, H3, H5). 13C-NMR (acetone-d6):  102.0 (d, J = 
216.8, CH2F), 116.6 (C3’), 124.7 (C5’), 128.2 (C3, C5), 130.2 (C2, C6), 130.3 (C4’), 131.8 (C6’), 131.9 
(d, J = 1.0, C1’), 134.1 (C4), 141.9 (C1), 154.6 (d, J = 3.0, C2’), 168.8 (CONH2). 19F-NMR (acetone-
d6):  -150.7. HPLC (Gradient-IV, column C18, tR, min): 18.98. MS (ESI, m/z, %): 246.1 ([M + H]+, 
100). 
2-(Fluoromethoxy)-4'-(methylsulfonyl)biphenyl, 29. Following general procedure C, 
compound 29 was obtained from 41 (50 mg, 0.202 mmol) as a solid (55 mg, 97%). 
Chromatography: DCM. 
 
M.p.: 117-119 ºC. Rf: 0.46 (DCM). IR (ATR):  1304 (SO2), 1217 (C-O-C), 1150 (SO2), 1085 
(C-F). 1H-NMR (CDCl3):  3.12 (s, 3H, CH3), 5.69 (d, J = 54.3, 2H, CH2F), 7.24 (td, J = 7.5, 1.0, 1H, 
H5), 7.28 (d, J = 8.1, 1H, H3), 7.38 (dd, J = 7.6, 1.7, 1H, H6), 7.44 (ddd, J = 8.1, 7.4, 1.8, 1H, H4), 
7.72 (d, J = 8.6 Hz, 2H, H2’, H6’), 8.00 (d, J = 8.5, 2H, H3’, H5’). 13C-NMR (CDCl3):  44.7 (CH3), 
101.1 (d, J = 220.0, CH2F), 115.7 (d, J = 1.7, C3), 124.1 (C5), 127.2 (C3’, C5’), 130.0 (d, J = 1.1, C1), 
130.2 (C4), 130.6 (C2’, C6’), 131.1 (C6), 139.1 (C4’), 143.6 (C1’), 153.6 (d, J = 3.1, C2). 19F-NMR 
(CDCl3):  -149.1. HPLC (Gradient-I, column C18, tR, min): 17.45. MS (ESI, m/z, %): 297.8 ([M + 
NH4]+, 100). 
2-(Fluoromethoxy)-4'-(methylsulfinyl)biphenyl, 30. Following general procedure C, 
compound 30 was obtained from 44 (47 mg, 0.203 mmol) as an oil (47 mg, 87%). Chromatography: 
DCM. 
 
Rf: 0.44 (DCM/EtOAc 1:1). IR (ATR):  1215 (C-O-C), 1083 (SO), 1046, 960 (C-F). 1H-NMR 
(acetone-d6):  2.75 (s, 3H, CH3), 5.83 (d, J = 54.4, 2H, CH2F), 7.24 (td, J = 7.5, 1.1, 1H, H5), 7.34 
(d, J = 7.5, 1H, H3), 7.44 (d, J = 7.4, 1H, H6), 7.46 (app td, J = 7.4, 1.7, 1H, H4), 7.70-7.77 (m, 4H, 
H2’, H3’, H5’, H6’). 13C-NMR (acetone-d6):  44.2 (CH3), 101.8 (d, J = 216.8, CH2F), 116.4 (d, J = 1.2, 
C3), 124.1 (C3’, C5’), 124.6 (C5), 130.4 (C4), 131.1 (C2’, C6’), 131.5 (C1), 131.9 (C6), 141.2 (C1’), 146.8 
(C4’), 154.5 (d, J = 3.3 Hz, C2). 19F-NMR (acetone-d6):  -150.8. HPLC (Gradient-I, column C18, tR, 
min): 13.32. MS (ESI, m/z, %): 264.8 ([M + H]+, 100). 
2-(Fluoromethoxy)-4'-(ethylsulfinyl)biphenyl, 31. Following general procedure C, 
compound 31 was obtained from 45 (40 mg, 0.162 mmol) as an oil (24 mg, 52%). Chromatography: 
preparative TLC in toluene/DCM 95:5. 
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Rf: 0.31 (toluene/DCM 95:5). IR (ATR):  1448 (Ar), 1217 (C-O-C), 1084, 1048 (SO), 975 (C-
F). 1H-NMR (acetone-d6, 500 MHz):  1.16 (t, J = 7.4, 3H, CH3), 2.74-2.81 (m, 1H, 1/2CH2), 2.97-
3.04 (m, 1H, 1/2CH2), 5.82 (d, J = 54.4, 2H, CH2F), 7.24 (td, J = 7.4, 1.2 Hz, 1H, H5), 7.34 (br dt, J 
= 8.7, 1.2, 1H, H3), 7.43-7.46 (m, 2H, H4, H6), 7.69-7.73 (m, 4H, H2’, H3’, H4’, H5’). 13C-NMR 
(acetone-d6, 125 MHz):  5.95 (CH3), 50.5 (CH2), 101.9 (d, J = 215.4, CH2F), 116.5 (d, J = 0.8, C3), 
124.6 (C5), 124.7 (C3’, C5’), 130.4 (C4), 131.0, (C2’, C6’), 131.5 (d, J = 0.8, C1), 131.9 (C6), 141.2 
(C1’), 144.3 (C4’), 154.5 (d, J = 2.9, C2). 19F-NMR (acetone-d6):  -150.8. HPLC (Gradient-I, column 
C18, tR, min): 13.10. MS (ESI, m/z, %): 279.1 ([M + H]+, 100). 
 
4.1.6. Final compounds 32-34 
 Intermediates 46-53 
1-Bromo-4-(S-ethylsulfonimidoyl)benzene, 46.59 A solution of 43 (635 mg, 2.72 mmol) and 
sodium azide (212 mg, 3.26 mmol) in anhydrous CHCl3 (2.7 mL) under an argon atmosphere was 
stirred in a pre-dried three neck round-bottom flask equipped with a reflux condenser and an 
addition funnel. Next, concentrated H2SO4 (0.70 mL, 12.5 mmol) was added dropwise at 0 ºC. The 
resulting mixture was then slowly warmed up to 45 ºC and maintained overnight with magnetic 
strirring. After that time, the reaction was cooled and ice water was added. When all the salts were 
dissolved, the organic layer was separated and the aqueous layer was extracted with DCM first, 
made slightly alkaline with 20% aqueous NaOH and re-extracted with DCM (3x). The combined 
organic extracts were dried over Na2SO4, filtered and concentrated under reduced pressure. The 
resulting residue was purified by column chromatography from DCM to DCM/methanol 96:4 to 
afford the desired sulfoximine 46 as an oil (620 mg, 92%). 
 
Rf: 0.30 (DCM/methanol 95:5). IR (ATR):  3261 (NH), 1571 (Ar), 1213 (SO). 1H-NMR 
(CDCl3):  1.26 (t, J = 7.4, 3H, CH3), 2.68 (br s, 1H, NH), 3.16 (q, J = 7.4, 2H, CH2), 7.69 (d, J = 
8.7, 2H, H2, H6), 7.83 (d, J = 8.7, 2H, H3, H5). 13C-NMR (CDCl3):  8.0 (CH3), 52.0 (CH2), 128.5 (C1), 
130.3 (C3, C5), 132.6 (C2, C6), 140.7 (C4). HPLC (Gradient-I, column C18, tR, min): 14.01. MS (ESI, 
m/z, %): 248.0 ([M(79Br) + H]+, 99), 250.0 ([M(81Br) + H]+, 100). 
4'-(S-Ethylsulfonimidoyl)biphenyl-2-ol, 47. Following general procedure B, compound 47 
was obtained from 46 (130 mg, 0.525 mmol) and (2-hydroxyphenyl)boronic acid (87 mg, 0.630 
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mmol) by heating at 120 ºC under MW irradiation for 20 min, as a solid (123 mg, 90%). 
Chromatography: hexane to hexane/EtOAc 1:1. 
 
M.p.: 141-143 ºC. Rf: 0.22 (hexane/EtOAc 2:8). IR (ATR):  3283 (OH, NH), 1596, 1452 (Ar), 
1277 (SO), 1207 (C-O), 1099 (SO). 1H-NMR (acetone-d6):  1.19 (t, J = 7.1, 3H, CH3), 3.16 (q, J = 
7.4, 2H, CH2), 3.15 (br s, 1H, NH), 6.97 (td, J = 7.6, 1.1, 1H, H5), 7.04 (dd, J = 8.1, 0.9, 1H, H3), 
7.25 (ddd, J = 7.4, 7.3, 1.8, 1H, H4), 7.37 (dd, J = 7.6, 1.6, 1H, H6), 7.82 (d, J = 8.5, 2H, H2’, H6’), 
7.96 (d, J = 8.5, 2H, H3’, H5’). 13C-NMR (acetone-d6):  8.4 (CH3), 52.5 (CH2), 117.1 (C3), 121.0 
(C5), 127.6 (C1), 129.0 (C3’, C5’), 130.4 (C4), 130.5 (C2’, C6’), 131.5 (C6), 141.1 (C1’), 144.2 (C4’), 
155.2 (C2). HPLC (Gradient-I, column C18, tR, min): 14.02. MS (ESI, m/z, %): 260.0 ([M - H]-, 100). 
[(4-Bromophenyl)(methyl)-λ4-sulfanylidene]cyanamide, 48. Following general procedure 
E(a), compound 48 was obtained from 1-bromo-4-(methylsulfanyl)benzene (0.69 g, 3.39 mmol) as 
a solid (0.82 g, quantitative). 
 
Rf: 0.33 (hexane/EtOAc 1:1). 1H-NMR (CDCl3):  3.02 (s, 3H, CH3), 7.67 (d, J = 8.8, 2H, H3, 
H5), 7.76 (d, J = 8.8, 2H, H2, H6). 
[(4-Bromophenyl)(methyl)oxido-λ6-sulfanylidene]cyanamide, 49. Following general 
procedure E(b), compound 49 was obtained from 48 (0.71 g, 2.91 mmol) as a solid (0.63 g, 83%). 
 
Rf: 0.30 (hexane/EtOAc 1:1). 1H-NMR (CDCl3):  3.34 (s, 3H, CH3), 7.81-7.88 (m, 4H, 4CHAr). 
1-Bromo-4-(S-methylsulfonimidoyl)benzene, 50. Following general procedure E(c), 
compound 50 was obtained from 49 (1.20 g, 4.63 mmol) as a white solid (0.83 mg, 77%). 
Chromatography: hexane to hexane/EtOAc 1:1. 
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M.p.: 88-89 ºC. Rf: 0.31 (hexane/EtOAc 2:8). IR (ATR):  3288 (NH), 1572 (Ar), 1387, 1221 
(SO). 1H-NMR (acetone-d6):  3.06-3.07 (m, 3H, CH3), 7.79 (d, J = 8.7, 2H, H2, H6), 7.92 (d, J = 
8.7, 2H, H3, H5). 13C-NMR (acetone-d6):  46.5 (CH3), 127.6 (C1), 130.6 (C3, C5), 133.0 (C2, C6), 
145.0 (C4). HPLC (Gradient-I, column C18, tR, min): 16.89. MS (ESI, m/z, %): 233.7 ([M(79Br) + H]+, 
99), 235.7 ([M(81Br) + H]+, 100). 
4'-(S-Methylsulfonimidoyl)-1,1'-biphenyl-2-ol, 51. Following general procedure B, 
compound 51 was obtained from 50 (40 mg, 0.173 mmol) and (2-hydroxyphenyl)boronic acid (27 
mg, 0.190 mmol) by heating at 120 ºC under MW irradiation for 20 min, as a solid (24 mg, 56%). 
Chromatography: hexane to hexane/EtOAc 1:1. 
 
M.p.: 196-197 ºC. Rf: 0.34 (hexane/EtOAc 2:8). IR (ATR):  3279 (OH, NH), 1217 (C-O), 1100 
(SO). 1H-NMR (acetone-d6, 500 MHz):  3.09 (s, 3H, CH3), 6.97 (td, J = 7.4, 1.2, 1H, H5), 7.04 (dd, 
J = 8.1, 0.6 Hz, 1H, H3), 7.25 (td, J = 8.2, 1.7, 1H, H4), 7.37 (dd, J = 7.6, 1.7, 1H, H6), 7.81 (d, J = 
8.6, 2H, H2’, H6’), 8.01 (d, J = 8.4, 2H, H3’, H5’), 8.65 (s, 1H, OH). 13C-NMR (acetone-d6, 125 MHz): 
 46.7 (CH3), 117.2 (C3), 121.1 (C5), 127.8 (C1), 128.2 (C3’, C5’), 130.4 (C4), 130.6 (C2’, C6’), 131.5 
(C6), 143.5 (C1’), 144.1 (C4’), 155.2 (C2). HPLC (Gradient-I, column C18, tR, min): 13.35. MS (ESI, 
m/z, %): 248.1 ([M + H]+, 100). 
1-Bromo-4-(N,S-dimethylsulfonimidoyl)benzene, 52. Following general procedure F, 
compound 52 was obtained from 50 (103 mg, 0.442 mmol) as an oil (110 mg, quantitative), and it 
was used in the next step without further purification. 
 
Rf: 0.41 (DCM/methanol 95:5). IR (ATR):  1571 (Ar), 1242, 1151 (SO). 1H-NMR (acetone-
d6):  2.54 (s, 3H, NCH3), 3.15 (s, 3H, SCH3), 7.84 (m, 4H, 4CHAr). 13C-NMR (acetone-d6):  29.2 
(NCH3), 44.4 (SCH3), 128.1 (C1), 131.6 (C3, C5), 133.5 (C2, C6), 139.5 (C4). HPLC (Gradient-I, 
column C18, tR, min): 14.83. MS (ESI, m/z, %): 248.0 ([M(79Br) + H]+, 99), 250.0 ([M(81Br) + H]+, 
100). 
Experimental section 
 
183 
4'-(N,S-Dimethylsulfonimidoyl)biphenyl-2-ol, 53. Following general procedure B, 
compound 53 was obtained from 52 (108 mg, 0.434 mmol) and (2-hydroxyphenyl)boronic acid (68 
mg, 0.477 mmol) by heating at 100 ºC under MW irradiation for 20 min, as an off-white solid (51 
mg, 45%). Chromatography: hexane to hexane/EtOAc 3:7. 
 
M.p.: 206-207 ºC. Rf: 0.22 (hexane/EtOAc 1:1). IR (ATR):  3456 (OH), 1596 (Ar), 1274, 1234 
(SO). 1H-NMR (methanol-d4):  2.63 (s, 3H, NCH3), 3.18 (s, 3H, SCH3), 6.91-6.96 (m, 2H, H3, H5), 
7.22 (td, J = 7.9, 1.6, 1H, H4), 7.33 (dd, J = 7.3, 1.2, 1H, H6), 7.84-7.91 (m, 4H, H2’, H3’, H5’, H6’). 
13C-NMR (methanol-d4):  29.6 (NCH3), 44.6 (SCH3), 117.1 (C3), 121.1 (C5), 127.9 (C1), 129.5 (C3’, 
C5’), 130.8 (C4), 131.5 (C6), 131.6 (C2’, C6’), 136.6 (C1’), 146.0 (C4’), 155.8 (C2). HPLC (Gradient-I, 
column C18, tR, min): 14.27. MS (ESI, m/z, %): 262.0 ([M + H]+, 100). 
 (Fluoromethoxy)biphenyl sulfoximines 32-34 
2-(Fluoromethoxy)-4'-(S-ethylsulfonimidoyl)biphenyl, 32. Following general procedure C, 
compound 32 was obtained from 47 (36 mg, 0.140 mmol) as a solid (34 mg, 84%). 
Chromatography: DCM. 
 
M.p.: 92-93 ºC. Rf: 0.46 (DCM/methanol 95:5). IR (ATR):  3322 (NH), 1215 (C-O-C), 1128, 
1084 (SO), 973 (C-F). 1H-NMR (acetone-d6):  1.20 (t, J = 7.4, 3H, CH3), 3.17 (q, J = 7.4, 2H, 
CH2), 5.84 (d, J = 54.3, 2H, CH2F), 7.26 (td, J = 7.9, 1.1, 1H, H5), 7.35 (d, J = 8.0, 1H, H3), 7.46 (d, 
J = 7.7, 1H, H6), 7.47 (td, J = 7.3, 1.7, 1H, H4), 7.74 (d, J = 8.5, 2H, H2’, H6’), 7.99 (d, J = 8.5, 2H, 
H3’, H5’). 13C-NMR (acetone-d6):  8.4 (CH3), 52.4 (CH2), 101.8 (d, J = 215.5, CH2F), 116.4 (d, J = 
1.1, C3), 124.6 (C5), 129.1 (C3’, C5’), 130.7 (C4), 130.8 (C2’, C6’), 131.1 (d, J = 1.3, C1), 131.9 (C6), 
141.9 (C1’), 143.1 (C4’), 154.5 (d, J = 3.0, C2). 19F-NMR (acetone-d6):  -151.0. HPLC (Gradient-I, 
column C18, tR, min): 12.85. MS (ESI, m/z, %): 294.1 ([M + H]+, 100). 
2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)biphenyl, 33 (UCM-01306). Following 
general procedure C, compound 33 was obtained from 51 (26 mg, 0.105 mmol) as a solid (23 mg, 
78%). Chromatography: preparative TLC in toluene/methanol 95:5. 
 
M.p.: 144-145 ºC. Rf: 0.40 (toluene/methanol 9:1). IR (ATR):  3341 (NH), 1220 (C-O-C), 
1129, 1083 (SO), 994, 972 (C-F). 1H-NMR (acetone-d6, 500 MHz):  3.10 (s, 3H, CH3), 5.84 (d, J = 
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54.4, 2H, CH2F), 7.26 (td, J = 7.5, 1.0, 1H, H5), 7.35 (d, J = 8.3, 1H, H3), 7.44-7.49 (m, 2H, H4, H6), 
7.73 (d, J = 8.5, 2H, H2’, H6’), 8.04 (d, J = 8.5, 2H, H3’, H5’). 13C-NMR (acetone-d6):  46.6 (CH3), 
101.8 (d, J = 216.8, CH2F), 116.4 (d, J = 1.1, C3), 124.7 (C5), 128.3 (C3’, C5’), 130.8 (C4), 130.9 (C2’, 
C6’), 131.2 (d, J = 1.1, C1), 131.9 (C6), 143.1 (C1’), 144.2 (C4’), 154.5 (d, J = 3.0, C2). 19F-NMR 
(acetone-d6):  -151.0. HPLC (Gradient-I, column C18, tR, min): 13.17. MS (ESI, m/z, %): 279.8 ([M 
+ H]+, 100). 
4'-(N,S-Dimethylsulfonimidoyl)-2-(fluoromethoxy)biphenyl, 34. Following general 
procedure C, compound 34 was obtained from 53 (14 mg, 0.054 mmol) as an oil (15 mg, 95%). 
Chromatography: DCM. 
 
Rf: 0.45 (DCM/methanol 95:5). IR (ATR):  1241, 1222 (C-O-C), 1151 (SO), 1108, 977 (C-F). 1H-
NMR (acetone-d6, 500 MHz):  2.57 (s, 3H, NCH3), 3.08 (s, 3H, SCH3), 5.85 (d, J = 54.3, 2H, 
CH2F), 7.26 (td, J = 7.8, 1.2, 1H, H5), 7.36 (dd, J = 7.6, 1.1, 1H, H3), 7.46 (d, J = 7.5, 1H, H6), 7.48 
(app td, J = 7.3, 1.2, 1H, H4), 7.77 (d, J = 8.6, 2H, H2’, H6’), 7.92 (d, J = 8.5, 2H, H3’, H5’). 13C-NMR 
(acetone-d6, 125 MHz):  29.3 (NCH3), 44.8 (SCH3), 101.8 (d, J = 215.7, CH2F), 116.4 (d, J = 1.2, 
C3), 124.7 (C5), 129.3 (C3’, C5’), 130.8 (C4), 131.1 (d, J = 1.5, C1), 131.2 (C2’, C6’), 131.9 (C6), 139.4 
(C1’), 143.2 (C4’), 154.5 (d, J = 3.0, C2). 19F-NMR (acetone-d6):  -151.0. HPLC (Gradient-I, column 
C18, tR, min): 15.31. MS (ESI, m/z, %): 294.1 ([M + H]+, 100). 
 
4.1.7. Final compounds 54-56 
 Intermediates 57-68 
2-Bromo-3-(fluoromethoxy)pyridine, 57. Following general procedure C, compound 57 was 
obtained from 2-bromo-3-pyridinol (500 mg, 2.87 mmol) as a solid (428 mg, 73%), which was used 
in the next step without further purification. 
 
M.p.: 37-38 ºC. Rf: 0.25 (hexane/DCM 1:1). IR (ATR):  1415 (Ar), 1291, 1097 (C-O-C), 989 
(CF). 1H-NMR (CDCl3):  5.76 (d, J = 53.5, 2H, CH2F), 7.27 (dd, J = 8.1, 4.6, 1H, H5), 7.46 (dt, J = 
8.1, 1.3, 1H, H4), 8.16 (dd, J = 4.6, 1.5, 1H, H6). 13C-NMR (CDCl3):  101.0 (d, J = 222.0, CH2F), 
123.7 (C5), 124.5 (d, J = 1.6, C4), 134.0 (d, J = 2.1, C2), 144.8 (C6), 150.6 (d, J = 3.0, C3). 19F-NMR 
(CDCl3): -151.0. HPLC (Gradient-I, column C18, tR, min): 19.10. MS (ESI, m/z, %): 205.6 
([M(79Br) + H]+, 92), 207.7 ([M(81Br) + H]+, 100). 
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4-Bromo-3-chlorobenzenethiol, 60.60 To a suspension of 4-bromo-3-chloroaniline (1.18 g, 
5.72 mmol) in a mixture of concentrated HCl (1.6 mL) and ice (3.0 g) at -5 to 0 ºC, a solution of 
NaNO2 (414 mg, 6.00 mmol) in water (2.7 mL) was slowly added. The resulting cold diazonium salt 
solution was added dropwise to a stirred solution of potassium O-ethyl carbonodithioate (1.83 g, 
11.4 mmol) in water (2.8 mL) at 75 ºC. After stirring the mixture at that temperature for 1.5 h, the 
reaction was cooled to rt, adjusted to pH 8 with a sat. aqueous NaHCO3 solution and extracted with 
Et2O (x4). The combined organic layers were washed with water, dried over Na2SO4, filtered and 
concentrated under reduced pressure. A solution of KOH (1.41 g, 26.3 mmol) in ethanol (9.8 mL) 
was added to the residue and the mixture was heated at reflux overnight. After that time, the 
solvent was evaporated under reduced pressure and the residue was partitioned between water 
and Et2O. The aqueous layer was acidified to pH 1-2 by slow addition of 1 M H2SO4 and then 
extracted with DCM (3x). The combined organic layers were washed with water, dried over 
Na2SO4, filtered and evaporated under reduced pressure. The crude benzenethiol 60 was obtained 
as an oil (1.02 g, 80%) and used in the next step without further purification. Spectroscopic data 
were in agreement with those reported.60 
 
Rf: 0.42 (hexane/DCM 7:3). 1H-NMR (CDCl3):  3.50 (s, 1H, SH), 7.05 (dd, J = 8.3, 2.2, 1H, 
H6), 7.37 (d, J = 2.2, 1H, H2), 7.45 (d, J = 8.3, 1H, H5). 
(Methylsulfanyl)benzenes 58, 59. General procedure. A mixture of the corresponding 
benzenethiol derivative (1.0 equiv), methyliodide (1.1 equiv) and K2CO3 (1.2 equiv) in anhydrous 
acetone (1.5 mL/mmol) was stirred at rt for 5 h. Next, the reaction was poured into water and 
extracted with EtOAc (x3). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by 
column chromatography, if necessary. 
4-Bromo-2-chloro-1-(methylsulfanyl)benzene, 58. Following the previous general 
procedure, compound 58 was obtained from 4-bromo-2-chlorobenzenethiol (520 mg, 2.32 mmol) 
as an oil (575 mg, quantitative), which was used in the next step without further purification. 
 
Rf: 0.46 (hexane/DCM 9:1). IR (ATR):  1443 (Ar), 1118, 1028 (C-Hal). 1H-NMR (CDCl3):  
2.46 (s, 3H, CH3), 7.00 (d, J = 8.5, 1H, H6), 7.36 (dd, J = 8.5, 2.1, 1H, H5), 7.49 (d, J = 2.1, 1H, H3). 
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13C-NMR (CDCl3):  15.4 (CH3), 118.0 (C4), 126.7 (C6), 130.4, 132.0 (C3, C5), 132.6 (C2), 137.3 
(C1). 
1-Bromo-2-chloro-4-(methylsulfanyl)benzene, 59. Following the previous general 
procedure, compound 59 was obtained from 60 (980 mg, 4.38 mmol) as an oil (586 mg, 56%). 
Chromatography: hexane. 
 
Rf: 0.42 (hexane/DCM 95:5). IR (ATR):  1567 (Ar), 1100, 1014 (C-Hal). 1H-NMR (CDCl3):  
2.47 (s, 3H, CH3), 6.98 (dd, J = 8.4, 2.2, 1H, H5), 7.29 (d, J = 2.2, 1H, H3), 7.48 (d, J = 8.4, 1H, H6). 
13C-NMR (CDCl3):  15.8 (CH3), 118.4 (C1), 126.0 (C5), 127.6 (C3), 133.7 (C6), 135.0 (C2), 140.0 
(C4). 
[(4-Bromo-2-chlorophenyl)(methyl)-λ4-sulfanylidene]cyanamide, 61. Following general 
procedure E(a), compound 61 was obtained from 58 (346 mg, 1.45 mmol) as a solid (344 mg, 
quantitative). 
 
Rf: 0.35 (hexane/EtOAc 1:1). 1H-NMR (CDCl3):  3.01 (s, 3H, CH3), 7.70 (d, J = 1.8, 1H, H3), 
7.75 (dd, J = 8.5, 1.9, 1H, H5), 8.00 (d, J = 8.5, 1H, H6). 
[(4-Bromo-3-chlorophenyl)(methyl)-λ4-sulfanylidene]cyanamide, 62. Following general 
procedure E(a), compound 62 was obtained from 59 (248 mg, 1.04 mmol) as a solid (247 mg, 
quantitative). 
 
Rf: 0.32 (hexane/EtOAc 1:1). 1H-NMR (CDCl3):  3.03 (s, 3H, CH3), 7.55 (dd, J = 8.4, 2.2, 1H, 
H6), 7.86 (d, J = 2.2, 1H, H2), 7.88 (d, J = 8.4, 1H, H5). 
[(4-Bromo-2-chlorophenyl)(methyl)oxido-λ6-sulfanylidene]cyanamide, 63. Following 
general procedure E(b), compound 63 was obtained from 61 (448 mg, 1.61 mmol) as a solid (395 
mg, 84%). 
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Rf: 0.34 (hexane/EtOAc 1:1). 1H-NMR (CDCl3):  3.53 (s, 3H, CH3), 7.74 (dd, J = 8.6, 1.9, 1H, 
H5), 7.85 (d, J = 1.8, 1H, H3), 8.06 (d, J = 8.6, 1H, H6). 
[(4-Bromo-3-chlorophenyl)(methyl)oxido-λ6-sulfanylidene]cyanamide, 64. Following 
general procedure E(b), compound 64 was obtained from 62 (280 mg, 1.01 mmol) as a solid (264 
mg, 89%). 
 
Rf: 0.32 (hexane/EtOAc 1:1). 1H-NMR (CDCl3):  3.36 (s, 3H, CH3), 7.73 (dd, J = 8.5, 2.2, 1H, 
H6), 7.96 (d, J = 8.5, 1H, H5), 8.06 (d, J = 2.2, 1H, H2). 
4-Bromo-2-chloro-1-(S-methylsulfonimidoyl)benzene, 65. Following general procedure 
E(c), compound 65 was obtained from 63 (70 mg, 0.238 mmol) as a white solid (33 mg, 51%). 
Chromatography: hexane to hexane/EtOAc 6:4. 
 
M.p.: 82-83 ºC. Rf: 0.28 (hexane/EtOAc 1:1). IR (ATR):  3275 (NH), 1227 (SO). 1H-NMR 
(CDCl3):  3.30 (s, 3H, CH3), 7.60 (dd, J = 8.5, 1.9, 1H, H5), 7.72 (d, J = 1.8, 1H, H3), 8.05 (d, J = 
8.5, 1H, H6). 13C-NMR (CDCl3):  43.6 (CH3), 128.2 (C4), 130.8, 132.0 (C3, C5), 133.5 (C2), 134.7 
(C6), 140.3 (C1). HPLC (Gradient-I, column C18, tR, min): 14.20. MS (ESI, m/z, %): 267.8 ([M(79Br, 
35Cl) + H]+, 76), 269.8 ([M(79Br, 37Cl) + H]+, 100), 271.9 ([M(81Br, 37Cl) + H]+, 28). 
1-Bromo-2-chloro-4-(S-methylsulfonimidoyl)benzene, 66. Following general procedure 
E(c), compound 66 was obtained from 64 (278 mg, 0.947 mmol) as a white solid (119 mg, 46%). 
Chromatography: hexane to hexane/EtOAc 6:4. 
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M.p.: 110-111 ºC. Rf: 0.27 (hexane/EtOAc 1:1). IR (ATR):  3275 (NH), 1227 (SO). 1H-NMR 
(CDCl3):  3.11 (s, 3H, CH3), 7.74 (dd, J = 8.4, 2.1, 1H, H5), 7.76 (d, J = 8.3, 1H, H6), 8.08 (d, J = 
2.1, 1H, H3). 13C-NMR (CDCl3):  46.2 (CH3), 126.9 (C5), 128.6 (C1), 129.7 (C3), 134.8 (C6), 136.1 
(C2), 144.4 (C4). HPLC (Gradient-I, column C18, tR, min): 13.79. MS (ESI, m/z, %): 267.8 ([M(79Br, 
35Cl) + H]+, 75), 269.8 ([M(79Br, 37Cl) + H]+, 100), 271.9 ([M(81Br, 37Cl) + H]+, 27). 
3'-Chloro-4'-(S-methylsulfonimidoyl)biphenyl-2-ol, 67. Following general procedure B, 
compound 67 was obtained from 65 (80 mg, 0.298 mmol) and (2-hydroxyphenyl)boronic acid (45 
mg, 0.328 mmol) by heating at 100 ºC under MW irradiation for 20 min, as a solid (64 mg, 77%). 
Chromatography: hexane to hexane/EtOAc 1:1. 
 
M.p.: 97-98 ºC. Rf: 0.24 (hexane/EtOAc 1:1). IR (ATR):  3414 (NH, OH), 1364 (SO), 1219 
(C-O). 1H-NMR (acetone-d6):  3.27 (s, 3H, CH3), 6.99 (td, J = 7.6, 1.1, 1H, H5), 7.04 (d, J = 8.1, 
1H, H3), 7.28 (ddd, J = 8.1, 7.6, 1.8, 1H, H4), 7.41 (dd, J = 7.6, 1.6, 1H, H6), 7.75 (dd, J = 8.2, 1.7, 
1H, H6’), 7.86 (d, J = 1.7, 1H, H2’), 8.18 (d, J = 8.3, 1H, H5’). 13C-NMR (acetone-d6):  44.1 (CH3), 
117.2 (C3), 121.2 (C5), 126.1 (C1), 128.8 (C6’), 130.9 (C4), 131.1 (C5’), 131.3 (C6), 132.2 (C3’), 133.1 
(C2’), 140.7 (C4’), 145.5 (C1’), 155.2 (C2). HPLC (Gradient-I, column C18, tR, min): 12.17. MS (ESI, 
m/z, %): 280.0 ([M(35Cl) - H]-, 100), 281.9 ([M(37Cl) - H]-, 38). 
2'-Chloro-4'-(S-methylsulfonimidoyl)biphenyl-2-ol, 68. Following general procedure B, 
compound 68 was obtained from 66 (35 mg, 0.130 mmol) and (2-hydroxyphenyl)boronic acid (20 
mg, 0.143 mmol) by heating at 120 ºC under MW irradiation for 20 min, as a solid (33 mg, 89%). 
Chromatography: hexane to hexane/EtOAc 8:2. 
 
M.p.: 175-176 ºC. Rf: 0.20 (hexane/EtOAc 3:7). IR (ATR):  3381 (NH), 1468 (Ar), 1373, 1225 
(SO), 1207 (C-O), 1025, 1000 (C-Cl). 1H-NMR (acetone-d6, 500 MHz):  3.15 (s, 3H, CH3), 6.95 
(td, J = 7.5, 1.0, 1H, H5), 7.02 (dd, J = 8.2, 0.6, 1H, H3), 7.17 (dd, J = 7.5, 1.6, 1H, H6), 7.29 (ddd, J 
= 8.2, 7.6, 1.6, 1H, H4), 7.58 (d, J = 8.0, 1H, H6’), 7.94 (dd, J = 8.0, 1.8, 1H, H5’), 8.05 (d, J = 1.8, 
1H, H3’). 13C-NMR (acetone-d6, 125 MHz):  46.4 (CH3), 116.7 (C3), 120.3 (C5), 126.3 (C1), 126.6 
(C5’), 129.2 (C3’), 130.7 (C4), 131.4 (C6), 133.6 (C6’), 135.1 (C2’), 143.2 (C1’), 145.9 (C4’), 155.2 (C2). 
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HPLC (Gradient-I, column C18, tR, min): 14.13. MS (ESI, m/z, %): 279.9 ([M(35Cl) - H]-, 100), 282.0 
([M(37Cl) - H]-, 40). 
 
 (Fluoromethoxy)biphenyl sulfoximines 54-56 
3-(Fluoromethoxy)-2-[4-(S-methylsulfonimidoyl)phenyl]pyridine, 54.61 A round-bottom 
flask was charged with 50 (55 mg, 0.230 mmol), bis(pinacolato)diboron (63 mg, 0.250 mmol), 
potassium acetate (39 mg, 0.400 mmol) and dicyclohexyl(2’,6’-dimethoxybiphenyl-2-yl)phosphane 
(SPhos) (7 mg, 0.020 mmol) and the system was evacuated and back-filled with argon (x3) before 
adding anhydrous 1,4-dioxane (0.8 mL). Next, Pd2(dba)3·CHCl3 (2.5 mg, 0.002 mmol) was added 
and the reaction was heated at 110 ºC overnight. After consumption of starting material (TLC and 
1H-NMR), a solution of 57 (39 mg, 0.190 mmol) in anhydrous 1,4-dioxane (0.2 mL), 5 M aqueous 
K3PO4 (233 mg, 1.100 mmol) and another charge of catalyst were added at rt and the reaction was 
heated at 110 ºC overnight. Next, the reaction was cooled to rt, filtered through Celite and the 
filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC in 
DCM/methanol 95:5 to afford the desired final product as a white solid (16 mg, 24%). 
 
M.p.: 131-132 ºC. Rf: 0.19 (DCM/methanol 95:5). IR (ATR):  3262 (NH), 1445 (Ar), 1223, 
1198 (SO), 1131, 1090 (C-O-C), 994 (C-F). 1H-NMR (acetone-d6, 500 MHz):  3.10 (CH3), 5.92 (d, 
J = 53.8, 2H, CH2F), 7.48 (dd, J = 8.4, 4.6, 1H, H5), 7.78 (dt, J = 8.4, 1.1, 1H, H4), 8.06 (d, J = 8.6, 
2H, H2’, H6’), 8.13 (d, J = 8.6, 2H, H3’, H5’), 8.49 (dd, J = 4.6, 1.2, 1H, H6). 13C-NMR (acetone-d6, 
125 MHz):  46.6 (CH3), 101.7 (d, J = 217.1, CH2F), 124.2 (d, J = 1.1, C4), 125.2 (C5), 128.0 (C2’, 
C6’), 130.8 (C3’, C5’), 142.3 (C1’), 145.2 (C4’), 145.3 (C6), 147.6 (d, J = 0.7, C2), 151.9 (d, J = 2.8, C3). 
19F-NMR (acetone-d6): -152.4. HPLC (Gradient-I, column C18, tR, min): 12.95. MS (ESI, m/z, %): 
281.1 ([M + H]+, 100). 
3'-Chloro-4'-(S-methylsulfonimidoyl)-2-(fluoromethoxy)biphenyl, 55. Following general 
procedure C, compound 55 was obtained from 67 (50 mg, 0.177 mmol) as an oil (45 mg, 80%). 
Chromatography: hexane to hexane/EtOAc 7:3. 
 
Rf: 0.41 (hexane/EtOAc 6:4). IR (ATR):  3273 (NH), 1587 (Ar), 1224 (C-O-C), 978 (C-F). 1H-
NMR (acetone-d6, 500 MHz):  3.28 (s, 3H, CH3), 3.78 (br s, 1H, NH), 5.87 (d, J = 54.2, 2H, CH2F), 
7.26 (td, J = 7.5, 1.0, 1H, H5), 7.36 (d, J = 8.4, 1H, H3), 7.47 (dd, J = 7.7, 1.7, 1H, H6), 7.50 (ddd, J 
= 8.0, 7.7, 1.8, 1H, H4), 7.67 (dd, J = 8.2, 1.7, 1H, H6’), 7.75 (d, J = 1.7, 1H, H2’), 8.21 (d, J = 8.2, 
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1H, H5’). 13C-NMR (acetone-d6, 125 MHz):  44.1 (CH3), 101.8 (d, J = 215.9, CH2F), 116.4 (d, J = 
1.4, C3), 124.7 (C5), 129.2 (C6’), 129.6 (d, J = 1.3, C1), 131.2 (C4), 131.3 (C5’), 131.8 (C6), 132.3 
(C3’), 133.3 (C2’), 141.5 (C4’), 144.5 (C1’), 154.4 (d, J = 2.9, C2). 19F-NMR (acetone-d6): -151.2. 
HPLC (Gradient-I, column C18, tR, min): 15.05. MS (ESI, m/z, %): 314.0 ([M(35Cl) + H]+, 100), 316.0 
([M(37Cl) + H]+, 37). 
2'-Chloro-4'-(S-methylsulfonimidoyl)-2-(fluoromethoxy)biphenyl, 56. Following general 
procedure C, compound 56 was obtained from 68 (17 mg, 0.060 mmol) as an oil (18 mg, 96%). 
Chromatography: preparative TLC in DCM/methanol 98:2. 
 
Rf: 0.41 (DCM/methanol 95:5). IR (ATR):  3269 (NH), 1217 (SO), 1085, 1068 (C-O-C), 968 
(C-F). 1H-NMR (acetone-d6, 700 MHz):  3.16 (s, 3H, CH3), 3.63 (br s, 1H, NH), 5.79 (d, J = 54.3, 
2H, CH2F), 7.26 (td, J = 7.4, 0.8, 1H, H5), 7.30 (dd, J = 7.5, 1.8, 1H, H6), 7.35 (d, J = 8.3, 1H, H3), 
7.52 (ddd, J = 8.5, 7.0, 2.2, 1H, H4), 7.58 (d, J = 8.0, 1H, H6’), 7.98 (dd, J = 8.0, 1.8, 1H, H5’), 8.07 
(d, J = 1.8, 1H, H3’). 13C-NMR (acetone-d6, 175 MHz):  46.3 (CH3), 101.8 (d, J = 215.7, CH2F), 
115.8 (d, J = 1.4 Hz, C3), 124.2 (C5), 126.8 (C5’), 129.2 (C3’), 130.0 (C1), 131.3 (C4), 131.7 (C6), 
133.3 (C6’), 134.8 (C2’), 142.2 (C1’), 146.5 (C4’), 154.7 (d, J = 3.2 Hz, C2). 19F-NMR (acetone-d6): -
150.5. HPLC (Gradient-I, column C18, tR, min): 15.14. MS (ESI, m/z, %): 314.0 ([M(35Cl) + H]+, 
100), 316.0 ([M(37Cl) + H]+, 38). 
 
4.1.8. Final compounds (R)-, (S)-33 
 Chiral ligands (R)-, (S)-71 
General procedure.39 A solution of the corresponding R or S form of tert-leucinol (1 equiv) in 
absolute ethanol (0.75 mL/mmol) was added to a suspension of 3,5-diiodosalicylaldehyde (1 equiv) 
in absolute ethanol (1.50 mL/mmol) under an argon atmosphere and the resulting deep-yellow 
mixture was stirred at rt overnight. Next solvent was evaporated under reduced pressure and the 
residue was purified by recrystallization in cyclohexane to afford pure chiral ligand (R)- or (S)-71. 
2-[(E)-{[(3R)-2,2-Dimethylpentan-3-yl]imino}methyl]-4,6-diiodophenol, (R)-71. Following 
the previous general procedure, compound (R)-71 was obtained from (R)-tert-leucinol (98 mg, 
0.836 mmol) and 3,5-diiodosalicylaldehyde (322, 0.836 mmol) as a yellow solid (310 mg, 78%). 
Spectroscopic data were in agreement with those reported.62 
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[]D20 = 15.9 (c = 1.00, acetone) (lit.62 []D20 = 13.68 (c = 1.045, acetone)). 1H-NMR (CDCl3):  
0.99 (s, 9H, 3CH3), 3.05 (dd, J = 9.6, 2.5, 1H, CH), 3.70 (br t, J = 9.7, 1H, 1/2CH2), 3.97-4.00 (m, 
1H, 1/2CH2), 7.54 (d, J = 2.1, 1H, CHAr), 8.04 (d, J = 2.1, 1H, CHAr), 8.12 (br s, 1H, CHN) 
2-[(E)-{[(3S)-2,2-Dimethylpentan-3-yl]imino}methyl]-4,6-diiodophenol, (S)-71. Following 
the previous general procedure, compound (S)-71 was obtained from (S)-tert-leucinol (165 mg, 
1.34 mmol) and 3,5-diiodosalicylaldehyde (516, 1.34 mmol) as a yellow solid (362 mg, 57%). 
Spectroscopic data were in agreement with those reported.39 
 
[]D20 = -16.2 (c = 1.00, acetone) (lit.39 []D20 = -16.6 (c = 1.00, acetone)). Spectroscopic data 
were in agreement with those described for enantiomer (R)-71. 
 Intermediates 70, (R)-, (S)-30 and (R)-, (S)-69 
2-(Fluoromethoxy)-4'-(methylsulfanyl)biphenyl, 70. Following general procedure C, 
compound 70 was obtained from 39 (40 mg, 0.185 mmol) as an oil (38 mg, 84%). Chromatography: 
hexane. 
 
Rf: 0.35 (hexane/DCM 9:1). IR (ATR):  1480 (Ar), 1215 (C-O-C), 971 (C-F). 1H-NMR 
(CDCl3):  2.54 (s, 3H, CH3), 5.62 (d, J = 54.6, 2H, CH2F), 7.17-7.26 (m, 2H, H3, H5), 7.32 (d, J = 
8.5, 2H, H3’, H5’), 7.34-7.38 (m, 2H, H4, H6), 7.46 (d, J = 8.6, 2H, H2’, H6’). 13C-NMR (CDCl3):  15.9 
(CH3), 101.1 (d, J = 219.0, CH2F), 116.2 (d, J = 1.2, C3), 124.0 (C5), 126.3 (C3’, C5’), 128.9 (C4), 
130.0 (C2’, C6’), 131.1 (C6), 131.6 (d, J = 1.3, C1), 134.6 (C1’), 137.7 (C4’), 153.7 (d, J = 3.1, C2). 19F-
NMR (CDCl3):  -148.6. HPLC (Gradient-VI, column C3, tR, min): 20.81. MS (ESI, m/z, %): 248.8 
([M + H]+, 100), 228.8 ([M - F]+, 63). 
Chiral sulfoxides (R)-, (S)-30. General procedure.63 A solution of VO(acac)2 (0.010 equiv) in 
anhydrous CHCl3 (0.25 mL/mmol sulfide) was added to a solution of the corresponding R or S form 
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of the chiral ligand 71 (0.015 equiv) in anhydrous CHCl3 (0.25 mL/mmol sulfide) under an argon 
atmosphere and the mixture was stirred at rt for 2 h. Next, a solution of 70 (1.00 equiv) in 
anhydrous CHCl3 (0.50 mL/mmol) was added and the reaction was stirred at rt for 30 min before 
cooling it to 0 ºC (ice bath). After 30 min, hydrogen peroxide (30%, 1.20 equiv) was added and the 
mixture was stirred vigorously at 0 ºC for 20 h. Then the reaction was quenched with 10% aqueous 
solution of Na2S2O3 (3.30 mL/mmol sulfide) and extracted with DCM (x3). The combined organic 
layers were dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. 
The crude residue was purified by column chromatography to afford desired enantiomerically pure 
30. 
(R)-2-(Fluoromethoxy)-4'-(methylsulfinyl)biphenyl, (R)-30. Following the previous general 
procedure, compound (R)-30 was obtained from 70 (318 mg, 1.28 mmol) using chiral ligand (R)-71 
(9.1 mg, 0.020 mmol), as an oil (198 mg, 59%, >99% ee). Chromatography: hexane to 
hexane/EtOAc 3:7. 
 
[]D20 = 81.2 (c = 0.24, acetone). Chiral HPLC (tR, min): 17.31. Spectroscopic data were in 
agreement with those described for racemate 30. 
(S)-2-(Fluoromethoxy)-4'-(methylsulfinyl)biphenyl, (S)-30. Following the previous general 
procedure, compound (S)-30 was obtained from 70 (152 mg, 0.610 mmol) using chiral ligand (S)-
71 (4.3 mg, 0.010 mmol), as an oil (103 mg, 64%, >99% ee). Chromatography: hexane to 
hexane/EtOAc 3:7. 
 
[]D20 = -80.3 (c = 0.24, acetone). Chiral HPLC (tR, min): 15.66. Spectroscopic data were in 
agreement with those described for racemate 30. 
Chiral N-nosylsulfoximines (R)-, (S)-69. General procedure.40 A mixture of 
enantiomerically pure sulfoxide (R)- or (S)-30 (1.00 equiv), 4-nitrobenzenesulfonamide (1.50 equiv), 
(diacetoxyiodo)benzene (1.60 equiv) and Fe(acac)3 (0.10 equiv) in anhydrous ACN (10 mL/mmol) 
was stirred at rt overnight under an argon atmosphere. Next, the solvent was evaporated under 
reduced pressure and the residue was purified by column chromatography to afford desired 
optically pure 69. 
(R)-N-{[2'-(Fluoromethoxy)biphenyl-4-yl](methyl)oxido-λ6-sulfanylidene}-4-
nitrobenzenesulfonamide, (R)-69. Following the previous general procedure, compound (R)-69 
was obtained from (R)-30 (191 mg, 0.723 mmol) as a white solid (198 mg, 59%). Chromatography: 
hexane to hexane/EtOAc 1:1. 
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Rf: 0.43 (hexane/EtOAc 1:1). []D20 = -140.2 (c = 0.40, acetone). IR (ATR):  1527 (NO2), 
1326 (SO2), 1219 (C-O-C), 1154 (SO2), 761 (NO2). 1H-NMR (acetone-d6, 500 MHz):  3.70 (s, 3H, 
CH3), 5.87 (d, J = 54.2, 2H, CH2F), 7.28 (td, J = 7.5, 1.0, 1H, H5’’), 7.37 (d, J = 8.3, 1H, H3’’), 7.47 
(dd, J = 7.6, 1.6, 1H, H6’’), 7.49-7.52 (m, 1H, H4’’), 7.84 (d, J = 8.7, 2H, H2’, H6’), 8.06 (d, J = 8.6, 2H, 
H3’, H5’), 8.14 (d, J = 8.9, 2H, H2, H6), 8.38 (d, J = 8.9, 2H, H3, H5). 13C-NMR (acetone-d6, 125 
MHz):  46.2 (CH3), 101.8 (d, J = 215.9, CH2F), 116.3 (d, J = 1.0, C3’’), 124.7 (C5’’), 124.9 (C3, C5), 
128.2 (C3’, C5’), 128.8 (C2, C6), 130.4 (d, J = 0.8, C1’’), 131.3 (C4’’), 131.5 (C2’, C6’), 132.0 (C6’’), 137.6 
(C1’), 145.2 (C4’), 150.6 (C4), 150.7 (C1), 154.5 (d, J = 2.9, C2’’). 19F-NMR (acetone-d6):  -151.2. 
HPLC (Gradient-I, column C18, tR, min): 17.33. MS (ESI, m/z, %): 465.0 ([M + H]+, 100). 
(S)-N-{[2'-(Fluoromethoxy)biphenyl-4-yl](methyl)oxido-λ6-sulfanylidene}-4-
nitrobenzenesulfonamide, (S)-69. Following the previous general procedure, compound (S)-69 
was obtained from (S)-30 (95 mg, 0.360 mmol) as a white solid (112 mg, 67%). Chromatography: 
hexane to hexane/EtOAc 1:1. 
 
[]D20 = +138.8 (c = 0.40, acetone). Spectroscopic data were in agreement with those 
described for enantiomer (R)-69. 
 Chiral (fluoromethoxy)biphenyl sulfoximines (R)-, (S)-33 
General procedure A.40 To a solution of optically pure (R)- or (S)-69 (1.00 equiv) in 
anhydrous ACN (15 mL/mmol) under an argon atmosphere, Cs2CO3 (1.80 equiv) and benzenethiol 
(1.60 equiv) were added and the reaction was stirred at rt overnight. Next, water was added and 
the mixture was extracted with DCM (x3). The combined organic layers were dried over Na2SO4, 
filtered and the solvent was evaporated under reduced pressure. The crude residue was purified by 
column chromatography to give the corresponding enantiomerically pure 33. 
General procedure B.41 The adequate enantiomerically pure (R)- or (S)-30 (1.00 equiv), 
ammonium carbamate (4.00 equiv) and (diacetoxyiodo)benzene (3.00 equiv) were dissolved in 
methanol (2.0 mL/mmol) and the mixture was stirred at rt for 30-60 min (TLC) in an open flask. 
After completion, the solvent was evaporated under reduced pressure and the residue was purified 
by column chromatography to afford the desired final optically pure 33. 
(R)-2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)biphenyl, (R)-33. Following the previous 
general procedure A, compound (R)-33 was obtained from (R)-69 (149 mg, 0.321 mmol) as a white 
solid (62 mg, 69%, >99% ee). Chromatography: hexane to EtOAc. 
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Alternatively, following the previous general procedure B, compound (R)-33 was obtained 
from (R)-30 (335 mg, 1.27 mmol) as a white solid (216 mg, 61%, >99% ee). Chromatography: 
hexane to hexane/EtOAc 7:3. 
 
M.p.: 95-96 ºC. []D20 = -21.5 (c = 0.20, acetone). Chiral HPLC (tR, min): 21.16. Spectroscopic 
data were in agreement with those described for racemic compound 33. 
(S)-2-(Fluoromethoxy)-4'-(S-methylsulfonimidoyl)biphenyl, (S)-33. Following the previous 
general procedure A, compound (S)-33 was obtained from (S)-69 (102 mg, 0.220 mmol) as a white 
solid (56 mg, 91%, >99% ee). Chromatography: hexane to EtOAc. 
Alternatively, following the previous general procedure B, compound (S)-33 was obtained 
from (S)-30 (282 mg, 1.07 mmol) as a white solid (200 mg, 67%, >99% ee). Chromatography: 
hexane to hexane/EtOAc 7:3. 
 
[]D20 = 20.8 (c = 0.20, acetone). Chiral HPLC (tR, min): 18.92. Spectroscopic data were in 
agreement with those described for racemic compound 33. 
 
4.1.9. Final compounds 72-79 
 Intermediates 92-103 
4-Chloro-2-methybenzenesulfonyl chloride, 96.42 To a solution of m-chlorotoluene (1.05 g, 
8.11 mmol) in anhydrous CHCl3 (3.7 mL) at 0 ºC and under argon atmosphere, chlorosulfonic acid 
(4.05 g, 34.10 mmol) was added dropwise and the reaction was stirred at room temperature for 45 
min. Next, the reaction mixture was cooled to 0 ºC, treated with water (1.0 mL) and extracted with 
DCM (x2). The combined organic extracts were dried over Na2SO4, filtered and concentrated under 
reduced pressure, to afford sulfonyl chloride 96 (1.82 g, quantitative) as a white solid, which was 
used in the next step without further purification. 
 
Rf: 0.31 (hexane/EtOAc 95:5). 1H-NMR (CDCl3):  2.77 (s, 3H, CH3), 7.39 (dd, J = 8.5, 2.1, 
1H, H5), 7.42-7.43 (m, 1H, H3), 8.01 (d, J = 8.5, 1H, H6). 
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4-Chloro-2-methylbenzenesulfonamide, 97. To a solution of 96 (1.86 g, 8.27 mmol) in 100 
mL of anhydrous DCM at 0 ºC and under an argon atmosphere, ammonia (0.5 M in 1,4-dioxane, 66 
mL) was added. The reaction mixture was stirred at rt for 5 h. Next, solvent was evaporated under 
reduced pressure and the solid residue was washed with water and dried under vaccum to obtain 
the crude sulfonamide, which was purified by column chromatography from hexane to 
hexane/EtOAc 7:3 to obtain compound 97 as a white solid (1.14 g, 67%). Spectroscopic data were 
in agreement with those reported.64 
 
M.p.: 185-186 ºC (lit.64 m.p.: 180-182 ºC). Rf: 0.11 (hexane/EtOAc 8:2). IR (ATR):  3356, 
3249 (NH2), 1559 (Ar), 1325, 1151 (SO2). 1H-NMR (methanol-d4):  2.65 (s, 3H, CH3), 7.34 (dd, J = 
8.5, 1.7, 1H, H5), 7.40 (d, J = 1.7, 1H, H3), 7.92 (d, J = 8.5, 1H, H6). 13C-NMR (methanol-d4):  20.2 
(CH3), 127.1 (C5), 130.4 (C6), 133.0 (C3), 138.9 (C4), 140.2 (C2), 141.8 (C1). HPLC (Gradiente-II, 
column C18, tR, min): 19.38. MS (ESI, m/z, %): 204.0 ([M(35Cl) - H]-, 100), 206.0 ([M(37Cl) - H]-, 37). 
N-(tert-Butyl)-3-chloro-2-methylbenzenesulfonamide, 98. Following general procedure G, 
compound 98 was obtained from 3-chloro-2-methylbenzenesulfonyl chloride (259 mg, 1.15 mmol) 
and tert-butylamine (0.13 mL, 1.21 mmol) as a beige solid (277 mg, 92%). Spectroscopic data were 
in agreement with those reported.43 
 
M.p.: 146-147 ºC (lit.43 m.p.: 146-148 ºC). Rf: 0.44 (hexane/EtOAc 9:1). IR (ATR):  3280 
(NH), 1313, 1148 (SO2). 1H-NMR (CDCl3):  1.23 (s, 9H, C(CH3)3), 2.75 (s, 3H, CH3), 7.25 (t, J = 
8.0, 1H, H5), 7.57 (dd, J = 8.0, 1.1, 1H, H4), 8.00 (dd, J = 8.0, 1.2, 1H, H6). 13C-NMR (CDCl3):  17.0 
(CH3), 30.3 (C(CH3)3), 55.1 (C(CH3)3), 126.7 (C5), 127.9 (C6), 133.4 (C4), 134.9 (C2), 136.9 (C3), 
143.3 (C1). HPLC (Gradient-I, column C18, tR, min): 20.48. MS (ESI, m/z, %): 262.0 ([M(35Cl) + H]+, 
100), 264.0 ([M(37Cl) + H]+, 36). 
N-(tert-Butyl)-5-chloro-2-methylbenzenesulfonamide, 99. Following general procedure G, 
compound 99 was obtained from 5-chloro-2-methylbenzenesulfonyl chloride (2.10 g, 9.03 mmol) 
and tert-butylamine (1.0 mL, 9.50 mmol) as a white solid (2.13 g, 90%). Spectroscopic data were in 
agreement with those reported.43 
 
M.p.: 141-143 °C (lit.43 m.p.: 140-142 ºC). Rf: 0.44 (hexane/EtOAc 9:1). IR (ATR):  3290 
(NH), 1320, 1138 (SO2). 1H-NMR (CDCl3):  1.24 (s, 9H, (CH3)3), 2.61 (s, 3H, CH3), 4.43 (br s, 1H, 
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NH), 7.23 (d, J = 8.2, 1H, H3), 7.39 (dd, J = 8.1, 2.3, 1H, H4), 8.02 (d, J = 2.3, 1H, H6). 13C-NMR 
(CDCl3):  19.8 (CH3), 30.3 ((CH3)3), 55.2 (C(CH3)3), 129.1 (C6), 132.1 (C5), 132.3 (C4), 133.8 (C3), 
135.2 (C2), 142.7 (C1). HPLC (Gradient-I, column C18, tR, min): 19.68. MS (ESI, m/z, %): 262.1 
([M(35Cl) + H]+, 100), 264.0 ([M(37Cl) + H]+, 39). 
N-(tert-Butyl)-6-chloro-2-methylbenzenesulfonamide, 100. Following general procedure G, 
compound 100 was obtained from 6-chloro-2-methylbenzenesulfonyl chloride (475 mg, 2.11 mmol) 
and tert-butylamine (0.23 mL, 2.22 mmol) as a white solid (514 mg, 93%). Spectroscopic data were 
in agreement with those reported.43 
 
M.p.: 161-163 ºC (lit.43 m.p.: 162-168 ºC). Rf: 0.38 (hexane/EtOAc 9:1). IR (ATR):  3311 
(NH2), 1320, 1146 (SO2). 1H-NMR (CDCl3):  1.24 (s, 9H, C(CH3)3), 2.75 (s, 3H, CH3), 7.22 (dd, J = 
7.6, 0.8 Hz, 1H, H3), 7.30 (t, J = 7.7 Hz, 1H, H4), 7.40 (dd, J = 7.8, 1.0 Hz, 1H, H5). 13C-NMR 
(CDCl3):  24.0 (CH3), 30.1 (C(CH3)3), 55.1 (C(CH3)3), 130.2 (C5), 131.8 (C4), 132.5 (C3), 132.7 
(C2), 139.6 (C6), 140.7 (C1). HPLC (Gradient-I, column C18, tR, min): 16.24. MS (ESI, m/z, %): 
262.0 ([M(35Cl) + H]+, 100), 264.0 ([M(37Cl) + H]+, 36). 
2-tert-Butyl-4-chloro-1,2-benzothiazol-3(2H)-one 1,1-dioxide, 101. Following general 
procedure H, compound 101 was obtained from 98 (1.03 g, 3.94 mmol) as a beige solid (514 mg, 
82%). Spectroscopic data were in agreement with those reported.43 
 
M.p.: 160-161 ºC (lit.43 m.p.: 162-164 ºC). Rf: 0.33 (hexane/EtOAc 9:1). IR (ATR):  1721 
(CO), 1331, 1154 (SO2). 1H-NMR (CDCl3):  1.79 (s, 9H, C(CH3)3), 7.71-7.79 (m, 3H, 3CHAr). 13C-
NMR (CDCl3):  27.9 (C(CH3)3), 61.8 (C(CH3)3), 118.9 (C7), 123.3 (C4), 133.4 (C3a), 135.2 (C5), 
136.3 (C6), 140.4 (C7a), 158.0 (C3). HPLC (Gradient-I, column C18, tR, min): 21.06. MS (ESI, m/z, 
%): 296.0 ([M(35Cl) + Na]+, 100), 298.0 ([M(37Cl) + H]+, 38). 
2-tert-Butyl-6-chloro-1,2-benzothiazol-3(2H)-one 1,1-dioxide, 102. Following general 
procedure H, compound 102 was obtained from 99 (1.34 g, 5.13 mmol) as a beige solid (1.17 g, 
84%). Spectroscopic data were in agreement with those reported.43 
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M.p.: 159-160 °C (lit.43 m.p.: 162-164 ºC). Rf: 0.40 (hexane/EtOAc 9:1). IR (ATR):  1717 
(CO), 1328, 1146 (SO2). 1H-NMR (CDCl3):  1.76 (s, 9H, (CH3)3), 7.73 (dd, J = 8.2, 1.7, 1H, H5), 
7.81 (d, J = 1.8, 1H, H7), 7.92 (d, J = 8.2, 1H, H4). 13C-NMR (CDCl3):  28.0 ((CH3)3), 61.8 
(C(CH3)3), 120.7 (C7), 125.9 (C6), 126.1 (C4), 134.6 (C5), 139.4 (C3a), 141.5 (C7a), 159.3 (C3). HPLC 
(Gradient-I, column C18, tR, min): 22.69. MS (ESI, m/z, %): 275.0 ([M(35Cl) + H]+, 100), 277.0 
([M(37Cl) + H]+, 38). 
2-tert-Butyl-7-chloro-1,2-benzothiazol-3(2H)-one 1,1-dioxide, 103. Following general 
procedure H, compound 103 was obtained from 100 (0.50 g, 1.90 mmol) as a white solid (0.43 mg, 
83%). Spectroscopic data were in agreement with those reported.43 
 
M.p.: 143-144 ºC (lit.43 m.p.: 141-143 ºC). Rf: 0.34 (hexane/EtOAc 9:1). IR (ATR):  1725 
(CO), 1340, 1188 (SO2). 1H-NMR (CDCl3, 500 MHz):  1.79 (s, 9H, C(CH3)3), 7.74-7.68 (m, 2H, H4, 
H5), 7.89 (dd, J = 6.9, 1.6 Hz, 1H, H6). 13C-NMR (CDCl3, 125 MHz):  28.0 (C(CH3)3), 61.9 
(C(CH3)3), 122.9 (C6), 128.1, 129.9 (C3a, C7), 135.2, 135.3 (C4, C5), 135.4 (C7a), 158.9 (C3). HPLC 
(Gradient-I, column C18, tR, min): 17.35. MS (ESI, m/z, %): 274.1 ([M(35Cl) + H]+, 100), 276.1 
([M(37Cl) + H]+, 33). 
4-Chloro-1,2-benzothiazol-3(2H)-one 1,1-dioxide, 92. Following general procedure I, 
compound 92 was obtained from 101 (508 mg, 1.86 mmol) as a beige solid (405 mg, quantitative). 
Spectroscopic data were in agreement with those reported.65 
 
M.p.: 241-243 ºC (decomp.) (lit.65 m.p.: 244-246 ºC). Rf: 0.42 (DCM/methanol/NH3 8:2:0.05). 
IR (ATR):  3519 (NH), 1735 (CO), 1329, 1179 (SO2). 1H-NMR (acetone-d6):  7.97 (dd, J = 7.3, 
1.7, 1H, H5), 8.05 (t, J = 7.5, 1H, H6), 8.09 (dd, J = 7.5, 1.7, 1H, H7). 13C-NMR (acetone-d6):  
120.8 (C7), 124.5 (C4), 133.7 (C3a), 137.2 (C5), 137.6 (C6), 143.0 (C7a), 158.6 (C3). HPLC (Gradient-
I, column C18, tR, min): 10.26. MS (ESI, m/z, %): 216.0 ([M(35Cl) - H]-, 100), 217.9 (([M(37Cl) - H]-, 
38). 
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5-Chloro-1,2-benzothiazol-3(2H)-one 1,1-dioxide, 93.43 97 (228 mg, 1.11 mmol) was added 
to a mixture of H5IO6 (2.03 g, 8.88 mmol) and CrO3 (6 mg, 0.06 mmol) in anhydrous ACN (11 mL) 
at rt under an argon atmosphere, and the reaction was heated at reflux overnight. After that time, 2-
propanol was added (1.1 mL) and the mixture was heated at reflux for 10 min. Next, the precipitate 
was eliminated by filtration, washing with acetone, and the filtrate was concentrated under reduced 
pressure. The residue was dissolved in EtOAc and washed twice with water. The organic layer was 
dried over Na2SO4, filtered and the solvent was evaporated under reduced pressure. The crude 
residue was purified by column chromatography from hexane to hexane/EtOAc 8:2 to afford 97 as 
a yellow solid (77 mg, 32%). Spectroscopic data were in agreement with those reported.65 
 
M.p. >210 ºC (decomp.) (lit.65 m.p.: 213-215 ºC). Rf: 0.30 (DCM/methanol/NH3 8:2:0.05). IR 
(ATR):  3244 (NH), 1735 (CO), 1337, 1178 (SO2). 1H-NMR (acetone-d6): 8.04 (dd, J = 1.9, 0.6, 
1H, H4), 8.08 (dd, J = 8.2, 1.9, 1H, H6), 8.16 (dd, J = 8.3, 0.6, 1H, H7). 13C-NMR (acetone-d6):  
123.6 (C7), 125.8 (C4), 130.7 (C5), 136.3 (C6), 139.2 (C7a), 141.2 (C3a), 159.6 (C3). HPLC (Gradient-
I, column C18, tR, min): 11.52. MS (ESI, m/z, %): 216.1 ([M(35Cl) - H]-, 100), 217.9 (([M(37Cl) - H]-, 
43). 
6-Chloro-1,2-benzothiazol-3(2H)-one 1,1-dioxide, 94. Following general procedure I, 
compound 94 was obtained from 102 (278 mg, 1.02 mmol) as a beige solid (222 mg, quantitative). 
Spectroscopic data were in agreement with those reported.65 
 
M.p.: 220-221 °C (lit.65 m.p.: 220-222 ºC). Rf: 0.38 (DCM/methanol/NH3 8:2:0.05). IR (ATR):  
3225 (NH), 1740 (CO), 1338, 1178 (SO2). 1H-NMR (acetone-d6):  8.02 (dd, J = 8.2, 1.6, 1H, H5), 
8.08 (d, J = 8.3, 1H, H4), 8.25 (d, J = 1.2, 1H, H7). 13C-NMR (acetone-d6):  122.3 (C7), 127.4 (C6), 
127.7 (C4), 135.8 (C5), 142.3 (C3a), 142.4 (C7a), 160.0 (C3). HPLC (Gradient-I, column C18, tR, min): 
11.81. MS (ESI, m/z, %): 216.0 ([M(35Cl) - H]-, 100), 217.9 ([M(37Cl) - H]-, 62). 
7-Chloro-1,2-benzothiazol-3(2H)-one 1,1-dioxide, 95. Following general procedure I, 
compound 95 was obtained from 103 (410 mg, 1.50 mmol) as a white solid (397 mg, quantitative). 
Spectroscopic data were in agreement with those reported.65 
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M.p.: 261-263 ºC (lit.65 m.p.: 260-262 ºC). Rf: 0.47 (DCM/methanol/NH3 8:2:0.05). IR (ATR):  
3345 (NH), 1733 (CO), 1333, 1174 (SO2). 1H-NMR (acetone-d6, 500 MHz):  7.98-8.04 (m, 3H, H4, 
H5, H6). 13C-NMR (acetone-d6, 125 MHz):  124.5 (C6), 128.4, 131.5 (C3a, C7), 136.6, 137.1 (C4, 
C5), 138.2 (C7a), 160.0 (C3). HPLC (Gradient-I, column C18, tR, min): 10.46. MS (ESI, m/z, %): 
215.9 ([M(35Cl) - H]-, 100), 217.9 ([M(37Cl) - H]-, 36). 
 
 N-(Carbamoylalkyl)- and N-(amidoalkyl)saccharins 72-79 
3-(4-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)propanamide, 72. Following 
general procedure J, compound 72 was obtained from 92 (200 mg, 0.920 mmol) and 3-
chloropropanamide (118 mg, 1.10 mmol) as a white solid (40 mg, 15%). 
 
M.p.: 180-181 ºC (hexane/EtOAc). Rf: 0.31 (DCM/EtOAc 6:4). IR (ATR):  3453, 3370 (NH2), 
1735 (CONSO2), 1672 (CONH2), 1332, 1179 (SO2). 1H-NMR (DMSO-d6, 500 MHz):  2.57 (m, 2H, 
CH2CO), 3.88 (m, 2H, NCH2), 6.97 (br s, 1H, NH2), 7.48 (br s, 1H, NH2), 8.00 (t, J = 8.0, 1H, H6), 
8.02 (m, 1H, H5), 8.27 (dd, J = 6.9, 1.5, 1H, H7). 13C-NMR (DMSO-d6, 125 MHz):  33.4 (CH2CO), 
35.1 (NCH2), 120.6 (C7), 122.6 (C4), 132.0 (C3a), 136.8 (C5), 136.9 (C6), 139.0 (C7a), 156.2 (C3), 
171.0 (CONH2). HPLC (Gradient-I, column C18, tR, min): 12.92. MS (ESI, m/z, %): 289.0 ([M(35Cl) + 
H]+, 100), 291.0 ([M(37Cl) + H]+, 37). 
2-(4-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-methylacetamide, 73. 
Following general procedure J, compound 73 was obtained from 92 (400 mg, 1.84 mmol) and 2-
chloro-N-methylacetamide (240 mg, 2.21 mmol) as a beige solid (79 mg, 15%). 
 
M.p.: 201-202 ºC (hexane/EtOAc). Rf: 0.55 (DCM/EtOAc 6:4). IR (ATR):  3307 (NH), 1741 
(CONSO2), 1673 (CONH), 1338, 1182 (SO2). 1H-NMR (DMSO-d6):  2.62 (d, J = 4.6, 3H, CH3), 
4.26 (s, 2H, CH2), 8.03 (t, J = 8.1, 1H, H6), 8.14 (m, 1H, H5), 8.14 (br q, J = 4.4, 1H, NH), 8.32 (dd, J 
= 6.6, 1.9, 1H, H7). 13C-NMR (DMSO-d6, 125 MHz):  25.7 (CH3), 40.0 (CH2), 120.8 (C7), 122.9 
(C4), 131.9 (C3a), 136.8 (C5), 137.0 (C6), 139.0 (C7a), 156.5 (C3), 164.9 (CONH). HPLC (Gradient-I, 
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column C18, tR, min): 11.09. MS (ESI, m/z, %): 289.0 ([M(35Cl) + H]+, 100), 291.0 ([M(37Cl) + H]+, 
37). 
3-(5-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)propanamide, 74. Following 
general procedure J, compound 74 was obtained from 93 (52 mg, 0.240 mmol) and 3-
chloropropanamide (31 mg, 0.290 mmol) as a white solid (19 mg, 28%). Chromatography: 
hexane/EtOAc 1:1. 
 
M.p.: 208-209 ºC. Rf: 0.38 (hexane/EtOAc 2:8). IR (ATR):  3395, 3172 (NH2), 1732 
(CONSO2), 1665 (CONH2), 1328, 1180 (SO2). 1H-NMR (DMSO-d6):  2.57 (m, 2H, CH2CO), 3.90 
(m, 2H, NCH2), 7.00 (br s, 1H, NH2), 7.50 (br s, 1H, NH2), 8.13 (dd, J = 8.3, 2.0, 1H, H6), 8.18 (dd, J 
= 2.0, 0.6, 1H, H4), 8.38 (dd, J = 8.3, 0.6, 1H, H7). 13C-NMR (DMSO-d6):  33.4 (CH2CO), 35.1 
(NCH2), 123.5 (C7), 125.1 (C4), 128.6 (C5), 135.3 (C7a), 135.6 (C6), 140.2 (C3a), 157.2 (C3), 170.8 
(CONH2). HPLC (Gradient-I, column C18, tR, min): 11.74. MS (ESI, m/z, %): 288.9 ([M(35Cl) + H]+, 
100), 290.9 ([M(37Cl) + H]+, 36). 
2-(5-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-methylacetamide, 75. 
Following general procedure J, compound 75 was obtained from 93 (51 mg, 0.230 mmol) and 2-
chloro-N-methylacetamide (30 mg, 0.280 mmol) as a beige solid (13 mg, 20%). Chromatography: 
hexane/EtOAc 1:1. 
 
M.p.: 218-219 ºC. Rf: 0.15 (hexane/EtOAc 1:1). IR (ATR):  3306 (NH), 1737 (CONSO2), 
1664 (CONH), 1340, 1184 (SO2). 1H-NMR (DMSO-d6, 500 MHz):  2.61 (d, J = 4.5, 3H, CH3), 4.28 
(s, 2H, CH2), 8.13 (br s, 1H, NH), 8.15 (dd, J = 8.3, 2.0, 1H, H6), 8.21 (d, J = 1.9, 1H, H4), 8.40 (d, J 
= 8.3, 1H, H7). 13C-NMR (DMSO-d6, 125 MHz):  25.7 (CH3), 40.1 (CH2), 123.6 (C7), 125.0 (C4), 
128.8 (C5), 135.3 (C7a), 135.6 (C6), 140.2 (C3a), 157.4 (C3), 164.8 (CONH). HPLC (Gradient-I, 
column C18, tR, min): 12.09. MS (ESI, m/z, %): 288.9 ([M(35Cl) + H]+, 100), 290.9 ([M(37Cl) + H]+, 
38). 
3-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)propanamide, 76. Following 
general procedure J, compound 76 was obtained from 94 (289 mg, 1.33 mmol) and 3-
chloropropanamide (175 mg, 1.60 mmol) as a solid (35 mg, 15%). Chromatography: glass column, 
DCM to DCM/EtOAc 6:4. 
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M.p.: 206-207 °C. Rf: 0.30 (DCM/EtOAc 6:4). IR (ATR):  3442 (NH2), 1731 (CONSO2), 1658 
(CONH2), 1331, 1179 (SO2). 1H-NMR (DMSO-d6, 500 MHz):  2.58 (t, J = 7.7, 2H, CH2CO), 3.91 
(t, J = 7.7, 2H, NCH2), 6.98 (br s, 1H, NH2), 7.49 (br s, 1H, NH2), 8.06 (dd, J = 8.2, 1.8, 1H, H5), 
8.11 (d, J = 8.2, 1H, H4), 8.65 (d, J = 1.6, 1H, H7). 13C-NMR (DMSO-d6, 125 MHz):  33.4 (CH2CO), 
35.1 (NCH2), 122.0 (C7), 125.2 (C6), 126.8 (C4), 135.4 (C5), 138.3 (C3a), 140.7 (C7a), 157.5 (C3), 
170.8 (CONH2). HPLC (Gradient-I, column C18, tR, min): 13.72. MS (ESI, m/z, %): 288.7 ([M(35Cl) + 
H]+, 100), 290.6 ([M(37Cl) + H]+, 39). 
2-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-methylacetamide, 77 (UCM-
01296). Following general procedure J, compound 77 was obtained from 94 (232 mg, 1.07 mmol) 
and 2-chloro-N-methylacetamide (77 mg, 1.28 mmol) as a solid (53 mg, 24%). Chromatography: 
glass column, DCM to DCM/EtOAc 6:4. 
 
M.p.: 238-239 °C. Rf: 0.52 (DCM/EtOAc 6:4). IR (ATR):  3397 (NH), 1742 (CONSO2), 1673 
(CONH), 1340, 1184 (SO2). 1H-RMN (DMSO-d6, 500 MHz):  2.62 (d, J = 4.6, 3H, CH3), 4.28 (s, 
2H, CH2), 8.08 (dd, J = 8.2, 1.8, 1H, H5), 8.12 (d, J = 8.2, 1H, H4), 8.14 (br s, 1H, NH), 8.67 (d, J = 
1.5, 1H, H7). 13C-RMN (DMSO-d6, 125 MHz):  25.7 (CH3), 39.9 (CH2), 122.2 (C7), 125.5 (C6), 
126.8 (C4), 135.4 (C5), 138.4 (C3a), 140.7 (C7a), 157.8 (C3), 164.9 (CONH). HPLC (Gradient-I, 
column C18, tR, min): 13.37. MS (ESI, m/z, %): 288.6 ([M(35Cl) + H]+, 100), 290.7 ([M(37Cl) + H]+, 
37). 
3-(7-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)propanamide, 78. Following 
general procedure J, compound 78 was obtained from 95 (150 mg, 0.690 mmol) and 3-
chloropropanamide (91 mg, 0.830 mmol) as a beige solid (30 mg, 15%). 
 
M.p.: 215-216 ºC (hexane/EtOAc). Rf: 0.48 (DCM/EtOAc/NH3 9:1:0.05). IR (ATR):  3452, 
3364 (NH2), 1765 (CONSO2), 1672 (CONH2), 1338, 1181 (SO2). 1H-NMR (DMSO-d6):  2.57 (t, J = 
7.7, 2H, CH2CO), 3.92 (t, J = 7.7, 2H, NCH2), 6.99 (br s, 1H, NH2), 7.49 (br s, 1H, NH2), 7.99 (t, J = 
7.8, 1H, H5), 8.07 (dd, J = 7.7, 1.0, 1H, H4), 8.13 (dd, J = 7.9, 0.9, 1H, H6). 13C-NMR (DMSO-d6, 
125 MHz):  33.4 (CH2CO), 35.2 (NCH2), 123.9 (C6), 127.0, 129.0 (C3a, C7), 134.1 (C7a), 136.1, 
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137.1 (C4, C5), 157.1 (C3), 170.8 (CONH2). HPLC (Gradient-I, column C18, tR, min): 12.47. MS 
(ESI, m/z %): 289.0 ([M(35Cl) + H]+, 100), 291.0 ([M(37Cl) + H]+, 39). 
2-(7-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-methylacetamide, 79. 
Following general procedure J, compound 79 was obtained from 95 (150 mg, 0.690 mmol) and 2-
chloro-N-methylacetamide (91 mg, 0.830 mmol) as a beige solid (70 mg, 35%). 
 
M.p.: 206-207 ºC (hexane/EtOAc). Rf: 0.49 (DCM/methanol/NH3 8:2:0.05). IR (ATR):  3311 
(NH), 1743 (CONSO2), 1674 (CONH), 1341, 1185 (SO2). 1H-NMR (DMSO-d6):  2.62 (d, J = 4.5, 
3H, CH3), 4.30 (s, 2H, CH2), 8.02 (t, J = 7.7, 1H, H5), 8.10 (d, J = 7.5, 1H, H4), 8.16 (d, J = 7.8, 1H, 
H6). 13C-NMR (DMSO-d6):  25.7 (CH3), 40.1 (CH2), 123.9 (C6), 127.1, 129.3 (C3a, C7), 134.2 (C7a), 
136.1, 137.1 (C4, C5), 157.4 (C3), 164.8 (CONH2). HPLC (Gradient-I, column C18, tR, min): 12.32. 
MS (ESI, m/z, %): 289.0 ([M(35Cl) + H]+, 100), 291.0 ([M(37Cl) + H]+, 37). 
 
4.1.10. Final compounds 80-85 
 Intermediates 104-107 
4-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)butyronitrile, 104. Following 
general procedure J, compound 104 was obtained from 94 (200 mg, 0.920 mmol) and 4-
bromobutyronitrile (163 mg, 1.10 mmol) as a solid (139 mg, 53%). Chromatography: hexane to 
hexane/EtOAc 8:2. 
 
M.p.: 125-126 ºC. Rf: 0.30 (hexane/EtOAc 7:3). IR (ATR):  2242 (CN), 1732 (CO), 1591 (Ar), 
1334, 1177 (SO2). 1H-NMR (acetone-d6):  2.18 (qt, J = 7.0, 2H, NCH2CH2), 2.67 (t, J = 7.3, 2H, 
CH2CN), 3.92 (t, J = 6.8, 2H, NCH2), 8.03 (dd, J = 8.2, 1.7, 1H, H5), 8.11 (d, J = 8.2, 1H, H4), 8.32 
(d, J = 1.7, 1H, H7). 13C-NMR (acetone-d6):  14.9 (CH2CN), 25.4 (NCH2CH2), 38.6 (NCH2), 119.9 
(CN), 122.4 (C7), 126.7 (C6), 127.5 (C4), 136.0 (C5), 139.9 (C3a), 142.1 (C7a), 158.9 (C3). HPLC 
(Gradient-I, column C18, tR, min): 21.57. MS (ESI, m/z, %): 315.0 ([M(35Cl) + MeOH]+, 100), 317.0 
([M(37Cl) + MeOH]+, 38). 
5-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)pentanenitrile, 105. Following 
general procedure J, compound 105 was obtained from 94 (290 mg, 1.33 mmol) and 5-
bromovaleronitrile (192 μL, 1.60 mmol) as a white solid (166 mg, 42%). Chromatography: 
hexane/EtOAc from 98:2 to 7:3. 
Experimental section 
 
203 
 
M.p.: 110-111 °C. Rf: 0.25 (hexane/EtOAc 7:3). IR (ATR):  2246 (CN), 1732 (CO), 1336, 
1175 (SO2). 1H-NMR (acetone-d6):  1.75-1.85 (m, 2H, CH2CH2CN), 1.92-1.99 (m, 2H, NCH2CH2), 
2.57 (t, J = 7.1, 2H, CH2CN), 3.83 (t, J = 6.9, 2H, NCH2), 8.04 (dd, J = 8.2, 1.7, 1H, H5), 8.12 (d, J = 
8.2, 1H, H4), 8.33 (d, J = 1.6, 1H, H7). 13C-NMR (acetone-d6):  16.7 (CH2CN), 23.5 (CH2CH2CN), 
28.2 (NCH2CH2), 39.1 (NCH2), 120.3 (CN), 122.3 (C7), 126.7 (C6), 127.5 (C4), 136.0 (C5), 140.1 
(C3a), 142.1 (C7a), 158.9 (C3). HPLC (Gradient-I, column C18, tR, min): 15.73. MS (ESI, m/z, %): 
316.1 ([M(35Cl) + NH4]+, 100), 318.0 ([M(37Cl) + NH4]+, 44). 
Sulfamoylbenzoic acids 106, 107. General procedure. A solution of the corresponding N-
cyanoalkylsaccharin (1.00 equiv) in a 10% aqueous solution of NaOH (1.00 equiv) was heated at 
130 °C overnight under an argon atmosphere. The mixture was then cooled to rt and washed with 
EtOAc. The aqueous phase was acidified with 1 M HCl until pH < 3 and extracted with EtOAc (x2). 
The combined organic layers were washed with water and brine, dried over Na2SO4, filtered and 
evaporated under reduced pressure. The crude was purified by column chromatography, if 
necessary, to yield the corresponding benzoic acid derivative. 
2-[(3-Carboxypropyl)sulfamoyl]-4-chlorobenzoic acid, 106. Following the previous general 
procedure, compound 106 was obtained from 104 (152 mg, 0.535 mmol) as a solid (100 mg, 58%), 
which was used in the next step without further purification. 
 
M.p.: 137-138 ºC. Rf: 0.15 (DCM/methanol 9:1). IR (ATR):  3291 (NH), 3098 (OH), 1705 
(CO), 1332, 1163 (SO2). 1H-NMR (acetone-d6):  1.78 (qt, J = 7.1, 2H, CH2CH2COOH), 2.35 (t, J = 
7.3, 2H, CH2COOH), 3.10 (br q, J = 5.7, 2H, NHCH2), 6.47 (br s, 1H, NH), 7.80 (dd, J = 8.3, 2.1, 
1H, H5), 7.96 (d, J = 8.2, 1H, H6), 8.01 (d, J = 2.1, 1H, H3). 13C-NMR (acetone-d6):  25.7 
(CH2CH2COOH), 31.0 (CH2COOH), 43.5 (NCH2), 130.1 (C3), 131.1 (C4), 133.2 (C5), 133.3 (C6), 
137.8 (C1), 142.1 (C2), 168.5 (COOHbenz.), 174.1 (COOHaliph.). HPLC (Gradient-I, column C18, tR, 
min): 18.43. MS (ESI, m/z, %): 320.0 ([M(35Cl) - H]-, 100), 322.0 ([M(37Cl) - H]-, 37. 
2-[(4-Carboxybutyl)sulfamoyl]-4-chlorobenzoic acid, 107. Following the previous general 
procedure, compound 107 was obtained from 105 (53 mg, 0.170 mmol) as an oil (51 mg, 96%). 
Chromatography: glass column, DCM/methanol from 98:2 to 7:3. 
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Rf: 0.27 (DCM/methanol 6:4). IR (ATR):  3283 (NH), 3084 (OH), 1703 (CO), 1333, 1162 
(SO2). 1H-NMR (acetone-d6):  1.53-1.61 (m, 4H, NCH2CH2CH2), 2.26 (t, J = 6.9, 2H, CH2COOH), 
3.04 (t, J = 6.4, 2H, NCH2), 7.80 (dd, J = 8.2, 2.0, 1H, H5), 7.96 (d, J = 8.2, 1H, H6), 8.01 (d, J = 2.1, 
1H, H3). 13C-NMR (acetone-d6):  22.6 (CH2CH2COOH), 30.6 (NCH2CH2), 33.5 (CH2COOH), 43.8 
(NCH2), 130.1 (C3), 131.4 (C4), 133.2 (C5), 133.4 (C6), 137.7 (C1), 142.1 (C2), 168.6 (COOHbenz.), 
174.3 (COOHaliph.). HPLC (Gradient-I, column C18, tR, min): 21.31. MS (ESI, m/z, %): 334.0 
([M(35Cl) - H]-, 100), 336.0 ([M(37Cl) - H]-, 41). 
 N-(Carbamoylalkyl)- and N-(amidoalkyl)saccharins 80-85 
2-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)acetamide, 80. Following general 
procedure J, compound 80 was obtained from 94 (40 mg, 0.184 mmol) and 2-bromoacetamide (30 
mg, 0.210 mmol) as a solid (24 mg, 48%). Chromatography: hexane/EtOAc from 9:1 to 1:1. 
 
M.p.: 230-231 °C. Rf: 0.16 (hexane/EtOAc 6:4). IR (ATR):  3426, 3329 (NH2), 1727 
(CONSO2), 1680 (CONH2), 1342, 1184 (SO2). 1H-RMN (DMSO-d6, 500 MHz):  4.26 (s, 2H, CH2), 
7.33 (br s, 1H, NH2), 7.66 (br s, 1H, NH2), 8.07 (dd, J = 8.2, 1.8, 1H, H5), 8.12 (d, J = 8.2, 1H, H4), 
8.66 (d, J = 1.7, 1H, H7). 13C-RMN (DMSO-d6, 125 MHz):  39.9 (CH2), 122.2 (C7), 125.4 (C6), 
126.8 (C4), 135.3 (C5), 138.4 (C3a), 140.7 (C7a), 157.8 (C3), 166.3 (CONH2). HPLC (Gradient-I, 
column C18, tR, min): 11.86. MS (ESI, m/z, %): 275.0 ([M(35Cl) + H]+, 100), 277.0 ([M(37Cl) + H]+, 
37). 
3-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-methylpropanamide, 81. 
Following general procedure J, compound 81 was obtained from 94 (232 mg, 1.07 mmol) and 3-
chloro-N-methylpropanamide (142 mg, 1.28 mmol) as a solid (70 mg, 24%). Chromatography: 
glass column, DCM to DCM/EtOAc 6:4. 
 
M.p.: 195-196 °C. Rf: 0.39 (DCM/EtOAc 6:4). IR (ATR):  3314 (NH), 1728 (CONSO2), 1631 
(CONH), 1337, 1179 (SO2). 1H-RMN (DMSO-d6, 500 MHz):  2.54-2.58 (m, 5H, CH3, CH2CO), 
3.92 (m, 2H, NCH2), 7.95 (br s, 1H, NH), 8.05 (dd, J = 8.2, 1.8, 1H, H5), 8.10 (d, J = 8.2, 1H, H4), 
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8.64 (d, J = 1.7, 1H, H7). 13C-RMN (DMSO-d6, 125 MHz):  25.5 (CH3), 33.8 (CH2CO), 35.4 
(NCH2), 122.0 (C7), 125.2 (C6), 126.7 (C4), 135.3 (C5), 138.3 (C3a), 140.7 (C7a), 157.5 (C3), 169.1 
(CONH). HPLC (Gradient-I, column C18, tR, min): 13.83. MS (ESI, m/z, %): 303.0 ([M(35Cl) + H]+, 
100), 305.0 ([M(37Cl) + H]+, 38). 
4-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)butanamide, 82. Following 
general procedure K, compound 82 was obtained from 106 (39 mg, 0.122 mmol) and ammonia (0.5 
M in 1,4-dioxane, 491 μL, 0.244 mmol) as an off-white solid (26 mg, 70%). Chromatography: glass 
column, DCM to DCM/methanol 99:1. 
 
M.p.: 189-190 ºC. Rf: 0.30 (DCM/methanol 95:5). IR (ATR):  3444, 3324 (NH2), 1731 
(CONSO2), 1667 (CONH2), 1334, 1178 (SO2). 1H-NMR (acetone-d6, 700 MHz):  2.07-2.10 (m, 2H, 
NCH2CH2), 2.33 (t, J = 7.4, 2H, CH2CO), 3.82 (t, J = 7.2, 2H, NCH2), 6.13 (br s, 1H, NH2), 6.76 (br 
s, 1H, NH2), 8.04 (dd, J = 8.2, 1.7, 1H, H5), 8.26 (d, J = 8.3, 1H, H4), 8.32 (d, J = 1.7, 1H, H7). 13C-
NMR (acetone-d6, 175 MHz):  25.0 (NCH2CH2), 32.8 (CH2CO), 39.6 (NCH2), 122.3 (C7), 126.8 
(C6), 127.5 (C4), 135.9 (C5), 140.1 (C3a), 142.0 (C7a), 158.8 (C3), 173.8 (CONH2). HPLC (Gradient-I, 
column C18, tR, min): 12.02. MS (ESI, m/z, %): 303.0 ([M(35Cl) + H]+, 100), 305.0 ([M(37Cl) + H]+, 
37). 
4-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-methylbutanamide, 83. 
Following general procedure K, compound 83 was obtained from 106 (24 mg, 0.073 mmol) and 
methylamine (2.0 M in THF, 145 μL, 0.146 mmol) as an off-white solid (11 mg, 48%). 
Chromatography: glass column, DCM to DCM/methanol 99:1. 
 
M.p.: 146-147 ºC. Rf: 0.51 (DCM/methanol 95:5). IR (ATR):  3306 (NH), 1732 (CONSO2), 
1646 (CONH), 1335, 1176 (SO2). 1H-NMR (acetone-d6, 700 MHz):  2.07-2.10 (m, 2H, NCH2CH2), 
2.29 (t, J = 7.4, 2H, CH2CO), 2.69 (d, J = 4.7, 3H, CH3), 3.81 (t, J = 7.2, 2H, NCH2), 6.96 (br s, 1H, 
NH), 8.04 (dd, J = 8.2, 1.7, 1H, H5), 8.11 (d, J = 8.3, 1H, H4), 8.32 (d, J = 1.6, 1H, H7). 13C-NMR 
(acetone-d6, 175 MHz):  25.2 (NHCH2CH2), 26.0 (CH3), 33.2 (CH2CO), 39.6 (NCH2), 122.3 (C7), 
126.8 (C6), 127.5 (C4), 135.9 (C5), 140.1 (C3a), 142.0 (C7a), 158.7 (C3), 172.2 (CONH). HPLC 
(Gradient-I, column C18, tR, min): 14.81. MS (ESI, m/z, %): 317.0 ([M(35Cl) + H]+, 100), 319.0 
([M(37Cl) + H]+, 37). 
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5-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)pentanamide, 84. Following 
general procedure K, compound 84 was obtained from 107 (21 mg, 0.070 mmol) and ammonia (0.5 
M in 1,4-dioxane, 0.3 mL, 0.140 mmol) as a solid (20 mg, 99%). Chromatography: glass column, 
DCM/methanol from 98:2 to 9:1. 
 
M.p.: 115-116 °C. Rf: 0.26 (DCM/MeOH 95:5). IR (ATR):  3388 (NH), 1734 (CONSO2), 1668 
(CONH2), 1336, 1177 (SO2). 1H-NMR (acetone-d6, 500 MHz):  1.68-1.74 (m, 2H, CH2CH2CO), 
1.82-1.87 (m, 2H, NCH2CH2), 2.24 (t, J = 7.3, 2H, CH2CO), 3.77 (t, J = 7.3, 2H, NCH2), 6.04 (br s, 
1H, NH), 6.69 (br s, 1H, NH), 8.03 (dd, J = 8.3, 1.8, 1H, H5), 8.10 (d, J = 8.2, 1H, H4), 8.31 (d, J = 
1.7, 1H, H7). 13C-NMR (acetone-d6, 125 MHz):  22.8 (CH2CH2CO), 28.3 (NCH2CH2), 34.8 
(CH2CO), 39.3 (NCH2), 121.8 (C7), 126.2 (C6), 127.0 (C4), 135.4 (C5), 139.7 (C3a), 141.5 (C7a), 
158.2 (C3), 173.9 (CONH2). HPLC (Gradient-I, tR, min): 14.76. MS (ESI, m/z, %): 317.0 ([M(35Cl) + 
H]+, 100), 319.0 ([M(37Cl) + H]+, 37). 
5-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-methylpentanamide, 85. 
Following general procedure K, compound 85 was obtained from 107 (25 mg, 0.080 mmol) and 
methylamine (2.0 M in THF, 80 μL, 0.160 mmol) as an off-white solid (7 mg, 27%). 
Chromatography: glass column, DCM/EtOAc from 7:3 to 3:7. 
 
M.p.: 124-126 °C. Rf: 0.35 (DCM/EtOAc 3:7). IR (ATR):  3307 (NH), 1732 (CONSO2), 1646 
(CONH), 1336, 1176 (SO2). 1H-NMR (acetone-d6, 500 MHz):  1.67-1.73 (m, 2H, CH2CH2CO), 
1.79-1.85 (m, 2H, NCH2CH2), 2.20 (t, J = 7.3, 2H, CH2CO), 2.67 (d, J = 4.6, 3H, CH3), 3.76 (t, J = 
7.3, 2H, NCH2), 8.03 (dd, J = 8.2, 1.8, 1H, H5), 8.10 (d, J = 8.2, 1H, H4), 8.31 (d, J = 1.9, 1H, H7). 
13C-NMR (acetone-d6, 125 MHz):  23.5 (CH2CH2CO), 26.0 (CH3), 28.8 (NCH2CH2), 35.8 (CH2CO), 
39.8 (NCH2), 122.3 (C7), 126.7 (C6), 127.5 (C4), 135.9 (C5), 140.2 (C3a), 142.0 (C7a), 158.7 (C3), 
172.8 (CONH). HPLC (Gradient-I, tR, min): 15.22. MS (ESI, m/z, %): 331.0 ([M(35Cl) + H]+, 100), 
333.0 ([M(37Cl) + H]+, 34). 
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4.1.11. Final compounds 86-91 
 N-(Carboxyalkyl)saccharins 108, 109 
2-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)acetic acid, 108. Following 
general procedure J, compound 108 was obtained from 94 (87 mg, 0.400 mmol) and bromoacetic 
acid (69 mg, 0.480 mmol) as a white solid (24 mg, 21%). Chromatography: DCM to DCM/methanol 
98:2. 
 
M.p.: >220 ºC (decomp.). Rf: 0.35 (DCM/methanol 8:2). IR (ATR):  1700 (CONSO2, COOH), 
1361 (SO2), 1246 (C-O). 1H-NMR (acetone-d6, 500 MHz):  4.51 (s, 2H, CH2), 8.06 (d, J = 8.1, 1H, 
H5), 8.14 (d, J = 8.2, 1H, H4), 8.36 (s, 1H, H7). 13C-NMR (acetone-d6, 175 MHz):  39.8 (br s, CH2), 
122.6 (C7), 126.4 (C6), 127.7 (C4), 136.1 (C5), 140.3 (C3a), 142.3 (C7a), 158.7 (C3), COOH not 
observed. HPLC (Gradient-I, column C18, tR, min): 12.04. MS (ESI, m/z, %): 273.9 ([M(35Cl) - H]-, 
100), 276.0 ([M(37Cl) - H]-, 36). 
3-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)propionic acid, 109. Following 
general procedure J, compound 109 was obtained from 94 (88 mg, 0.406 mmol) and 3-
bromopropionic acid (77 mg, 0.487 mmol) as a white solid (43 mg, 36%). Chromatography: DCM to 
DCM/methanol 98:2. 
 
M.p.: >205 ºC (decomp.). Rf: 0.37 (DCM/methanol 8:2). IR (ATR):  3091 (OH), 1730 
(CONSO2), 1705 (COOH), 1332 (SO2), 1283 (C-O), 1176 (SO2). 1H-NMR (acetone-d6):  2.84-2.89 
(m, 2H, CH2CO), 4.05 (t, J = 7.5, 2H, NCH2), 8.05 (dd, J = 8.2, 1.7, 1H, H5), 8.12 (d, J = 8.0, 1H, 
H4), 8.33 (d, J = 1.3, 1H, H7). 13C-NMR (acetone-d6):  33.5 (CH2CO), 35.7 (NCH2), 122.4 (C7), 
126.7 (C6), 127.6 (C4), 136.0 (C5), 140.1 (C3a), 142.1 (C7a), 158.5 (C3), 172.8 (COOH). HPLC 
(Gradient-I, column C18, tR, min): 13.34. MS (ESI, m/z, %): 215.9 ([M(35Cl) - (CH2CH2CO2H)]+, 
100), 217.9 ([M(37Cl) - (CH2CH2CO2H)]+, 36). 
 N-(Amidoalkyl)saccharins 86-91 
2-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-cyclopropylacetamide, 86. 
Following general procedure J, compound 86 was obtained from 94 (58 mg, 0.266 mmol) and 2-
chloro-N-cyclopropylacetamide (44 mg, 0.320 mmol) as a white solid (25 mg, 30%). 
Chromatography: hexane to hexane/EtOAc 7:3. 
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M.p.: 217-218 ºC. Rf: 0.20 (hexane/EtOAc 1:1). IR (ATR):  3291 (NH), 1742 (CONSO2), 
1671 (CONH), 1341, 1183 (SO2). 1H-NMR (acetone-d6, 500 MHz):  0.45-0.48 (m, 2H, CH2 cpr), 
0.64-0.68 (m, 2H, CH2 cpr), 2.69-2.74 (m, 1H, CHCpr.), 4.31 (s, 2H, NCH2), 7.50 (br s, 1H, NH), 8.06 
(dd, J = 8.3, 1.8, 1H, H5), 8.13 (d, J = 8.2, 1H, H4), 8.34 (d, J = 1.7, 1H, H7). 13C-NMR (acetone-d6, 
125 MHz):  6.3 (2CH2 cpr), 23.3 (CHcpr), 41.3 (NCH2), 122.5 (C7), 126.9 (C6), 127.6 (C4), 136.0 (C5), 
140.2 (C3a), 142.2 (C7a), 158.8 (C3), 166.3 (CONH). HPLC (Gradient-I, column C18, tR, min): 14.89. 
MS (ESI, m/z, %): 347.1 ([M(35Cl) + H+ MeOH]+, 100), 349.0 ([M(37Cl) + H+ MeOH]+, 35). 
2-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-cyclopropylacetamide, 87. 
Following general procedure K, compound 87 was obtained from 109 (98 mg, 0.338 mmol) and 
cyclopropylamine (47 μL, 0.676 mmol) as a white solid (10 mg, 10%). Chromatography: glass 
column, hexane to hexane/EtOAc 7:3. 
 
M.p.: 181-183 ºC. Rf: 0.45 (hexane/EtOAc 1:1). IR (ATR):  3292 (NH), 1735 (CONSO2), 
1648 (CONH), 1338, 1177 (SO2). 1H-NMR (acetone-d6, 700 MHz):  0.44-0.46 (m, 2H, CH2 cpr), 
0.62-0.64 (m, 2H, CH2 cpr), 2.63 (t, J = 7.8, 2H, CH2CO), 2.68-2.71 (m, 1H, CHcpr), 4.00-4.02 (m, 2H, 
NCH2), 7.30 (br s, 1H, NH), 8.04 (dd, J = 8.3, 1.8, 1H, H5), 8.10 (d, J = 8.2, 1H, H4), 8.32 (d, J = 1.8, 
1H, H7). 13C-NMR (acetone-d6, 175 MHz):  6.3 (2CH2 cpr), 23.1 (CHcpr), 34.9 (CH2CO), 36.3 
(NCH2), 122.3 (C7), 126.7 (C6), 127.5 (C4), 136.0 (C5), 140.1 (C3a), 142.1 (C7a), 158.5 (C3), 170.6 
(CONH). HPLC (Gradient-I, column C18, tR, min): 15.13. MS (ESI, m/z, %): 329.0 ([M(35Cl) + H]+, 
100), 331.0 ([M(37Cl) + H]+, 40). 
2-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-cyclohexylacetamide, 88. 
Following general procedure K, compound 88 was obtained from 108 (16 mg, 0.057 mmol) and 
cyclohexylamine (13 μL, 0.114 mmol) as a white solid (11 mg, 21%). Chromatography: 
hexane/EtOAc from 9:1 to 7:3. 
 
M.p.: 197-199 ºC. Rf: 0.21 (hexane/EtOAc 6:4). IR (ATR):  3312 (NH), 1743 (CONSO2), 
1667 (CONH), 1344, 1183 (SO2). 1H-NMR (acetone-d6, 500 MHz):  1.12-1.37 (m, 5H, 2CH2 cy, 
1/2CH2 cy), 1.56-1.60 (m, 1H, 1/2CH2 cy), 1.68-1.72 (m, 2H, CH2 cy), 1.83-1.87 (m, 2H, CH2 cy), 3.65-
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3.73 (m, 1H, CHcy), 4.33 (s, 2H, NCH2), 7.26 (br s, 1H, NH), 8.06 (dd, J = 8.2, 1.8, 1H, H5), 8.13 (d, 
J = 8.2, 1H, H4), 8.34 (d, J = 1.6, 1H, H7). 13C-NMR (acetone-d6, 125 MHz):  25.6 (2CH2 cy), 26.3 
(CH2 cy), 33.4 (2CH2 cy), 41.5 (NCH2), 49.4 (CHcy), 122.5 (C7), 126.9 (C6), 127.6 (C4), 136.0 (C5), 
140.2 (C3a), 142.2 (C7a), 158.9 (C3), 164.2 (CONH). HPLC (Gradient-I, column C18, tR, min): 14.69. 
MS (ESI, m/z, %): 389.1 ([M(35Cl) + H + MeOH]+, 100), 391.1 ([M(37Cl) + H + MeOH]+, 40). 
3-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-cyclohexylpropanamide, 89. 
Following general procedure K, compound 89 was obtained from 109 (10 mg, 0.036 mmol) and 
cyclohexylamine (8 μL, 0.072 mmol) as a white solid (5 mg, 39%). Chromatography: glass column, 
hexane/EtOAc from 9:1 to 7:3. 
 
M.p.: 198-199 ºC. Rf: 0.23 (hexane/EtOAc 6:4). IR (ATR):  3302 (NH), 1739 (CONSO2), 
1664 (CONH), 1338, 1183 (SO2). 1H-NMR (acetone-d6, 500 MHz):  1.12-1.22 (m, 2H, CH2 cy), 
1.28-1.36 (m, 3H, CH2 cy, 1/2CH2 cy), 1.56-1.60 (m, 1H, 1/2CH2 cy), 1.67-1.71 (m, 2H, CH2 cy), 1.83-
1.86 (m, 2H, CH2 cy), 2.63-2.66 (m, 2H, CH2CO), 3.64-3.72 (m, 1H, CHcy), 4.00-4.03 (m, 2H, NCH2), 
7.08 (br s, 1H, NH), 8.04 (dd, J = 8.2, 1.8, H5), 8.11 (d, J = 8.2, H4), 8.31 (d, J = 1.6, H7). 13C-NMR 
(acetone-d6, 125 MHz):  25.6 (2CH2 cy), 26.4 (CH2 cy), 33.6 (2CH2 cy), 35.2 (CH2CO), 36.5 (NCH2), 
48.8 (CHcy), 122.4 (C7), 126.7 (C6), 127.5 (C4), 136.0 (C5), 140.2 (C3a), 142.1 (C7a), 158.5 (C3), 
168.5 (CONH). HPLC (Gradient-I, column C18, tR, min): 14.80. MS (ESI, m/z, %): 371.1 ([M(35Cl) + 
H]+, 100), 373.0 ([M(37Cl) + H]+, 40). 
2-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-phenylacetamide, 90. 
Following general procedure J, compound 90 was obtained from 94 (50 mg, 0.230 mmol) and 2-
chloro-N-phenylacetamide (47 mg, 0.276 mmol) as a white solid (27 mg, 37%). Chromatography: 
glass column, from hexane to hexane/EtOAc 7:3. 
 
M.p.: 232-233 ºC. Rf: 0.32 (hexane/EtOAc 7:3). IR (ATR):  3307 (NH), 1740 (CONSO2), 
1688 (CONH), 1339, 1182 (SO2). 1H-NMR (acetone-d6):  4.61 (s, 2H, CH2), 7.09 (tt, J = 7.4, 1.3, 
1H, H4 Ph), 7.28-7.34 (m, 2H, 2CHPh), 7.60-7.64 (m, 2H, 2CHPh), 8.08 (dd, J = 8.2, 1.8, 1H, H5), 8.16 
(d, J = 8.1, 1H, H4), 8.39 (d, J = 1.7, 1H, H7), 9.50 (br s, 1H, NH). 13C-NMR (acetone-d6):  41.9 
(CH2), 120.3 (2CHPh), 122.6 (C7), 124.8 (C4 Ph), 126.7 (C6), 127.7 (C4), 129.6 (2CHPh), 136.1 (C5), 
139.5 (C1 Ph), 140.2 (C3a), 142.3 (C7a), 158.9 (C3), 163.8 (CONH). HPLC (Gradient-I, column C18, 
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tR, min): 14.41. MS (ESI, m/z, %): 383.0 ([M(35Cl) + H + MeOH]+, 100), 385.0 ([M(37Cl) + H + 
MeOH]+, 39). 
3-(6-Chloro-1,1-dioxido-3-oxo-1,2-benzothiazol-2(3H)-yl)-N-phenylpropanamide, 91. 
Following general procedure K, compound 91 was obtained from 109 (10 mg, 0.036 mmol) and 
aniline (4 μL, 0.042 mmol) as a white solid (3 mg, 23%). Chromatography: glass column, from 
hexane to hexane/EtOAc 8:2. 
 
M.p.: 218-219 ºC. Rf: 0.34 (hexane/EtOAc 7:3). IR (ATR):  3383 (NH), 1736 (CONSO2), 
1673 (CONH), 1338, 1180 (SO2). 1H-NMR (acetone-d6, 700 MHz):  2.91-2.94 (m, 2H, CH2CO), 
4.12-4.14 (m, 2H, NCH2), 7.05 (br t, J = 7.4, 1H, H4 Ph), 7.28-7.30 (m, 2H, 2CHPh), 7.65 (d, J = 7.7, 
2H, 2CHPh), 8.04 (dd, J = 8.2, 1.8, 1H, H5), 8.12 (d, J = 8.2, 1H, H4), 8.32 (d, J = 1.7, 1H, H7), 9.31 
(br s, 1H, NH). 13C-NMR (acetone-d6, 175 MHz):  36.0, 36.1 (CH2CO, NCH2), 120.2 (2CHPh), 
122.4 (C7), 124.3 (C4 Ph), 126.7 (C6), 127.5 (C4), 129.5 (2CHPh), 136.0 (C5), 140.1 (C3a), 142.1 (C7a), 
158.5 (C3), 168.5 (CONH). HPLC (Gradient-I, column C18, tR, min): 14.40. MS (ESI, m/z, %): 365.1 
([M(35Cl) + H]+, 100), 367.0 ([M(37Cl) + H]+, 36). 
 
4.2. In vitro pharmacokinetic assays 
4.2.1. HSA binding assay 
The assessment of compounds binding to HSA was performed by incubating a fixed 
concentration of the compound with different concentrations of immobilized HSA, using the 
TRANSILXL HSA Binding Kit (TMP-0210-2096, Sovicell). An eightwell unit of the TRANSIL assay 
plate was used for each compound; six wells contain increasing concentrations of HSA immobilized 
on silica beads suspended in PBS at pH 7.4, and two wells contain buffer only and serve as 
references to account for nonspecific binding. 
The TRANSIL assay plate was thawed for 3 h at rt and centrifuged at 750 g for 5 s. Then, 15 
μL of an 80 μM stock solution of the compound in PBS (for a final concentration of 5 μM) was 
added to each well of the eight-well unit, and the plate was incubated on a plate shaker at 1000 
rpm for 12 min at rt. After this time, the plate was centrifuged at 750 g for 10 min, and 50 μL of the 
supernatants are transferred for analytical quantification by HPLC-MS using selected ion 
monitoring (SIM). 
The binding percentage was calculated from the remaining free compound concentration in 
the supernatant of each well, using the spreadsheet and algorithms supplied with the kit. 
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4.2.2. Chemical stability66 
To a vial containing 50 μL of a 10 mg/mL (0.1 mg/mL in the case of compound UCM-01212) 
solution of test compound in DMSO was added 400 μL of additive: 0.1 M HCl, 0.1 M NaOH, water, 
PBS pH 7.4 and/or DMSO. The vials were sealed under air and allowed to stand at rt. Aliquots 
were taken at t = 0, 2 and 7 days (t = 0, 8, 24 and 48 h in the case of compound UCM-01212), and 
remaining compound at each time was quantified by HPLC-MS (SIM mode) using the peak area 
integration normalized with an internal standard. 
4.2.3. Stability in mouse serum 
Stability for selected compounds and reference compound enalapril was assayed by adding 
625 μL of a 250 μM solution of test compound in PBS pH 7.4 to 1.875 mL of mouse serum (Europa 
Bioproducts, EQSM-0100) pre-warmed at 37 ºC. Next, solutions were incubated at 37 ºC for 4 h, 
taking aliquots of 250 μL at t = 0, 1, 2, 3 and 4 h. Each aliquot was quenched in 375 μL of cold 
ACN, vortexed, incubated for 10 min in ice and centrifuged at 39000 g for 10 min. Supernatants 
were then analyzed by HPLC-MS using SIM mode and quantification was estimated by using the 
peak area integration normalized with an internal standard. 
4.2.4. Stability assay in mouse liver homogenate 
Stability of test compounds and reference compound propranolol was determined by 
incubation in liver homogenates following previously reported procedure.67 Livers from male 
C57BL6/J mice weighing 20-24 g (Charles Rivers Laboratories France, L'Arbresle Cedex, France) 
were weighed, cut into small pieces and transferred to a glass dounce homogenizer, keeping the 
tissues at 0 ºC during the whole procedure. Next, 4 mL of ice-cold incubation buffer (50 mM Tris-
HCl, pH 7.4) were added per gram of tissue, and the mixtures were first dounced with a Teflon 
pestle, and then homogenized 3 times using a Teflon digital homogenizer (15 s each time). The 
solutions were allowed to cool on ice between each homogenation step. The homogenates were 
centrifuged at 2000 g for 10 min at 4 ºC, and the supernatants were stored at -80 ºC until 
biochemical assay. 
Prior to the experiment, the total protein concentration in the tissue homogenates was 
determined using the Folin-based DC Protein Assay kit (500-0112, Bio-Rad) with bovine serum 
albumin as a reference standard. 
To perform metabolic stability assay, liver homogenates were diluted to 2.5 mg protein/mL 
using ice-cold incubation buffer (50 mM Tris-HCl, pH 7.4). The metabolic reaction was initiated by 
addition of a 50 μM solution of test compound in 50 mM Tris-HCl pH 7.4 (for a final concentration of 
10 μM), and the mixtures were vortexed and incubated at 37 ºC. Aliquots (50 μL) were withdrawn at 
times t = 0, 1, 4, 8 and 24 h (t = 0, 5, 15, 30 and 60 min in the case of propranolol), and mixed with 
3 volumes of ice-cold ACN to terminate the enzymatic activity. Samples were vortexed, centrifuged 
at 10000 g for 10 min at 4 ºC, and the resulting supernatants were analyzed by HPLC-MS using 
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SIM mode and quantification was estimated by using the peak area integration normalized with an 
internal standard. 
4.2.5. Stability assays in mouse and human liver microsomes 
Compounds were incubated at 37 °C and a final concentration of 1 or 5 μM in PBS together 
with a solution of NADPH in PBS (final concentration of 2 mM) and a solution of MgCl2 in PBS (final 
concentration of 5 mM). Metabolic reactions were initiated by the addition of a suspension of MLMs 
(male CD-1 mice pooled, Sigma-Aldrich) or HLMs (male human pooled, Sigma-Aldrich), 
respectively, at a final protein concentration of 1 mg/mL. The solutions were shaken in a vortex and 
kept in a water bath open to the air at 37 °C. Aliquots of 100 μL were quenched at time zero and at 
seven points ranging to 1 h (MLM) or 2 h (HLM) by pouring into 100 μL of ice-cold ACN. Quenched 
samples were centrifuged at 10000 g for 5 min, and the supernatants were filtered through a 
polytetrafluoroethylene (PTFE) membrane syringe filter (pore size of 0.2 μm, Albet Labscience). 
The relative loss of parent compound over the course of the incubation was monitored by 
HPLC-MS using SIM mode. Concentrations were quantified by measuring the area under the peak 
([M + H]+) and converted to the percentage of compound remaining, using the time zero peak area 
value as 100%. The natural logarithm of the percentage remaining versus time data for each 
compound was fit to linear regression, and the slope was used to calculate the degradation half-life. 
4.2.6. Parallel artificial membrane permeability assay (PAMPA) 
The assessment of the membrane permeability of selected compounds and reference 
compounds propranolol and metoprolol was performed in a commercially available 96-well Corning 
Gentest pre-coated PAMPA plate system (Cultek S.L.U., Spain). Prior to use, the pre-coated 
PAMPA plate system was warmed to room temperature for 30 min and 300 μL of 200 μM solution 
of tested compound in 2% DMSO in PBS were added into wells in the receiver (donor) plate. Then 
200 μL of PBS were added into wells in the filter (acceptor) plate. The filter plate was placed on the 
receiver plate by slowly lowering the pre-coated PAMPA plate until it sits on the receiver plate. The 
assembly was incubated at room temperature for 5 h, and then buffer samples were collected 
carefully from each plate. The final concentrations of compound in both donor and acceptor wells 
were analyzed by HPLC-MS using SIM mode and quantification was estimated by using the peak 
area integration normalized with an internal standard. Permeability value of the compounds was 
calculated using the following formula: P (cm/s) = {-ln[1-CA(t)/Ceq]}/[A*(1/VD+1/VA)*t], where A = 
filter area (0.3 cm2), VD = donor well volume (0.3 mL), VA = acceptor well volume (0.2 mL), t = 
incubation time (s), CA(t) = compound concentration (μM) in acceptor well at time t, CD(t) = 
compound concentration (μM) in donor well at time t, and Ceq = [CD(t)*VD+CA(t)*VA]/(VD+VA). 
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